---
document_datetime: 2023-09-21 20:43:47
document_pages: 158
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/opdivo-h-c-003985-ii-0096-epar-assessment-report-variation_en.pdf
document_name: opdivo-h-c-003985-ii-0096-epar-assessment-report-variation_en.pdf
version: success
processing_time: 281.3023403
conversion_datetime: 2025-12-26 13:45:36.914526
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

16 September 2021 EMA/556100/2021 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## OPDIVO

International non-proprietary name: nivolumab

Procedure No. EMEA/H/C/003985/II/0096

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure ..............................................6                                  |                                                                                                           |
|-----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 2. Scientific discussion ................................................................................7                  |                                                                                                           |
| 2.1. Introduction.........................................................................................................7 |                                                                                                           |
| 2.1.1. Problem statement                                                                                                    | ............................................................................................7             |
| 2.1.2. About the product............................................................................................10      |                                                                                                           |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific advice                                            | ......11                                                                                                  |
| 2.1.4. General comments on compliance with GCP........................................................11                    |                                                                                                           |
| 2.2. Non-clinical aspects                                                                                                   | ............................................................................................11            |
| 2.2.1. Ecotoxicity/environmental risk assessment                                                                            | .........................................................11                                               |
| 2.2.2. Discussion and conclusion on non-clinical aspects................................................11                  |                                                                                                           |
| 2.3. Clinical aspects                                                                                                       | ..................................................................................................11      |
| 2.3.1. Introduction....................................................................................................11   |                                                                                                           |
| 2.3.2. Pharmacokinetics.............................................................................................12      |                                                                                                           |
| 2.3.3. Pharmacodynamics..........................................................................................32         |                                                                                                           |
| 2.3.4. PK/PD modelling..............................................................................................32      |                                                                                                           |
| 2.3.5. Discussion on clinical pharmacology...................................................................38             |                                                                                                           |
| 2.3.6. Conclusions on clinical pharmacology.................................................................39              |                                                                                                           |
| 2.4. Clinical efficacy                                                                                                      | ..................................................................................................39      |
| 2.4.1. Dose response study(ies)                                                                                             | .................................................................................39                       |
| 2.4.2. Main study......................................................................................................39   |                                                                                                           |
| 2.4.3. Discussion on clinical efficacy............................................................................89        |                                                                                                           |
| 2.4.1. Conclusions on the clinical efficacy.....................................................................96          |                                                                                                           |
| 2.5. Clinical safety                                                                                                        | ....................................................................................................96    |
| 2.5.1. Discussion on clinical safety                                                                                        | ............................................................................ 145                          |
| 2.5.2. Conclusions on clinical safety ..........................................................................            | 149                                                                                                       |
| 2.5.3. PSUR cycle                                                                                                           | ................................................................................................... 149   |
| 2.6. Risk management plan......................................................................................             | 149                                                                                                       |
| 2.7. Changes to the Product Information ...................................................................                 | 152                                                                                                       |
| 2.7.1. User consultation...........................................................................................         | 152                                                                                                       |
| 3. Benefit-Risk Balance............................................................................153                      |                                                                                                           |
| 3.1. Therapeutic Context                                                                                                    | ......................................................................................... 153             |
| 3.1.1. Disease or condition.......................................................................................          | 153                                                                                                       |
| 3.1.2. Available therapies and unmet medical need.....................................................                      | 153                                                                                                       |
| 3.1.3. Main clinical studies                                                                                                | ....................................................................................... 153               |
| 3.2. Favourable effects                                                                                                     | ............................................................................................ 153          |
| 3.3. Uncertainties and limitations about favourable effects...........................................                      | 154                                                                                                       |
| 3.4. Unfavourable effects.........................................................................................          | 154                                                                                                       |
| 3.5. Uncertainties and limitations about unfavourable effects                                                               | ....................................... 155                                                               |
| 3.6. Effects Table....................................................................................................      | 155                                                                                                       |
| 3.7. Benefit-risk assessment and discussion...............................................................                  | 156                                                                                                       |
| 3.7.1. Importance of favourable and unfavourable effects............................................                        | 156                                                                                                       |
| 3.7.2. Balance of benefits and risks...........................................................................             | 157                                                                                                       |
| 3.7.3. Additional considerations on the benefit-risk balance                                                                | ......................................... 157                                                             |
| 3.8. Conclusions                                                                                                            | ..................................................................................................... 157 |

<div style=\"page-break-after: always\"></div>

## 4. Recommendations ...............................................................................  157 5. EPAR changes  ......................................................................................  158

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ADA

anti-drug antibody

ADR

adverse drug reaction

AE

adverse event

ALT

alanine aminotransferase

AST

aspartate aminotransferase

BID

twice daily

BIRC

blinded independent review committee

Chemo

chemotherapy

CI

confidence interval

CNS

central nervous system

CPS

combined positive score

CSR

clinical study report

CTC

Common Terminology Criteria

DBL

database lock

DMC

data monitoring committee

FOLFOX

folinic acid, fluorouracil and oxaliplatin

GC

gastric cancer

GCP

good clinical practice

GEJC

gastric oesophageal junction carcinoma

GI

gastrointestinal

HLGT

high-level group term

HR

hazard ratio

IMAE

immune-mediated adverse event

IMM

immune-modulating medication

IR

ISR

infusion reaction

incurred sample reanalysis

IV

intravenous

LLN

lower limit of normal

MAH

Marketing Authorization Holder

MedDRA

Medical Dictionary for Regulatory Activities

MID

minimum important difference

NA

not available

NCI CTCAE

National Cancer Institute Common Terminology Criteria for Adverse Events

Nivo

nivolumab

Nivo+chemo

nivolumab + chemotherapy

OAC/EAC

oesophageal adenocarcinoma

OESI

other events of special interest

ORR

overall response rate

OS

overall survival

PBRER

Periodic Benefit-Risk Evaluation Report

PD-L1

programmed cell death ligand 1

PFS

progression free survival

PK

pharmacokinetics

<div style=\"page-break-after: always\"></div>

| PT    | preferred term                     |
|-------|------------------------------------|
| QD    | daily                              |
| RMP   | Risk Management Plan               |
| SAE   | serious adverse event              |
| SCS   | Summary of Clinical Safety         |
| SI    | International System of Units      |
| SmPC  | Summary of Product Characteristics |
| SMQ   | Standardized MedDRA Query          |
| SOC   | system organ class                 |
| TSH   | thyroid-stimulating hormone        |
| ULN   | upper limit of normal              |
| XELOX | capecitabine and oxaliplatin       |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Bristol-Myers Squibb Pharma EEIG submitted to the European Medicines Agency on 25 November 2020 an application for a variation.

The following changes were proposed:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to use OPDIVO (nivolumab) in combination with fluoropyrimidine- and platinum-based combination chemotherapy, in first-line treatment of adult patients with advanced or metastatic gastric, gastro-oesophageal junction (GEJ) or oesophageal adenocarcinoma (Study CA209649); as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 21.0 of the RMP has also been submitted.

The requested variation proposed amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included EMA Decisions P/0432/2020, P/0433/2020, on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application P/0433/2020, was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The MAH did not seek scientific advice at the CHMP.

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Blanca Garcia-Ochoa

Co-Rapporteur:

Paula Boudewina van Hennik

| Timetable           | Actual dates     |
|---------------------|------------------|
| Submission date     | 25 November 2020 |
| Start of procedure: | 26 December 2020 |

<div style=\"page-break-after: always\"></div>

| Timetable                                                                                   | Actual dates      |
|---------------------------------------------------------------------------------------------|-------------------|
| CHMP Rapporteur's preliminary assessment report circulated on:                              | 24 February 2021  |
| CHMP Co-Rapporteur's Rapporteur's preliminary assessment report circulated on:              | 24 February 2021  |
| PRAC Rapporteur's preliminary assessment report circulated on:                              | 26 February 2021  |
| PRAC RMP advice and assessment overview adopted by PRAC on:                                 | 11 March 2021     |
| CHMP Rapporteurs' updated joint assessment report circulated on:                            | 19 March 2021     |
| Request for supplementary information adopted by the CHMP on:                               | 25 March 2021     |
| MAH's responses submitted to the CHMP on:                                                   | 19 May 2021       |
| CHMP Rapporteurs' preliminary joint assessment report on the MAH's responses circulated on: | 6 July 2021       |
| CHMP Rapporteurs' updated joint assessment report on the MAH's responses circulated on:     | 16 July 2021      |
| 2 nd Request for supplementary information adopted by the CHMP on:                          | 22 July 2021      |
| MAH's responses submitted to the CHMP on:                                                   | 13 August 2021    |
| CHMP Rapporteurs' preliminary joint assessment report on the MAH's responses circulated on: | 1 September 2021  |
| CHMP Rapporteurs' updated joint assessment report on the MAH's responses circulated on:     | 15 September 2021 |
| CHMP Opinion adopted on:                                                                    | 16 September 2021 |

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

Gastric cancer (GC) is the 5 th  leading cancer and the 3rd leading cause of cancer-related deaths worldwide 1 . Oesophageal cancer is the 7 th  leading cancer and the 6 th  leading cause of cancer-related deaths worldwide. GC/gastric oesophageal junction carcinoma (GEJC)/oesophageal adenocarcinoma (OAC) remain a leading cause of cancer-related mortality worldwide, with an estimated 1 million deaths worldwide in 2018. 2

Adenocarcinoma is the most common (&gt; 90%) histological subtype for GCs worldwide and OAC has increased in North America and Europe (EU) 3,4 . GEJC anatomically straddles the distal oesophagus and proximal stomach and due to its location and the same adenocarcinoma histology, GEJ tumours are

1  Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol. 2019; 14: 26-38.

2  Lin D, Khan U, Goetze TO, et al. Gastroesophageal Junction Adenocarcinoma: Is There an Optimal Management? American Society of Clinical Oncology Educational Book 2019; 39, e88-e95.

3  Ajani JA, Lee J, Sano T, et al. Gastric adenocarcinoma. Nat Rev Dis Primers 2017; 3:17036.

4  Rustgi AK and El-Serag HB. Esophageal carcinoma. N Engl J Med 2014; 371:2499-2509.

<div style=\"page-break-after: always\"></div>

frequently grouped together with GC. Advanced or metastatic OAC, GEJC, and GC are considered similar diseases and the same treatment approach is recommended .5,6,7,8,9

GC, including GEJ carcinoma, is a heterogeneous disease with several established risk factors, including environmental, genetic, and behavioural risks. The aetiology of this disease is complex and multifactorial. Environmental and lifestyle factors such as Helicobacter pylori infection, smoking, high salt intake, low vegetable intake, and obesity have been associated with GC. There has been a steady decline in GC mortality attributable to dietary and lifestyle changes worldwide and to decreasing infection with H. pylori, which is considered the main cause in Asian countries. However, the incidence of GEJ tumours has increased in the US and Europe (~35%) considerably due to increases in risk factors such as obesity and gastroesophageal reflux disease, while remaining only 20% in Asian countries.

OAC predominantly occurs in patients with chronic gastro-oesophageal reflux disease and their risk is correlated with the patient's body mass index with a higher risk for obese persons. OAC is three to four times as common in men as it is in women.

## Claimed therapeutic indication

The new claimed indication for OPDIVO is:

- -OPDIVO in combination with fluoropyrimidine- and platinum-based combination chemotherapy, is indicated for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro oesophageal junction or oesophageal adenocarcinoma whose tumours express PDL1 with a combined positive score (CPS)≥5 .

Proposed dosage and administration:

The recommended dose is 360 mg nivolumab administered intravenously (IV) over 30 minutes in combination with fluoropyrimidine- and platinum-based chemotherapy Q3W or 240 mg nivolumab administered IV over 30 minutes in combination with fluoropyrimidine- and platinum-based chemotherapy Q2W (see Section 5.1 of the SmPC). Treatment with nivolumab is recommended until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.

## Management

Platinum compounds (oxaliplatin and cisplatin) and fluoropyrimidines (5-fluorouracil [5-FU], capecitabine, and tegafur/gimeracil/oteracil potassium [S1]) are considered first-line standard-of-care

5  National Comprehensive Cancer Network (NCCN) Guideline Esophageal and Esophagogastric Junction cancer (Version 3.2020).

6  Lordick F, Mariette C, Haustermans K, R. et al. Oesophageal Cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2016; 27 (suppl 5): v50-v57.

7  National Comprehensive Cancer Network (NCCN) Guideline Gastric cancer (Version 2.2019).

8 Smyth EC, VerheijnM, Allum W, et al. Gastric cancer: European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2016; 27:38-49.

9  Cunningham D, Rao S, Starling N, et al. Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL 2 trial. Journal of Clinical Oncology 2006; 24: Abstract LBA4017.

<div style=\"page-break-after: always\"></div>

treatments for metastatic GC/GEJC/OAC across geographic regions. 10,11,12,13,14  With GC/GEJC/OAC, different survival outcomes have been reported across regions; the median OS ranges from 12 to 14 months in Asian countries and from 8 to 11 months in the United States (US) and Europe. 15,16,17

In the past decade, multiple new investigational drugs with mainly molecular targets have been investigated in the first-line setting as add-ons to backbone platinum and fluoropyrimidine treatment. These agents, with the exception of trastuzumab, which targets and benefits only the human epidermal growth factor receptor 2 (HER2)-positive population (approximately 20% of subjects are HER2 positive in first-line GC/GEJC), have failed to show a survival benefit in randomized trials. Trastuzumab + chemotherapy provided an improvement in survival over chemotherapy in subjects who were HER2 positive; at a median follow up of 17.1 months, median OS was 13.5 vs. 11.0 months (HR = 0.74). 18

To date, no immunotherapy agents with or without chemotherapy have been approved for the first-line treatment of GC/GEJC/OAC in the EU.

10 Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3).Gastric Cancer 2011; 14:113-123.

11  Ohtsu A, Shah MA, Cutsem EV, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011; 29:3968-3976. 12  Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358:36-46.

13  Yamada Y, Higuchi K, Nishikawa K, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Annals of Oncology 2015; 26:141-148.

14   Van Cutsem E, Kang Y, Chung H, et al. T Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 2009; 27: Abstract LBA4509.

15  Bang YJ, Cutsem EV, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376:687-97.

16  HERCEPTIN® (trastuzumab) USPI. Genentech, Inc. 2010.

17  Lordick F, Kang YK, Chung HC, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 2013; 14:490-499. 18  Fuchs C , Shitara K, Di Bartolomeo M et al RAINFALL: A randomized, double-blind, placebo-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma. ASCO GI Cancers Symposium2018, abstract # 5.

<div style=\"page-break-after: always\"></div>

## Agents Relevant to First-line Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, or Oesophageal Adenocarcinoma (GC/GEJC/OAC)

| Product (s) Name                                                                    | Reference                                                                                 | Relevant Indication                                                          | YearofApproval                                                                                                                                                                                                                                                                             | Dosing/Administration                                                                                                                                                               | EfficacyInformation                                                  | Important Safety and Tolerability Issues                                                                                                                                                                                                          |
|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| HER2 inhibitor + chemotherapy                                                       | HER2 inhibitor + chemotherapy                                                             | HER2 inhibitor + chemotherapy                                                | HER2 inhibitor + chemotherapy                                                                                                                                                                                                                                                              | HER2 inhibitor + chemotherapy                                                                                                                                                       | HER2 inhibitor + chemotherapy                                        | HER2 inhibitor + chemotherapy                                                                                                                                                                                                                     |
| Herceptin (trastuzumab) chemotherapy                                                | Van Cutsem E, et al. 200917 Trastuzumab                                                   | HER2-over- expressing metastatic gastric or GEJ adeno- carcinoma             | 2010 in US and EU                                                                                                                                                                                                                                                                          | Trastuzumab8mg/kg Q3W followed by 6 mg/kg Q3W + chemotherapy (cisplatin + capecitabine or 5-FU)                                                                                     | Trastuzumab+chemo mOS:13.5 months ORR: 47% updated mOS: 13.1 months  | Most common Grade3/4 AEs: neutropenia (27%), anemia (12%), diarrhea (9%) nausea(7%),and anorexia and vomiting (6% each), and asthenia, febrile neutropenia. and thrombocytopenia (5% each).                                                       |
| Chemotherapy:Platinum +fluoropyrimidine-containingregimens                          | Chemotherapy:Platinum +fluoropyrimidine-containingregimens                                | Chemotherapy:Platinum +fluoropyrimidine-containingregimens                   | Chemotherapy:Platinum +fluoropyrimidine-containingregimens                                                                                                                                                                                                                                 | Chemotherapy:Platinum +fluoropyrimidine-containingregimens                                                                                                                          | Chemotherapy:Platinum +fluoropyrimidine-containingregimens           | Chemotherapy:Platinum +fluoropyrimidine-containingregimens                                                                                                                                                                                        |
| Fluorouracil (FU)+ leucovorin+ oxaliplatin (FOLFOX) FU+ leucovorin+ cisplatin (FLP) | A1-Batran S-E, et al. 200825 Enzinger, et al.26 NCCN Guidelines8,10 ESMO Guide- lines9,11 | Untreated gastric or esophago- gastric adeno- carcinoma                      | 2006in US and 2011 in EU FU, as a component of a platinum- multidrug containing chemotherapy regimen. FOLFOX isrecommended in the NCCN and ESMO guidelines Modified FOLFOX6: oxaliplatin 85 mg/m leucovorin 400 mg/m2 + fluorouracil 400 mg/m2 IV on Day 1, and fluorouracil 1200 mg/m2 IV | FOLFOX:FU 2,600 mg/m²via 24-hour infusion, leucovorin 200 mg/m² + oxaliplatin 85 mg/m^Q2W FLP: FU 2.000 mg/m'via 24-hour infusion, leucovorin 200 mg/m2 QW + cisplatin 50 mg/m² Q2W | FOLFOX vs FLP mOS: 10.7 vs 8.8 months ORR: 41.3% vs 16.7%            | MostcommonGrade3/4 AEs (FLP vs FOLFOX): neutropenia (14.7% vs 11.6%), leukopenia (11.8% 2.7%), nausea (8.8% vs vs 6.3%), anemia (6.9% vs 4.5%), vomiting (5.9% vs 2.7%), thromboembolic (5.9% vs 0.9%), and fatigue (6.9% vs 3.6%).               |
| Chemotherapy:Platinum+fluoropyrimidine-containingregimens(continued)                | Chemotherapy:Platinum+fluoropyrimidine-containingregimens(continued)                      | Chemotherapy:Platinum+fluoropyrimidine-containingregimens(continued)         | Chemotherapy:Platinum+fluoropyrimidine-containingregimens(continued)                                                                                                                                                                                                                       | Chemotherapy:Platinum+fluoropyrimidine-containingregimens(continued)                                                                                                                | Chemotherapy:Platinum+fluoropyrimidine-containingregimens(continued) | Chemotherapy:Platinum+fluoropyrimidine-containingregimens(continued)                                                                                                                                                                              |
| Capecitabine + oxaliplatin (XELOX or CapeOx)                                        | Park YH, et al. 200827                                                                    | Advanced gastric cancer                                                      | Not approved, but XELOX (CapeOx) is recommended in NCCN guidelines and ESMO Guidelines                                                                                                                                                                                                     | Capecitabine (1,000 mg/m² BID, Days 1-14) + oxaliplatin (130 mg/m² IV infusion on Day 1) Q3W                                                                                        | mOS:11.9 months ORR: 63%                                             | Most common Grade 3/4 AEs:thrombocytopenia (11%), neutropenia (8%), diarrhea and bleeding (7% each), and leukopenia (6%).                                                                                                                         |
| Docetaxel + cisplatin + fluorouracil (DCF) Cisplatin + fluorouracil (CF)            | Van CutsemE et al. 200628,                                                                | First-line treatment of advanced GC/GEJC Docetaxel +cisplatin + fluorouracil | 2006in US and 2007in EU Docetaxel +cisplatin + fluorouracil                                                                                                                                                                                                                                | Docetaxel 75 mg/m2- cisplatin 75 mg/m2 (Day 1) + fluorouracil 750 mg/m^/day (Days 1-5) Q3W Cisplatin 100 mg/m2 (Day 1) + fluorouracil 1,000 mg/m2/day (Days 1-5) Q4W                | DCF and CF mOS: 9.2 and 8.6 months ORR: 37% and 25%                  | MostcommonGrade3/4 AEs (DCF vs CF): neutropenia (82% vs 57%), leukopenia (65% vs 31%), anemia (18% vs 26%), stomatitis (21% vs 27%), diarrhea (19% vs 8%), lethargy (19% vs14%), nausea and vomiting (both: 14%vs 17%), and anorexia (10% vs 9%). |
| Capecitabine + cisplatin                                                            | Lordick F, et al. 201320 Kang et al. 200929 NCCN Guidelines8,10 ESMO Guide- lines9,11     | Previously untreated advanced gastric cancer                                 | Not approved, but capecitabine + cisplatin is recommended in NCCN guidelines and ESMO guidelines                                                                                                                                                                                           | 3-wk cycles of capecitabine BID 1000 mg/m² (on Days 1- 14) + cisplatin 80 mg/m2 (on Day 1)                                                                                          | Capecitabine + cisplatin mOS:10.7 months ORR: 29%                    | Most common Grade 3/4 AEs:neutropenia (32%), anemia (11%), hypokalemia and nausea (9% each), vomiting(8%),and fatigue, asthenia, hyponatremia, and decreased appetite (6% each).                                                                  |

Abbreviations: AEs - adverse events,BID - twice daily, CF -cisplatin + fluorouracil, chemo - chemotherapy,DCF - docetaxel + cisplatin + fluorouracil, ESMO EuropeanSocietyforMedical Oncology,FLP-FU+leucovorin+cisplatin,FOLFOX-folinic acid(leucovorin)\"FOL\",fluorouracil(5-FU)\"F\",and oxaliplatin (eloxatin) \"OX\", FU - fluorouracil, GC - gastric cancer, GEJC - gastroesophagealjunction cancer, HER2 -human epidermal growth factor receptor 2, HR hazard ratio, mOS -median overall survival, NCCN - National Comprehensive Cancer Network, ORR - objective response rate, QXW - every X weeks, XELOX - Xeloda (capecitabine)\"XEL\" and oxaliplatin \"OX\"

## 2.1.2. About the product

OPDIVO (nivolumab) is a human immunoglobulin G4 (IgG4) monoclonal antibody (mAb), which binds to the programmed death-1 (PD-1) receptor and blocks its interaction with PD-L1 and PD-L2. The PD-1 receptor is a negative regulator of T-cell activity that has been shown to be involved in the control of T-cell immune responses. Engagement of PD-1 with the ligands PD-L1 and PD-L2, which are expressed in antigen presenting cells and may be expressed by tumours or other cells in the tumour microenvironment, results in inhibition of T-cell proliferation and cytokine secretion. Nivolumab

<div style=\"page-break-after: always\"></div>

potentiates T-cell responses, including anti-tumour responses, through blockade of PD-1 binding to PDL1 and PD-L2 ligands. In syngeneic mouse models, blocking PD-1 activity resulted in decreased tumour growth.

In the EU nivolumab as monotherapy has been approved for the treatment of melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), classical Hodgkin's lymphoma (cHL), squamous cell carcinoma of the head and neck (SCCHN), urothelial carcinoma, oesophageal squamous cell carcinoma (OSCC), and adjuvant treatment of oesophageal or gastro-osesophageal junction cancer (OC or GEJC) (OPDIVO SmPC). The combination of nivolumab with ipilimumab (Yervoy) has been approved for the treatment of melanoma, RCC, malignant pleural mesothelioma (MPM) and colorectal cancer (CRC) and in combination with ipilimumab and platinum-based chemotherapy for the first-line treatment of metastatic NSCLC. The combination of nivolumab with cabozantinib has been approved for the treatment of RCC.

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

The MAH did not seek scientific advice at the CHMP concerning the current procedure.

## 2.1.4. General comments on compliance with GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted in this application, which is considered acceptable.

## 2.2.1. Ecotoxicity/environmental risk assessment

Nivolumab is a protein composed of natural amino acids. Proteins are expected to biodegrade in the environment and not be a significant risk. As a protein, nivolumab is exempt from preparation of an Environmental Risk Assessment under the 1 June 2006 'Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use' (EMEA/CHMP/S/4447/00). Nivolumab and the product excipients do not pose a significant risk to the environment.

## 2.2.2. Discussion and conclusion on non-clinical aspects

Not applicable.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

- Tabular overview of clinical studies

<div style=\"page-break-after: always\"></div>

## BMS-Sponsored Phase 3 Study Supporting the Proposed Indication of Nivolumab + Chemotherapy for the Treatment of GC/GEJC/EAC

<!-- image -->

| Study/Phase/ Status                                                                                                         | Population                                                            | Design*                                                                                                              | Endpoints                                                                                                                                                                                                                                                                                                                                                                                       | Test Drugs and Dose                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Number of Subjects                                                                                                                                 |
|-----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|
| CA209649 Phase 3 Ongoing Database lock: 10-Jul-2020 for the primary analysis of PFS per BICR and OS for nivo+chemo vs chemo | Subjects with previously untreated advanced or metastatic GC/GEJC/EAC | Phase 3, randomized,  open-label, 3-arm study of nivo+ipi nivo+chemo or FOLFOX) (XELOX or or chemo (XELOX or FOLFOX) | For nivo+chemovs chemo Primary:OS and PFS (per BICR) in subjects with PD-L1CPS≥5 Secondary: OS in subjects all randomized subjects withPD-L1 CPS≥1 andin subjects with PD-L1 CPS ≥ (hierarchically tested); OS in 10; PFS (per BICR)in subjects with PD-L1 CPS ≥ 10, CPS ≥1, or all randomized subjects; ORR (per BICR) in subjects with PD-L1 CPS≥10,CPS≥5, CPS ≥1, or all randomized subjects | Nivo+Chemo Arm Nivolumab+XELOX(Q3W): Nivo360mgIVover30minonDay1+ oxaliplatin130mg/m²IVonDay1+ capecitabine1000mg/m²POBIDon Nivolumab + FOLFOX(Q2W): Days1to14 Nivo240mgIVover30minonDay1+ 400mg/m²+fluorouracil400mg/m²IVon oxaliplatin85mg/m²+leucovorin Day 1, and fluorouracil 1200 mg/m² IV continuous infusionover 24hours orper local standard on Days 1 and 2 ChemoArm XELOX (Q3W): 0xaliplatin 130 mg/m2 IV on Day1+ capecitabine 1000 mg/m² PO BID on Days1 to14 FOLFOX (Q2W): Oxaliplatin 85 mg/m2 + leucovorin 400 mg/m² + fluorouracil 400 mg/m² IV on Day 1,and fluorouracil 1200mg/m²IVcontinuousinfusionover | 2031 subjects randomized in all 3 arms 1581 concurrently randomized to the nivo+chemo or chemo arms: nivo+chemo arm 789in the 792 in the chemo arm |

Abbreviations:BICR-blinded independent central review,BID-twice daily,chemo-chemotherapy,BMS -Bristol-MyersSquibb,CPS -combined positive score, EAC - esophageal adenocarcinoma, FOLFOX - leucovorin + fluorouracil + oxaliplatin, GC - gastric cancer, GEJC - gastroesophageal junction cancer, IV intravenous,ipi-ipilimumab,nivo-nivolumab,ORR-objective responserate,OS-overall survival,PD-L1-programmeddeathligand1,PFS-progressionfree survival, PO - orally, QXW - every X weeks, XELOX - capecitabine + oxaliplatin

Source:summarizedbasedonCA209649PrimaryClinicalStudyReport

*This submissionis onlyfor nivo+chemovschemo

## 2.3.2. Pharmacokinetics

## PK analytical methods

## Pre-study validation

In support of study CA209649, human serum samples for nivolumab were analyzed at either PPD, Inc. (Richmond, VA) or at WuXi AppTec (Shanghai, P. R. China; for subjects from China) using validated ECL Methods, ICD 416 or 14BASM122, respectively.

## In-study validation

The details of the assay and sample analysis as well as management details are provided in the respective bioanalytical reports.

## Clinical Study CA209649

For both methods, the quantification of BMS-936558 in human serum samples was performer by ECL Method over a quantitative range of 0.2 μg/mL and 6.5 μg/mL. In addition, each batch consisted of one set of standards [0.100 (anchor), 0.200, 0.300, 1.000, 2.500, 4.000, 5.500 and 6.500 μg/mL] and

<div style=\"page-break-after: always\"></div>

two sets of three QCs (0.600, 1.500 and 4.800 μg/mL) and 3 sets of DQC (for study sample which requires dilution).

## PPD Project RHDS Bioanalytical Report

Sample analysis for the quantification of BMS-936558 in human serum samples was performed at PPD Laboratories, 2244 Dabney Road, Richmond, Virginia 23230 (804) 359-1900, USA from January 15th, 2018 to June 10th, 2020.

A total of 3842 samples were received and 3825 samples were analysed (17 samples were not analysed per protocol SOP) in 183 bioanalytical runs (175 runs met the acceptance criteria). Out of 3825 samples, 3787 samples were reported and 38 samples were not reported in data transfer files (sample outstanding reconciliation with Watson database).

The between-run precision (%CV) and accuracy (%Bias) of the calibration curve standards ranged from 0.945% to 4.92% and from -0414% to 3.98%, respectively. A total of seven calibration standards were rejected. In all valid runs, no more than one was rejected at the same run. In three runs the ULOQ and in one run the LLOQ was rejected.

The between-run precision (%CV) and accuracy (%Bias) of the QCs ranged from 5.28% to 6.36% and from 0.706% to 6.93%, respectively (including all QCs). A total of fifteen QCs was outside the acceptance range. In all valid runs, no more than two QCs was outside the acceptance range at the same run, and not at the same concentration level.

A total of 326 samples were re-analysed due to the following reasons: sample result above upper limit of ULOQ, diluted sample quantitated below limit of quantitation, inadvertently re-assayed at incorrect dilution, re-assayed inadvertently (for all these samples the original values were reported), limit of quantitation (LLOQ) raised due to deletion of calibration standard and confirmatory potential quantitating pre-dose.

A total of 441 samples were subjected for ISR. Out these, 434 samples met the ISR acceptance criteria (± 30%), which has resulted in 98.4% ISR pass rate for study samples.

The maximum storage for samples was 1690 days at nominally -80 ºC. The long-term stability of nivolumab in human plasma covers 2373 days at nominally -80 ºC.

## WuXi AppTec Study Number: 400040-181151-PSA

Sample analysis for the quantification of BMS-936558 in human serum samples by ECL Method over a quantitative range of 0.2 μg/mL and 6.5 μg/mL was performed at WuXi A ppTec in Shanghai from July 25th, 2019 to May 25th, 2020.

A total of 599 samples were analysed in 26 bioanalytical runs (all runs met the acceptance criteria) and all of them were reported.

The between-run precision (%CV) and accuracy (%Bias) of the calibration curve standards ranged from 0.4% to 2.0% and from 0.0% to 3.0%, respectively. No calibration curve standard was rejected.

The between-run precision (%CV) and accuracy (%Bias) of the QCs ranged from 4.4% to 5.5% and from -7.5% to -2.6%, respectively). No QC was outside the acceptance range

A total of 51 samples were re-analysed due to sample result above ULOQ (48 samples) and sample reassayed inadvertently (3 samples; for these samples the original values were reported),

A total of 60 samples were subjected for ISR. All the samples met the ISR acceptance criteria (± 30%), which has resulted in 100.0% ISR pass rate for study samples.

Study samples analysed and reported for Nivolumab (BMS-936558) in support of study CA209649

<div style=\"page-break-after: always\"></div>

were covered by 2373 days of long-term stability at nominal at -70 ºC.

## Pharmacokinetics in the target population

Pharmacokinetic data from Study CA209649 were pooled with data from 6 other studies for an updated PPK analysis. In total, the updated PPK dataset included data from 1825 subjects with either 2L NSCLC (reference population), 1L GC/GEJC/EAC, 2L+ GC, or other solid tumours from a total of 7 studies in which subjects received nivolumab monotherapy or nivo+chemo.

<div style=\"page-break-after: always\"></div>

Table 3-1: Summary of Clinical Studies Included in Pharmacometric PPK Analyses

| Protocol#:Title StudyPopulation                                                                                                                                                                                                                                                                                                                                                  | Treatment                                                                                                                                                                                                                                                                                                                                               |   Planned Sample Size? | Nominal PK/PD Sampling Schedule                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Analysis                                               |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| MDX1106-01(CA209001):Phase 1, open-labelmuticenter, dose-escalation phamacokinetics ofBMS-936588in study to evaluate the safety and subjects with selected refractory or relapsed maliguancies Adultsubjectswithpathologicallyveriffed adrecurentortreatment-rqfiractory colorectaladenocarcinomamelanoma, NSCLC,castration-resistantprostate adenocarcinoma,andRcc              | Nivo Monotherapy Single-dose Phase (Cycle 1): administered over 60minutes 0.3,1,3,or 10 mg/kg IV infusion Re-treatment Phase (Cycle 2): 0.3, 1,3, or 10 mg/kg IV infusion administeredover60minutesonDays 1 and 29; eligible subjects were treated with the same dose level as in the Single-dose Phase and could receive additionalre-treatment cycles |                     39 | Single-dose Phase. Pre-dose,30 minutes into dosing,immediately post-infusion, and 30 minutes, 1, 2,4, 6, 8, 24, 48, and 72 hous post-infusion end time; on Days 8,15,22,29,43,57,71,nd85 Re-treatment Phase: Pre-dose and peak on treatment Days 1 and 29; single samples on Days 8, 15, 22,36, 43, 57, 85, and 113                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | PPK                                                    |
| MDX1106-03 (CA209003): Phase 1, open-label multicenter, multidose, dose- escalation study to evaluate the safety and tolerabilityof BMS-936588in subjects with selected advanced or recurrent maliguancies Adultsubjectswithpathologicallyveriffed adacvancedorrecurentand progressingcolorectal adenocarcinoma. melanomaNSCLC,castration-resistant prostateadeocarcinoma,andRcC | Nivo Monotherapy 0.1,0.3,1,3,or10mg/kgIVinfusion depending upon tumor type, administeredover60minutesQ2Wfor up to twelve 8-week cycles                                                                                                                                                                                                                  |                    306 | Pre-Amendment. Cycle l:End of Infusion andpre-infusionlevels on infusion days: Days 1, 15, 29,and 43 and Cycle 2: Single samples were collected Post-Amendment: Serial PK samples were collected from all subjects enrolled in 0.1, 0.3, and 1 mg/kg melanoma cohorts and first 16 subjects each from 3 and10 mg/kgNSCLC cohorts.Cycle 1: Day 1 (after 60-minute infiusion, 4, 8hr),Days 2, 3,5,8, 15;Cycle 2:Day 1 (pre-infusion); Cycle 3: Day 1 (pre-infusion, after 60-minute infusion),andDays2,3,5,8,and15 Limited PK samples Were collected from subjects enrolled in 1 mg/kg RCC cohort, 1 mg/kg NSCLC, andremaining 16 subjects eachfrom3and 10 mg/kgNSCLC.Cycle 1: Day 1 (after 60-minute infiusion)and Days3,8, 15; Cycle 2: Day 1 (pre-infusion); Cycle 3: Day 1 (pre-infusion, after 60-minute infusion), and Days 3,8,and 15 Each treamment cycle is compnised of 4 doses of study drug administeredonDays 1,15,29,and | ppK Only include subjects with melanoma, NSCLC,and RCC |

| Table 3-1:                                                                                                                                                                                                                                                                                                                                                    | Summary of Clinical Studies Included in Pharmacometric PPK Analyses    | Summary of Clinical Studies Included in Pharmacometric PPK Analyses   | Summary of Clinical Studies Included in Pharmacometric PPK Analyses                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|-----------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|
| Protocol#:Title StudyPopulation                                                                                                                                                                                                                                                                                                                               | Treatment                                                              | Planned Sample Size?                                                  | NominalPK/PD Sampling Schedule                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Analysis                       |
| CA209017:Anopen-label,randomized Phase3tialofBMS-936558(nivolumab) versus docetaxel inpreviously treated advancedormetastaticSQNSCLC SubjeciswithSQNSCLC                                                                                                                                                                                                      | Nivo Monotherapy Dose: 3 mg/kg, 1-hr IV infusion Regimen: Q2W          | 132 (mivolumab treated)                                               | Day 1 (Cycle 1) and Day 99 (Cycle 8), pre- infusion, after 60-minute infusion and pre- infusionat Cycles 2and3andevery8thcycle afterCycle8Day1untildiscontinuationof study treabment Each 14-day dosing periodis considered a cycle                                                                                                                                                                                                                                                                                                 | PPK                            |
| CA209057: An open-label, randomized Phase3Trialof BMS-936558(nivolumab) advanced or metastatic NSQ NSCLC versus docetaxel in previously treated Subjeciswith NSQNSCLC                                                                                                                                                                                         | Nivo Monotherapy Dose: 3 mg/kg, 1-hr IV imfusion Regimen: Q2W          | 287 (mivolumab treated)                                               | Day 1 (Cycle 1) and Day 99 (Cycle 8),pre- infusion,after60-minute infiusion andpre- infiusionatCycles2and3andevery8thcycle afterCycle8Day1untildiscontinuationof study treabment Each 14-day dosing period is considered a cycle                                                                                                                                                                                                                                                                                                    | PPK                            |
| CA209032:A Phase 1/2,open-label shudy of mivolumabmonotherapy ornivolumab with advanced ormetastatic solid tumors combinedwithipilimumabin subjects Subjectswithpathologicallyconfimed locallyaavancedormetastaticdiseaseof breastcarcinoma,gastricorgastro- esophagealjunctioncarcinoma, pamcreatic adenocarcinoma, SCLC, rothelialcarcinomaovariancarcinoma | Nivo Monotherapy Dose: 3 mg/kg, 1-hr IV infusion Regimen: Q2W          | 58 (nivolumab treated GC cohort)                                      | Pre-doseonC1D1,C4D1,C10D1,C13D1, C25Dl and onDay1ofevery16th week thereafter uwtil discontinuation of study treatmentorcompletionof2yearsofstudy treatment                                                                                                                                                                                                                                                                                                                                                                          | PPK (Nivo monotherapy am only) |
| ONO-4538-12(CA209310):APha5e3 mticenter,double-blind,randomized studyin patients with umresectable advanced or recurent gastric cancer Subjectswithgastriccamcer                                                                                                                                                                                              | Nivo Monotherapy Dose:3 mg/kg, 1-hrIV infiusion Regimen: Every 2 weeks | 290 (nivolumab treated)                                               | Treatmentperiod(Cycle 1): Day 1 pre-dose, Day 1 post dose (just before the end ofinfusion), Day 15 pre-dose, Day 29 pre-dose Treatment period (Cycles 2, 4, 5, 7, and 9): Day1re-dose,Day1post dose（inCycle4,just before the end of infusion only) Post-treabment observation period: At the examination 28 days after the end ofthe treatmment period (only in subjects proceeding to thepost-treamentobservationperiodbytheend of Cycle 9), and 6-12 weeks after the last dose of theinvestigational product (as far as possible) | PPK                            |

<div style=\"page-break-after: always\"></div>

Table 3-1:

Summaryof ClinicalStudiesIncludedinPharmacometricPPKAnalyses

| Protocol#:Title Study Population                                                                                                                                                                                                                                                                                                                                                                                                                                                | Treatment                                                                                                  | Planned Sample Sizea                     | Nominal PK/PD Sampling Schedule                                                                                  | Analysis                          |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|------------------------------------------|------------------------------------------------------------------------------------------------------------------|-----------------------------------|
| CA209649: A randomized, multicenter, open-label, Phase 3 study of mivolumab plus ipilimumab or mivolumab in fluoropyrimidine versus oxaliplatin plus combination with oxaliplatin plus fluoropyrimidine in subjects with previously untreated advanced or metastatic gastric or gastroesophageal junction cancer (nivolumab plus chemotherapy cohort only,DBL07/2020) Subjeciswithacvancedormetastatic gastric or gastroesoplhageal junction orr esophagealadenocarcinomacancer | Nivo+Chemo Dose: 240 mg, 30-min IV infiusion Regimen: Q2W Or Dose: 360 mg, 30-min IV infusion Regimen: Q3W | 791 (mivolumab plus chemotherapy teated) | Q2W Cycles 1, 2, 3, 7, 9, 17, 25,37, and 49: Predose on Day 1 Q3W Cycles 1,2,5, 11,17,25, and33:Predose on Day 1 | pPK. E-R efficacy. and E-R safety |

Abbreviations:C= cycle; D=day; DBL=database lock; E-R=exposure-response; GC=gastic cancer, hr=hour, IV=inhravenous; min =minutes; Nivo = nivolumab; Nivo+Chemo =nivolumab in combination with oxaliplatin plus fluoropyrimidine; NSCLC = non-small cell lung cancer, NSQ NSCLC =non-squamous cell non-small cell lung cancer, PK = phamacokinetic(s); PK/PD = pharmacokinetic/phamacodymamic; PPK = population pharmacokinetics;Q2W=every2weeks;Q3W=every3weeks;RCC=renalcellcarcinoma;SCLC=smallcell lumg cancer;SQNSCLC=squamous cell non-small cell lumg cancer.

Table 3.2.1.1-1: Subjects Included in the PPK Analysis Dataset

| Study                  | #Subjects          | #Subjects              | #Subjects   | #Subjects                            |
|------------------------|--------------------|------------------------|-------------|--------------------------------------|
| Study                  | Nivolumab Treateda | PK Database (eToolbox) | Flagged     | Included (% of Subjects in eToolbox) |
| MDX1106-01 (CA209001)  | 39                 | 39                     | 0           | 39 (100)                             |
| MDX1106-03 (CA209003)  | 269                | 269                    | 1           | 268 ( 99.63)                         |
| CA209017               | 125                | 127                    | 2           | 125 (98.43)                          |
| CA209032               | 58                 | 58                     | 0           | 58 ( 100)                            |
| CA209057               | 280                | 282                    | 2           | 280 (99.29)                          |
| ONO-453S-12 (CA209316) | 330                | 330                    | 1           | 329 ( 99.7)                          |
| CA209649               | 763                | 773                    | 47          | 726 ( 93.92)                         |
| Total                  | 1878               | 1878                   | 53          | 1825 (97.18)                         |

Abbreviations: PK = pharmacokinetic; PPK = population pharmacokinetic.

Source: dlpklasmbdatl10060-nivoppk-data-disposition.xlsx

<div style=\"page-break-after: always\"></div>

Table 3.2.1.2-1: Samples Included in the PPK Analysis Dataset

| Study                  |   Database\" PK |   Pre-Dose (FLG=3) Day1 |   (FLG=1) Dosing No |   (FLG=2) LLOQ Below |   Same Time (Set Up for NCA) Samples at Duplicate (FLG=4) |   >2000 μg/mL (S=210) Conc | Duplicate (Different Sample () (FLG=6)   | Amount (FLG=8) in Dose   |   Crossover (6=)14) Samples PK | (FLG=25) [CWRESI >6   | Database) Included (% ofPK Samples   |
|------------------------|----------------|-------------------------|---------------------|----------------------|-----------------------------------------------------------|----------------------------|------------------------------------------|--------------------------|--------------------------------|-----------------------|--------------------------------------|
| MDX1106-01 (CA209001)  |            915 |                      40 |                  33 |                   42 |                                                         0 |                          0 | 0                                        | 0                        |                              0 | 1                     | 799 (87.32)                          |
| MDX1106-03 (CA209003)  |           3363 |                     295 |                  22 |                   73 |                                                        76 |                          2 | 71                                       | 0                        |                              0 | 9                     | (83.71) 2815                         |
| CA209017               |            585 |                     122 |                   0 |                    9 |                                                         0 |                          0 | 1                                        | 0                        |                              0 | 1                     | 452 (77.26)                          |
| CA209032               |            274 |                      53 |                   1 |                    2 |                                                         0 |                          0 | 0                                        | 0                        |                             24 | 0                     | 194 (70.8)                           |
| CA209057               |           1355 |                     267 |                  13 |                   15 |                                                         0 |                          0 | 5                                        | 0                        |                              0 | 3                     | 1052 (77.64)                         |
| ONO-4538-12 (CA209316) |           1758 |                     330 |                   2 |                    2 |                                                         3 |                          0 |                                          |                          |                              0 | 1                     | (80.72) 1419                         |
| CA209649               |           3115 |                     726 |                  18 |                   29 |                                                         0 |                          0 | 0                                        |                          |                              0 |                       | 2340 (75.12)                         |
| Total                  |          11365 |                    1833 |                  89 |                  172 |                                                        79 |                          2 | 77                                       | 2                        |                             24 | 16                    | 9071 (79.82)                         |

<div style=\"page-break-after: always\"></div>

Table3.2.1.4-1: Summary of Covariates Included in PPK Analysis by Study and Overall

<!-- image -->

| Subject Characteristic        |                        | CA209001 (n=39)   | CA209003 (n=268)   | CA209017 (n=125)   | CA209032 (n=58)   | CA209057 (n=280)   | CA209316 (n=329)   | CA209649 (n= 720)   | Overall (n=1825)   |
|-------------------------------|------------------------|-------------------|--------------------|--------------------|-------------------|--------------------|--------------------|---------------------|--------------------|
| Baseline Body Weight (kg)     | Mean (SD) Median       | 84.5 (18.5) 81.3  | 81.9 (19.2) 79.8   | 76.3 (17.1)        | 75 (14.7)         | 71.2 (15.3)        | 55.3 (10.2)        | 68.2 (16.8) 66      | 69.6 (18) 67.1     |
| Baseline Body Weight (kg)     |                        |                   |                    | 75                 | 73.8              | 69.8               | 55                 |                     |                    |
| Baseline Body Weight (kg)     | Min, Max               | 54.8, 136         | 41.6, 153          | 46.3, 136          | 42, 112           | 43.5, 158          | 31.5, 91.8         | 36, 154             | 31.5, 158          |
| Baseline Body Weight (kg)     | Missing n (%)          | 0 (0.0)           | (0°0) 0            | 1 (0.8)            | 0 (0.0)           | 0 (0.0)            | 11 (3.3)           | 0 (0.0)             | 12 (0.7)           |
| Baseline GFR (mL/min/1.73 m²) | Mean (SD)              | 77.5 (20.2)       | 80.3 (19.9)        | 83.3 (19.4)        | 95 (22.4)         | 83.1 (19.4)        | 92.1 (17)          | 91.5 (18.2)         | 87.9 (19.3)        |
| Baseline GFR (mL/min/1.73 m²) | Median                 | 85.4              | 82.6               | 83.6               | 96.2              | 84.7               | 94.9               | 93                  | 90.5               |
| Baseline GFR (mL/min/1.73 m²) | Min, Max               | 34.5, 104         | 31.2, 135          | 40.6, 128          | 45.2, 181         | 31.9,128           | 36.6, 141          | 36.3, 236           | 31.2,236           |
| Baseline Tumor                | Missing n (%)          | 0 (0.0)           | 5 (1.9)            | 0 (0.0)            | 0 (0.0)           | 0 (0.0)            | 0 (0.0)            | 0 (0.0)             | 5 (0.3)            |
| Burden (cm)                   | Mean (SD)              | 12.8 (9.65)       | 12.2 (8.31)        | 9.17 (4.59)        | 8.67 (6.72)       | 8 (4.91)           | 8.19 (5.73)        | 6.87 (4.46)         | 8.56 (6.11)        |
| Burden (cm)                   | Median                 | 10.5              | 10.3               | 8.8                | 6.95              | 7.1                | 6.76               | 5.6                 | 7.13               |
| Burden (cm)                   | Min, Max               | 2, 41.3           | 1, 61.5            | 1.2, 25            | 1, 25.9           | 1, 29.8            | 1, 31.3            | 1.1, 27.6           | 1, 61.5            |
| Burden (cm)                   | Missing n (%)          | 3 (7.7)           | 0 (0.0)            | 0 (0.0)            | 0 (0.0)           | 1 (0.4)            | 62 (18.8)          | 169 (23.3)a         | 235 (12.9)         |
| Sex, n (%)                    | Male                   | 22 (56.4)         | 176 (65.7)         | 102 (81.6)         | 44 (75.9)         | 144 (51.4)         | 228 (69.3)         | 498 (68.6)          | 1214 (66.5)        |
| Sex, n (%)                    | Female                 | 17 (43.6)         | 92 (34.3)          | 23 (18.4)          | 14 (24.1)         | 136 (48.6)         | 101 (30.7)         | 228 (31.4)          | 611 (33.5)         |
| Baseline                      | 0                      | 13 (33.3)         | 111 (41.4)         | 27 (21.6)          | 29 (50.0)         | 81 (28.9)          | 87 (26.4)          | 304 (41.9)          | 652 (35.7)         |
| Perfonmance Status, n (%)     | 1                      | 26 (66.7)         | 152 (56.7)         | 98 (78.4)          | 29 (50.0)         | 197 (70.4)         | 242 (73.0)         | 421 (58.0)          | 1165 (63.8)        |
| Perfonmance Status, n (%)     | 2                      | 0 (0.0)           | 5 (1.9)            | 0 (0.0)            | 0 (0.0)           | 2 (0.7)            | 0 (0.0)            | 1 (0.1)             | 8 (0.4)            |
| Perfonmance Status, n (%)     | White                  | 29 (74.4)         | 253 (94.4)         | 112 (89.6)         | 55 (94.8)         | 256 (91.4)         | 0 (0.0)            | 502 (69.1)          | 1207 (66.1)        |
| Perfonmance Status, n (%)     | Black/African American | 10 (25.0)         | 11 (4.1)           | 6 (4.8)            | 3 (5.2)           | 6 (2.1)            | (0:0)0             | 7 (1.0)             | 43 (2.4)           |
| Race, n (%)                   | Asian                  | 0 (0.0)           | 1 (0.4)            | 4 (3.2)            | 0 (0.0)           | 9 (3.2)            | 328 (99.7)         | 183 (25.2)          | 525 (28.8)         |
| Race, n (%)                   | Others                 | 0 (0.0)           | 2 (0.7)            | 1 (0.8)            | 0 (0.0)           | 8 (2.9)            | 1 (0.3)            | 32 (4.4)            | 44 (2.4)           |
| Race, n (%)                   | Unkuown b              | 0 (0.0)           | 1 (0.4)            | 0 (0.0)            | 0 (0.0)           | 1 (0.4)            | 0 (0.0)            | 2 (0.3)             | 4 (0.2)            |
| Race, n (%)                   | Missing n (%)          | 0 (0.0)           | 0 (0.0)            | 2 (1.6)            | 0 (0.0)           | 0 (0.0)            | 0 (0.0)            | 0 (0.0)             | 2 (0.1)            |
| Baseline Senm                 | Mean (SD)              | 3.79 (0.375)      | 4.09 (0.476)       | 3.92 (0.538)       | 3.79 (0.427)      | 3.89 (0.492)       | 3.67 (0.517)       | 3.87 (0.457)        | 3.87 (0.495)       |
| Albumin [g/dL]                | Median                 | 3.8               | 4.1                | 4                  | 3.8               | 3.9                | 3.7                | 3.9                 | 3.9                |
|                               | Min, Max               | 2.3,4.7           | 2.5, 5.1           | 2.2, 5.2           | 2.8, 4.7          | 1.9, 5.1           | 2.1, 5.1           | 2.3, 5.1            | 1.9, 5.2           |

Table 3.2.1.4-1: Summary of Covariates Included in PPK Analysis by Study and Overall

| Subject Characteristic                      |                    | CA209001 (n=39)   | CA209003 (n=268)   | CA209017 (n=125)   | CA209032 (n=58)   | CA209057 (n=280)   | CA209316 (n=329)   | CA209649 (n=720)   | Overall (n=1825)   |
|---------------------------------------------|--------------------|-------------------|--------------------|--------------------|-------------------|--------------------|--------------------|--------------------|--------------------|
|                                             | Missing n (%)      | 0 (0.0)           | 5 (1.9)            | 4 (3.2)            | 18 (31.0)         | 7 (2.5)            | 0 (0.0)            | 26 (3.6)           | 60 (3.3)           |
|                                             | Mean (SD)          | 352 (323)         | 263 (318)          | 349 (281)          | 366 (235)         | 378 (293)          | 335 (278)          | 309 (366)          | 323 (324)          |
| Baseline Lactate Dehydrogenase [U/L]        | Median             | 198               | 187                | 273                | 327               | 277                | 238                | 212                | 225                |
| Baseline Lactate Dehydrogenase [U/L]        | Min, Max           | 131, 1410         | 91,2980            | 101, 2330          | 119, 1390         | 111, 3090          | 110, 2940          | 80,4020            | 80,4020            |
| Baseline Lactate Dehydrogenase [U/L]        | Missing n (%)      | 0 (0.0)           | 8 (3.0)            | 0 (0.0)            | 0 (0.0)           | 2 (0.7)            | 0 (0.0)            | 7 (1.0)            | 17 (0.9)           |
| Combination Treatment, n (%)                | Nivo Ouly          | 39 (100.0)        | 268 (100.0)        | 125 (100.0)        | 58 (100.0)        | 280 (100.0)        | 329 (100.0)        | 0 (0.0)            | 1099 (60.2)        |
| Combination Treatment, n (%)                | Nivo + Chemo       | 0 (0.0)           | 0 (0.0)            | (0°0) 0            | 0 (0.0)           | 0 (0.0)            | 0 (0.0)            | 726 (100.0)        | 726 (39.8)         |
| Combination Treatment, n (%)                | 2LNSCLC            | 0 (0.0)           | 25 (9.3)           | 125 (100.0)        | 0 (0.0)           | 243 (86.8)         | 0 (0.0)            | 0 (0.0)            | 393 (21.5)         |
| Subject Population, n (%)                   | 2L+GC              | 0 (0.0)           | 0 (0.0)            | 0 (0.0)            | 58 (100.0)        | 0 (0.0)            | 329 (100.0)        | 1 (0.1)            | 388 (21.3)         |
| Subject Population, n (%)                   | IL GC/GEIC/EAC     | 0 (0.0)           | 0 (0.0)            | 0 (0.0)            | 0 (0.0)           | 0 (0.0)            | 0 (0.0)            | 725 (99.9)         | 725 (39.7)         |
| Subject Population, n (%)                   | OTHERd             | 39 (100.0)        | 243 (90.7)         | 0 (0.0)            | 0 (0.0)           | 37 (13.2)          | 0 (0.0)            | 0 (0.0)            | 319 (17.5)         |
| Subject Population, n (%)                   | Japanese           | 0 (0.0)           | 0 (0.0)            | 0 (0.0)            | 0 (0.0)           | 0 (0.0)            | 152 (46.2)         | 57 (7.9)           | 209 (11.5)         |
| Japanese Ethnicity, (%)                     | Non-Japamese Asian | 0 (0.0)           | 1 (0.4)            | 4 (3.2)            | 0 (0.0)           | 9 (3.2)            | 176 (53.5)         | 126 (17.4)         | 316 (17.3)         |
| Japanese Ethnicity, (%)                     | Non-Asian          | 39 (100.0)        | 267 (99.6)         | 119 (95.2)         | 58 (100.0)        | 271 (96.8)         | 1 (0.3)            | 543 (74.8)         | 1298 (71.1)        |
| Japanese Ethnicity, (%)                     | Missing n (%)      | 0 (0.0)           | 0 (0.0)            | 2 (1.6)            | 0 (0.0)           | 0 (0.0)            | 0 (0.0)            | 0 (0.0)            | 2 (0.1)            |
| Japanese Ethnicity, (%)                     | Chinese            | 0 (0.0)           | 0 (0.0)            | 0 (0.0)            | 0 (0.0)           | 0 (0.0)            | 0 (0.0)            | 97 (13.4)          | 97 (5.3)           |
| Chinese Ethnicity, (%)                      | Non-Chinese Asian  | 0 (0.0)           | 1 (0.4)            | 4 (3.2)            | 0 (0.0)           | 9 (3.2)            | 328 (99.7)         | 86 (11.8)          | 428 (23.5)         |
| Chinese Ethnicity, (%)                      | Non-Asian          | 39 (100.0)        | 267 (99.6)         | 119 (95.2)         | 58 (100.0)        | 271 (96.8)         | 1 (0.3)            | 543 (74.8)         | 1298 (71.1)        |
| Chinese Ethnicity, (%)                      | Missing n (%)      | 0 (0.0)           | 0 (0.0)            | 2 (1.6)            | 0 (0.0)           | 0 (0.0)            | 0 (0.0)            | 0 (0.0)            | 2 (0.1)            |
| Chinese Ethnicity, (%)                      | EAC                | 0 (0.0)           | 0 (0.0)            | 0 (0.0)            | 0 (0.0)           | 0 (0.0)            | 0 (0.0)            | 92 (12.7)          | 92 (5.0)           |
| Primary Tumor Location at Study Enty, n (%) | GC                 | 0 (0.0)           | 0 (0.0)            | 0 (0.0)            | 0 (0.0)           | 0 (0.0)            | 0 (0.0)            | 515 (70.9)         | 515 (28.2)         |
| Primary Tumor Location at Study Enty, n (%) | GEIC               | 0 (0.0)           | 0 (0.0)            | (0°0) 0            | 0 (0.0)           | 0 (0.0)            | (00)0              | 119 (16.4)         | 119 (6.5)          |
| Primary Tumor Location at Study Enty, n (%) | Missing n (%)      | 39 (100.0)        | 268 (100.0)        | 125 (100.0)        | 58 (100.0)        | 280 (100.0)        | 329 (100.0)        | 0 (0.0)            | 1099 (60.2)        |
| Primary Tumor Location at Study Enty, n (%) | sa1                | 0 (0.0)           | 0 (0.0)            | (0°0) 0            | 0 (0.0)           | 0 (0.0)            | 0 (0.0)            | 275 (37.9)         | 275 (15.1)         |
| Presence of Liver Metastases, n (%)         | No                 | 0 (0.0)           | 0 (0.0)            | 0 (0.0)            | 0 (0.0)           | 0 (0.0)            | 0 (0.0)            | 429 (59.1)         | 429 (23.5)         |
| Presence of Liver Metastases, n (%)         | Missing n (%)      | 39 (100.0)        | 268 (100.0)        | 125 (100.0)        | 58 (100.0)        | 280 (100.0)        | 329 (100.0)        | 22 (3.0)           | 1121 (61.4)        |
| Presence of Liver Metastases, n (%)         |                    | 0 (0.0)           | (00) 0             | 0 (0.0)            | (00) 0            | 0 (0.0)            | 0 (0.0)            | 133 (18.3)         | 133 (7.3)          |
| Presence of Liver Metastases, n (%)         | No                 | 0 (0.0)           | 0 (0.0)            | 0 (0.0)            | 0 (0.0)           | 0 (0.0)            | 0 (0.0)            | 593 (81.7)         | 593 (32.5)         |

<div style=\"page-break-after: always\"></div>

Table3.2.1.4-1: Summary of CovariatesIncluded in PPK Analysisby Study and Overall

| Subject Characteristic                          |                    | CA209001 (n =39)   | CA209003 (n=268)   | CA209017 (n=125)   | CA209032 (n=58)   | CA209057 (n=280)   | CA209316 (n=329)   | CA209649 (n=720)   | Overall (n=1825)   |
|-------------------------------------------------|--------------------|--------------------|--------------------|--------------------|-------------------|--------------------|--------------------|--------------------|--------------------|
| Histology Presence of Siguet Ring Cell-N, n (%) | Missing n (%)      | 39 (100.0)         | 268 (100.0)        | 125 (100.0)        | 58 (100.0)        | 280 (100.0)        | 329 (100.0)        | 0 (0.0)            | 1099 (60.2)        |
| Prior Surgery, n (%)                            |                    | 0 (0.0)            | 0 (0.0)            | 0 (0.0)            | 37 (63.8)         | 0 (0.0)            | 205 (62.3)         | 152 (20.9)         | 394 (21.6)         |
| Prior Surgery, n (%)                            | No or Not Reported | 0 (0.0)            | 0 (0.0)            | 0 (0.0)            | 21 (36.2)         | 0 (0.0)            | 124 (37.7)         | 574 (79.1)         | 719 (39.4)         |
| Prior Surgery, n (%)                            | Missing n (%)      | 39 (100.0)         | 268 (100.0)        | 125 (100.0)        | 0 (0.0)           | 280 (100.0)        | 0 (0.0)            | 0 (0.0)            | 712 (39.0)         |
| Immunogenicity by Visit Level, (%) N            | Negative           | 689 (86.2)         | 1311 (46.6)        | 405 (89.6)         | 171 (88.1)        | 947 (90.0)         | 1338 (94.3)        | 2192 (93.7)        | 7053 (77.8)        |
| Immunogenicity by Visit Level, (%) N            | Positive           | 61 (7.6)           | 31 (1.1)           | 43 (9.5)           | 20 (10.3)         | 99 (9.4)           | 73 (5.1)           | 96 (4.1)           | 423 (4.7)          |
| Immunogenicity by Visit Level, (%) N            | Missing N (%)      | 49 (6.1)           | 1473 (52.3)        | 4 (0.9)            | 3 (1.5)           | 6 (0.6)            | 8 (0.6)            | 52 (2.2)           | 1595 (17.6)        |

- CA209649 allowed enrollment of subjects with non-measurable disease.Therefore, missing tumor burden refers to subjects w/o reported BICR assessment.

b Unknown race was defined as race that could not be determined.

Abbreviations: IL = first-line; 2L =second-line; 3L =third-line; ADA= anti-dnug antibody; EAC=esophageal adenocarcinoma cancer; GC =gastic cancer, GEJC = gastroesophageal jumction cancer; GFR = glomerular fltration rate; Max = maximum; Min = minimum; N = number of ADA measurements; n = number of subjects; Nivo=nivolumab;Nivo+Chemo=mivoluumab incombination with oxaliplatin plus fluoropyrimidine;NSCLC=non-small cell lumg cancer,PPK=population phanmacokinetic; SD = standard deviation.

Missing race was defined as race criterion was not selected.

- The OTHER population included subjects with melanoma, or renal cellin Studies CA209001 and CA209003, colorectal or prostate cancer in Study CA209001, or 3L+ NSCLC inStudies CA209001,CA209003,and CA209057.

Note: The suummary statistics for continuous covariates exclude missing values, however, the number (percentage) of missing values (if any)is shown in the table. Source: dlpktablesrtfsumstat-covs-bystudy.rtf

## Base model

A previously developed 2L+ GC monotherapy final PPK model was revised and used as the base model for this updated analysis. The 1L GC/GEJC/EAC data, as a new patient population, was incorporated into the base and full model to obtain unbiased estimates of the magnitude of covariate effects on model parameters. Nivolumab PK, including data in 1L GC/GEJC/EAC, was well described by a linear 2 compartment model with time-varying CL in the full model.

The base model was a 2-compartment, zero-order IV infusion with time-varying elimination. The parameters of this model were re-estimated with the inclusion of data from Study CA209649. Lognormal random effects were estimated for CL, VC, and VP, a normally distributed random effect on Emax, and a correlation between the CL and VC random effects. The base model included covariate relationships between BBWT, BGFR, BALB, PS, sex, race, baseline LDH, tumour burden, and subject population and time-varying CL; BBWT and sex on VC as described in Section 4.1.1.1. Covariate relationships between BBWT and Q, and BBWT and VP were assumed to be identical to the relationships between BBWT and CL, and BBWT and VC. Parameter estimates and standard errors for this base model are presented in Table 5.1.1.1-1.

<div style=\"page-break-after: always\"></div>

Table 5.1.1.1-l: Parameter Estimates of the Base PPK Model

<!-- image -->

| Name [Units]a     | Symbol            | Estimate b        | Standard Error (%RSE)c   | 95%6 Confidence Intervald   |
|-------------------|-------------------|-------------------|--------------------------|-----------------------------|
| Fired Effects     | Fired Effects     | Fired Effects     | Fired Effects            | Fired Effects               |
| CLO [mL/h]        |                   | 11.0              | 0.453 (4.13)             | 10.1 - 11.8                 |
| vC [L]            |                   | 4.67              | 0.0674 (1.44)            | 4.54-4.81                   |
| Q[mL/h]e          | 83                | 34.0              | 3.24 (9.53)              | 27.7 - 40.4                 |
| VP [L]            | 64                | 2.91              | 0.155 (5.32)             | 2.61 -3.21                  |
| CLBBWT            | 06                | 0.557             | 0.0492 (8.84)            | 0.46 - 0.653                |
| f                 |                   | 0.109             | 0.0364 (33.4)            | 0.0376-0.18                 |
|                   |                   | -0.126            | 0.0212 (16.7)            | (-0.168) - (-0.0849)        |
|                   |                   | 0.0852            | 0.0181 (21.3)            | 0.0496-0.121                |
| CLRAAS            | θ10               | -0.0817           | 0.0237 (29)              | (-0.128) - (-0.0352)        |
| VCBBWT f          | 011               | 0.5               | 0.0403 (8.06)            | 0.421 -0.579                |
| VCSEx             | 812               | -0.215            | 0.027 (12.5)             | (-0.268) -(-0.162)          |
| EMAXe             | 013               | -0.277            | 0.0438 (15.8)            | (-0.363)-(-0.192)           |
| 150 [b]e          | 014               | 1410              | 158 (11.3)               | 1100 -1720                  |
| HILL [-]          | B1s               | 2.89              | 0.752 (26)               | 1.41 -4.36                  |
| CLBALB f          | 016               | -0.939            | 0.0702 (7.48)            | (-1.08) -(-0.801)           |
| CLBLDH f          | 817               | 600               | 0.0918 (22.4)            | 0.229 -0.589                |
| CLBTSIZE 工        | 818               | 0.0799            | 0.0147 (18.3)            | 0.0512 - 0.109              |
| CLMISSBTSIZE 山    | 819               | 0.00814           | 0.0269 (331)             | (-0.0446) - 0.0609          |
| CLPOPGCILE        | 020               | -0.009            | 0.0253 (281)             | (-0.0585) - 0.0405          |
| CLPOPGCZL.E       | 621               | 0.0988            | 0.0334 (33.8)            | 0.0334 - 0.164              |
| CLFOFOTH          | 022               | 0.0815            | 0.0336 (41.3)            | 0.0156-0.147                |
| hi Random Effects | hi Random Effects | hi Random Effects | hi Random Effects        | hi Random Effects           |
| α²-CL [-]         | 01,1              | 0.0855 (0.292)    | 0.00714 (8.34)           | 0.0716- 0.0995              |

<div style=\"page-break-after: always\"></div>

Table 5.1.1.1-l: Parameter Estimates of the Base PPK Model

| Name [Units]     | Symbol         | Estimate b     | Standard Error (%RSE)c   | 95% Confidence Interrald   |
|------------------|----------------|----------------|--------------------------|----------------------------|
| ²-vC[H]          | 022            | 0.121 (0.348)  | 0.0202 (16.7)            | 0.0813-0.16                |
| 2-VP [-]         | 0033           | 0.204 (0.452)  | 0.0431 (21.1)            | 0.12-0.288                 |
|                  | 044            | 0.0586 (0.242) | 0.0137 (23.3)            | 0.0319-0.0854              |
| α² CL: o²vc[-]   | 012            | 0.0298 (0.173) | 0.00566 (19)             | 0.0187 -0.0409             |
| Residual Error   | Residual Error | Residual Error | Residual Error           | Residual Error             |
| Proportional [-] | 83             | 0.214          | 0.0089 (4.15)            | 0.197-0.232                |

- %RSE is the relative standard error (standard error as a percentage of estimate).
- Confidence intervals of random effects and residual error parameters are for variance or covariance.
- eCLReF, VCRer, VPREF, and QReF are typical values of CL, VC, VP, and Q at the reference covaniate values. Covariate effects were estimated relative to a reference subject who is a male, with baseline ALB of 4.0 g/dL baseline LDH of 200 IU/L, tumor buden of 7.7 cm, weighing 80 kg, estimated GFR of 90 mL/min/l.73 m², PS of O, race = white or other, defined as not Asian, and population type of 2L NSCLC.

<!-- formula-not-decoded -->

- CLrv. = CLREr x (eflsex)SExt x (eClrs)PSt x (eCLRaas)RAA5t x (eClroruc)PoPuLGCt x (eCLPOPzLIGC)POP2L+GCt x (gCLPOrOTH)POPOTHt x (eCLMISSSTSIzE)MISSBTSIZE:

<!-- formula-not-decoded -->

- Eta shrimkage: ETA\\_CL: 17.5%, ETA\\_VC: 29.2%, ETA\\_VP: 50.6%, EIA\\_EMAX: 50.5%; Epsilon shrinkage: 16.2%.
- The caleulated correlation coefficient (r) of the off-diagonal omega was 0.293 for cov(IIV in VC, IIV in CL). Note: The condition number was 201, indicating there was no evidence for ill-conditioning. Source:KIWIRumID272809

## Full model

<div style=\"page-break-after: always\"></div>

Table 5.1.1.2-1: Parameter Estimates of the Full Nivolumab PPK Model

| Name [Units]   | Symbol        | Estimate b    | Standard Error (%RSE)   | 95% Confidence Interral (Bootstrap Derired)d   |
|----------------|---------------|---------------|-------------------------|------------------------------------------------|
| Fixed Effects  | Fixed Effects | Fixed Effects | Fixed Effects           | Fixed Effects                                  |
| CLO [mL/h]e    |               | 10.4          | 0.386 (3.71)            | 9.78 - 11.3                                    |
| VC [L]         | 82            | 4.64          | 0.0585 (1.26)           | 4.54 -4.75                                     |
| Q[mL/h]        | 83            | 33.2          | 2.56 (7.7)              | 28.6 -38.9                                     |
| VP[L]          | 04            | 3.02          | 0.149 (4.94)            | 2.71 -3.29                                     |
| CLEBWT f       | 86            | 0.543         | 0.0486 (8.96)           | 0.442 -0.636                                   |
| CLGFR f        | 87            | 0.131         | 0.0349 (26.6)           | 0.0609 -0.204                                  |
| CLsEx          |               | -0.133        | 0.0208 (15.6)           | (-0.176)-(-0.0959)                             |
|                | Bg            | 0.115         | 0.0217 (18.8)           | 0.0725-0.159                                   |
|                | θ10           | -0.0808       | 0.0234 (28.9)           | (-0.125) - (-0.0370)                           |
| VCeBWT f       | B11           | 0.465         | 0.0352 (7.58)           | 0.395 -0.532                                   |
| VCsEx          | B12           | -0.221        | 0.0222 (10.1)           | (-0.263) -(-0.173)                             |
| EMAXe          | B13           | -0.157        | 0.0481 (30.5)           | (-0.260) -(-0.0678)                            |
| 150 [b]        | 014           | 1550          | 138 (8.94)              | 1280-1860                                      |
| HILL [-]       | 815           | 4.35          | 2.13 (48.9)             | 2.34-37.8                                      |
| CLaALB f       | 816           | -0.945        | 0.0669 (7.09)           | (-1.08)-(-0.811)                               |
| CLBLDH f       | 017           | 0.410         | 0.0894 (21.8)           | 0.231 -0.591                                   |
| CLAISEE        | 018           | 0.0799        | 0.0143 (17.9)           | 0.0513 -0.109                                  |
| CLMISSBTSIZE   | 819           | 0.0138        | 0.0269 (195)            | (-0.0435)-0.0680                               |
| CLPOPGCIL      | 820           | 0.00613       | 0.0297 (485)            | (-0.0470)-0.0674                               |
| CLPOPGCZL+ 名   | B21           | 0.0563        | 0.0369 (65.6)           | (-0.0175)-0.131                                |
| CLpOrOTH       | 622           | 0.112         | 0.0354 (31.6)           | 0.0384 -0.181                                  |
| EMAX,\"         | 83            | -0.0821       | 0.0295 (36)             | (-0.149) - (-0.0262)                           |
| EMAXFOPGCIL    | 824           | -0.0824       | 0.037 (44.9)            | (-0.165) - (-0.0124)                           |

<div style=\"page-break-after: always\"></div>

| Name [Units]     | Symbol         | Estimate       | (%RSE)         | Derived)d         |
|------------------|----------------|----------------|----------------|-------------------|
| EMAXFOPGC2L+     | 025            | 0.0963         | 0.0467 (48.5)  | (-0.00138)-0.182  |
| EMAXpOrOTH       | 826            | -0.0417        | 0.048 (115)    | (-0.143) - 0.0580 |
| 2 -CL [-]        | 01,1           | 0.0874         | 0.00625 (7.15) | 0.0742-0.0973     |
| α²-vc[-1]        | 022            | 0.0827         | 0.0092 (11.1)  | 0.0654-0.0994     |
| α²-VP[-]         |                | 0.166          | 0.0386 (23.2)  | 0.111 -0.278      |
| ²-EMAX[-]        | 044            | 0.0503         | 0.0112 (22.2)  | 0.0319-0.0784     |
| 2 cL: ² vc []    | 012            | 0.0298         | 0.00409 (13.7) | 0.0221-0.0384     |
| Residual Error   | Residual Error | Residual Error | Residual Error | Residual Error    |
| Proportional [-] |                | 0.197          | 0.00427 (2.17) | 0.188-0.205       |

- %RSE is the relative standard enror (standard error as a percentage of estimate).
- d Confidence Interval values are taken from bootstrap caleulations (889 successful out of a total of l,000).
- CLRer, VCRer, VPRer, and QRer are typical values of CL, VC, VP, and Q at the reference covaniate values. Covariate effects were eshimated relative to a reference subject who is a male, with baseline ALB of 4.0 g/dL, baseline LDH of 200 IU/L, tumor burden of 7.7 em, weighing 80 kg, estimated GFR of 90 mL/min/l.73 m², PS of 0, race = white or other, defined as not Asian, and population type of 2L NSCLC.

<!-- formula-not-decoded -->

- The typieal values of CL, VC, and EMAX corresponding to categorical valued covariates of subject i are modeled a5: CLrv = CLRE x (eClsex)SExt x (eCLp)St x (eCLRaAs)RAASt x (eClporec)PoPGCt x VCTv,1 = VCREF X (eVCsex)SEx:

<!-- formula-not-decoded -->

- 16.5%.
- i The caleulated correlation coefficient () of the off-diagonal omega was 0.351 for cov(IIV in VC, IIV in CL).

Note: Although S0 kg was the reference in NONMEM fitting, because the exponent would not change, all the model application was caleulated based on the median BBWT of 67 kg.

Note: The condition number was 239, indicating there was no evidence for ill-conditioning.

Source: KIWI Rum ID 272231

<div style=\"page-break-after: always\"></div>

Figure 5.1.2-1: Prediction-corrected Visual Predictive Check of Trough Concentrations (Log Scale) Versus Actual Time After First Dose for Data from the IL GC/GEJC/EAC Subject Population

Population:1LGC/GEJC/EAC

<!-- image -->

KIW1 Version kiwi4 202003 - Run: 272827 - VPC Profle: 7765

Abbreviations:1L =first-line; CI= confidence interval; Conc=concentration; EAC =esophageal adenocarcinoma cancer; GC = gashic cancer; GEJC =gashroesophageal junction cancer; Pred Coir = prediction coirected. Source: dlpk graphspnghilvpclvpc-r272827-vpc-final-pk-model-atafd-troughs-popn2-1lgc-tl-p7765-s1-001.png

Figure 5.1.2-2: Prediction-correctedVisualPredictiveCheckofAll Concentrations (Log Scale) Versus Actual Time After Previous Dose for Data from the lL GC/GEJC/EAC Subject Population

Population:1LGC/GEJC/EAC

<!-- image -->

Medians and percentiles are plotted at the midpoint of each time a.fter previous dose interval

KIWI Version khwi4 202003 - Run: 272835 - vPC Profle: 7853

Abbreviations: 1L = first-line; CI= confidence interval; Conc = concenhation; EAC = esophageal adenocarcinoma cancer; GC = gastric cancer; GEJC = gastroesophageal jumction cancer; Pred Coir = prediction colrected. Sowce: dlpk graphs/pnghilvpclvpc-r272835-vpe-final-pk-model-atapd-stratbypopn-tl-p7853-s3-001.png

<div style=\"page-break-after: always\"></div>

No covariates were found to have a clinically meaningful effect on nivolumab PK in this updated analysis. Graphical representations of the effect of categorical and continuous covariates on the typical value of the structural model parameters of CL, volume of central compartment (VC), and CLss/CL0 (EXP[EMAX]) are presented in Figure 3.1.1-1. All covariate effects were within ± 20% boundaries, except for the effect of baseline body weight on CL and VC and baseline albumin (ALB) on CL. Baseline body weight was associated with a 26% increase in CL and a 22% increase in VC in subjects with 95th percentile weight relative to subjects with median body weight. Nivolumab CL increased approximately 31% in subjects with 5th percentile baseline ALB relative to subjects with median baseline ALB value. However, the magnitudes of body weight, VC, and ALB effect on CL were consistent with findings of previous analyses. These findings were not considered to be clinically relevant, as the 95th percentile body weight or 5th percentile ALB only resulted in approximately 18.5% or 21.4% lower Cavgss, respectively, relative to those observed in subjects with median body weight or median ALB at baseline in Study CA209649.

Figure 3.1.1-1: Covariate Effects on Pharmacokinetic Model Parameters (Full Nivolumab Population Pharmacokinetic Model)

<!-- image -->

Estimate (95%Cl): Continuous (P95)

Note 1: Categorical covariate effects (95% CI) are represented by open symbols (horizontal lines).

Note 2: Continuous covariate effects (95% CI) at the 5th/95th percentiles of the covariate are represented by the end of horizontal boxes (horizontal lines). Open/shaded area of boxes represents the range of covariate effects from the median to the 5th/95th percentile of the covariate.

<div style=\"page-break-after: always\"></div>

Note 3: Reference subject is male, PS = 0, eGFR = 90 mL/min/1.73 m 2 , with baseline ALB of 4.0 g/dL, baseline LDH of 200 IU/L, tumour burden of 7.7 cm, body weight = 67.1 kg, 2L NSCLC tumour type, and race = white or other, defined as not Asian. Parameter estimate in reference subject is considered as 100% (vertical solid line) and dashed vertical lines are at 80% and 120% of this value.

Abbreviations: 1L =first-line; 2L = second-line; CI = confidence interval; CL = clearance; CLss = clearance at steady state; CL0 = clearance at time 0; eGFR = estimated glomerular filtration rate; GC = gastric cancer; GFR = glomerular filtration rate;

LDH = lactate dehydrogenase; NSCLC = non-small cell lung cancer; PPK = population pharmacokinetic; PS = performance status;

VC = volume of the central compartment

Source: Refer to Figure 5.1.1.2-1 in the PPK Analysis Report

Figure 3.1.3.1-2: Boxplots of Predicted Exposures (Cavgss) by Body Weight Quartiles (240 mg Q2W and 360 mg Q3W) for Subjects with 1L GC/GEJC/EAC

<!-- image -->

Body Weight [kg]

Abbreviations:  1L = first-line;  Cavgss = time-averaged  serum  concentration  at  steady  state;  EAC = esophageal adenocarcinoma  cancer;  GC = gastric  cancer;  GEJC = gastroesophageal  junction  cancer;  Q2W = every  2 weeks; Q3W = every 3 weeks.

Boxes are 25th, 50th, and 75th percentiles; whiskers are 5th to 95th percentiles. The number of subjects is above each box

Source: Refer to Figure 5.1.3.2-1 in the PPK Analysis Report

<div style=\"page-break-after: always\"></div>

Table 5.1.3.3-1: Predicted Exposures for the 5th/95th Percentiles of Baseline Serum Albumin for a Typical Subject and % Differences in Relation to the Median for the Nivolumab 240 mg Q2W and 360 mg Q3W Treatment Groups

| Exposure   | P05          | P95          | P05            | P95            | P05-Median      | P95-Median      | P05-Median      | P95-MIedian     |
|------------|--------------|--------------|----------------|----------------|-----------------|-----------------|-----------------|-----------------|
|            | 240 mgQ2WArm | 240 mgQ2WArm | 360 mg Q3W Arm | 360 mg Q3W Arm | % Diff (240 mg) | % Diff (240 mg) | % Diff (360 mg) | % Diff (360 mg) |
| Cavgl      | 27.1         | 29.9         | 34.8           | 39.6           | -6.39           | 3.12            | -8.48           | 4.25            |
| Cminl      | 17.5         | 21.4         | 20.1           | 26.6           | -13             | 6.58            | -17.5           | 9.29            |
| Cmaxl      | 56           | 56           | t8             | 84             | -0.02           | 0.01            | -0.02           | 0.01            |
| Cavgss     | 76.1         | 111          | 76.1           | 111            | -21.4           | 14.1            | -21.4           | 14.1            |
| Cminss     | 57.9         | 91.6         | 51.6           | 84.6           | -25.9           | 17.2            | -27.7           | 18.5            |
| Cmaxss     | 114          | 148          | 136            | 169            | -15.1           | 10              | -12.8           | 8.52            |

Note: The BALB values for the 5th and 95th percentiles were 3.1 g/dl and 4.1 g/dl, respectively.

Abbreviations: BALB = baseline albumin; Cavgl = time-averaged serum concentration over the first dosing interval; Cavgss = time-averaged serum concentration at steady state; Cmaxl = post dose l peak serum concentration; Cmaxss =peak serum concenhration at steady state; Cminl = trough serum concentration after the first nivolumab dose; Cminss = trough serum concentration at steady state; Diff= difference; P05 = 5th percentile; P95 = 95th percentile; Q2W = every 2 weeks; Q3W = every 3 weeks

Source: dlpktablesrtfsumstat-cavgl-med-balb.rtf

Figure 3.1.3.3-3: Distributions of Cavgss of Nivolumab by Dose Regimen and Overall in Study CA209649 in Relation to Asian Versus Non-Asian Subjects

<!-- image -->

s

Asterisks show data points outside thisrange.The number of subjectsis above eachbox.

Abbreviations: Cavgss = time-averaged serum concentration at steady state; Conc = concentration; GM = geometric mean; Q2W = every 2 weeks; Q3W = every 3 weeks.

Source: Refer to Figure 5.1.3.5-2 in the PPK Analysis Report

## Dosing regimens

Results of the PPK analysis demonstrated that nivolumab PK in subjects with 1L GC/GEJC/EAC following nivo + chemo was consistent with the known PK characteristics of nivolumab, and were

<div style=\"page-break-after: always\"></div>

similar to that of the 2L+ GC, 2L NSCLC, or OTHER populations following nivolumab monotherapy (Table 3.1.2-1). The OTHER population included subjects with melanoma, or renal cell in Studies CA209001 and CA209003, colorectal or prostate cancer in Study CA209001, or 3L+ NSCLC in Studies CA209001, CA209003, and CA209057.

Table 3.1.2-1:  Summary Statistics of Nivolumab PK Parameter Estimates by Patient Population and Overall Population in the PPK Analysis by Tumour Type

|                 | Geometric Mean (%CV)   | Geometric Mean (%CV)   | Geometric Mean (%CV)   | Geometric Mean (%CV)   | Geometric Mean (%CV)   |
|-----------------|------------------------|------------------------|------------------------|------------------------|------------------------|
| Parameter       | 1L GC/GEJC/EAC (n=725) | 2L+ GC (n=387)         | 2L NSCLC (n=393)       | OTHER (n=319)          | ALL (n=1824)           |
| CLss (mL/h)     | 7.46 (35.0)            | 9.06 (38.4)            | 8.22 (38.9)            | 9.3 (63.6)             | 8.25 (46.5)            |
| Vs.s (L)        | 6.76 (19.0)            | 6.51 (21.7)            | 6.54 (22.0)            | 7.28 (28.0)            | 6.75 (22.7)            |
| T1/2β,ss (days) | 27.4 (25.4)            | 22 (49.7)              | 24.3 (27.6)            | 23.9 (65.5)            | 24.9 (40.9)            |

Note: n = 1824 is the sum of the 2L NSCLC, 2L+ GC, 1L GC/GEJC/EAC, and OTHER populations comprising the ALL population (overall PPK analysis population, except for 1 subject [NMID = 649134535] excluded from the model application).

Abbreviations: 1L = first-line; 2L = second-line; CLss = clearance at steady state; %CV = coefficient of variation expressed as a percentage; EAC = esophageal adenocarcinoma cancer; GC = gastric cancer; GEJC = gastroesophageal junction cancer; n = number of subjects; NSCLC = non-small cell lung cancer; PK = pharmacokinetic; PPK = population pharmacokinetic; T1/2β,ss = terminal half-life at steady state; Vs.s = volume of distribution at steady state.

Source: Refer to Table 5.1.3.1-1 in the PPK Analysis Report .

The steady state exposure measures were comparable between the 2 regimens, with the differences in geometric mean values less than 20% for all exposure measures (Table 3.1.2-2).

Table 3.1.2-2:  Geometric Mean Exposure for Nivolumab 240 mg Q2W and 360 mg Q3W Regimens in Combination with Chemotherapy in Subjects with 1L GC/GEJC/EAC

|                  |                                                   | GeoMean (% CV) a                                 | GeoMean (% CV) a          |
|------------------|---------------------------------------------------|--------------------------------------------------|---------------------------|
| Summary Exposure | Nivo 240 mg + FOLFOX Q2W GM [μg/mL] (%CV) (n=392) | Nivo 360 mg + XELOX Q3W GM [μg/mL] (%CV) (n=333) | %Diff GM (240 mg) G1-G2 a |
| Cavgss           | 93.2 (33.6)                                       | 98.7 (33.3)                                      | -5.57                     |
| Cmaxss           | 134 (28.4)                                        | 166 (26.6)                                       | -19.3                     |
| Cminss           | 73.4 (38.5)                                       | 70.5 (40.1)                                      | 4.11                      |
| Cavg1            | 28.5 (21.7)                                       | 39.5 (21.2)                                      | -27.8                     |
| Cmax1            | 58.7 (22.5)                                       | 93.3 (20.9)                                      | -37.1                     |
| Cmin1            | 18.8 (26.3)                                       | 24.1 (27.3)                                      | -22                       |

Abbreviations: 1L = first-line; Cavg1 = time-averaged serum concentration over the first dosing interval; Cavgss = time-averaged serum concentration at steady state; Cmax1 = post dose 1 peak serum concentration; Cmaxss = peak serum concentration at steady state; Cmin1 = trough serum concentration after the first nivolumab

<div style=\"page-break-after: always\"></div>

dose; Cminss = trough serum concentration at steady state; %CV = coefficient of variation expressed as a percentage; Diff = difference; EAC = esophageal adenocarcinoma cancer; GC = gastric cancer; GEJC = gastroesophageal junction cancer; GM = geometric mean; n = number of subjects; Nivo = nivolumab; p5 = 5th percentile; p95 = 95th percentile; Q2W = every 2 weeks; Q3W = every 3 weeks;

Source: Refer to Table 5.1.3.1-2 in the PPK Analysis Report

Figure 5.1.3.1-1:

Predicted Geometric Mean (90% PI) Nivolumab Concentration-time Profiles (First l6 Weeks) (Linear Scale) by Dosing Regimen (Nivolumab 240 mg Q2WW + FOLFOX and Nivolumab 360 mg Q3 W + XELOX), in Subjects with 1L GC/GEJC/EAC

<!-- image -->

Abbreviations: lL = first-line; Conc = concentation; EAC = esophageal adenocarcinoma cancer; GC = gashric cancer; GEJC = gastroesophageal junction cancer; Geo = geomehic; PI= prediction interval; Q2W =every 2 weeks; Q3W = every 3 weeks.

Source: dlpkgraphslCI-figure51391-PI.png

## Immunogenicity

Table 4.1.2-3: ADA Assessments Summary - All Nivolumab Treated Subjects With with Baseline and At Least One Post-Baseline Assessment in CA209649

|                                                                       | Nivo + Chemo              | Nivo + Chemo               | Nivo + Chemo              |
|-----------------------------------------------------------------------|---------------------------|----------------------------|---------------------------|
| Subject ADA Status (%)                                                | Nivolumab + XELOX N = 320 | Nivolumab + FOLFOX N = 361 | Nivolumab + Chemo N = 681 |
| BASELINE ADA POSITIVE                                                 | 17 (5.3)                  | 16 (4.4)                   | 33 (4.8)                  |
| ADA POSITIVE                                                          | 33(10.3)                  | 27 (7.5)                   | 60 ( 8.8)                 |
| PERSISTENT POSITIVE (PP) NOT PP - LAST SAMPLE POSITIVE OTHER POSITIVE | 1 0.3) 16 5.0) 16 5.0)    | 0 9 2.5) 18 5.0)           | 1 0.1) 25 3.7) 34 5.0)    |
| NEUTRALIZINGPOSITIVE                                                  | 1( 0.3)                   | 1 (0.3)                    | 2 ( 0.3)                  |
| ADA NEGATIVE                                                          | 287 (89.7)                | 334 ( 92.5)                | 621 ( 91.2)               |

Baseline ADA Positive : A subject with baseline ADA-positive sample;

<div style=\"page-break-after: always\"></div>

ADA Positive: A subject with at least one ADA-positive sample relative to baseline (ADA negative at baseline or ADA titer to be at least 4fold or greater [≥] than baseline positive titer) at any time after initiation of treatment; Persistent Positive (PP): ADA-positive sample at 2 or more consecutive timepoints, where the first and last ADApositive samples are at least 16 weeks apart;

Not PP-Last Sample Positive: Not persistent but with ADA-positive sample at the last sampling timepoint; Other Positive: Not persistent but some ADA-positive samples with the last sample being negative;

Neutralizing Positive: At least one ADA-positive sample with neutralizing antibodies detected post-baseline; ADA Negative: A subject with no ADA-positive sample after initiation of treatment.

Post-baseline assessments are assessments reported after initiation of treatment.

Note: At the time of data generation, there were 8 nivolumab NAb samples pending analysis due to the impact of BMS site COVID-19 closure and assay method issues. All 8 NAb samples have since been analyzed and all antibodies were non-neutralizing.

Source: Refer to Table 11.1-1 in the CA209649 CSR

Table 4.1.3-4: Summary of Select Adverse Events of Hypersensitivity/Infusion Reaction by ADA Status (Positive, Negative) - All Nivolumab + Chemotherapy Treated 1L GC/GEJC/EAC Subjects with ADA Positive or ADA Negative

|                                            | Nivo + Chemo                  | Nivo + Chemo                   |
|--------------------------------------------|-------------------------------|--------------------------------|
| Preferred Tem (%)                          | Nivolumab ADA Positive N = 60 | Nivolumab ADA Negative N = 621 |
| TOTALSUBJECTSWITHANEVENT                   | 11 (18.3)                     | 98 (15.8)                      |
| Anaphylactic reaction                      | 2030 （ 3.3)                   | 0.5)                           |
| Bronchospasm                               |                               | 0.2)                           |
| Hypersensitivity                           | 5.0)                          | 7.2)                           |
| Infusion related hypersensitivity reaction |                               | 0.5)                           |
| Infusion related reaction                  | 6 ( 10.0)                     | 57 9.2)                        |

MedDRA Version: 23.0

CTC Version 4.0

Includes events between first dose and within the last dose of therapy + 1oo days.

Source: Refer to Table 11.1.2-1 in the CA209649 CSR

Figure 4.1.5-4: Time Course of Observed Nivolumab Trough Concentrations by Nivolumab ADA (A) and Neutralizing Antibody (B) Status in Study CA209649

(A)

<!-- image -->

Boxesare25th，50th，and75thpercentiles;whiskers are5thto95thpercentiles. Asterisks show data points outside thisrange.The number of samples is above each box.

<!-- image -->

Boxes are25th，50th，and 75thpercentiles;whiskers are 5thto95thpercentiles. Asterisks show data points outside thisrange.The number of samples is above each box.

<div style=\"page-break-after: always\"></div>

## (B)

<!-- image -->

Boxesare25th，5oth，and75thpercentiles;whiskersare5thto95thpercentiles. Asterisks show data points outside thisrange.The number of samples is above eachbox.

Boxesare25th，50th，and75thpercentiles;whiskersare5thto95thpercentiles. Asterisks show data points outside thisrange.The number of samples is above eachbox.

Note: The number above each boxplot is the number of trough concentrations within a ± 3-day window by study day from subjects with (A) ADA negative status and (B) NAB negative status.

Abbreviations: ADA = anti-drug antibody; NAB = neutralizing antibody; Q2W = every 2 weeks; Q3W = every 3 weeks.

Source: Refer to Figure 3.2.1.5-2 and Figure 3.2.1.5-3 in the PPK Analysis Report

<div style=\"page-break-after: always\"></div>

Figure 4.1.5-5: Distributions of Cavgss for Nivolumab + Chemotherapy in Study CA209649 in Relation to Immunogenicity Status (Positive or Negative)

<!-- image -->

Abbreviations: ADA = anti-drug antibody; Cavgss = time-averaged serum concentration at steady state; Conc = concentration; GM = geometric mean; Q2W = every 2 weeks; Q3W = every 3 weeks.

Source: Refer to Figure 5.1.3.4-2 in the PPK Analysis Report

## 2.3.3. Pharmacodynamics

## 2.3.4. PK/PD modelling

## Exposure-efficacy relationship

A CPH model was developed to describe the relationship between nivolumab Cmin1 or Cavg1 and the hazard of death in all randomized subjects from the nivo + chemo (n= 725 [nivolumab 240 mg + FOLFOX n=392; nivolumab 360 mg + XELOX n=333]) and chemo (n=791 [FOLFOX n=421; XELOX n=370]) arms in CA209649.

Figure 3.2.1.1-1 is a graphical presentation of all the estimated effects in the Cmin1-OS (A) and Cavg1-OS (B) full models, showing the HR of OS across the covariate ranges and the associated 95% CIs, relative to the median value (for continuous covariates except exposure) or reference group (for categorical covariates). The effect of nivolumab exposure on HR of OS was calculated relative to the corresponding chemotherapy only arm (nivolumab 360 mg + XELOX Q3W versus XELOX; nivolumab

<div style=\"page-break-after: always\"></div>

240 mg + FOLFOX Q2W versus FOLFOX). The findings from the Cmin1-OS and the Cavg1-OS models were generally consistent.

Figure 3.2.1.1-6: Estimated Covariate Effects on the Hazard Ratio of OS in All Randomized Subjects in CA209649 (Full Model)

<!-- image -->

Abbreviations: ALB = albumin; CI = confidence interval; Cmin1 = trough serum concentration after the first nivolumab dose; Cont. Var = continuous variable; EAC = esophageal adenocarcinoma cancer; Folfox = chemotherapy regimen of folinic acid,  fluorouracil,  and  oxaliplatin;  GC  =  gastric  cancer;  GEJC  =  gastroesophageal  junction  cancer;  LDH  =  lactate dehydrogenase; N = number of subjects; Nivo = nivolumab; PD-L1 = programmed death-ligand 1; OS = overall survival; Q2W = every 2 weeks; Q3W = every 3 weeks; ROW = Rest of World; ULN = upper limit of normal; US = United States; Xelox = chemotherapy regimen of capecitabine plus oxaliplatin.

Source: Refer to Figure 5.2.1.1-1 and Figure 5.2.1.2-1 in the E-R Analysis Report

<div style=\"page-break-after: always\"></div>

Table 3.2.1.1-5: Exposure by Dosing Regimen in All Randomized Subjects in

## Predicted OS HRs (95% CI) at 5th and 95th percentile of Nivolumab CA209649

|                    | HR (95% CI)                        | HR (95% CI)                        | HR (95% CI)                          | HR (95% CI)                          |
|--------------------|------------------------------------|------------------------------------|--------------------------------------|--------------------------------------|
| Nivolumab exposure | Nivolumab 360 mg + XELOX vs. XELOX | Nivolumab 360 mg + XELOX vs. XELOX | Nivolumab 240 mg + FOLFOX vs. FOLFOX | Nivolumab 240 mg + FOLFOX vs. FOLFOX |
| (µg/mL)            | 5th percentile of exposure         | 95th percentile of exposure        | 5th percentile of exposure           | 95th percentile of exposure          |
| Cmin1              | 0.928 (0.796, 1.08)                | 0.671 (0.527, 0.848)               | 0.846 (0.794, 0.901)                 | 0.666 (0.571, 0.776)                 |
| Cavg1              | 0.908 (0.772, 1.06)                | 0.725 (0.577, 0.904)               | 0.845 (0.788, 0.904)                 | 0.705 (0.611, 0.812)                 |

Abbreviations:  Cavg1  -  Concentration  following  the  1st  dose,  Cmin1  -  trough  serum  concentration  after  the  first nivolumab dose

Source: Refer to Figure 5.2.1.1-1 and Figure 5.2.1.2-1 of the E-R Analysis Report

A CPH model was developed to describe the relationship between nivolumab Cmin1 or Cavg1 and the hazard of disease progression or death in all randomized subjects with PD-L1 CPS ≥ 5 from the nivo+chemo (n= 434 [nivolumab 240 mg + FOLFOX n=218; nivolumab 360 mg + XELOX n=216]) and chemo (n=481 [FOLFOX n=253; XELOX n=228]) arms in CA209649.

Figure 3.2.1.2-1 is a graphical presentation of all of the estimated effects in the Cmin1-PFS (A) and Cavg1-PFS (B) full models, showing the HR of PFS across the covariate ranges and the associated 95% CIs, relative to the median value (for continuous covariates except exposure) or reference group (for categorical covariates). The effect of nivolumab exposure on HR of PFS was calculated relative to the corresponding chemotherapy only arm (nivolumab 360 mg + XELOX Q3W versus XELOX; nivolumab 240 mg + FOLFOX Q2W versus FOLFOX). The findings from the Cmin1-PFS and the Cavg1-PFS models were generally consistent.

The effect of chemotherapy on PFS was evaluated in an E-R PFS model; XELOX was suggested to be a significant predictor (95% CI did not include 1) with a slightly higher risk than FOLFOX as backbone chemotherapy (Figure 3.2.1.2-1). The interaction term between chemotherapy and nivolumab exposure was also tested and was not kept in either full model, as it did not reduce BIC.

PFS HRs favored (HR &lt; 1) nivo+chemo compared to chemo within the exposure range produced by the 2 nivolumab dosing regimens (Figure 3.2.1.2-1). Both Cmin1 and Cavg1 were identified as significant predictors (95% CI did not include 1) for PFS, because chemotherapy control arm data were included, and exposure in the model represented the nivolumab treatment effect. The effect of Cavg1 on the HR of OS (0.988) (refer to Table 5.1.1.2-1 in the E-R Analysis Report) was slightly flatter as compared to that of Cmin1 (0.981) (refer to Table 5.1.1.1-1 in the E-R Analysis Report). The magnitude of treatment effect on PFS was similar for the 2 nivolumab dosing regimens. Although increasing nivolumab exposure appeared to be associated with numerically smaller HRs of PFS (Figure 3.2.1.21),the predicted PFS HR (95% CI) for nivolumab 360 mg + XELOX Q3W overlapped between the 5th and 95th percentile of Cmin1 and Cavg1 (Table 3.2.1.2-1); the predicted OS HR (95% CI) for nivolumab 240 mg + FOLFOX Q2W overlapped between the 5th and 95th percentile of Cavg1 (Table 3.2.1.2-1).

<div style=\"page-break-after: always\"></div>

Figure 3.2.1.2-7: Estimated Covariate Effects on the Hazard Ratio of PFS in All Randomized Subjects with PD-L1 CPS ≥

## 5 in CA209649 (Full Model)

<!-- image -->

Abbreviations: ALB = albumin; CI = confidence interval; Cavg1 = average serum concentration after the first nivolumab dose; Cmin1 = trough serum concentration after the first nivolumab dose; Cont. Var = continuous variable; EAC = esophageal adenocarcinoma cancer; Folfox = chemotherapy regimen of folinic acid, fluorouracil, and oxaliplatin; GC = gastric cancer; GEJC = gastroesophageal junction cancer; LDH = lactate dehydrogenase; N = number of subjects; Nivo = nivolumab; PDL1 = programmed death-ligand 1; PFS = progression-free survival; Q2W = every 2 weeks; Q3W = every 3 weeks; ROW = Rest of World; ULN = upper limit of normal; US = United States; Xelox = chemotherapy regimen of capecitabine + oxaliplatin.

Source: Refer to Figure 5.1.1.1-1 and Figure 5.1.1.2-1 in the E-R Analysis Report

<div style=\"page-break-after: always\"></div>

Table 3.2.1.2-6: Predicted PFS HRs (95% CI) at 5th and 95th percentile of Nivolumab Exposure by Dosing Regimen in All Randomized Subjects with PD-L1 CPS ≥ 5 in CA209649

|                            | HR (95% CI)                        | HR (95% CI)                        | HR (95% CI)                          | HR (95% CI)                          |
|----------------------------|------------------------------------|------------------------------------|--------------------------------------|--------------------------------------|
| Nivolumab exposure (µg/mL) | Nivolumab 360 mg + XELOX vs. XELOX | Nivolumab 360 mg + XELOX vs. XELOX | Nivolumab 240 mg + FOLFOX vs. FOLFOX | Nivolumab 240 mg + FOLFOX vs. FOLFOX |
|                            | 5th percentile of exposure         | 95th percentile of exposure        | 5th percentile of exposure           | 95th percentile of exposure          |
| Cmin1                      | 0.934 (0.766, 1.14)                | 0.596 (0.435, 0.809)               | 0.793 (0.728, 0.863)                 | 0.574 (0.468, 0.703)                 |
| Cavg1                      | 0.895 (0.726, 1.10)                | 0.635 (0.468, 0.853)               | 0.783 (0.713, 0.860)                 | 0.616 (0.511, 0.742)                 |

Abbreviations:  Cavg1  -  Concentration  following  the  1st  dose,  Cmin1  -  trough  serum  concentration  after  the  first nivolumab dose

Source: Refer to Figure 5.1.1.1-1 and Figure 5.1.1.2-1 of the E-R Analysis Report

## Exposure-safety

A CPH model was developed to describe the relationship between daily Cavg and time to first occurrence of Gr 2+ IMAEs in all treated subjects from the nivo+chemo (n= 725 [nivolumab 240 mg + FOLFOX n=392; nivolumab 360 mg + XELOX n=333]) and chemo (n=767 [FOLFOX n=406; XELOX n=361]) arms in CA209649.

Figure 3.2.2.1-1 is a graphical presentation of all the estimated effects in the full model, showing the HR of Gr 2+ IMAEs across the covariate ranges and the associated 95% CIs, relative to the median value (for continuous covariates except exposure) or reference group (for categorical covariates). The effect of nivolumab log daily Cavg on HR was calculated relative to the corresponding chemotherapy only arm (360 mg Q3W nivolumab + XELOX versus XELOX; 240 mg Q2W nivolumab + FOLFOX versus FOLFOX).

Log daily Cavg was identified as a significant predictor (95% CI did not include 1) in E-R safety modeling for Gr 2+ IMAE, because chemotherapy control arm data were included, and exposure in the model represented the nivolumab treatment effect.

<div style=\"page-break-after: always\"></div>

Figure 3.2.2.1-8: Estimated Effects of Exposure-response Grade 2+ IMAE in CA209649 (Full Model)

Covariate

<!-- image -->

Abbreviations: ALB = albumin; CI = confidence interval; Cavg = daily average nivolumab concentration Cont. Var = continuous  variable;  EAC  =  esophageal  adenocarcinoma  cancer;  Folfox  =  chemotherapy  regimen  of  folinic  acid, fluorouracil, and oxaliplatin; GC = gastric cancer; GEJC = gastroesophageal junction cancer; Gr 2+ IMAEs = Grade ≥ 2 immune -mediated adverse events; LDH = lactate dehydrogenase; N = number of subjects; Nivo = nivolumab; PDL1 = programmed death-ligand 1; Q2W = every 2 weeks; Q3W = every 3 weeks; ROW = Rest of World; ULN = upper limit of normal; US = United States; Xelox = chemotherapy regimen of capecitabine plus oxaliplatin.Source: Source: Refer to Figure 5.3.1.1-1 in the E-R Analysis Report

<div style=\"page-break-after: always\"></div>

Table 3.2.2.1-7: Predicted Grade 2+ IMAE HRs (95% CI) at 5th and 95th percentile of Nivolumab Daily Cavg by Dosing Regimen in All Randomized Subjects in CA209649

| Nivolumab exposure (µg/mL)   | HR (95% CI) of Grade 2+ IMAEs      | HR (95% CI) of Grade 2+ IMAEs      | HR (95% CI) of Grade 2+ IMAEs        | HR (95% CI) of Grade 2+ IMAEs        |
|------------------------------|------------------------------------|------------------------------------|--------------------------------------|--------------------------------------|
| Nivolumab exposure (µg/mL)   | Nivolumab 360 mg + XELOX vs. XELOX | Nivolumab 360 mg + XELOX vs. XELOX | Nivolumab 240 mg + FOLFOX vs. FOLFOX | Nivolumab 240 mg + FOLFOX vs. FOLFOX |
| Nivolumab exposure (µg/mL)   | 5th percentile of exposure         | 95th percentile of exposure        | 5th percentile of exposure           | 95th percentile of exposure          |
| Daily Cavg                   | 1.21 (0.983, 1.49)                 | 1.34 (1.06, 1.68)                  | 1.26 (1.18, 1.34)                    | 1.50 (1.34, 1.68)                    |

Source: Refer to Figure 5.3.1.1-1 of the E-R Analysis Report

## 2.3.5. Discussion on clinical pharmacology

Both analytical methods used for the quantification of BMS-936558 in human serum samples in support of study CA209649 were previously assessed. Since the data were obtained within a study from two different laboratories comparison of those data was performed by a cross validation. The outcome of the cross validation show that the obtained data were reliable and they can be compared and used. All study samples analysed at both sites and reported for nivolumab (BMS-936558) were covered by 2373 days of long-term stability at nominal at -70 ºC.

Both in-study validations show acceptable calibration standards and QCs. The reasons for the reanalysis of samples are considered acceptable. For samples re-assayed inadvertently, the original values were reported. Incurred Sample Reproducibility was performed at both sites and the reanalysis confirms the validity and performance of the Analytical Method Procedure for all analytes.

The MAH has conducted a Phase 3 study (CA209649) to characterize the pharmacokinetics, immunogenicity, and exposure-response relationship of nivolumab in subjects with advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (GC/GEJC/EAC) to support the administration of nivolumab 240 mg every 2 weeks (Q2W) or nivolumab 360 mg every 3 weeks (Q3W) intravenous (IV) in combination with fluoropyrimidine and platinumcontaining chemotherapy (hereafter referred to as nivo+chemo) for first-line (1L) treatment.

The modelling strategy consisted in a pooled analysis of PK data in subjects with 1L GC/GEJC/EAC from Study CA209649 and data from other relevant nivolumab monotherapies, across multiple tumour types, which is endorsed. The pooled analysis offered the advantage of a solid, robust and precise estimation of the PK properties of nivolumab (parameters and covariate effects) and allowed to identify differences in PK elements due to disease type. The updated population PK model adequately characterized the time-course of nivolumab in patients with 1L GC/GEJC/EAC based on the GOF, pcVPC and parameter estimates.

No covariates were found to have a clinically meaningful effect on nivolumab PK in the updated analysis. Graphical representations of the effect of categorical and continuous covariates on the typical value of the structural model parameters of CL, volume of central compartment (VC), and CLss/CL0 (EXP[EMAX]) are presented in Figure 3.1.1-1. All covariate effects were within ± 20% boundaries, except for the effect of baseline body weight on CL and VC and baseline albumin (ALB) on CL. Baseline body weight was associated with a 26% increase in CL and a 22% increase in VC in subjects with 95th percentile weight relative to subjects with median body weight. Nivolumab CL increased approximately 31% in subjects with 5th percentile baseline ALB relative to subjects with median baseline ALB value. However, the magnitudes of body weight, VC, and ALB effect on CL were consistent with findings of previous analyses. These findings were not considered to be clinically relevant, as the 95th percentile body weight or 5th percentile ALB only resulted in approximately 18.5% or 21.4% lower Cavgss,

<div style=\"page-break-after: always\"></div>

respectively, relative to those observed in subjects with median body weight or median ALB at baseline in Study CA209649.

A forest plot (Figure 3.1.1-1 above) has been provided to assess the clinical relevance of the covariates selected based on the change on main PK parameters, suggesting differences in general less than 20% in PK values. Predicted exposure metrics were evaluated across different body weight stratified for each regimen, showing a slightly higher exposure for patients with low body weight and lower exposure levels in patients with higher body weight and no differences in exposure due to the schedule administered. Similar exposure was predicted between both regimens for each sub-group of body weight category.

The immunogenicity evaluation revealed the lack of any clinical concern in terms of differences in clearance or exposure. The incidence of immunogenicity is of minor relevance.

The exposure-efficacy relationship has been established to characterize the probability of OS and predict at the proposed dosing regimens. The forest plot analysis of the Hazard Ratio for the two exposure parameters Cave1 and Cmin1, suggested a better efficacy in subjects with higher nivolumab exposures although the point estimate of the Hazard ratio remained &lt; 1 even for subjects with low nivolumab exposures (5 th  percentile). Since only one dose level was evaluated, the confounding effect of disease/health condition on exposure cannot be distinguished, and hence the exposure-efficacy analyses should be cautiously interpreted.

The exposure-safety analysis characterized the probability of Gr2+ imAE for the proposed dosing regimens (nivolumab 240mg Q2W +FOLFOX and nivolumab 360 mg Q3W + XELOX). The results show higher probability (21-26%) of Gr2+ imAE and roughly no differences between the proposed dosing regimens.

## 2.3.6. Conclusions on clinical pharmacology

The clinical pharmacology properties of nivolumab for the adjuvant treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (GC/GEJC/EAC) have been adequately characterized through a pooled analysis using previous clinical data together with experimental evidence from study CA209649. The population PK model, which shares the same structural elements as previous submissions, adequately describes the experimental data. The exposure-response analysis should be interpreted with caution, since only one dose level was evaluated and different populations were considered, where confounding factors (effect of disease/health conditions) may affect.

## 2.4. Clinical efficacy

## 2.4.1. Dose response study(ies)

No dose response studies were included in this application.

## 2.4.2. Main study

Study CA209649 (CheckMate 649): A randomized, multicenter, open-label, phase 3 study of nivolumab plus ipilimumab or nivolumab in combination with oxaliplatin plus fluoropyrimidine versus oxaliplatin plus fluoropyrimidine in subjects with previously untreated advanced or metastatic gastric,

<div style=\"page-break-after: always\"></div>

## gastroesophageal junction cancer or oesophageal adenocarcinoma (GC/GEJC/OAC).

## Methods

Figure 1. Study Design Schematic

<!-- image -->

Abbreviations: Chemo = chemotherapy, ECOG PS = Eastern Cooperative Oncology Group Performance Status, FOLFOX =leucovorin plus fluorouracil plus oxaliplatin,GC = gastric cancer, GEJC = gastroesophageal junction cancer, Ipi = ipilimumab, Mono = monotherapy, Nivo = nivolumab, Q2W = every 2 weeks, Q3W = every 3 weeks, PD = progressive disease, PD-L1 = programmed death-ligand 1, ROW = rest of world, XELOX = capecitabine plus oxaliplatin

## Study participants

## Main inclusion criteria

- a) Males and Females, ≥ 18 years of age.
- b) All subjects must have inoperable, advanced or metastatic GC or GEJ or distal esophageal carcinoma and have histologically confirmed predominant adenocarcinoma. The documentation of GEJ involvement can include biopsy, endoscopy, or imaging.
- c) Subject must be previously untreated with systemic treatment (including HER 2 inhibitors) given as primary therapy for advanced or metastatic disease.
- d) Allowed Prior Therapies: Prior adjuvant or neoadjuvant chemotherapy, radiotherapy and/or chemoradiotherapy for GC or GEJ cancer are permitted as long as the last administration of the last regimen (whichever was given last) occurred at least 6 months prior to randomization. Palliative radiotherapy is allowed and must be completed 2 weeks prior to randomization.
- e) Subject must have at least one measurable lesion or evaluable disease by CT or MRI per RECIST 1.1 criteria; radiographic tumour assessment should be performed within 28 days prior to randomization.
- f) ECOG performance status score of 0 or 1.
- g) Tumour tissue must be provided for biomarker analyses. In order to be randomized, a subject must have an evaluable PDL1 expression classification (≥ 1% or &lt; 1%, or indeterminate) as determined by the central lab. Subjects with non-evaluable results will not be allowed to be

<div style=\"page-break-after: always\"></div>

randomized. Either a formalin-fixed, paraffin-embedded (FFPE) tissue block or unstained tumour tissue sections, with an associated pathology report, must be submitted for biomarker evaluation prior to randomization. The tumour tissue sample may be fresh or archival if obtained within 6 months prior to randomization, and there can have been no systemic therapy (e.g. adjuvant) given after the sample was obtained. Tissue must be a core needle biopsy, excisional or incisional biopsy.

- h) Subject re-enrolment: this study permits the re-enrolment of a subject who has discontinued the study as a pre-treatment failure (i.e. subject has not been randomized). If re-enrolled, the subject must be re-consented.

## Main exclusion criteria

- a) Known HER2 positive status.
- b) Subjects with untreated known CNS metastases. Subjects are eligible if CNS metastases are adequately treated and subjects are neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks prior to randomization. In addition, subjects must be either off corticosteroids, or on a stable or decreasing dose of ≤ 10 mg daily prednisone (or equivalent) for at least 2 weeks prior to randomization.
- c) Subjects with ascites which cannot be controlled with appropriate interventions.
- d) Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.
- e) Subjects with active, known, or suspected autoimmune disease. Subjects with Type I diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement, or skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment are permitted to enrol.
- f) Subjects with a condition requiring systemic treatment with either corticosteroids (&gt; 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids, and adrenal replacement doses &gt; 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
- g) Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways. e) All toxicities attributed to prior anti-cancer therapy other than hearing loss, alopecia and fatigue must have resolved to Grade 1 (NCI CTCAE version 4) or baseline before administration of study drug.
- h) Subjects with &gt; Grade 1 peripheral neuropathy.
- i) Any serious or uncontrolled medical disorder or active infection that, in the opinion of the investigator, may increase the risk associated with study participation, study drug administration, or would impair the ability of the subject to receive study drug.
- j) Known history of positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS). NOTE: Testing for HIV must be performed at sites where mandated locally.
- k) Subjects who have received a live/attenuated vaccine within 30 days of first treatment. (eg, varicella, zoster, yellow fever, rotavirus, oral polio and measles, mumps, rubella [MMR]).

<div style=\"page-break-after: always\"></div>

- l) Any positive test result for hepatitis B virus or hepatitis C virus indicating presence of virus, e.g., hepatitis B surface antigen (HBsAg, Australia antigen) positive, or hepatitis C antibody (anti-HCV) positive (except if HCV RNA negative).

## Treatments

## The treatments were

## Nivo+chemo (XELOX or FOLFOX) Arm :

- o Nivolumab plus XELOX:
- -Nivolumab 360 mg intravenous (IV) over 30 minutes on Day 1 of each treatment cycle, Q3W
- -Oxaliplatin 130 mg/m 2  IV on Day 1 of each treatment cycle + capecitabine 1000 mg/m 2 orally twice daily (BID) on Days 1 to 14 of each treatment cycle, Q3W
- o Nivolumab plus FOLFOX:
- -Nivolumab 240 mg IV over 30 minutes on Day 1 of each treatment cycle, Q2W
- -Oxaliplatin 85 mg/m 2  + leucovorin 400 mg/m 2  + fluorouracil 400 mg/m2 IV on Day 1 of each treatment cycle, and fluorouracil 1200 mg/m 2  IV continuous infusion over 24 hours daily (QD) or per local standard on Days 1 and 2 of each treatment cycle, Q2W

The treatment of nivolumab could be given up to 24 months in the absence of disease progression or unacceptable toxicity. Nivolumab monotherapy (240 mg Q2W, 360 mg Q3W or 480 mg Q4W) was permitted in cases where all chemotherapy components were discontinued per standard of care or toxicity.

## Chemo (XELOX or FOLFOX) Arm :

- o XELOX: Oxaliplatin 130 mg/m 2  IV on Day 1 of each treatment cycle + capecitabine 1000 mg/m 2  orally (PO) BID on Days 1 to 14 of each treatment cycle, Q3W
- o FOLFOX: Oxaliplatin 85 mg/m 2  + leucovorin 400 mg/m 2  + fluorouracil 400 mg/m 2  IV on Day 1 of each treatment cycle, and fluorouracil 1200 mg/m 2  IV continuous infusion over 24 hours QD or per local standard on Days 1 and 2 of each treatment cycle, Q2W.

Dose reductions for nivolumab were not permitted. Dose reductions for chemotherapy were permitted according to local standard or local package insert.

## Objectives

## Primary Objectives

- -To compare OS in subjects with advanced or metastatic GC or GEJC with PD-L1 CPS ≥ 5.
- -To compare PFS, as assessed by BICR in subjects with advanced or metastatic GC or GEJC with PD-L1 CPS ≥ 5.

## Hierarchically Tested Secondary Objectives

- -To compare OS in subjects with advanced or metastatic GC or GEJC with PDL1 CPS ≥ 1 or all randomized subjects

## Other Secondary Objectives

<div style=\"page-break-after: always\"></div>

- -To evaluate OS in subjects with advanced or metastatic GC or GEJC with PDL1 CPS ≥10
- -To evaluate PFS, as assessed by BICR, in subjects with advanced or metastatic GC or GEJC with PDL1 CPS ≥ 10, CPS ≥ 1 or all randomized subjects
- -To evaluate ORR, as assessed by BICR, in subjects with advanced or metastatic GC or GEJC with PDL1 CPS ≥10, CPS ≥ 5, CPS ≥ 1, or all randomized subjects

## Exploratory Objectives

- -To assess time to symptom deterioration (TTSD) as assessed using Gastric Cancer Subscale (GaCS) of Functional Assessment of Cancer Therapy-Gastric (FACT-Ga) in subjects with advanced or metastatic GC or GEJC with PDL1 CPS ≥ 10, CPS ≥ 5, CPS ≥ 1, or all randomized subjects
- -To assess PFS and ORR, as assessed by the investigator in subjects with advanced or metastatic GC or GEJC across CPS cut-offs
- -To evaluate duration of response (DOR) as assessed by BICR and by investigator, in subjects with advanced or metastatic GC or GEJC
- -To evaluate the durable response rate (DRR: objective response lasting continuously &gt; 6 months) as assessed by BICR and by investigator, in subjects with advanced or metastatic GC or GEJC
- -To evaluate second disease progression (PFS2) or time to second subsequent line therapy (TSST) in subjects with advanced or metastatic GC or GEJC
- -To assess PFS, ORR as assessed by either BICR or investigator, OS in subjects with advanced or metastatic GC or GEJC across tumour cell PD-L1 cut-offs
- -To assess the overall safety and tolerability of nivolumab in combination with oxaliplatin plus fluoropyrimidine vs. oxaliplatin plus fluoropyrimidine in subjects with advanced or metastatic GC or GEJC
- -To explore potential biomarkers predictive of or associated with clinical efficacy (OS, PFS and ORR) including microsatellite instability (MSI) status in subjects with advanced or metastatic GC or GEJC
- -To characterize the immunogenicity (IMG) of nivolumab in combination with oxaliplatin plus fluoropyrimidine when administered in combination to subjects with advanced or metastatic GC or GEJC
- -To assess changes from baseline in the subject's overall health status using the 3-level version of the EQ-5D (EQ-5D-3L) index and visual analog scale (EQ-5D-3L VAS) of nivolumab in combination with oxaliplatin plus fluoropyrimidine vs. oxaliplatin plus fluoropyrimidine in subjects with advanced or metastatic GC or GEJC
- -To assess the subject's cancer-related quality of life using the FACT-Ga questionnaire and selected components, including the GaCS and 7-item version of the FACT-General (FACT-G7) of nivolumab in combination with oxaliplatin plus fluoropyrimidine vs. oxaliplatin plus fluoropyrimidine in subjects with advanced or metastatic GC or GEJC

<div style=\"page-break-after: always\"></div>

## Outcomes/endpoints

Table 1. Key Objectives/Endpoints for Nivo+Chemo vs. Chemo (CA209649)

| Primary Endpoints                                   | • OS in randomized subjects with PD- L1 CPS ≥ 5 • PFS by BICR in randomized subjects with PD- L1 CPS ≥ 5                                                                                                                                                                                                                                                                                                                                                                         |
|-----------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Secondary Endpoints (in hierarchical testing order) | • OS in randomized subjects with PD- L1 CPS ≥ 1 • OS in all randomized subjects.                                                                                                                                                                                                                                                                                                                                                                                                 |
| Secondary Endpoints (descriptive)                   | • OS in randomized subjects with PD- L1 CPS ≥ 10 • PFS by BICR in randomized subjects with PD- L1 CPS ≥ 10, 1 or all randomized subjects • ORR by BICR in randomized subjects with PD- L1 CPS ≥ 10, 5, 1 or all randomized subjects                                                                                                                                                                                                                                              |
| Exploratory Endpoints                               | • ORR, a,b PFS by investigator in randomized subjects with PD-L1 CPS ≥10, 5, 1 or all randomized subjects • OS, PFS, a ORR a,b in randomized subjects across TC PD-L1 cut-offs • PFS2 or TSST of next line treatment • DOR a,b • DRR: objective response lasting continuously > 6 months, only in subjects with PD- L1 CPS ≥ 5) a,b • PRO in randomized subjects with PD-L1 CPS ≥ 10, 5, 1, or all randomized subjects • Biomarkers, safety and tolerability, and immunogenicity |

Abbreviations: BICR - blinded independent central review, CPS - combined positive score, DOR - duration of response, DRR - durable response rate, ORR - objective response rate, OS - overall survival, PD-L1 - programmed death ligand 1, PFS - progression-free survival, PFS2 - PFS after next line of treatment, PRO - patient reported outcomes, TC - tumour cell, TSST - time to second subsequent line therapy

## Biomarkers

Subjects were enrolled regardless of tumour cell PD-L1 expression. Per revised Protocol 07 (included Amendment 23 dated 14-Sep-2018, 'Protocol amendments' below), the primary population was changed to subjects with PDL1 CPS ≥ 5, however, stra tification by tumour cell PD-L1 remained unchanged.

An archival (or fresh) formalin-fixed paraffin embedded (FFPE) tissue block or 20 unstained tumour tissue sections (with an associated pathology report) were required to be collected within 6 months prior to enrolment. No systemic therapy (e.g. adjuvant or neoadjuvant chemotherapy) was to be given after the sample was obtained. Tissue was required to be from a core needle, excisional or incisional biopsy. An optional fresh biopsy at the time of suspected tumour progression might also have been collected.

## Tumour cell PD-L1

Tumour cell PD-L1 at 1% cut-off was one of the stratification factors. Tumour tissue specimens were sent to the central lab (LabCorp Center for Molecular Biology and Pathology [CMBP] in North Carolina, USA or Covance Shanghai) for PD-L1 testing during the screening period. Tumour cell PD-L1 expression was defined as the percent of tumour cells with membrane staining in a minimum of 100 evaluable tumour cells per validated Agilent/Dako PD-L1 IHC 28-8 pharmDx test according to the manufacturer's instructions with the DAKO Autostainer Link-48 system.

<div style=\"page-break-after: always\"></div>

## PD-L1 combined positive score (CPS):

CPS was generated centrally by rescoring the tumour cell PD-L1 stained slides using the central lab DAKO CPS algorithm. CPS is a scoring algorithm taking into account immunoreactivity for PDL1 in both tumour cells and tumour associated immune cells (restricted to lymphocytes and macrophages) within or directly associated with tumour cell strands. As such, CPS is the number of PD-L1 positive cells (tumour cells, lymphocytes and macrophages) divided by the total number of viable tumour cells within the evaluated tumour area, multiplied by 100. Although the calculation might have been greater than 100, the maximum CPS is defined as 100.

## Microsatellite Instability (MSI)

MSI status was determined retrospectively on pre-treatment FFPE tissues using the Idylla™ MSI Test by a central laboratory. The Idylla™ MSI Test is an automated PCR based qualitative test and determines microsatellite stability/instability through mathematical scoring related to the detection of a novel panel of seven monomorphic biomarkers: ACVR2A, BTBD, DIDO1, MRE11, RYR3, SEC31A, and SULF2. The Idylla™ MSI Test reports results as microsatellite stable (MSS), microsatellite instability high (MSI-H), or invalid in cases where the MSI status of tested samples cannot be reliably determined.

## Sample size

This section summarizes power calculation of the primary endpoints of PFS and OS per the last revised protocol before the database lock (DBL) (Revised Protocol 09 [Amendment 29]). The study enrolment was completed prior to Revised Protocol 09 based on the sample size as determined by the original design assumptions. This revision changed the final PFS and interim OS analyses to be conducted at a minimum follow-up time of 12 months and final OS analysis at a minimum follow-up time of 24 months after the last subject was randomized. Under the assumption that the prevalence of PD-L1 CPS ≥ 5 was 35%, it was estimated that the primary population would consist of 554 subjects concurrently randomized to the nivo+chemo and chemo arms. The hazard ratio (HR) for PFS was modelled as a 2piece hazard ratio with a delayed effect (HR=1) of the first 3 or 6 months followed by a constant HR of 0.56 thereafter. With a type I error of 2% at 12 months minimum follow-up, the expected number of PFS events was estimated to be 497 for a 3-month delay and approximately 99% power; or 506 for a 6-month delay and approximately 60% power.

For OS, the HR was modelled as a 2-piece hazard ratio, a delayed effect with a HR of 1 vs. chemotherapy for the first 6 months followed by a constant HR of 0.65 thereafter. At 24 months minimum follow-up at final analysis, it was expected that 466 events would be observed providing an adequate power of approximately 85% with a type I error of 3% (two-sided).

The actual observed prevalence of PDL1 CPS ≥ 5 was 60% in the locked database of 10-Jul-2020 among the randomized subjects pooled over the 3 treatments arms. Therefore, prior to the DMC efficacy review meeting and unblinding of BMS study team, the power for PFS and OS were updated using this actual prevalence of PDL1 CPS ≥ 5 (reflected in statistical analysis plan [SAP] V4.0 Appendix 5). Based on randomization schema, the primary population would consist of 949 subjects concurrently randomized to nivo+chemo and chemo. Using the same PFS model as in the design, with 3 months or 6 months delayed treatment effect, the expected number of PFS events would be 841 and 857, with corresponding power of 99.9% and 84%, respectively. For OS, the expected number of events, using the same model as in the design, was 800 events providing a power of 97.9%.

<div style=\"page-break-after: always\"></div>

## Randomisation

Once enrolled in Interactive Web Response System (IWRS), subjects who had met all eligibility were randomized 1:1 to treatment with either nivo+ipi or chemo per original study design, with stratification by tumour cell PD-L1 expression level ( ≥ 1% vs. &lt; 1% or indeterminate), region (Asia vs. North America [US and Canada] vs. rest of the world) and ECOG performance status (0 vs. 1). After implementation of Revised Protocol 02 (Amendment 08), subjects were randomized 1:1:1 to treatment with either nivo+ipi, nivo+chemo, or chemo, with the above 3 original stratification factors and the choice of chemotherapy regimen (XELOX vs. FOLFOX) as an additional stratification factor. As of 05Jun-2018, the nivo+ipi arm was closed to enrolment per DMC recommendation and, following implementation of Revised Protocol 06 (Amendment 20), subjects were then randomized 1:1 to treatment with either nivo+chemo or chemo.

Table 2. Randomisation allocation

| Protocol Periods                       | Randomization allocation                                               | Number of Randomized Subjects Curent/Cumulative   |
|----------------------------------------|------------------------------------------------------------------------|---------------------------------------------------|
| First patient randomized - Amendment 8 | 1:1 (Nivolumab +Ipilimumab: Chemotherapy)                              | 83/83                                             |
| Amendment 08 - Amendment 20            | 1:1:1 (Nivolumab + Ipilimumab: Chemotherapy: Nivolumab + Chemotherapy) | 1098/1181                                         |
| Amendment 20 to amendment 26           | 1:1 (Chemotherapy: Nivolumab + Chemotherapy)                           | 468/1649                                          |
| Amendment 26 to the end of enrollment  | 1:1 (Chemotherapy. Nivolumab + Chemotherapy)                           | 382/2031                                          |

## Blinding (masking)

The trial is open-label.

## Statistical methods

The initial study SAP version 1.0 was finalized on 25-Apr-2017. Version 2.0 of the SAP reflected the changes according to the Revised Protocol 09 (Amendment 29) and was issued on 02-Dec-2019. Version 3.0 was finalized on 03-Jun-2020, prior to the CSR DBL (10-Jul-2020) and introduced additional sensitivity analyses for PFS and OS. The final version 4.0 was issued on 05-Aug-2020, this version introduced one additional Appendix 5 to the SAP reflecting the expected number of events for PFS and OS in the primary population based on the actual prevalence of PDL1 CPS ≥ 5 rather than the assumed prevalence used in previous versions of the SAP.

## Type I error control

The hierarchical testing strategy as per the last SAP described in Figure 2 ensures control of familywise error rate (FWER) at a 2-sided significance (alpha) level of 5 % for the primary and key secondary endpoints.

For the dual primary endpoints of PFS and OS in the comparison of nivo+chemo vs. chemo in randomized subjects with PD-L1 CPS ≥ 5, a 2-sided significance level of 2% was allocated to PFS and 3% was allocated to OS. If the OS comparison in subjects with PDL1 CPS ≥ 5 between nivo+chemo vs. chemo was significant, then OS in subjects with PDL1 CPS ≥ 1 and OS in all randomized were planned to be sequentially tested at a 2-sided 1.5% significance level.

<div style=\"page-break-after: always\"></div>

For OS in PDL1 CPS ≥ 5, 1 and all randomize d subjects, the significance levels at the interim and final analyses were obtained following group sequential design using the Lan-DeMets alpha spending function with O'Brien-Fleming type boundary. At the time of the interim analysis, the significance level was based on actual OS events observed and the estimated final number of events. At the final analysis, the significance level will be calculated using the number of events in the database at the time of database lock (DBL) with consideration of the alpha already spent at the interim analysis. For the interim analysis of OS in randomized subjects with PDL1 CPS ≥ 1 and all randomized subjects, the significance levels were obtained using the same information fraction as the randomized subjects with PD-L1 CPS ≥ 5.

Figure 2. Testing Procedure for Primary and Secondary Endpoints

<!-- image -->

Abbreviations:AC:all comers;chemo:chemotherapy;CPS:combined positive score;ipi:ipilimumab;nivo: nivolumab;OS:overall survival;PFS:progression-free survival;TTSD:time to symptom deterioration.

## Key statistical analyses methods

The dual primary endpoints of PFS by BICR and OS for subjects with PDL1 CPS ≥ 5 were compared between nivo+chemo and chemo arms using a 2-sided stratified log rank test. The estimate of the hazard ratio between treatment groups was calculated using a stratified Cox proportional hazards model, with treatment as the sole covariate. Ties were handled using the exact method. Confidence intervals (CIs) adjusted for the corresponding significance level for the hazard ratio were provided.

The PFS and OS function for each treatment group was estimated using the KM product limit method and displayed graphically. Two-sided 95% CI for the median in each treatment group were obtained via the log-log transformation method. PFS and OS rates at fixed time points (depending on the minimum follow-up) were presented along with their associated 95% CIs. These estimates were derived from the Kaplan Meier estimate and corresponding CIs were derived based on the Greenwood formula for variance derivation and on log-log transformation applied on the survivor function. Stratification factors for stratified analyses were region (Asia vs. North America [US and Canada] vs. ROW), ECOG PS status (0 vs. 1), chemotherapy regimen (XELOX vs. FOLFOX), and TC PD-L1 ( ≥ 1% vs. &lt; 1% or indeterminate) as recorded in the interactive response technology (IRT).

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

The clinical cut-off occurred on 27-May-2020 (last patient last visit [LPLV]) and database lock occurred on 10-Jul-2020. Minimum follow-up (date of the last subject randomized to LPLV) for all randomized subjects in the nivo+chemo and chemo arms was 12.1 months.

A total of 1581 subjects were concurrently randomized in the nivo+chemo and chemo arms: 789 to the nivo+chemo arm and 792 to the chemo arm; see figure below. 1549 subjects were treated: 782 with nivo+chemo and 767 with chemo. 32 subjects were randomized but not treated (7 in the nivo+chemo arm and 25 in the chemo arm). Of the 1549 treated subjects, 123 (7.9%) subjects were continuing in the treatment period at the time of database lock: 84 (10.7%) nivo+chemo subjects and 39 (5.1%) chemo subjects.

Participant Flow Chart - Concurrently Randomized Subjects in the Nivo+Chemo and Chemo Arms in CA209649

<!-- image -->

The overall rates of treatment discontinuation were 89.3% and 94.9% in the nivo+chemo and chemo arms, respectively.

- The primary reason for not continuing the treatment period was disease progression in both treatment arms (1043 subjects, 67.3%): 515 (65.9%) nivo+chemo-treated subjects and 528 (68.8%) chemo-treated subjects.
- Subjects who discontinued due to study drug toxicity were 60 (7.7%) and 40 (5.2%) subjects in the nivo+chemo and chemo arms, respectively.

<div style=\"page-break-after: always\"></div>

- 61 (3.9%) subjects overall withdrew consent and did not complete the treatment period: 20 (2.6%) in the nivo+chemo arm and 41 (5.3%) in the chemo arm.

Table 3. End of Treatment Period Status Summary - All Enrolled, Randomized and Treated Subjects

|                                                    | Nivo + Chemo   |              | Total        |
|----------------------------------------------------|----------------|--------------|--------------|
| ENROLLEDA                                          |                |              | 2687         |
| RANDOMIZED                                         | 789            | 792          | 1581         |
| TREATEDb (%)                                       | 782 (99.1)     | 767 (96.8)   | 1549 ( 98.0) |
| NOT TREATED (%)                                    | 7 (0.9)        | 25 (3.2)     | 32 (2.0)     |
| REASON FOR NOT BEING TREATEDP (%)                  |                |              |              |
| DISEASEPROGRESSION                                 | 000２４１         | 0.1)         | <0 .1)       |
| ADVERSEEVENTUNRELATEDTOSTUDYDRUG                   |                | 0.3)         |              |
| SUBJECTREQUESTTODISCONTINUESTUDYTREATMENT          |                | 0.3)         | 6.8          |
| SUBJECTWITHDRENCONSENT                             | 0.3)           | 2.4)         | 1.3 3)       |
| SUBJECTNOIONGER MEETSSTUDYCRITERIA                 | 0.5)           | 0.1)         | 5 0.3) 1     |
| OTHER                                              | 0.1)           |              | <0.1)        |
| CONTINUING IN THE TREATMENT PERIODC                | 84 (10.7)      | 39 (5.1)     | 123 (7.9)    |
| NOT CONTINUING IN THE TREATMENT PERIODC            | 698 (89.3)     | 728 (94.9)   | 1426 (92.1)  |
| REASON FOR NOT CONTINUING IN THE TREATMENT PERIODC |                |              |              |
| DISEASEPROGRESSION                                 | 515 65.9)      | 528 68.8)    | 1043 67.3)   |
| STUDY DRUG TOXICITY                                | 60 7.7)        | 40 5.2) 1    | 100 6.5)     |
| DEATH                                              |                | 0.1)         | 1 <0.1)      |
| ADVERSEEVENTUNRELATEDTOSTUDYDRUG                   | 90 5.91        | 4.6)         | 81 5.2)      |
| SUBJECTREQUESTTODISCONTINUESTUDYTREATMENT          | 13 1.7)        | 55 4.6)      | 48 3.1)      |
| SUBJECTWITHDRENCONSENT                             | 20 2.6)        | 41 5.3) 0.3) | 61 3.9)      |
| LOSTTOFOLIOW-UP                                    | 2 0.3)         | 2            | 4 0.3)       |
| MAXIMUMCLINICALBENEFIT                             | 10 1.3)        | 25 3.3)      | 35 2.3) 5    |
| POOR/NON-OOMPLIANCE                                | 1 0.1)         | 430 0.5)     | 0.3)         |
| SUBJECTNOIONGER MEETSSIUDYCRITERIA                 | 1 0.1)         | 0.4)         | 4 0.3)       |
| COMPLETEDTREATMENTASPERPROIOCOL                    | 20 2.6)        |              | 20 1.3)      |
| OTHER                                              | 10 1.3)        | 14 1.8)      | 24 1.5)      |
|                                                    | 624 ( 79.8)    | 625 ( 81.5)  | 1249 (80.6)  |
| CONTINUING IN THE SIUDYC,d,e                       |                |              |              |
| NOT CONTINUING IN THE STUDYC,d                     | 158 ( 20.2)    | 142 (18.5)   | 300 (19.4)   |
| DEATH                                              | 121 15.5)      | 88 11.5)     | 209 13.5)    |
| SUBJECTWITHDRENCONSENT                             | 20 2.6)        | 4.71         | 3.6)         |
| LOST TO FOLIOW-UP                                  | 5 0.6)         | 0.8)         | 0.7)         |
| OTHER                                              | 12 1.5)        | 12 1.6)      | 24 1.5)      |

## Recruitment

This study was conducted at 175 sites in 29 countries (Argentina, Australia, Brazil, Canada, Chile, China, Colombia, Czech Republic, France, Germany, Greece, Hong Kong, Hungary, Israel, Italy, Japan, Mexico, Peru, Poland, Portugal, Republic of Korea, Romania, Russian Federation, Singapore, Spain, Taiwan, Turkey, United Kingdom, and United States [US]).

Enrollment in CA209649 started in Oct-2016 for the nivo+ipi and chemo arms and enrollment in the additional nivo+chemo arm started in Mar-2017. Enrollment to the nivo+ipi arm was closed in Jun2018 (per Revised Protocol 06/Amendment 20) as recommended by the DMC; however, enrollment continued in the nivo+chemo and chemo arms.

<div style=\"page-break-after: always\"></div>

The CSR includes data for 1581 subjects concurrently randomized to the nivo+chemo or chemo arms from 17-Apr-2017 (first subject randomized) to 27-May-2019 (last subject randomized). The analysis for concurrently randomized subjects in the nivo+ipi vs. chemo arms is planned for 2021 and is not included in the CSR.

## Conduct of the study

## Protocol amendments

The original protocol for this study was dated 04-May-2016. The original study design compared nivo+ipi vs. chemo (XELOX or FOLFOX) with OS in subjects with tumour cell PDL1 ≥ 1% as the primary endpoint. As of the 10-Jul-2020 DBL, there were 29 amendments to the protocol (including 9 global amendments and 20 country specific amendments), many of which were based on emerging data external to the CA209649 study. A description of the 9 global protocol amendments and the key study design changes are provided in Table 4.

Table 4. Summary of the 9 Global Protocol Revisions for CA209649

| Document (Amendment) Date                      | Key Changes in Study Design                                                                                                                                       |   Planned Sample Size | Rationale                                                                                                                                                                                                                                                                                                                                                       | Total Subjects Randomized at Time of Amendment   |
|------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------|
| Original Protocol 04-May-2016                  | Original study design: nivo+ipi vs. chemo (XELOX or FOLFOX); the primary endpoint was OS in subjects with TC PD- L1 ≥ 1%.                                         |                   750 | Not applicable                                                                                                                                                                                                                                                                                                                                                  | 0                                                |
| Revised Protocol 01 (Amendment 07) 20-Oct-2016 | No impact on study design                                                                                                                                         |                   750 | Updated study procedures                                                                                                                                                                                                                                                                                                                                        | 0                                                |
| Revised Protocol 02 (Amendment 08) 07-Dec-2016 | Added a new arm nivo+chemo (XELOX or FOLFOX) and randomization changed to 1:1:1. Primary endpoint for nivo+chemo vs. chemo was OS in subjects with TC PD- L1 ≥ 1. |                  1349 | CA209012 1 (data available: Jun-2016 in JCO) * and KEYNOTE 059 2 (data available: Jun-2016 at ASCO) * data supported the clinical activity of immunotherapy + chemo. The primary endpoint was changed to be consistent for nivo+ipi vs. chemo and nivo+chemo vs. chemo. TC PD-L1 ≥ 1% was considered a promising biomarker for immuno-oncology therapy in 2016. | 3 a                                              |
| Revised Protocol 03 (Amendment 13) 10-May-2017 | No impact on study design                                                                                                                                         |                  1349 | Updated study procedures                                                                                                                                                                                                                                                                                                                                        | 97                                               |
| Revised Protocol 04 (Amendment 17) 05-Jan-2018 | Changed the primary population to all randomized subjects, and endpoints to OS, PFS and ORR for nivo+chemo vs. chemo comparison                                   |                  1349 | Attraction-4 (ONO-4538-37; data available Sep-2017 at ESMO) * Part 1 3 data supported the clinical activity of nivo+chemo in all randomized subjects with promising ORR and PFS results.                                                                                                                                                                        | 679                                              |
| Revised Protocol 05 (Amendment 19) 29-May-2018 | Increased sample size to 1649                                                                                                                                     |                  1649 | Increased interest in PD-L1 CPS as new biomarker. Data from KEYNOTE- 61 4 (data available from ASCO abstract: May-2018) * and CA209032 (internal data available: Mar-2018) * suggested CPS ≥ 10 (prevalence less                                                                                                                                                | 1158                                             |

<div style=\"page-break-after: always\"></div>

| Document (Amendment) Date                      | Key Changes in Study Design                                                                                                                                                                                                                                                                             | Planned Sample Size   | Rationale                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Total Subjects Randomized at Time of Amendment   |
|------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------|
|                                                |                                                                                                                                                                                                                                                                                                         |                       | than 20%) is a better predictor of efficacy. Increased sample size in order to have sufficient robust analyses at different PD-L1 cutoffs.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                  |
| Revised Protocol 06 (Amendment 20) 11-Jun-2018 | Closed nivo+ipi enrollment                                                                                                                                                                                                                                                                              | 1649                  | Accepted the following DMC recommendation: 'Due to the concern of the observed increased early death rate in nivolumab plus ipilimumab arm as well as the increased toxicity rate, the DMC recommends to stop the future enrollment of the nivolumab plus ipilimumab arm. The current patients who are already in the nivolumab plus ipilimumab arm should continue as planned, as should the other two arms.'                                                                                                                                                                                                                | 1205                                             |
| Revised Protocol 07 (Amendment 23) 14-Sep-2018 | Changed the primary population to subjects with PD-L1 CPS ≥ 5 for both comparisons, assumed the prevalence of PD-L1 CPS ≥ 5 as 35% Moved OS to a secondary endpoint for nivo+ipi vs. chemo Maintained the primary endpoints of OS and PFS, and moved ORR to secondary endpoint for nivo+chemo vs. chemo | 1649                  | CA209032 (internal data available: Mar-2018), * KEYNOTE-059 5, (data available: Jun-2018 at ASCO) * and KEYNOTE-061 (data available: Jun- 2018 at ASCO) * data suggested PD-L1 CPS as a better predictor for efficacy than TC PD-L1. The number of subjects in the nivo+ipi arm was less than targeted due to the early closure of enrollment. Moving the OS endpoint for nivo+ipi vs. chemo to a secondary endpoint allocated more alpha to the primary endpoints for nivo+chemo vs. chemo. Limited the primary endpoints to PFS and OS for nivo+chemo vs. chemo in order to have robust analyses for the primary endpoints. | 1449                                             |
| Revised Protocol 08 (Amendment 26) 15-Nov-2018 | Increased sample size to 2005                                                                                                                                                                                                                                                                           | 2005                  | Initial monitoring of PD-L1 CPS ≥ 5 prevalence in a pooled blinded fashion indicated that the prevalence was lower than the assumed 35% (internal data from CA209649 available for the first 203 subjects: Nov-2018). * Increased the total sample size in order to maintain the planned sample size for primary PFS and OS analyses in the primary population                                                                                                                                                                                                                                                                | 1646                                             |

<div style=\"page-break-after: always\"></div>

| Document (Amendment) Date                      | Key Changes in Study Design                                                                                                                                                                       |   Planned Sample Size | Rationale                                                                                                                                        | Total Subjects Randomized at Time of Amendment   |
|------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------|
| Revised Protocol 09 (Amendment 29) 16-Sep-2019 | Changed the primary analyses of nivo+chemo vs. chemo from event driven to time-driven with a minimum follow-up of 12 months (interim OS analysis and final PFS analysis), and 24 months for final |                  2005 | KEYNOTE-062 (data available: Jun- 2019 at ASCO) * study suggested sufficient follow up was needed in order to capture the full treatment effects | 2031 (accrual was completed in May 2019)         |

a  There was a lag time between protocol amendment and the randomisation system update, 83 patients were already randomized when the randomization changed to 1:1:1

Table 5. Changes in the statistical analysis plan through the protocol amendments (summary made by the assessor)

| Protocol Amend- ment date   | Multiple testing procedure regarding OS in AC (N+C vs. C) : order, alpha ( α) allocation, timing of analyses including interims)                                                                                                                                    | Planned sample size (since the 1:1:1 randomisation started)   |
|-----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|
| Prot.02 Amend.08 07Dec2016  | (nivolumab + chemotherapy arm added) (stratification on type of chemo added) when 149 events in chemo patients with PD-L1 ≥ 1%: OS in PD-L1 ≥ 1% ( α =0.025) ⇓ OS in AC ( α =0.025 )                                                                                | 507 patients with PD-L1 ≥ 1% across three arms (1266)         |
| Prot.04 Amend.17 05Jan2018  | In AC: ORR ( α =0.001); PFS ( α =0.009); OS ( α =0.015 in total) • IA at 488 events ( α =0.006), • FA at 610 ( α =0.013) (O'Brien-Fleming boundaries)                                                                                                               | 844 AC patients in N+C vs. C (1266)                           |
| Prot.05 Amend.17 29May2018  |                                                                                                                                                                                                                                                                     | + 300 subjects (1566)                                         |
| (Prot.06 11Jun2018)         | (N+I arm stopped)                                                                                                                                                                                                                                                   |                                                               |
| Prot.07 Amend.23 14Sep2018  | (PD-L1 CPS added) PFS in CPS ≥5 (α =0.02); OS in CPS ≥5 (α=0.03 or 0.05 if PFS stat.sign ): • IA1 at 248 events • IA2 at 301 event • FA at 354 events (O'Brien-Fleming boundaries) ⇓ OS in CPS ≥1 (half α, so =0.015 or 0.025) ⇓ OS in AC (half so =0.015 or 0.025) |                                                               |
| Prot.08 Amend.26 15Nov2018  |                                                                                                                                                                                                                                                                     | + 356 subjects (1922)                                         |
| Prot.09                     | OS in CPS ≥5 ( α=0.03 ):                                                                                                                                                                                                                                            |                                                               |

<div style=\"page-break-after: always\"></div>

| Amend.29 16Sep2019   | • IA at 12 months since last patient randomized to N+C vs. C • FA at 24 months since last patient randomized to N+C vs. C (O'Brien-Fleming boundaries on actual number of events) ⇓ OS in CPS ≥1 (half α, so =0.015) ⇓ OS in AC (half α so =0.015)   |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

N=nivolumab, C=chemotherapy, AC=all comers, ⇓ hierarchical testing: the endpoint below the arrow is only tested if the endpoint above the arrow is statistically significant, IA=interim analysis, FA=final analysis, CPS=combined positivity score.

## Protocol deviations

Relevant protocol deviations are those that are related to inclusion or exclusion criteria, study conduct, study management, or subject assessment that were programmable and could potentially affect the interpretability of study results.

Overall, relevant protocol deviations (at study entry and on-treatment) were reported in a total of 21 (1.3%) randomized subjects: 10 (1.3%) in the nivo+chemo arm and 11 (1.4%) in the chemo arm. The most common relevant protocol deviation in the nivo+chemo arm was prohibited anti-cancer therapy while on-treatment reported in 8 (1.0%) of subjects. The most common relevant protocol deviations in the chemo arm were baseline ECOG &gt; 1 at study entry and prohibited anti-cancer therapy while on treatment, both reported in 4 (0.5%) of subjects.

Table 6. Relevant Protocol Deviations Summary - All Randomized Subjects

|                                                              |                      | Number of Subjects (%)   | Number of Subjects (%)   |
|--------------------------------------------------------------|----------------------|--------------------------|--------------------------|
|                                                              | Nivo + Chemo N = 789 | Chemo N = 792            | Total N = 1581           |
| SUBJECTSWITHATLEASTONEDEVIATION ATENTRANCE                   | 10 (1.3)             | 11 1.4)                  | 21 (1.3)                 |
| WRONG CANCER DIAGNOSIS (A) *                                 |                      | 0.3)                     | 21 0.1)                  |
| PROHIBITED PRIOR ANTI-CANCER THERAPY (B)                     | TO 0.1)              |                          | <0.1)                    |
| BASELINEECOG>1                                               | OL 0.1)              | 0.5)                     | 5 0.3)                   |
| NO DISEASE AT BASELINE (C)                                   |                      | 0.1)                     | 1 (<0.1)                 |
| NO PD-L1 RESULT (D)                                          | 0                    | 204１0                    | 0                        |
| ON-TREATMENTDEVIATIONS PROHIBITED ANTI-CANCER THERAPY (E) ** | 8 (1.0)              | 4（ 0.5)                  | 12（ 0.8)                 |
| NOTTREATEDAS RANDOMIZED                                      | 0                    | 0                        | 0                        |

(A) Subjects without inoperable, advanced or metastatic GC or GEJ or distal esophageal carcinoma or without histologically

(B) Prior neo-adjuvant and/or adjuvant treatment is allowed.

confirmed predominant adenocarcinoma

(C) No disease at baseline is assessed based on investigator tumor assessments.

(E) Palliative radiotherapy is not counted as a deviation.

(D) Per tumor cells score.

*Of the 2 subjects with a wrong cancer diagnosis, 1 subject was diagnosed after randomization and was immediately discontinued from the study when corrected and 1 subject's corrected diagnosis was multiple myeloma which was found after the subject discontinued study treatment.

**One subject with prohibited therapy listed in the table received Human Granulocyte Colony Stimulating Factor which was allowed.

## Baseline data

## Demographic and baseline characteristics

<div style=\"page-break-after: always\"></div>

Table 7. Demographic and Baseline Characteristics in All Randomized Subjects

|                                      | Nivo_+ Chemo N = 789   | Chemo N = 792   | Total N = 1581   |
|--------------------------------------|------------------------|-----------------|------------------|
| AGE (YEARS)                          |                        |                 |                  |
| MEAN                                 | 60.3                   | 59.9            | 60.1             |
| MEDIAN                               | 62.0                   | 61.0            | 61.0             |
| MIN ， MAX                            | 18,88                  | 21,90           | 18，90            |
| AGE CATEGORIZATION (%)               |                        |                 |                  |
| < 65                                 | 473 ( 59.9)            | 488 (61.6)      | 961 (60.8)       |
| >= 65 AND<75                         | 237 （ 30.0)            | 229 (28.9)      | 466 (29.5)       |
| >= 75 AND<85                         | 77 9.8)                | 69 8.7)         | 146  （ 9.2)      |
| >= 85                                | 2 0.3)                 | 6 (0.8)         | 8 (0.5)          |
| >= 75                                | 79 10.0)               | 75 9.5)         | 154 9.7)         |
| >= 65                                | 316 40.1)              | 304 (38.4)      | 620 ( 39.2)      |
| SEX (%)                              |                        |                 |                  |
| MALE                                 | 540 (68.4)             | 560 (70.7)      | 1100 (69.6)      |
| FEMAIE                               | 249 ( 31.6)            | 232 ( 29.3)     | 481 ( 30.4)      |
| RACE (%)                             |                        |                 |                  |
| WHITE                                | 556 70.5)              | 541 68.3) 1.4)  | 1097 69.4)       |
| BLACK OR AFRICAN AMERICAN            | 7 0.9)                 | 11              | 18 1.1)          |
| AMERICAN INDIAN OR ALASKA NATIVE     | 12 1.5)                | 14              | 26 1.6)          |
| ASIAN                                | 186 23.6)              | 1.8) 189 23.9)  | 375 23.7)        |
| ASIAN INDIAN                         | 4 0.5) 116 14.7)       | 4 0.5)          | 8 0.5) 237 15.0) |
| JAPANESE                             |                        | 15.3) 54 6.8)   |                  |
| CHINESE                              | 57 7.2) 1.1            | 121             | 111 7.0)         |
| ASIAN OTHER                          | 9                      | 106 1.3)        | 19 1.2)          |
| OTHER                                | 28 3.5)                | 4.5) 0.1)       | 64 4.0)          |
| NOT REPORTED                         |                        | 1               | 1 (<0.1)         |
| REGION (%)                           |                        |                 |                  |
| ASIA [INCLUDING CHINA]               | 178 (22.6)             | 178 (22.5) 8.7) | 356 ( 22.5)      |
| ASIA [EXCLUDING CHINA]               | 79 10.0)               | 69              | 148 9.4)         |
| CHINA                                | 99 12.5)               | 109 13.8)       | 208 13.2)        |
| US                                   | 131 (16.6)             | 132 (16.7)      | 263 (16.6)       |
| REST OF WORLD                        | 480 ( 60.8)            | 482 2(60.9)     | 962 ( 60.8)      |
| INITIAL DIAGNOSIS                    |                        |                 |                  |
| GASTROESOPHAGEAL JUNCTION CANCER (A) | 132 16.7)              | 128 (16.2)      | 260 (16.4)       |
| GASTRIC CANCER                       | 554 70.2)              | 556 70.2)       | 1110 70.2)       |
| ESOPHAGEAL ADENOCARCINOMA (B)        | 103 ( 13.1)            | 108 (13.6)      | 211 ( 13.3)      |
| DISEASESTAGEAT INITIALDIAGNOSIS      |                        |                 |                  |
| STAGE I                              | 7 0.9)                 | 4               | 11 0.7)          |
| STAGE II                             | 25 3.2)                | 0.5) 5.1)       | 4.1)             |
| STAGE III                            | 108                    | 40 118          | 65 226 14.3)     |
| STAGE IV                             | 13.7) 646              | 14.9) 628 79.3) | 1274 80.6)       |
| NOT REPORTED                         | 81.9) 3 0.4)           | 2 0.3)          | 5 0.3)           |
| DISEASESTATUSCLASSIFICATION          |                        |                 |                  |
| LOCALLY RECURRENT                    | 5 0.6)                 | 2 0.3)          | 7 0.4)           |
| METASTATIC                           |                        |                 | 95.7)            |
| LOCALLY ADVANCED                     | 27 3.4)                | 34 4.3)         | 61 3.9)          |
|                                      | 272 ( 34.5)            | 267 ( 33.7)     |                  |
|                                      | 757 95.9)              | 756 95.51       | 1513             |
|                                      |                        |                 | 527              |
| LAURENCLASSIFICATION                 |                        |                 |                  |
| INTESTINAL TYPE                      |                        |                 | 539 (34.1)       |
| DIFFUSE TYPE                         | 254 32.2) 7.4)         | 273 (34.5)      | (33.3)           |
| MIXED                                | 58                     | 48(6.1)         | 106 (6.7)        |
| UNKNOWN                              | 205 (26.0)             | 204 ( 25.8)     | 409 ( 27.9)      |

<div style=\"page-break-after: always\"></div>

|                                           | Nivo + Chemo N = 789   | Chemo N = 792         | Total N = 1581   |
|-------------------------------------------|------------------------|-----------------------|------------------|
| WHO HISTOLOGIC CLASSIFICATION (CELL TYPE) |                        |                       |                  |
| ADENOSQUAMOUSCARCINOMA                    | 107 (13.6)             | 113 (14.3)            | 220 (13.9)       |
| MUCINOUSADENOCARCINOMA                    | 50 (6.3)               | 49                    |                  |
|                                           |                        | 6.2)                  | 66 6.3)          |
| PAPILLARYSEROUSADENOCARCINOMA             | 7 0.9)                 | 5 0.6)                | 12 0.8)          |
| SIGNET RING CELL TUBULAR ADENOCARCINCMA   | 145 18.4)              | 136 (17.2) 130 16.4)  | 281 17.8) 258    |
|                                           | 128 16.2)              | 357 (45.1)            | 16.3) 709        |
| OTHER. NOT REPORTED                       | 352 (44.6) 0           | 2(0.3)                | 44.8) 2 0.1)     |
| TNM CLASSIFICATION                        |                        |                       |                  |
| TUMORS                                    |                        |                       |                  |
|                                           | 248 31.4)              | 233 29.4)             | 481 30.4)        |
|                                           | 607 0.8)               | 4:0129 0.5)           | 10 0.6)          |
| TIS                                       |                        |                       |                  |
| T1                                        | 0.9)                   | 1.4)                  | 18 1.1)          |
| T2                                        | 27 3.4)                | 3.7)                  | 56 3.5)          |
| T3                                        | 184 23.3)              | 192 24.2)             | 376 23.8)        |
| T4                                        | 205 26.0)              | 212 26.8)             | 417 26.4)        |
| UNKNOWN                                   | 76 9.6)                | 73 9.2)               | 149 9.4)         |
| NOT REPORTED                              | 36 4.6)                | 38 4.8)               | 74 4.7)          |
| NODES                                     |                        |                       |                  |
| NX                                        | 251 （ 31.8)            | 226 5(28.5)           | 477 (30.2)       |
| NO                                        | 58 7.4)                | 69 (8.7)              | 127 8.0)         |
| N1                                        | 117 14.8)              | 126 (15.9)            | 243 15.4)        |
| N2                                        | 100 12.7)              | 125 15.8)             | 225 14.2)        |
| N3                                        | 146 18.5)              | 135 17.0)             | 281 17.8)        |
|                                           |                        | 73 9.2)               | 154 9.7)         |
| UNKNOWN NOT REPORTED                      | 81 10.3) 36 4.6)       | 38 4.8)               | 74 4.7)          |
| METASTASES                                |                        |                       |                  |
| MX                                        | 7 0.9)                 | 9 1.1)                | 16 1.0)          |
| MO                                        | 725 3.8)               | 73 3.9)               | 61 3.9)          |
| M1                                        | 90.6)                  | 90.0)                 | 1428 90.3)       |
| UNKNOWN                                   | 5 0.6)                 | 0.1)                  | 6 0.4)           |
| NOT REPORTED                              | 32 4.1)                | 1 38 4.8)             | 70 4.4)          |
| SMOKING STATUS                            |                        |                       |                  |
| CURRENT/FORMER                            | 376 (47.7)             | 385 (48.6)            | 761 (48.1)       |
| NEVER SMOKED                              | 395 (50.1)             | 378 3(47.7)           | 773 （ 48.9)      |
| UNKNONN                                   | 18 (2.3)               | 29 (3.7)              | 47 (3.0)         |
| CNS METASTASES (C)                        |                        |                       |                  |
| YES                                       | 1 (0.1)                | 0                     | 1 (<0.1)         |
| NO                                        | 765 (97.0)             | 766 (96.7)            | 1531 ( 96.8)     |
| NOT REPORTED                              | 23 (2.9)               | 26 (3.3)              | 49 (3.1)         |
| LIVER METASTASES (C)                      |                        |                       |                  |
| YES                                       | 301 (38.1)             | 314 (39.6)            | 615 ( 38.9)      |
| NO                                        | 465 ( 58.9)            | 452 ( 57.1)           | 917 ( 58.0)      |
| NOT REPORTED                              | 23 (2.9)               | 26 (3.3)              | 49 (3.1)         |
| PERITONEAL METASTASES (C)                 |                        |                       |                  |
| YES                                       | 188 ( 23.8)            | 188 (23.7)            | 376 23.8)        |
| NO                                        | 578 (73.3)             | 578 (73.0)            | 1156 73.1)       |
| NOT REPORTED                              | 23 (2.9)               | 26 (3.3)              | 49 （ 3.1)        |
| MICROSATELLITEINSTABILITY                 |                        |                       |                  |
| MSI-H                                     | 23 (2.9)               | 21 2.7)               | 2.8)             |
| MSS                                       | 695 (88.1)             | 682 86.1)             | 1377 87.1)       |
| INVALID                                   | 11 1.4)                | 17 2.1)               | 28 1.8)          |
| NOT REPORTED                              | 60 (7.60)              | 72 9.1)               | 132 8.3)         |
| HER-2 STATUS                              |                        |                       |                  |
| POSITIVE                                  | 3 (.0.4)               | 4 0.5)                | 7 0.4)           |
| NEGATIVE                                  | 459 (58.2)             | 472 (59.6)            | 931 ( 58.9)      |
| UNKNOWN                                   | 5 (0.6)                | 4 0.5)                | 9 0.6)           |
| 0                                         | 349 44.2)              |                       | 869 (44.1)       |
| 1                                         | 440 55.8)              | 349 (44.1) 443 (55.9) | (55.9)           |
| NOT REPORTED                              | 322 (40.8)             | 312 (39.4)            | 634 ( 40.1)      |
| ECOG PS (based on IRT)                    |                        |                       |                  |
|                                           |                        |                       | 883              |

Percentages based on all randomized subjects.

US:United States ofAmerica and Canada

Type II or III or unknown

Junction Cancer with Siewert-Stein Type I

(B) Esophageal Adenocarcinoma represents patients with diagnosis EAC or Gastroesophageal

(C) Presence of metastases per BIcR assessment.

## Previous Cancer Therapy - All Randomized Subjects

105 (13.3%) subjects in the nivo+chemo arm and 112 (14.1%) subjects in the chemo arm received prior systemic anticancer therapy (platinum-based agent or other chemotherapy) in the adjuvant, neo-

<div style=\"page-break-after: always\"></div>

adjuvant, or definitive chemoradiation setting. 160 (20.3%) subjects in the nivo+chemo arm and 176 (22.2%) subjects in the chemo arm received prior surgery related to cancer. 75 (9.5%) subjects in the nivo+chemo arm and 77 (9.7%) subjects in the chemo arm received prior radiotherapy.

Table 8. Prior Cancer Therapy Summary All Randomized Subjects

|                                              | Number of Subjects (%)   | Number of Subjects (%)   | Number of Subjects (%)   |
|----------------------------------------------|--------------------------|--------------------------|--------------------------|
|                                              | Nivo + Chemo N=789       | Chemo N = 792            | Total N = 1581           |
| NUMBEROFSYSTEMICCANCERTHERAPYREGIMENRECEIVED |                          |                          |                          |
| 0                                            | 684 86.7)                | 680 85.9)                | 1364 86.3)               |
| 1                                            | 99 12.5)                 | 108 13.6)                | 207 13.1)                |
| 2                                            | 5 0.6)                   | 4 0.5)                   | 9 0.6)                   |
| >=3                                          | 1 0.1)                   | 0                        | 1 <0.1)                  |
| SETTINGOFPRIORSYSTEMICTHERAPY                |                          |                          |                          |
| ADJUVANT THERAPY                             | 63 8.0)                  | 56 7.1)                  | 119 7.5)                 |
| METASTATICDISEASE                            | 1 0.13                   | 0                        | 1 <0.1)                  |
| NEO-ADJUVANTTHERAPY                          | 48 6.1)                  | 61 7.7)                  | 109 6.9)                 |
| TIMEFROMCOMPLETIONOFMOSTRECENTPRIORADJUVANT/ |                          |                          |                          |
| <6MONTHS                                     | 1.0)                     | 3 2.7)                   | 4 1.9)                   |
| 6-12 MONTHS                                  | 37 35.6)                 | 34.8)                    | 76 35.2)                 |
| >= 12 MONTHS                                 | 66 63.5)                 | 38  62.5)                | 136 63.0)                |
| PRIOR SURGERY RELATEDTO CANCER               |                          |                          |                          |
| YES                                          | 28  28:3)                |                          | 336                      |
| NO                                           |                          | 6  %:3                   | 1245 ( 28:3)             |
| PRIOR RADIOTHERAPY                           |                          |                          |                          |
| YES                                          | 75 (9.5)                 | 77 ( .9.7)               | 152 (9.6)                |
| NO                                           | 714 ( 90.5)              | 715 ( 90.3)              | 1429( 90.4)              |

(A) Percentages are based on subjects with prior adjuvant/neo-adjuvant therapy.

## Subsequent Anti-Cancer Therapy - All Randomized Subjects

Among all randomized subjects, subsequent cancer therapy (radiotherapy, surgery, and/or systemic therapy) was received by 297 (37.6%) subjects in the nivo+chemo arm compared to 326 (41.2%) subjects in the chemo arm (Table 9). Subsequent systemic therapy was received by 268 (34.0%) subjects in the nivo+chemo arm and 311 (39.3%) subjects in the chemo arm. Subsequent immunotherapy was received by a lower percentage of subjects in the nivo+chemo arm compared with the chemo arm (1.5% vs 8.1%). A similar percentage of subjects in the nivo+chemo arm and chemo arm received subsequent chemotherapy (32.7% vs 36.6%).

<div style=\"page-break-after: always\"></div>

Table 9. Subsequent Cancer Therapy Summary - All Randomized Subjects

|                                                                    | Number of Subjects (%)   | Number of Subjects (%)   |
|--------------------------------------------------------------------|--------------------------|--------------------------|
|                                                                    | Nivo + Chemo N = 789     | Chemo N = 792            |
| SUBJECTS WITH ANY SUBSEQUENT THERAPY (%）(1)                        | 297 ( 37.6)              | 326 (41.2)               |
| SUBJECTS WHO RECEIVED SUBSEQUENT RADIOTHERAPY* (%)                 | 37 (4.7)                 | 44 (5.6)                 |
| SUBJECTS WHO RECEIVED SUBSEQUENT SURGERY (%)                       | 17 2.2)                  | 23（ 2.9)                 |
| SUBJECTS WHO RECEIVED SUBSEQUENT SYSTEMIC THERAPY (%)              | 268 (34.0)               | 311 ( 39.3)              |
| IMMUNOTHERAPY                                                      | 12 1.5)                  | 64 8.1)                  |
| ANTI-PD1                                                           | 1.1)                     | 58                       |
| NIVOLUMAB                                                          | 96216 0.8)               | 7.3)                     |
| PEMBROLIZUMAB                                                      | 0.3)                     | 28 3.5) 27 3.4)          |
|                                                                    | 0.1)                     |                          |
| TORIPALIMAB                                                        | 0:o                      | 3 0.4) 4 0.5)            |
| ANTI-PD-L1                                                         |                          |                          |
| ATEZOLIZUMAB                                                       |                          |                          |
|                                                                    |                          | 0.5)                     |
| ANTI-CTLA4                                                         | 0.1)                     | 0.3)                     |
| IPILIMUMAB                                                         | 1 0.1)                   | 0.3)                     |
| OTHER IMMUNOTHERAPY                                                | 3 0.4)                   | 42220 0.3)               |
|                                                                    | 0.1)                     |                          |
| INVESTIGATIONALIMMUNOMODULATING AGENT INVESTIGATIONALIMMUNOTHERAPY | 20 0.3)                  | 0.1)                     |
| TUMOR NECROSIS FACTOR                                              |                          |                          |
|                                                                    | 113 14.3)                | 0.1) 116 14.6)           |
| TARGETEDTHERAPY AFLIBERCEPT                                        | 1 0.1) 12 1.5)           | 0 19 2.4) 0.3)           |
| APATINIB BEVACIZUMAB                                               |                          | 21 0.1) 1 0.1)           |
| CABOZANTINIB CRENOLANIB                                            | 00211 0.3)               |                          |
| ENDOSTAR                                                           | 0.1)                     | 0.1)                     |
| IBRUTINIB                                                          |                          |                          |
| LAPATINIB                                                          | 0.1) 0.3)                | 0.1) 0                   |
| LENVATINIB                                                         | 1200                     | 1 1                      |
|                                                                    |                          | 0.1)                     |
| MONOCLONAL ANTIBODY                                                |                          | 0.1)                     |
|                                                                    |                          | 0                        |
| OLAPARIB RAMUCIRUMAB REGORAFENIB                                   | 1 0.1) 91                | 85 10.7) 2               |
|                                                                    | 11.5) 20 0.3)            | 0.3) 1                   |
| SELUMETINIB TRASTUZUMAB                                            | 7 0.9)                   | 0.1) 8                   |
|                                                                    |                          | 1.0)                     |
| OTHERSYSTEMICCANCERTHERAPY-EXPERIMENTALDRUGS                       | 28 3.5) 28               | 35 4.4) 35               |
| INVESTIGATIONALANTINEOPLASTIC                                      | 3.5)                     | 4.4)                     |
| OTHERSYSTEMICCANCERTHERAPY-CHEMOTHERAPY                            | 258 32.7) 2 0.3) 2.7)    | 290 ( 36.6) 0            |
| ANTINEOPLASTIC CAPECITABINE CARBOPLATIN                            | 21 7                     | 22 2.8) 9                |
| CISPLATIN                                                          | 14                       | 1.1) 15 1.9)             |
|                                                                    | 0.9)                     |                          |
| DOCETAXEL                                                          | 1.8) 18 2.3)             | 22 2.8)                  |
| DOXORUBICIN EPIRUBICIN                                             | 0 0 0.1)                 | 1 0.1) 3                 |
| ETOPOSIDE                                                          | 1                        | 1                        |
| FLOXURIDINE                                                        | 0                        | 0.4) 0.1) 1 1            |
|                                                                    | 0                        |                          |
| FLUOROPYRIMIDINE FLUOROURACIL                                      | 68                       | 0.1) 0.1) 106 13.4)      |
| FLUR/IRINOT/LEUCO                                                  | 1                        | 0                        |
| GIMER/OTERA/TEGFUR                                                 | 8.6) 0.1) 14 1.8)        | 17                       |
|                                                                    |                          | 1                        |
| HERBALANTICANCERREMEDIES                                           | 0                        | 2.1) 0.1) 118 14.9)      |
| IRINOTECAN                                                         | 91                       |                          |
| METHOTREXATE                                                       | 11.5) 1                  | 1                        |
| MITOMYCIN                                                          | 0.1) 0                   | 0.1) 1                   |
| OXALIPLATIN                                                        | 27                       | 0.1) 43                  |
|                                                                    | 154                      | 170                      |
| PACLITAXEL                                                         |                          | 5.4) 21.5)               |
|                                                                    | 3.4)                     |                          |
| PIRARUBICIN                                                        | 19.5) 0                  |                          |
| RALTITREXED                                                        | 4 0.5)                   | 0.1) 0.9)                |

(1) Subject may .have received more than one type of subsequent therapy. Includes paliiative radiotherapy

## Baseline Tumour Specimen Characteristics

Tumour Cell PD-L1 (TC PD-L1)

Overall, 789/789 (100.0%) randomized subjects in the nivo+chemo arm and 787/792 (99.4%) randomized subjects in the chemo arm had quantifiable TC PD-L1 expression at baseline. TC PD-L1

<div style=\"page-break-after: always\"></div>

expression was well balanced across treatment arms in all randomized subjects with PD-L1 quantifiable at baseline:

- -In all randomized subjects with PD-L1 quantifiable at baseline, 11.5% (91/789) and 11.7% (92/787) had a baseline TC PDL1 ≥ 5% in the nivo+chemo and chemo arms, respectively.
- -In all randomized subjects with PD-L1 quantifiable at baseline, 16.0% (126/789) and 16.1% (127/787) had a baseline TC PDL1 ≥ 1% in the nivo+chemo and chemo arms, respectively.

Table 10. Frequency of TC PD-L1 Expression Status - All Randomized Subjects

| Population PD-L1 Expression Category                                                                                                                                                                                                            | Nivo+ Chemo N = 789                                                                        | Chemo N = 792                                                                                | Total N = 1581                                                                                         |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|
| SUBJECTS WITH PD-L1 EXPRESSION MISSING AT BASELINE (N(&))                                                                                                                                                                                       | 0                                                                                          | 1 (0.1)                                                                                      | 1 (<0.1)                                                                                               |
| SUBJECTS WITH PD-L1 QUANTIFIABIE AT BASELINE(N(&)) PD-L1 EXPRESSION (&) MEAN MEDIAN MIN ， MAX Q1，Q3 STANDARDDEVIATION                                                                                                                           | 789 (100.0) 3.7 0.0 0,95 0.0,0.0 13.3                                                      | 787 (99.4) 4.4 0.0 0，100 0.0,0.0 15.3                                                        | 1576 (99.7) 4.0 0.0 0，100 0.0,0.0 14.4                                                                 |
| SUBJECTSWITHBASELINEPD-L1EXPRESSION>=18 SUBJECTSWITHBASELINEPD-L1EXPRESSION<18 SUBJECTSWITHBASELINEPD-L1EXPRESSION>=5% SUBJECTSWITHBASELINEPD-L1EXPRESSION<58 SUBJECTSWITHBASELINE PD-L1EXPRESSION>=10% SUBJECTSWITHBASELINEPD-L1EXPRESSION<108 | 126/ 789 9(16.0) 663/ 789 84.0) 91/ 789 11.5) 698/ 789 (88.5) 76/ 789 (9.6) 713/789 (90.4) | 127/ 787 (16.1) 660/ 787 83.9) 92/ 787 (11.7) 695/ 787 ( 88.3) 75/ 787 (9.5) 712/ 787 (90.5) | 253/ 1576 (16.1) 1323/ 1576 83.9) 183/1576（1 11.6) 1393/ 1576 (88.4) 151/ 1576 (9.6) 1425/ 1576 (90.4) |
| SUBJECTS WITH INDETERMINATE PD-L1 EXPRESSION AT BASELINE (N(&))                                                                                                                                                                                 | 0                                                                                          | 4(0.5)                                                                                       | 4(0.3)                                                                                                 |
|                                                                                                                                                                                                                                                 | 0                                                                                          | 0                                                                                            | 0                                                                                                      |

PD-L1 CPS

Among the 1581 subjects concurrently randomized to the nivo+chemo and chemo arms, 781/789 (99.0%) and 780/792 (98.5%) subjects had quantifiable PD-L1 CPS expression at baseline, respectively. PD-L1 CPS expression was well balanced across treatment arms in all randomized subjects with PD-L1 quantifiable at baseline:

- In all randomized subjects with PD-L1 CPS quantifiable at baseline, 60.6% (473/781) and 61.8% (482/780) had a baseline PDL1 CPS ≥ 5 in the nivo+chemo and chemo arms, respectively.
- In all randomized subjects with PD-L1 CPS quantifiable at baseline, 82.1% (641/781) and 84.0% (655/780) had a baseline PDL1 CPS ≥ 1 in the nivo+chemo and chemo arms, respectively.

<div style=\"page-break-after: always\"></div>

Table 11. Frequency of PD-L1 CPS Expression Status - All Randomized Subjects

<!-- image -->

| Population PD-Ll Expression Category                                                                                                                                                                                                            | Nivo + Chemo N = 789                                                                          | Chemo N = 792                                                                              | Total N = 1581                                                                                          |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| SUBJECTS WITH PD-L1 EXPRESSION MISSING AT BASELINE (N(%))                                                                                                                                                                                       | 0                                                                                             | 1 (0.1)                                                                                    | 1 (<0.1)                                                                                                |
| SUBJECTS WITH PD-L1 QUANTIFIABIE AT BASELINE (N(&)) PD-L1 EXPRESSION MEAN MEDIAN MIN， MAX Q1，Q3 STANDARDDEVIATION                                                                                                                               | 781 (99.0) 18.2 5.0 0，100 1.0,25.0 25.0                                                       | 780 (98.5) 19.9 10.0 0，100 1.0, 30.0 26.6                                                  | 1561 (98.7) 19.1 8.0 0，100 1.0，30.0 25.8                                                                |
| SUBJECTSWITHBASELINEPD-L1EXPRESSION>=1 SUBJECTSWITHBASELINEPD-L1EXPRESSION<1 SUBJECTSWITHBASELINEPD-L1EXPRESSION>=5 SUBJECTS WITH BASELINE PD-L1 EXPRESSION < 5 SUBJECTSWITHBASELINEPD-L1 EXPRESSION>=10 SUBJECTSWITHBASELINEPD-L1EXPRESSION<10 | 641/ 781 (82.1) 140/781 17.9) 473/ 781 60.6) 308/ 781 (39.4) 375/ 781 (48.0) 406/ 781 ( 52.0) | 655/780(84.0) 125/780 (16.0) 482/ 780 (61.8) 298/ 780 (38.2) 393/ 780 (50.4) 387/780(49.6) | 1296/ 1561 ( 83.0) 265/1561 17.0) 955/ 1561 61.2) 606/ 1561 38.8) 768/1561 (49.2) 793/ 1561 (50.8) 0.3) |
| SUBJECTS WITH INDETERMINATE PD-L1 EXPRESSION AT BASELINE (N(&))                                                                                                                                                                                 | 0                                                                                             | 4( 0.5)                                                                                    |                                                                                                         |
| SUBJECTS WITH PD-L1 EXPRESSION AT BASELINE NOT EVALUABIE (N(&))                                                                                                                                                                                 | 8 (1.0)                                                                                       | 7( 0.9)                                                                                    | 15 (0.9)                                                                                                |

## Cross-tabulation of TC PD-L1 and PD-L1 CPS

TC PD-L1 at the 1% cut-off was one of the stratification factors; the percentage of subjects with TC PDL1 ≥ 1% was balanced across the treatment arms in the pre -specified primary efficacy population (subjects with PDL1 CPS ≥ 5) and in the pre-specified secondary efficacy populations (subjects with PDL1 CPS ≥ 1 and all randomized subjects).

Table 12. Frequency of Subjects with TC PDL1 ≥ 1% Among Pre -Specified PD-L1 CPS Populations

| EfficacyPopulation   | Subjects with TC PD-L1 ≥1% / All Randomized Subjects (n/N, %)   | Subjects with TC PD-L1 ≥1% / All Randomized Subjects (n/N, %)   | Subjects with TC PD-L1 ≥1% / All Randomized Subjects (n/N, %)   |
|----------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|
|                      | Nivo+Chemo                                                      | Chemo                                                           | Total                                                           |
| PD-L1 CPS≥ 5         | 110/473 (23.3)                                                  | 120/482 (24.9)                                                  | 230/955 (24.1)                                                  |
| PD-L1 CPS≥1          | 122/641 (19.0)                                                  | 123/655 (18.8)                                                  | 245/1296 (18.9)                                                 |
| AllRandomized        | 127/789 (16.1)                                                  | 127/792 (16.0)                                                  | 254/1581 (16.1)                                                 |

Abbreviations: CPS - combined positive score, PD L1 - programmed death-ligand 1

## MSI Status in All Randomized Subjects

MSI status was determined retrospectively on pre-treatment FFPE tissues using the Idylla™ MSI Test by central laboratories. The Idylla™ MSI Test reported results as MSS, MSI-H, or invalid in cases where the MSI status of tested samples could not be reliably determined. Of the 1581 randomized subjects, 44 (2.8%) subjects were MSI-H, 1377 (87.1%) subjects were MSS, 132 (8.3%) subjects had no tumour tissue for MSI testing, and 28 (1.8%) subjects had invalid results.

<div style=\"page-break-after: always\"></div>

## Numbers analysed

Table 13. Analysis Populations in CA209649

| Population                                                                                                                                          |   Nivo+Chemo |   Chemo |   Total |
|-----------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------|---------|
| Randomized: subjects randomized concurrently to nivo+chemo or chemo from 17-Apr-2017 (included, the start date of randomization)                    |          789 |     792 |    1581 |
| Randomized with measurable disease(BICR):randomized subjects whohave at least one target/measurable or non-measurable lesion at baseline (per BICR) |          603 |     608 |    1211 |
| Randomized,CPS≥5:randomized subjects with CPS≥ 5                                                                                                    |          473 |     482 |     955 |
| Randomized, CPS ≥1: randomized subjects with CPS ≥ 1                                                                                                |          641 |     655 |    1296 |
| All Treated:all randomized subjects whoreceived at least one dose of study drug                                                                     |          782 |     767 |    1549 |
| All TC PD-L1 Quantifiable: all PD-L1 tested subjects with quantifiable TC PD-L1 expression at baseline                                              |          789 |     787 |    1576 |
| AllPD-L1 CPS Quantifiable: all PD-L1 tested subjects with quantifiable PD-L1 CPS expression at baseline                                             |          781 |     780 |    1561 |

Abbreviations: BICR - blinded independent central review, chemo - chemotherapy, CPS - combined positive score, MSI - microsatellite instability, nivo - nivolumab, TC PD-L1 - tumor cell programmed death ligand 1

## Outcomes and estimation

Efficacy analyses were performed on the population of all subjects concurrently randomized (using the interactive response technology [IRT]) to either the nivo+chemo or chemo arms from 17-Apr-2017 to 27-May-2019.

Table 14. Summary of Key Efficacy Results

|                                                  | AllRandomizedSubjectswith PD-L1 CPS ≥ 5          | AllRandomizedSubjectswith PD-L1 CPS ≥ 5          | AllRandomizedSubjectswith PD-L1 CPS ≥ 1   | AllRandomizedSubjectswith PD-L1 CPS ≥ 1   | All Randomized Subjects     | All Randomized Subjects     |
|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|-------------------------------------------|-------------------------------------------|-----------------------------|-----------------------------|
| EfficacyParameter                                | Nivo+Chemo (N = 473)                             | Chemo (N = 482)                                  | Nivo+Chemo (N = 641)                      | Chemo (m = 655)                           | Nivo+Chemo (N = 789)        | Chemo (N =792)              |
| OS                                               |                                                  |                                                  |                                           |                                           |                             |                             |
| Events, n (%)                                    | 309 (65.3)                                       | 362 (75.1)                                       | 434 (67.7)                                | 492 (75.1)                                | 544 (68.9)                  | 591 (74.6)                  |
| Median OS (95% CI)*, months                      | 14.39 (13.11, 16.23)                             | 11.10 (10.02, 12.09)                             | 13.96 (12.55, 14.98)                      | 11.33 (10.64, 12.25)                      | 13.83 (12.55,14.55)         | 11.56 (10.87, 12.48)        |
| HR (CI b                                         | 0.71 (98.4% CI: 0.59, 0.86)                      | 0.71 (98.4% CI: 0.59, 0.86)                      | 0.77 (99.3% CI: 0.64, 0.92)               | 0.77 (99.3% CI: 0.64, 0.92)               | 0.80 (99.3% CI: 0.68, 0.94) | 0.80 (99.3% CI: 0.68, 0.94) |
| p-valuec                                         | <0.0001                                          | <0.0001                                          | <0.0001                                   | <0.0001                                   | 0.0002                      | 0.0002                      |
| 12 month OS Rates (95% CI)a, %                   | 57.3 (52.6, 61.6)                                | 46.4 (41.8, 50.8)                                | 55.5 (51.5, 59.3)                         | 47.0 (43.1, 50.9)                         | 55.0 (51.4, 58.4)           | 47.9 (44.4, 51.4)           |
| PFSperBICR (1°Definition)                        |                                                  |                                                  |                                           |                                           |                             |                             |
| Events, n (%)                                    | 328 (69.3)                                       | 350 (72.6)                                       | 454 (70.8)                                | 472 (72.1)                                | 559 (70.8)                  | 557 (70.3)                  |
| Median PFS (95% CI)a, months                     | 7.69 (7.03,9.17)                                 | 6.05 (5.55,6.90)                                 | 7.49 (7.03,8.41)                          | 6.90 (6.08,7.03)                          | 7.66 (7.10,8.54)            | 6.93 (6.60, 7.13)           |
| HR (CI) b                                        | 0.68 (98% CI: 0.56, 0.81)                        | 0.68 (98% CI: 0.56, 0.81)                        | 0.74 (95% CI: 0.65, 0.85)                 | 0.74 (95% CI: 0.65, 0.85)                 | 0.77 (95% CI: 0.68, 0.87)   | 0.77 (95% CI: 0.68, 0.87)   |
| p-valuec                                         | <0.0001                                          | <0.0001                                          | Not tested                                | Not tested                                | Not tested                  | Not tested                  |
| 12 month OS Rates (95% CI)²,%                    | 36.3 (31.7,41.0)                                 | 21.9 (17.8, 26.1)                                | 34.2 (30.3, 38.2)                         | 22.4 (18.8, 26.1)                         | 33.4 (29.9, 37.0)           | 23.2 (19.9, 26.7)           |
| ORRperBICR(CR+PR) inAll RandomizedSubjects       | ORRperBICR(CR+PR) inAll RandomizedSubjects       |                                                  |                                           |                                           |                             |                             |
| N responders/N (%)                               | 237/473 (50.1)                                   | 184/482 (38.2)                                   | 314/641 (49.0)                            | 249/655 (38.0)                            | 370/789 (46.9)              | 293/792 (37.0)              |
| pID %S6                                          | (45.5, 54.7)                                     | (33.8, 42.7)                                     | (45.1, 52.9)                              | (34.3, 41.9)                              | (43.4, 50.4)                | (33.6, 40.5)                |
| Difference of ORR (95% CI)                       | 12.7 (6.7, 18.8)                                 | 12.7 (6.7, 18.8)                                 | 12.4 (7.3, 17.6)                          | 12.4 (7.3, 17.6)                          | 12.2 (7.5, 16.8)            | 12.2 (7.5, 16.8)            |
| ORRperBICR(CR+PR)inSubjectswithMeasurableDisease | ORRperBICR(CR+PR)inSubjectswithMeasurableDisease | ORRperBICR(CR+PR)inSubjectswithMeasurableDisease |                                           |                                           |                             |                             |
| N responders/N (%)                               | 226/378 (59.8)                                   | 177/391 (45.3)                                   | 300/504 (59.5)                            | 239/515 (46.4)                            | 350/603 (58.0)              | 280/608 (46.1)              |
| pIO %S6                                          | (54.7, 64.8)                                     | (40.3, 50.4)                                     | (55.1, 63.8)                              | (42.0, 50.8)                              | (54.0, 62.0)                | (42.0, 50.1)                |
| Difference of ORR (95% CI)é                      | 16.1 (9.4, 22.8)                                 | 16.1 (9.4, 22.8)                                 | 14.2 (8.3, 20.1)                          | 14.2 (8.3, 20.1)                          | 12.8 (7.3, 18.2)            | 12.8 (7.3, 18.2)            |

<div style=\"page-break-after: always\"></div>

| DORperBICRinSubjectswithMeasurableDisease   | DORperBICRinSubjectswithMeasurableDisease   |                     |                     |                     |                     |                     |
|---------------------------------------------|---------------------------------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| Nevents/N responders (%)                    | 143/226 (63.3) 9.49                         | 125/177 (70.6) 6.97 | 194/300 (64.7) 8.54 | 177/239 (74.1) 6.93 | 231/350 (66.0) 8.51 | 206/280 (73.6) 6.93 |
| Median (95% CI)*, months                    | (7.98, 11.37)                               | (5.65, 7.85)        | (7.69,10.22)        | (5.78, 7.56)        | (7.23,9.92)         | (5.82, 7.16)        |
| Min, Max, months                            | 1.1+, 29.6+                                 | 1.2+,30.8+          | 1.1+, 29.6+         | 1.2+,30.8+          | 1.0+,29.6+          | 1.2+,30.8+          |
| % with DOR (95% CI)a ≥ 12 months            | 42.5 (35.6, 49.2)                           | 29.9 (22.8, 37.3)   | 41.2 (35.3, 47.0)   | 28.2 (22.2, 34.5)   | 40.4 (34.9, 45.8)   | 27.9 (22.3, 33.7)   |

a Based onKaplan-Meier estimates.

Stratified Cox proportional hazards model.HR is Nivo+Chemo over Chemo.

2-sided p-value using a stratified log-rank test. Stratified by region (Asia vs. US vs ROW), ECOG (0 vs 1), Tumor Cell PD-L1 (≥ 1% vs &lt;1% [including indeterminate]) and chemotherapy (XELOX vs FOLFOX).

Confirmed CR or PR per RECIST 1.1. CI based on the Clopper and Pearson method.

The difference in response rate (Nivo + Chemo vs Chemo) is not the simple difference between the rates but is adjusted for the stratification factors based on theDerSimonian and Laird methodology

Symbol+indicates a censoredvalue.

Databaselock:10-Jul-2020;Minimumfollow-upwas12.1months.

Abbreviations:BICR-blinded independent central review,chemo-chemotherapy,CI-confidenceinterval,CPS-combinedpositive score,CR-complete response, DOR - duration of response, HR - hazard ratio, Nivo - nivolumab, ORR - objective response rate, OS - overall survival, PD-L1 - programmed deathligand 1, PFS -progression-free survival, PR -partial response

## Primary endpoints

## OS in subjects with PD-L1 CPS ≥ 5

In all randomized subjects with PD-L1 CPS ≥ 5, nivo+chemo demonstrated a statistically significant improvement in OS compared with chemo: HR = 0.71 (98.4% CI: 0.59, 0.86); stratified log-rank test p-value &lt; 0.0001. Median OS (95% CI) was longer in the nivo+chemo arm compared with the chemo arm: 14.39 (13.11, 16.23) vs. 11.10 (10.02, 12.09) months.

OS rates (95% CI) were higher in the nivo+chemo arm compared with the chemo arm: 81.4% (77.5, 84.6) vs. 74.8% (70.6, 78.5) at 6 months and 57.3% (52.6, 61.6) and 46.4% (41.8, 50.8) at 12 months. At database lock (minimum follow-up 12.1 months), 34.7% and 24.9% of all randomized subjects with PD-L1 CPS ≥ 5 in the nivo+chemo and chemo arms, respectively, were censored for OS. 147/473 (31.1%) and 90/482 (18.7%) subjects are either continuing on-treatment or in follow-up in the nivo+chemo and chemo arms, respectively.

Table 15. Status of censored subjects, overall survival - All randomised subjects with PD-L1 CPS≥5

|                                                           | Number of Subjects (%)       | Number of Subjects (%)       |
|-----------------------------------------------------------|------------------------------|------------------------------|
|                                                           | Nivo + Chemo N = 473         | Chemo N = 482                |
| NUMBER OF DEATHS (%)                                      | 309 ( 65.3)                  | 362 (75.1)                   |
| NUMBER OF SUBJECTS CENSORED (%)                           | 164 (34.7)                   | 120 (24.9)                   |
| STATUS OF CENSORED SUBJECTS (%)                           |                              |                              |
| STILL ON TREATMENT NOT PROGRESSED PROGRESSED (1)          | 62 (13.1) 57( 12.1) 5 ( 1.1) | 25 (5.2) 25 (5.2) 0          |
| IN FOLLOW-UP                                              |                              | 65                           |
|                                                           | 85 (18.0)                    | (13.5)                       |
| OFFSTUDY SUBJECT WITHDREW CONSENT LOST TO FOLLOW-UP OTHER | 17 3.6) 10 2.1) 7 1.5) 0     | 30 6.2) 19 3.9) 10 2.1) 0.2) |

(1)Radiographic or Clinical Progression

Separation of the Kaplan-Meier curves favouring nivo+chemo over chemo occurred early (at &lt; 1 month), with increased separation over time.

<div style=\"page-break-after: always\"></div>

Figure 3. Kaplan Meier Plot of Overall Survival - All Randomized Subjects with PDL1 ≥ 5

<!-- image -->

Symbols represent censored observations.

Stratified Cox proportional hazard model for hazard ratio.

Stratified log-rank tcst for p-value.

Results for the following sensitivity analyses were consistent with the primary OS analysis:

- -unstratified analysis: HR = 0.70 (98.4% CI: 0.58, 0.84)
- -unstratified analysis with the stratification factors as covariates: HR = 0.68 (98.4% CI: 0.57, 0.83)
- -stratified analysis based on the first 420 randomized subjects with PD-L1 CPS ≥ 5: HR = 0.70 (98.4% CI: 0.53, 0.92). Stratified analysis based on the population with the first 354 events among all randomized subjects with PD-L1 CPS ≥ 5: HR = 0.64 (98.4% CI: 0.49, 0.83). These analyses were conducted to reflect the OS analysis planned under Revised Protocol 07.

In a multivariate analysis of OS, the treatment effect of nivo+chemo vs. chemo was consistent with the primary OS analysis when adjusted for the baseline factors listed below (HR = 0.71; 95% CI: 0.61, 0.84; multivariate Cox model p value &lt; 0.0001): age (&lt; 65 vs. ≥ 65), sex (male vs. female), primary tumour location (GC vs. EAC and EAC vs. GEJC), disease status (locally recurrent/advanced vs. metastatic), Lauren classification (intestinal type vs. diffuse type, mixed vs. diffuse type, and unknown vs. diffuse type), peritoneal metastases (no vs. yes), prior surgery or radiotherapy (yes vs. no), number of organs with baseline lesion (≤ 1 vs. ≥ 2), and presence of signet ring cells (no vs. yes).

<div style=\"page-break-after: always\"></div>

Overall in subjects with PDL1 CPS ≥ 5, 37.2% and 40.2% of subjects in the nivo+chemo and chemo arms, respectively, received subsequent cancer therapy. In the nivo+chemo arm, 33.4% received subsequent systemic therapy; this included 1.3% who received subsequent immunotherapy, 13.1% who received targeted therapy, and 31.9% who received subsequent chemotherapy. In the chemo arm, 38.6% received subsequent systemic therapy; this included 8.7% who received subsequent immunotherapy (7.7% who received subsequent anti-PD-1 therapy), 14.1% who received targeted therapy, and 36.7% who received subsequent chemotherapy.

## PFS per BICR (Primary Definition) in subjects with PDL1 CPS ≥ 5

In all randomized subjects with PD-L1 CPS ≥ 5, nivo+chemo demonstrated a statistically significant improvement in PFS per BICR (primary definition) compared with chemo: HR = 0.68 (98% CI: 0.56, 0.81); stratified log-rank test p-value &lt; 0.0001. Median PFS (95% CI) was longer with nivo+chemo compared with chemo: 7.69 (7.03, 9.17) vs. 6.05 (5.55, 6.90) months, respectively.

PFS rates were higher with nivo+chemo compared with chemo: 62.4% vs. 50.1% at 6 months, respectively, and 36.3% vs. 21.9% at 12 months, respectively. At database lock, 30.7% and 27.4% of randomized subjects in the nivo+chemo and chemo arms, respectively, were censored for PFS (see Table S.5.24.1 for the reasons for censoring).

Separation of the Kaplan-Meier curves favouring nivo+chemo over chemo occurred at approximately 2 months, with increased separation over time.

<div style=\"page-break-after: always\"></div>

Figure 4. Kaplan Meier Plot of Progression-Free Survival per BICR, Primary Definition - All Randomized Sujects with PDL1 CPS ≥ 5

<!-- image -->

Symbols represent censored observations.

Stratified Cox proportional hazard model for hazard ratio. Stratifiedlog-rank test for p-value.

Results for the following sensitivity analyses were consistent with the primary PFS analysis per BICR:

- -unstratified analysis: HR = 0.69 (98% CI: 0.58, 0.83)
- -unstratified analysis with the stratification factors as covariates: HR = 0.68 (98% CI: 0.57, 0.81)
- -stratified analysis based on subjects with the first 228 events among the first 298 randomized subjects with PD-L1 CPS ≥ 5: HR = 0.69 (98% CI: 0.49, 0.97) This sensitivity analysis was conducted to reflect the design per Revised Protocol 07.

In a multivariate analysis of PFS, the treatment effect of nivo+chemo vs. chemo was consistent with the primary PFS analysis when adjusted for the baseline factors listed below (HR = 0.66; 95% CI: 0.56, 0.77; multivariate Cox model p value &lt; 0.0001): age (&lt; 65 vs. ≥ 65), sex (male vs. female), primary tumour location (GC vs. EAC and EAC vs. GEJC), disease status (locally recurrent/advanced vs. metastatic), Lauren classification (intestinal type vs. diffuse type, mixed vs. diffuse type, and unknown vs. diffuse type), peritoneal metastases (no vs. yes), prior surgery or radiotherapy (yes vs. no), number of organs with baseline lesion (≤ 1 vs. ≥ 2), and presence of signet ring cells (no vs. yes).

<div style=\"page-break-after: always\"></div>

Analysis of PFS per BICR using the secondary PFS definition, which accounts for the tumour scans post subsequent therapies (HR = 0.69; 98% CI: 0.58, 0.81; p-value &lt; 0.0001), was consistent with the analysis using the primary PFS definition.

Figure 5. Kaplan-Meier Plot of Progression-free Survival per BICR, Secondary Definition - All Randomized Subjects with PDL1 CPS ≥ 5

<!-- image -->

The concordance between BICR and investigator PFS (primary definition) assessments of events and censoring was high: 87.9% for nivo+chemo and 88.4% for chemo.

## Secondary endpoints (hierarchically tested)

OS in subjects with PDL1 CPS ≥1

The OS HR was 0.77 (99.3% CI: 0.64, 0.92) for nivo+chemo vs. chemo with a stratified log rank test p-value &lt;0.0001. Median OS was 13.96 (95% CI: 12.55, 14.98) vs. 11.33 (95% CI: 10.64, 12.25) months, respectively.

<div style=\"page-break-after: always\"></div>

Figure 6. Kaplan-Meier Plot of Overall Survival - All Randomized Subjects with PD-L1 CPS ≥ 1

<!-- image -->

Nivo + Chemo vs Chemo - hazard ratio (99.3% Cl): 0.77 (0.64, 0.92). p-value: &lt;0.0001

## OS in All Randomized Subjects

Median follow up for survival (date of randomization to the last known date alive or death date) was 13.08 months for subjects in the nivo+chemo arm and 11.06 months for subjects in the chemo arm.

In all randomized subjects, nivo+chemo demonstrated a statistically significant improvement in OS compared with chemo: HR = 0.80 (99.3% CI: 0.68, 0.94); stratified log-rank test p-value = 0.0002. Median OS (95% CI) was longer in the nivo+chemo arm compared with the chemo arm: 13.83 (12.55, 14.55) vs. 11.56 (10.87, 12.48) months.

OS rates (95% CI) were higher in the nivo+chemo arm compared with the chemo arm: 80.1% (77.2, 82.8) vs. 76.3% (73.1, 79.1) at 6 months and 55.0% (51.4, 58.4) and 47.9% (44.4, 51.4) at 12 months. At database lock (minimum follow-up 12.1 months), 31.1% and 25.4% of all randomized subjects in the nivo+chemo and chemo arms, respectively, were censored for OS. 10.6% and 4.9% subjects in the nivo+chemo and chemo arms respectively were still on treatment, and 17.1% and 14.9% subjects in the 2 arms respectively were in follow-up.

Separation of the Kaplan-Meier curves favouring nivo+chemo over chemo occurred at approximately 2 months, with increased separation over time.

Table 16. Overall Survival of Nivo+Chemo vs. Chemo in All Randomized Subjects (CA209649)

<div style=\"page-break-after: always\"></div>

|                                 | All Randomized Subjects     | All Randomized Subjects     |
|---------------------------------|-----------------------------|-----------------------------|
| Efficacy Parameter              | Nivo+Chemo (N = 789)        | Chemo (N = 792)             |
| OS (formally tested endpoint)   |                             |                             |
| Events, n (%)                   | 544 (68.9)                  | 591 (74.6)                  |
| Median OS (95% CI) a , months   | 13.83 (12.55, 14.55)        | 11.56 (10.87, 12.48)        |
| HR (CI) b                       | 0.80 (99.3% CI: 0.68, 0.94) | 0.80 (99.3% CI: 0.68, 0.94) |
| p-value c                       | 0.0002                      | 0.0002                      |
| 12 month OS rates (95% CI) a ,% | 55.0 (51.4, 58.4)           | 47.9 (44.4, 51.4)           |

a Based on Kaplan-Meier estimates.

b Stratified Cox proportional hazards model. HR is Nivo+Chemo over Chemo.

c 2-sided p-value using a stratified log-rank test. Stratified by region (Asia [China, Japan, Korea, Taiwan, Hong Kong, and Singapore] vs. US [US and Canada] vs. ROW [Europe, Australia, Latin America, Israel, Russian Federation, and Turkey]), ECOG PS (0 vs. 1), TC PDL1 (≥ 1% vs. &lt;1%/indeterminate) and chemotherapy (XELOX vs. FOLFOX).

Database lock: 10-Jul-2020; Minimum follow-up was 12.1 months.

Abbreviations:  CI  -  confidence  interval,  ECOG  -  Eastern  Cooperative  Oncology  Group,  FOLFOX  -  folinic  acid (leucovorin) \"FOL\", (fluorouracil [5-FU]) \"F\", and oxaliplatin (eloxatin) \"OX\", HR - hazard ratio, Nivo - nivolumab, OS - overall survival, PS - performance status, ROW - rest of world, XELOX - Xeloda (capecitabine)\"XEL\" and oxaliplatin \"OX\"

Table 17. Status of Censored Subjects, Overall Survival All Randomized Subjects

|                                 | Number of Subjects (%)   | Number of Subjects (%)   |
|---------------------------------|--------------------------|--------------------------|
|                                 | Nivo + Chemo N = 789     | Chemo N = 792            |
| NUMBER OFDEATHS(%)              | 544 ( 68.9)              | 591 ( 74.6)              |
| NUMBER OF SUBJECIS CENSORED (%) | 245 ( 31.1)              | 201 ( 25.4)              |
| STATUS OF CENSORED SUBJECIS (%) |                          |                          |
| STILLONTREATMENT                | 84 (10.6)                | 39 (4.9)                 |
| NOT PROGRESSED                  | 77 (9.8)                 | 39 (4.9)                 |
| PROGRESSED (1)                  | 7 0.9)                   | 0                        |
| IN FOLIOW-UP                    | 135 ( 17.1)              | 118 (14.9)               |
| OFF STUDY                       | 26 3.3)                  | 44 5.6)                  |
| SUBJECTWITHDREWCONSENT          | 15 1.9)                  | 3.9)                     |
| LOSTTOFOLLOW-UP                 | 10 1.4)                  | 31 1.3)                  |
| OTHER                           |                          | 3 0.4)                   |

(1) Radioqraphic or Clinical Proqression

<div style=\"page-break-after: always\"></div>

Figure 7. Kaplan Meier Plot of Overall Survival - All Randomized Subjects

<!-- image -->

Symbols represent censored observations.

Stratified Cox proportional hazard model for hazard ratio.

Stratified log-rank test for p-value.

Results for the following sensitivity analyses were consistent with the primary OS analysis:

- -unstratified analysis: HR = 0.79 (99.3% CI: 0.67, 0.93)
- -unstratified analysis with stratification factors as covariates: HR = 0.78 (99.3% CI: 0.67, 0.92)

In a multivariate analysis of OS, the treatment effect of nivo+chemo vs. chemo was consistent with the primary OS analysis when adjusted for the baseline factors listed below (HR = 0.82; 95% CI: 0.73, 0.92; multivariate Cox model p-value = 0.0011). age (&lt; 65 vs. ≥ 65), sex (male vs. female), primary tumour location (GC vs. EAC and EAC vs. GEJC), disease status (locally recurrent/advanced vs. metastatic), Lauren classification (intestinal type vs. diffuse type, mixed vs. diffuse type, and unknown vs. diffuse type), peritoneal metastases (no vs. yes), prior surgery or radiotherapy (yes vs. no), number of organs with baseline lesion (≤ 1 vs. ≥ 2), and presence of Signet Ring Cells (no vs. yes).

Subsequent cancer therapy was reported in 37.6% and 41.2% of subjects in the nivo+chemo and chemo arms, respectively. In the nivo+chemo arm, 34.0% received subsequent systemic therapy; this included 32.7% and 1.5% who received subsequent chemotherapy and immunotherapy respectively.

<div style=\"page-break-after: always\"></div>

In the chemo arm, 39.3% received subsequent systemic therapy; this included 36.6% and 8.1% who received subsequent chemotherapy and immunotherapy respectively.

## Other secondary endpoints

## PFS per BICR in All Randomized Subjects

In all randomized subjects, an improvement of PFS per BICR (primary definition) was observed with nivo+chemo compared with chemo (pre-specified but not formally tested): HR = 0.77 (95% CI: 0.68, 0.87). Median PFS (95% CI) was longer with nivo+chemo compared with chemo: 7.66 (7.10, 8.54) vs. 6.93 (6.60, 7.13) months, respectively. 559 (70.8%) and 557 (70.3%) subjects in the nivo+chemo vs. chemo arms respectively had an event. PFS rates were higher with nivo+chemo compared with chemo: 62.6% vs. 55.7% at 6 months, respectively, and 33.4% vs. 23.2% at 12 months, respectively.

Separation of the Kaplan-Meier curves favouring nivo+chemo over chemo occurred at approximately 2 months, with increased separation over time.

Analysis of PFS per BICR using the secondary PFS definition (HR = 0.77; 98% CI: 0.67, 0.87), was consistent with the analysis using the primary PFS definition.

Figure 8. Kaplan-Meier plot of Progression-free Survival per BICR, Primary Definition - All Randomized Subjects

<!-- image -->

Symbols represent censored observations. Stratified Cox proportional hazard model for hazard ratio.

<div style=\"page-break-after: always\"></div>

Figure 9. Kaplan-Meier Plot of Progression-free Survival per BICR, Secondary Definition - All Randomized Subjects

<!-- image -->

Results for PFS per investigator assessment were consistent with those for PFS per BICR. Median PFS by investigator (primary definition) was consistent with that reported by BICR, with median (95% CI) PFS of 7.52 (6.97, 8.34) months for nivo+chemo and 6.31 (5.68, 6.93) months for chemo (HR = 0.75, 95% CI: 0.67, 0.84)

## ORR in All Randomized Subjects

At baseline, 603 subjects in the nivo+chemo arm and 608 subjects in the chemo arm had measurable disease per BICR. In all randomized subjects with measurable disease, an improvement in BICRassessed ORR was observed in nivo+chemo over chemo: 58.0% (95% CI: 54.0, 62.0) vs. 46.1% (95% CI: 42.0, 50.1); odds ratio = 1.61 (95% CI: 1.28, 2.02).

The magnitude of benefit in ORR was consistent per Investigator assessment (ORR difference of 10.9% [95% CI: 5.9, 16.0]), though ORR rates were lower (52.2% [95% CI: 48.4, 55.9] for nivo+chemo vs. 41.1% [95% CI: 37.4, 44.8] for chemo), driven by lower CR rates (4.5% vs. 1.3%). PR rates were consistent with BICR assessment.

<div style=\"page-break-after: always\"></div>

Table 18. Best Overall Response per BICR - All Randomized Subjects with Measurable Disease at Baseline

|                                                                                                                     | Nivo + Chemo N = 603                            | Chemo N = 608                                   |
|---------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| BEST OVERALL RESPONSE:                                                                                              |                                                 |                                                 |
| COMPLETE RESPONSE (CR) PARTIAL RESFONSE (PR) STABLE DISEASE (SD) PROGRESSIVE DISEASE (PD) UNABIE TO DETERMINE (UTD) | 59 9.8) 291 48.3) 171 28.4) 41 6.8) 41 6.8)     | 39 6.4) 241 39.6) 200 32.91 61 10.0) 67 ( 11.0) |
| DIFFERENCE OF OBJECTIVE RESPONSE RATES (2, 3) (95% CI)                                                              | 350/603 ( 58.0%) (54.0, 62.0) 12.8% (7.3, 18.2) | 280/608 (46.1%)                                 |
| OBJECTIVE RESFONSE _RATE (1) (95% CI)                                                                               |                                                 |                                                 |
|                                                                                                                     |                                                 | (42.0, 50.1)                                    |
| ESTIMATE OF ODDS RATIO (3, 4) (95号 CI)                                                                              | 1.61                                            |                                                 |
|                                                                                                                     | (1.28, 2.02)                                    |                                                 |
| P-VALUE (3, 5)                                                                                                      | <0.0001                                         |                                                 |

(1) Confirmed CR or PR per RECIST 1.1. Confidence interval based on Clopper-Pearson method.

- (3) Stratified by region (Asia vs US vs. RoW), EooG (0 vs 1), Tumor Cell PD-Ll (2 1% vs &lt; 1%/indeterminate) and chemotherapy (XELOX vs. FOLFox) .

(2) Laird method of weighting.

- [4] Strata adjusted odds ratio (Nivo + Chemo over Chemo) using Mantel-Haenszel method.

(5) Two-sided p-value from stratified CMH Test.

## Table 19 (bis). Best Overall Response per BICR - All Randomized Subjects

Prot00ol:CA209649

|                                                                                                                          | BestOverall RespcnseperBIcR All Randcmized Subjeets   | Pag1of1                                              |
|--------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|------------------------------------------------------|
| BEST OVERALLRESPCNSE:                                                                                                    |                                                       |                                                      |
| COMPLETE RESPONSE(CR) PARTTALRESPCNSE(FR) STABLE DISEASE(SD) FROGRESSIVE DISEASE (ED) (GTO）ENTNHGIGIOLEIENN NOT REFCRTED | 78 9.9) 292 37.0) 301 (38.1) 53 6.7) 64 8.1) 1 0.1)   | 52(6.6) 241 30.4) 326 41.2) 66 8.3) 102 12.9) 5 0.6) |
| CBJECTIVERESRCNSERATE(1) （95%CT）                                                                                         | 370/789(46.9) (43.4,50.4)                             | 293/792(37.0%) (33.6,40.5)                           |
| DIFFERENCEOFCBJECTIVE RESPONSERATES(2,3) （95%CT）                                                                         | 12.28 (7.5,16.8)                                      |                                                      |
| E9TDMATEOFODDS RATIO （3,4） （95%CI）                                                                                       | 1.50 (1.23,1.83)                                      |                                                      |
| P-VALUE（3,5）                                                                                                             | <0.0001                                               |                                                      |

## ORR in subjects with PDL1 CPS≥5

In all randomized subjects with measurable disease and PD-L1 CPS ≥ 5, an improvement in BICRassessed ORR was observed with nivo+chemo over chemo, 59.8% (95% CI: 54.7, 64.8) vs. 45.3% (95% CI: 40.3, 50.4); odds ratio = 1.80 (95% CI: 1.34, 2.41).

128EF2020:20:52:52

<div style=\"page-break-after: always\"></div>

Table 20. Best Overall Response per BICR - All Measurable Subjects with PDL1 CPS ≥ 5

|                                                        | Nivo + Chemo N = 378           | Chemo N = 391                  | Chemo N = 391                  | Chemo N = 391                  | Chemo N = 391                  | Chemo N = 391                  | Chemo N = 391                  | Chemo N = 391                  | Chemo N = 391                  | Chemo N = 391                  | Chemo N = 391                  |
|--------------------------------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|
| BESTOVERALL RESPONSE:                                  |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |
| COMPLETE RESPONSE (CR)                                 | 44 (11.6) 182 48.1) 104 (27.5) | 27 (6.9) 150 (38.4) 132 (33.8) | 27 (6.9) 150 (38.4) 132 (33.8) | 27 (6.9) 150 (38.4) 132 (33.8) | 27 (6.9) 150 (38.4) 132 (33.8) | 27 (6.9) 150 (38.4) 132 (33.8) | 27 (6.9) 150 (38.4) 132 (33.8) | 27 (6.9) 150 (38.4) 132 (33.8) | 27 (6.9) 150 (38.4) 132 (33.8) | 27 (6.9) 150 (38.4) 132 (33.8) | 27 (6.9) 150 (38.4) 132 (33.8) |
| OBJECTIVE RESPONSE RATE (1) (95% CI)                   | 226/378 ( 59.8%) (54.7, 64.8)  |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |
| PARTIAL RESPONSE  (PR) STABLE DISEASE (SD)             |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |
| PROGRESSIVEDISEASE (PD)                                | 26 6.9)                        | 42 (10.7)                      | 42 (10.7)                      | 42 (10.7)                      | 42 (10.7)                      | 42 (10.7)                      | 42 (10.7)                      | 42 (10.7)                      | 42 (10.7)                      | 42 (10.7)                      | 42 (10.7)                      |
|                                                        | 22                             | 40                             | 40                             | 40                             | 40                             | 40                             | 40                             | 40                             | 40                             | 40                             | 40                             |
| UNABLE TO DETERMINE (UTD)                              | 5.8)                           |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |
|                                                        |                                | ( 10.2)                        | ( 10.2)                        | ( 10.2)                        | ( 10.2)                        | ( 10.2)                        | ( 10.2)                        | ( 10.2)                        | ( 10.2)                        | ( 10.2)                        | ( 10.2)                        |
|                                                        |                                | 177/391 (_45.3%) (40.3, 50.4)  | 177/391 (_45.3%) (40.3, 50.4)  | 177/391 (_45.3%) (40.3, 50.4)  | 177/391 (_45.3%) (40.3, 50.4)  | 177/391 (_45.3%) (40.3, 50.4)  | 177/391 (_45.3%) (40.3, 50.4)  | 177/391 (_45.3%) (40.3, 50.4)  | 177/391 (_45.3%) (40.3, 50.4)  | 177/391 (_45.3%) (40.3, 50.4)  | 177/391 (_45.3%) (40.3, 50.4)  |
| DIFFERENCE OF OBJECTIVE RESPONSE RATES (2, 3) (95% CI) | 16.1%                          |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |
|                                                        | (9.4, 22.8)                    |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |
| ESTIMATE OF ODDS RATIO(3，4) (95% CI)                   | 1.80 (1.34, 2.41)              |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |
| P-VALUE (3，5)                                          | <0.0001                        |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |
| DURABLE (>=6 MONTHS) RESPONSE RATE (1) (95% CI)        | 133/378 (.35.2%)               | 86/391 ( 22.0%)                | 86/391 ( 22.0%)                | 86/391 ( 22.0%)                | 86/391 ( 22.0%)                | 86/391 ( 22.0%)                | 86/391 ( 22.0%)                | 86/391 ( 22.0%)                | 86/391 ( 22.0%)                | 86/391 ( 22.0%)                | 86/391 ( 22.0%)                |
|                                                        | (30.4, 40.2)                   | (18.0, 26.4)                   | (18.0, 26.4)                   | (18.0, 26.4)                   | (18.0, 26.4)                   | (18.0, 26.4)                   | (18.0, 26.4)                   | (18.0, 26.4)                   | (18.0, 26.4)                   | (18.0, 26.4)                   | (18.0, 26.4)                   |
| DIFFERENCE OF DURABLE RESPONSE RATES (2，3)             | 11.8%                          |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |
| (95% CI)                                               |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |
| ESTIMATEOFODDSRATIOFOR                                 | 1.89                           |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |
|                                                        | (5.6, 18.0)                    |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |
|                                                        | (1.37, 2.61)                   | (1.37, 2.61)                   | (1.37, 2.61)                   | (1.37, 2.61)                   | (1.37, 2.61)                   | (1.37, 2.61)                   | (1.37, 2.61)                   | (1.37, 2.61)                   | (1.37, 2.61)                   | (1.37, 2.61)                   | (1.37, 2.61)                   |
| DURABLE RESPONSE (3，4）(95% CI)                         |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |

(1) ) Confirmed CR or PR per RECIST 1.l. Confidence interval based on Clopper-Pearson method. (2) Strata adjusted difference in response rate (Nivo + Chemo - Chemo) based on DerSimonian and Laird method of weighting.

(3) Stratified by region (Asia vs US vs. RoW), ECOG (0 vs l), Tumor Cell PD-Ll (&gt; 1% vS &lt; 1%/indeterminate) and chemotherapy (XELOX vs. FOLFOX) .

2-sided p value from CMH test.

Strata adjusted odds ratio (Nivo + Chemo over Chemo) using using Mantel-Haenszel method.

Exploratory endpoints

Time to response and duration of response in subjects with PDL1 CPS≥5

Table 21. Time to Response and Duration of Response per BICR - All Measurable Responders with PD-L1 C PS ≥ 5

|                                                                      | Nivo + Chemo N = 226                                                 | Chemo N = 177                                                        |
|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|
| TIME TO OBJECTIVE RESPONSE (MONTHS)                                  | TIME TO OBJECTIVE RESPONSE (MONTHS)                                  | TIME TO OBJECTIVE RESPONSE (MONTHS)                                  |
| MEAN                                                                 | 2.16                                                                 | 1.96                                                                 |
| MEDIAN                                                               | 1.48                                                                 | 1.45                                                                 |
| MIN, MAX                                                             | 0.8, 10.2                                                            | 1.0, 7.1                                                             |
| Q1,Q3                                                                | 1.38, 2.76                                                           | 1.38, 2.69                                                           |
| STANDARD DEVIATION                                                   | 1.35                                                                 | 0.96                                                                 |
| DURATION OF RESPONSE (MONTHS)                                        | DURATION OF RESPONSE (MONTHS)                                        | DURATION OF RESPONSE (MONTHS)                                        |
| MIN，MAX  (A)                                                         | 1.1+, 29.6+ 9.49' (7.98, 11.37)                                      | 1.2+, 30.8+ 6.97* (5.65, 7.85)                                       |
| MEDIAN  (95% CI) (B) N EVENT/N RESP (%)_                             | 143/226 (63.3)                                                       | 125/177 (70.6)                                                       |
| PROPORTIONOFSUBJECTSWITHDURATION OF RESPONSE OF AT LEAST (95% CI）(C) | PROPORTIONOFSUBJECTSWITHDURATION OF RESPONSE OF AT LEAST (95% CI）(C) | PROPORTIONOFSUBJECTSWITHDURATION OF RESPONSE OF AT LEAST (95% CI）(C) |
| 3MONTHS                                                              | 91.7(87.1, 94.7)                                                     | 87.3 ( 81.2, 91.5)                                                   |
| 6 MONTHS                                                             | 64.5 ( 57.6, 70.6)                                                   | 55.5 ( 47.5, 62.8)                                                   |
| 9 MONTHS                                                             | 50.6 43.6, 57.2)                                                     | 35.6( 28.1) 43.1)                                                    |
| 12 MONTHS                                                            | 42.5 (35.6) 49.2)                                                    | 29.9 ( 22.8, 37.3)                                                   |

(C) Based on Kaplan-Meier estimates of duration of response.

(B) Median computed using Kaplan-Meier method.

<div style=\"page-break-after: always\"></div>

Figure 10. Kaplan-Meier Plot of Duration of Response per BICR - All Responders with PD-L1 CPS ≥ 5

<!-- image -->

Time to response and duration of response in all randomised subjects

Table 22. Time to Response and Duration of Response per BICR - All Measurable Responders

|                                                                     | Nivo + Chemo N = 350                                                | Chemo N = 280                                                       |
|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|
| TIME TO OBJECTIVE RESPONSE (MONTHS)                                 | TIME TO OBJECTIVE RESPONSE (MONTHS)                                 | TIME TO OBJECTIVE RESPONSE (MONTHS)                                 |
| MEAN                                                                | 2.20                                                                | 2.11 1.48                                                           |
| MEDIAN                                                              | 1.51                                                                |                                                                     |
| MIN, MAX                                                            | 0.8, 10.9                                                           | 0.6, 7.1                                                            |
| 01,03                                                               | 1.38, 2.79                                                          | 1.40,2.79                                                           |
| STANDARDDEVIATION                                                   | 1.40                                                                | 1.17                                                                |
| DURATION OF RESPONSE(MONTHS)                                        | DURATION OF RESPONSE(MONTHS)                                        | DURATION OF RESPONSE(MONTHS)                                        |
| MIN, MAX (A)                                                        | 1.0+,29.6+                                                          | 1.2+， 30.8+                                                         |
| MEDIAN (95% CI） (B)                                                 | 8.51 (7.23, 9.92)                                                   | 6.93 (5.82, 7.16)                                                   |
| N EVENT/N RESP (%)                                                  | 231/350 (66.0)                                                      | 206/280 (73.6)                                                      |
| PROPORTIONOFSUBJECTSWITHDURATION OF RESPONSE OF AT LEAST(95% CI）(C) | PROPORTIONOFSUBJECTSWITHDURATION OF RESPONSE OF AT LEAST(95% CI）(C) | PROPORTIONOFSUBJECTSWITHDURATION OF RESPONSE OF AT LEAST(95% CI）(C) |
| 3 MONTHS                                                            | 91.0( 87.4, 93.6)                                                   | 89.4 ( 85.0, 92.5)                                                  |
| 6 MONTHS                                                            | 64.2 58.7, 69.1)                                                    | 55.4( 49.1) 61.2)                                                   |
| 9 MONTHS                                                            | 47.4 ( 41.8, 52.7)                                                  | 34.3 ( 28.4, 40.3)                                                  |
| 12 MONTHS                                                           | 40.4( 34.9, 45.8)                                                   | 27.9 (22.3, 33.7)                                                   |

<div style=\"page-break-after: always\"></div>

Figure 11. Kaplan-Meier Plot of Duration of Response per BICR - All Measurable Responders

<!-- image -->

Chemo (events:206/280),median and 95% Cl:6.93 (5.82,7.16)

Progression-Free Survival Including Next Line of Therapy (PFS2) per Investigator - All Randomized Subjects

In all randomized subjects, median PFS2 (95% CI) per investigator was 11.99 (11.14, 13.1) and 10.05 (9.53, 10.81) months for nivo+chemo vs. chemo, respectively; HR = 0.77 (95% CI: 0.69, 0.86). PFS2 is defined as the time from randomization to objectively documented progression after the next line of therapy, per investigator assessment, or to death from any cause, whichever occurred first. Subjects who were alive and without progression after the next line of therapy were censored at their last known alive date.

<div style=\"page-break-after: always\"></div>

Figure 12. Kaplan-Meier Plot of Progression-free Survival Including Next Line of Therapy (PFS2) - All Randomized Subjects

<!-- image -->

Nivo +Chemo vs Chemo -hazard ratio (95% Cl):0.77(0.69,0.86)

<div style=\"page-break-after: always\"></div>

## Efficacy by tumour cell PD-L1 expression

Table 23. Efficacy of Nivolumab + Chemotherapy vs. Chemotherapy by Baseline Tumour Cell PD-L1 Levels - All Randomized Subjects

|                                   | PD-L1<1%                          | PD-L1<1%                          | PD-L1 ≥1%            | PD-L1 ≥1%          | PD-L1<5%            | PD-L1<5%             | PD-L1 ≥ 5%           | PD-L1 ≥ 5%         | PD-L1<10%            | PD-L1<10%            | PD-L1 ≥ 10%          | PD-L1 ≥ 10%        |
|-----------------------------------|-----------------------------------|-----------------------------------|----------------------|--------------------|---------------------|----------------------|----------------------|--------------------|----------------------|----------------------|----------------------|--------------------|
|                                   | Nivo+ Chemo N =663                | Chemo N=660                       | Nivo+ Chemo N=126    | Chemo N =127       | Nivo+ Chemo N=698   | Chemo N=695          | Nivo+ Chemo N=91     | Chemo N=92         | Nivo+ Chemo N=713    | Chemo N=712          | Nivo+ Chemo N=76     | Chemo N=75         |
| OS                                |                                   |                                   |                      |                    |                     |                      |                      |                    |                      |                      |                      |                    |
| HR (95% CIa                       | 0.85 (0.75, 0.96)                 | 0.85 (0.75, 0.96)                 | 0.57 (0.42,0.77)     | 0.57 (0.42,0.77)   | 0.83 (0.73, 0.94)   | 0.83 (0.73, 0.94)    | 0.59 (0.41, 0.84)    | 0.59 (0.41, 0.84)  | 0.83 (0.73,0.93)     | 0.83 (0.73,0.93)     | 0.57 (0.38, 0.84)    | 0.57 (0.38, 0.84)  |
| Events, n (%)                     | 469 (70.7)                        | 489 (74.1)                        | 75 (59.5)            | 97 (76.4)          | 489 (70.1)          | 515 (74.1)           | 55 (60.4)            | 71 (77.2)          | 500 (70.1)           | 529 (74.3)           | 44 (57.9)            | 57 (76.0)          |
| Median OS, mo (95% cIb            | 13.60 (12.09, 14.39)              | 11.99 (11.14, 12.78)              | 15.64 (11.76, 23.06) | 9.66 (7.20, 11.24) | 13.7 (12.39, 14.42) | 11.96 (11.10, 12.71) | 16.13 (10.15, 23.06) | 9.23 (6.28, 11.63) | 13.60 (12.29, 14.39) | 11.76 (10.97, 12.58) | 16.23 (10.15, 23.92) | 9.82 (6.21, 13.21) |
| PFS per BICR (primary definition) | PFS per BICR (primary definition) | PFS per BICR (primary definition) |                      |                    |                     |                      |                      |                    |                      |                      |                      |                    |
| HR (95% CIa                       | 0.84 (0.74, 0.96)                 | 0.84 (0.74, 0.96)                 | 0.52 (0.39, 0.71)    | 0.52 (0.39, 0.71)  | 0.81 (0.72, 0.92)   | 0.81 (0.72, 0.92)    | 0.56 (0.40, 0.80)    | 0.56 (0.40, 0.80)  | 0.80 (0.70, 0.90)    | 0.80 (0.70, 0.90)    | 0.60 (0.41, 0.89)    | 0.60 (0.41, 0.89)  |
| Events, n (%)                     | 478 (72.1)                        | 461 (69.8)                        | 81 (64.3)            | 91 (71.7)          | 499 (71.5)          | 482 (69.4)           | 60 (65.9)            | 70 (76.1)          | 507 (71.1)           | 498 (69.9)           | 52 (68.4)            | 54 (72.0)          |
| Median PFS, mo. (95% C1) b        | 7.52 (7.03, 8.44)                 | 7.03 (6.90, 7.72)                 | 9.66 (6.97, 12.35)   | 5.26 (4.17, 6.05)  | 7.62 (7.06, 8.54)   | 7.03 (6.87, 7.59)    | 8.31 (5.45, 11.37)   | 5.29 (3.55, 6.21)  | 7.66 (7.06, 8.57)    | 6.97 (6.83, 7.29)    | 7.29 (4.73, 11.43)   | 5.29 (3.55, 6.77)  |
| ORR perBICR(CR+PR)                | ORR perBICR(CR+PR)                | ORR perBICR(CR+PR)                |                      |                    |                     |                      |                      |                    |                      |                      |                      |                    |
| ORR (95% CI)                      | 58.5 (54,63)                      | 48.2 (44, 53)                     | 55.8 (46,66)         | 36.2 (27,46)       | 58.1 (54, 62)       | 47.8 (44,52)         | 57.5 (45, 69)        | 34.6 (24, 46)      | 58.0 (54, 62)        | 47.6 (43,52)         | 58.1 (45, 71)        | 33.3 (22,46)       |

a Unstratified Cox proportional hazards model.

Based onKaplan-Meier estimates.

In subjects with measurable discase. Confidence interval based on the Clopper and Pearson method.

Abbreviations: BICR - blinded independent central review, CI - confidence interval, CR - complete response, HR - hazard ratio, ORR - objcctive response rate, OS - ovcrall survival, PD-L1 -programmed dcath-ligand 1, PFS - progression-frce survival, PR -partial response

<div style=\"page-break-after: always\"></div>

## Efficacy by CPS PD-L1 Status

Table 24. Efficacy of Nivolumab + Chemotherapy vs. Chemotherapy by Baseline CPS PD-L1 Status - All Randomized Subjects

|                                     | CPS <1                            | CPS <1                            | CPS ≥1               | CPS ≥1               | CPS <5               | CPS <5               | CPS ≥5               | CPS ≥5               | CPS<10               | CPS<10               | CPS ≥10              | CPS ≥10             |
|-------------------------------------|-----------------------------------|-----------------------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|---------------------|
|                                     | Nivo+ Chemo N =140                | Chemo N=125                       | Nivo+ Chemo N =641   | Chemo N=655          | Nivo+ Chemo N =308   | Chemo N =298         | Nivo+ Chemo N =473   | Chemo N =482         | Nivo+ Chemo N=406    | Chemo N=387          | Nivo+ Chemo N =375   | Chemo N=393         |
| OS                                  |                                   |                                   |                      |                      |                      |                      |                      |                      |                      |                      |                      |                     |
| HR (95% CI)a                        | 0.92 (0.70,1.23)                  | 0.92 (0.70,1.23)                  | 0.76 (0.67, 0.87)    | 0.76 (0.67, 0.87)    | 0.94 (0.78, 1.13)    | 0.94 (0.78, 1.13)    | 0.70 (0.60, 0.81)    | 0.70 (0.60, 0.81)    | 0.94 (0.80, 1.10)    | 0.94 (0.80, 1.10)    | 0.65 (0.55, 0.78)    | 0.65 (0.55, 0.78)   |
| Events, n (%)                       | 103 (73.6)                        | 91 (72.8)                         | 434 (67.7)           | 492 (75.1)           | 228 (74.0)           | 221 (74.2)           | 309 (65.3)           | 362 (75.1)           | 302 (74.4)           | 288 (74.4)           | 235 (62.7)           | 295 (75.1)          |
| Median OS, mo (95% CI)b             | 13.08 (9.82, 16.66)               | 12.48 (10.12, 13.83)              | 13.96 (12.55, 14.98) | 11.33 (10.64, 12.25) | 12.42 (10.61, 14.26) | 12.25 (10.97, 13.24) | 14.39 (13.11, 16.23) | 11.10 (10.02, 12.09) | 12.55 (11.07, 14.19) | 12.52 (11.24, 13.27) | 15.01 (13.77, 16.79) | 10.87 (9.82, 11.83) |
| PFS per BICR (primary definition)   | PFS per BICR (primary definition) | PFS per BICR (primary definition) |                      |                      |                      |                      |                      |                      |                      |                      |                      |                     |
| HR (95% CI)a,                       | 0.93 (0.69, 1.26)                 | 0.93 (0.69, 1.26)                 | 0.75 (0.65, 0.85)    | 0.75 (0.65, 0.85)    | 0.93 (0.76, 1.12)    | 0.93 (0.76, 1.12)    | 0.69 (0.59, 0.80)    | 0.69 (0.59, 0.80)    | 0.91 (0.77, 1.08)    | 0.91 (0.77, 1.08)    | 0.65 (0.55, 0.77)    | 0.65 (0.55, 0.77)   |
| Events, n (%)                       | 99 (70.7)                         | 77 (61.6)                         | 454 (70.8)           | 472 (72.1)           | 225 (73.1)           | 199 (66.8)           | 328 (69.3)           | 350 (72.6)           | 301 (74.1)           | 260 (67.2)           | 252 (67.2)           | 289 (73.5)          |
| Median PFS, mo. (95% CI)b           | 8.67 (6.93, 9.69)                 | 8.11 (6.87, 9.82)                 | 7.49 (7.03, 8.41)    | 6.90 (6.08, 7.03)    | 7.49 (6.97, 8.67)    | 8.15 (7.06, 8.67)    | 7.69 (7.03, 9.17)    | 6.05 (5.55, 6.90)    | 7.49 (7.03, 8.44)    | 7.72 (6.97, 8.31)    | 8.31 (6.97, 9.69)    | 5.78 (5.45, 6.87)   |
| ORR per BICR (CR + PR)              | ORR per BICR (CR + PR)            | ORR per BICR (CR + PR)            |                      |                      |                      |                      |                      |                      |                      |                      |                      |                     |
| Subjects with measurable discase, N | 93                                | 85                                | 504                  | 515                  | 219                  | 209                  | 378                  | 391                  | 297                  | 281                  | 300                  | 319                 |
| ORR (95% CI)                        | 50.5 (40, 61)                     | 41.2 (31, 52)                     | 59.5 (55,64)         | 46.4 (42,51)         | 55.3 (48, 62)        | 46.4 (40,53)         | 59.8 (55, 65)        | 45.3 (40,50)         | 57.9 (52,64)         | 47.3 (41,53)         | 58.3 (53,64)         | 44.2 (39,50)        |
| CR, n/N (%)                         | 7/93 (7.5)                        | 4/85 (4.7)                        | 51/504 (10.1)        | 32/515 (6.2)         | 14/219 (6.4)         | 9/209 (4.3)          | 44/378 (11.6)        | 27/391 (6.9)         | 27/297 (9.1)         | 15/281 (5.3)         | 31/300 (10.3)        | 21/319 (6.6)        |
| PR, n/N (%)                         | 40/93 (43.0)                      | 31/85 (36.5)                      | 249/504 (49.4)       | 207/515 (40.2)       | 107/219 (48.9)       | 88/209 (42.1)        | 182/378 (48.1)       | 150/391 (38.4)       | 145 (48.8)           | 118 (42.0)           | 144 (48.0)           | 120 (37.6)          |

a Unstratified Cox proportional hazards model.

Based on Kaplan-Meier cstimates.

In subjects with measurable disease. Confidence interval based on the Clopper and Pearson method.

Abbreviations: BICR - blinded independent central review, BOR - best overall response, CI - confidence interval, CPS - combined positive score, CR - complete response,HR -hazard ratio, ORR - objective response rate, OS -overall survival, PD-L1 -programmed death-ligand 1, PFS -progression-free survival, PR -partial response

<div style=\"page-break-after: always\"></div>

Figure 13. Pre-specified Subgroup Analyses of OS by PD-L1 CPS cut-offs - All Randomized Subjects

<!-- image -->

Only OS byPD-L1 CPS≥5 and PD-L1 CPS≥1 were formally tested.

Figure 14. Forest Plot of Treatment Effect on OS by PD-L1 CPS Status - All randomised Subjects

<!-- image -->

|                                                            |      | Nivo+Chemo              | Nivo+Chemo           | Chemo                   | Chemo                | Unstratified                           | Unstratified   |
|------------------------------------------------------------|------|-------------------------|----------------------|-------------------------|----------------------|----------------------------------------|----------------|
|                                                            | N    | NofEvents （NofSubjects) | mos (95%CI)          | NofEvents (NofSubjects) | mos (95%CI)          | Hazard Ratio(95%Cl) Nivo+Chemovs.Chemo |                |
| Overall                                                    | 1581 | 544 (789)               | 13.83 (12.55,14.55)  | 591 (792)               | 11.56 （10.87.12.48)  | 0.79 (0.70,0.89)                       |                |
| CPS PD-L1Expression>=1                                     | 1296 | 434 (641)               | 13.96 (12.55,14.98)  | 492 (655)               | 11.33 (10.64,12.25)  | 0.76 (0.67,0.87)                       |                |
| CPSPD-L1Expression<1                                       | 265  | 103 (140)               | 13.08 (9.82,16.66)   | 91 (125)                | 12.48 (10.12,13.83)  | 0.92 (0.70,1.23)                       |                |
| CPSPD-L1Expression>=1and<5                                 | 341  | 125 (168)               | 12.29 (9.63,14.26)   | 130 （173)               | 11.99 (10.87,13.90)  | 0.97 (0.76,1.24)                       |                |
| CPS PD-L1Expression>=5                                     | 955  | 309 9(473)              | 14.39 (13.11.16.23)  | 362 (482)               | 11.10 (10.02,12.09)  | 0.70 (0.60,0.81)                       |                |
| CPS PD-L1Expression<5                                      | 606  | 228 (308)               | 12.42 (10.61,14.26)  | 221 (298)               | 12.25 (10.97,13.24)  | 0.94 (0.78,1.13)                       |                |
| CPSPD-L1Expression>=5and<10                                | 187  | 74(98)                  | 12.62 (10.71,16.23)  | 67 （89）                 | 12.94 (9.40,14.42)   | 0.92 (0.66,1.28)                       |                |
| CPSPD-L1Expression>=10                                     | 768  | 235 (375)               | 15.01 (13.77,16.79)  | 295 (393)               | 10.87 (9.82,11.83)   | 0.65 (0.55,0.78)                       |                |
| CPSPD-L1Expression<10                                      | 793  | 302 (406)               | 12.55 (11.07, 14.19) | 288 (387)               | 12.52 (11.24, 13.27) | 0.94 (0.80,1.10)                       |                |
| CPSPD-L1ExpressionIndeterminate/NotEvaluable/NotReported20 |      | 7(8)                    | 13.19 (1.22, 19.25)  | 8 (12)                  | 12.14 (6.97, N.A.)   |                                        |                |

HR is not computed for subset category with less than 10 subjects per treatment group.

## Efficacy by MSI Status

The MSI prevalence by category was calculated based on the number of subjects for whom MSI data were available. Of the 1581 randomized subjects 1449 (91.7%) subjects had tumour tissue available for MSI testing; 132 (8.3%) subjects had no tumour tissue for MSI testing, 44 (2.8%) subjects were MSI-H and 1377 (87.1%) subjects were MSS.

<div style=\"page-break-after: always\"></div>

Table 25. Efficacy of Nivolumab + Chemotherapy vs. Chemotherapy by Baseline MSI status All Randomized Subjects

|                                 | MSI-H             | MSI-H               | MSS                 | MSS                  | Invalid/NotReported   | Invalid/NotReported   |
|---------------------------------|-------------------|---------------------|---------------------|----------------------|-----------------------|-----------------------|
|                                 | Nivo+Chemo N=23   | Chemo N=21          | Nivo+Chemo N =695   | Chemo N=682          | Nivo+Chemo N=71       | Chemo N=89            |
| OS                              |                   |                     |                     |                      |                       |                       |
| HR (95% CI)a                    | 0.37 (0.16, 0.87) | 0.37 (0.16, 0.87)   | 0.80 (0.71, 0.91)   | 0.80 (0.71, 0.91)    | 0.83 (0.58, 1.20)     | 0.83 (0.58, 1.20)     |
| Events, n (%)                   | 9 (39.1)          | 15 (71.4)           | 483 (69.5)          | 507 (74.3)           | 52 (73.2)             | 69 (77.5)             |
| Median OS, mo. (95% CI) b       | NA (8.38, NA)     | 12.25 (4.11, 21.55) | 13.83 (12.42,14.62) | 11.37 (10.74, 12.48) | 11.79 (8.87, 16.66)   | 11.76 (10.48,13.54)   |
| PFSper BICR (PrimaryDefinition) |                   |                     |                     |                      |                       |                       |
| HR (95% CIa                     | 0.37 (0.17, 0.81) | 0.37 (0.17, 0.81)   | 0.77 (0.68, 0.87)   | 0.77 (0.68, 0.87)    | 1.03 (0.71,1.48)      | 1.03 (0.71,1.48)      |
| Events, n (%)                   | 11 (47.8)         | 16 (76.2)           | 493 (70.9)          | 478 (70.1)           | 55 (77.5)             | 63 (70.8)             |
| Median PFS, mo. (95% CI)b       | 14.00 (4.21, NA)  | 4.27 (2.76, 8.34)   | 7.75 (7.13, 8.57)   | 6.93 (6.28, 7.06)    | 6.93 (5.75, 8.67)     | 7.85 (5.78, 9.56)     |
| ORR per BICR (CR + PR)C         |                   |                     |                     |                      |                       |                       |
| ORR (95% CI), %                 | 52.6 (28.9, 75.6) | 38.9 (17.3, 64.3)   | 59.1 (54.8, 63.3)   | 46.4 (42.1, 50.8)    | 49.0 (34.4, 63.7)     | 44.6 (31.3, 58.5)     |

Abbreviations: BICR -blinded independent central review, CI - confidence interval, CR - complete response; HR - hazard ratio,MSI -microsomal instability, ORR - objective response rate, OS - overall survival, PD-L1 - programmed death-ligand 1, PFS - progression-free survival, PR - partial response

## Ancillary analyses

## Subgroup analyses

Figure 15. Forest Plot of Treatment Effect on Overall Survival in Predefined Subsets - All Randomized Subjects with PDL1 CPS ≥ 5

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                                            |                                                            | Nivo+Chemo NofEvents                                       | Nivo+Chemo NofEvents                                       | Chemo NofEvents                                            | Chemo NofEvents                                            | Unstratified HazardRatio(95%Cl)                            | Unstratified HazardRatio(95%Cl)                            |
|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|
|                                                            | N                                                          | (Nof Subjects)(95%Cl)                                      | (Nof Subjects)(95%Cl)                                      | (Nof Subjects)(95%Cl)                                      | (Nof Subjects)(95%Cl)                                      | Nivo+Chemovs.Chemo                                         | Nivo+Chemovs.Chemo                                         |
| LaurenClassification                                       |                                                            |                                                            |                                                            |                                                            |                                                            |                                                            |                                                            |
| IntestinalType                                             | 347                                                        | 102 (171)                                                  | 16.79 (13.96, 20.17)                                       | 127 (176)                                                  | 12.48 (10.78, 13.54)                                       | 0.69 (0.53,0.90)                                           |                                                            |
| DiffuseType                                                | 278                                                        | 96 (137)                                                   | 13.11 (9.69, 16.13)                                        | 109 (141)                                                  | 10.48 (7.98, 12.52)                                        | 0.73 (0.56,0.97)                                           |                                                            |
| Mixed                                                      | 67                                                         | 26 (37)                                                    | 14.16 (9.82, 17.15)                                        | 22(30)                                                     | 13.17 (10.02,15.70)                                        | 0.86 (0.49, 1.53)                                          |                                                            |
| Unknown                                                    | 263                                                        | 85 (128)                                                   | 14.19 (11.24, 16.66)                                       | 104 (135)                                                  | 9.92 (7.89, 11.56)                                         | 0.65                                                       |                                                            |
| WHOHistologicClassificationPresenceofSignetRingCell        |                                                            |                                                            |                                                            |                                                            |                                                            | (0.48,0.86) (0.49,1.03)                                    |                                                            |
| Yes                                                        | 141                                                        | 55 （.72)                                                   | 12.06 (8.61,15.51)                                         | 57(.69)                                                    | 9.00 (6.87,12.52)                                          | 0.71(                                                      |                                                            |
| No                                                         | 814                                                        | 254 (401)                                                  | 15.11 (13.54, 16.79)                                       | 305 (413)                                                  | 11.27 (10.05, 12.52)                                       | 0.69                                                       |                                                            |
| TNMClassificationMetastasis                                |                                                            |                                                            |                                                            |                                                            |                                                            | (0.59,0.82)                                                |                                                            |
| MO                                                         | 37                                                         | 9 (.18)                                                    | 16.85 (10.25, N.A.)                                        | 16 (.19)                                                   | 12.25 (6.90,17.31)                                         | 0.48 (0.21,1.09)                                           |                                                            |
| M1                                                         | 869                                                        | 284 (428)                                                  | 14.16 (12.32, 15.97)                                       | 328 (441)                                                  | 11.10 (9.99,12.48)                                         |                                                            |                                                            |
| Unknown/Mx                                                 | 12                                                         | 5 8                                                        | 22.19 (8.05, N.A.)                                         | 4)                                                         | 11.45 (4.04, N.A.)                                         | 0.74 (0.63, 0.86)                                          |                                                            |
| NotReported                                                | 37                                                         | 11 (19)                                                    | 20.50 (10.87,N.A.)                                         | 15 (18)                                                    | 7.20 (5.29, 13.14)                                         | 0.32 (0.14,0.73)                                           |                                                            |
| At LeastOneTargetLesionperBICR                             |                                                            |                                                            |                                                            |                                                            |                                                            |                                                            |                                                            |
| Yes                                                        | 770                                                        | 248 (379)                                                  | 14.19 (12.32, 16.23)                                       | 299 (391)                                                  | 10.64 (9.40, 11.37)                                        | 0.68 (0.57,0.80)                                           |                                                            |
| No                                                         | 156                                                        | 54(80)                                                     | 14.98 (11.76,18.83)                                        | 55(76)                                                     | 12.98 (10.12, 15.74)                                       | 0.81 (0.56,1.18)                                           |                                                            |
| NotReported                                                | 29                                                         | 7(14)                                                      | 25.66 (4.70, N.A.)                                         | 8(15)                                                      | 19.09 (9.89,24.87)                                         | 0.56 (0.18,1.73)                                           |                                                            |
| <=1                                                        | 196                                                        | 61 99)                                                     | 16.59 (14.26,19.84)                                        | 65 （97)                                                    | 15.38 (12.88,17.31)                                        | 0.83 (0.58,1.17)                                           |                                                            |
| >=2                                                        | 759                                                        | 248 (374)                                                  | 13.93 (11.86, 15.64)                                       | 297 (385)                                                  | 10.05 (9.00, 11.20)                                        | 0.67                                                       |                                                            |
| TimefromInitialDiseaseDiagnosistoRandomization             |                                                            |                                                            |                                                            |                                                            |                                                            | (0.57, 0.79)                                               |                                                            |
| <6Months                                                   | 805                                                        | 260 (399)                                                  | 14.16 (12.39, 16.33)                                       | 308 (406)                                                  | 10.64 (9.40,11.63)                                         | 0.67 (0.57,0.80)                                           |                                                            |
| 6 Months-<1 Year                                           | 30                                                         | 7 9                                                        | 10.32 (1.77, N.A.)                                         | 17(21)                                                     | 13.73 (11.24, 17.74)                                       |                                                            |                                                            |
| >=1Year                                                    | 120                                                        | 42 (65)                                                    | 15.64 (12.62, 19.52)                                       | 37 (55)                                                    | 12.91 (10.15, 18.04)                                       | 0.84 (0.54,1.31)                                           |                                                            |
| Peritoneal Metastases                                      |                                                            |                                                            |                                                            |                                                            |                                                            |                                                            |                                                            |
| Yes                                                        | 197                                                        | 82 (101)                                                   | 11.37 (7.89, 13.80)                                        | 81 (.96)                                                   | 8.25 (6.18,10.12)                                          | 0.81 (0.59, 1.10)                                          |                                                            |
| No                                                         | 729                                                        | 220 (358)                                                  | 15.67 (13.83,17.81)                                        | 273 (371)                                                  | 11.56 (10.68,12.58)                                        | 0.66 (0.55,0.79)                                           |                                                            |
| NotReported                                                | 29                                                         | 7 (14)                                                     | 25.66 (4.70, N.A.)                                         | 8(15)                                                      | 19.09 (9.89,24.87)                                         | 0.56(0.18,1.73)                                            |                                                            |
| LiverMetastases                                            |                                                            |                                                            |                                                            |                                                            |                                                            |                                                            |                                                            |
| Yes                                                        | 408                                                        | 125 (191)                                                  | 13.08 (11.24,16.10)                                        | 172 (217)                                                  | 9.82 (8.15, 11.37)                                         | 0.63 (0.50,0.80)                                           |                                                            |
| No                                                         | 518                                                        | 177 (268)                                                  | 15.51( (13.57,16.79)                                       | 182 (250)                                                  | 11.96 (10.64,12.98)                                        | 0.76 (0.62, 0.94)                                          |                                                            |
| NotReported                                                | 29                                                         | 7(14)                                                      | 25.66 (4.70, N.A.)                                         | 8(15)                                                      | 19.09 (9.89,24.87)                                         | 0.56 (0.18,1.73)                                           |                                                            |
| HER-2 Status at Study Entry                                |                                                            |                                                            |                                                            |                                                            |                                                            |                                                            |                                                            |
| Positive                                                   | 7                                                          | o（ 3)                                                      | N.A.                                                       | 3（ 4)                                                      | 13.34 (7.00,18.10)                                         |                                                            |                                                            |
| Negative                                                   | 543                                                        | 184 (272)                                                  | 14.46 (13.14,16.46)                                        | 189 (271)                                                  | 13.14( (11.56,14.42)                                       | 0.87 (0.71,1.06)                                           |                                                            |
| Unknown                                                    | 5                                                          | 1 2                                                        | N.A. (2.04, N.A.)                                          | 2 3)                                                       | 3.58 (3.19, N.A.)                                          |                                                            |                                                            |
| Not Reported                                               | 400                                                        | 124 (196)                                                  | 13.93 (11.14,16.85)                                        | 168 (204)                                                  | 8.48 (7.52,9.95)                                           | 0.53 (0.42, 0.67)                                          |                                                            |
| BaselineAlbumin                                            |                                                            |                                                            |                                                            |                                                            |                                                            |                                                            |                                                            |
| < LLN                                                      | 222                                                        | 82 (106)                                                   | 9.82 (7.62,12.55)                                          | 88 (116)                                                   | 8.25 (6.37,9.33)                                           | 0.82 (0.60, 1.11)                                          |                                                            |
| >= LLN                                                     | 698                                                        | 215 (351)                                                  | 16.13( (14.26,18.00)                                       | 260 (347)                                                  | 12.09 (11.07,13.08)                                        | 0.66 (0.55,0.79)                                           |                                                            |
| Not Reported                                               | 35                                                         | 12 (16)                                                    | 12.12 (7.39, 16.23)                                        | 14 (19)                                                    | 9.13 (6.31, 16.82)                                         | 0.82 (0.38,1.78)                                           |                                                            |
| MicrosatelliteInstability                                  |                                                            |                                                            |                                                            |                                                            |                                                            |                                                            |                                                            |
| MSI-H                                                      | 34                                                         | 7 (.18)                                                    | N.A. (5.39, N.A.)                                          | 12 (.16)                                                   | 8.80 (3.71,16.46)                                          | 0.33 (0.12,0.87)                                           |                                                            |
| MSS                                                        | 846                                                        | 279 (423)                                                  | 14.39(13.04,16.23)                                         | 313(423)                                                   | 11.14 (10.05,12.48)                                        | 0.73 (0.62,0.85)                                           |                                                            |
| Invalid                                                    | 14                                                         | 5 6)                                                       | 11.37 (3.38,18.83)                                         | 7（ 8)                                                      | 14.14 (6.34, 19.32)                                        |                                                            |                                                            |
| Not Reported                                               | 61                                                         | 18 (26)                                                    | 11.79 (8.28, 14.39)                                        | 30 (35)                                                    | 10.25 (6.67, 12.71)                                        | 0.62 (0.34,1.13)                                           |                                                            |
| H.Pylori                                                   |                                                            |                                                            |                                                            |                                                            |                                                            |                                                            |                                                            |
| Yes                                                        | 126                                                        | 39 (65)                                                    | 16.33 (8.74, 24.57)                                        | 50 (61)                                                    | 12.16 (9.89, 14.42)                                        | 0.64 (0.42, 0.97)                                          |                                                            |
| No                                                         | 608                                                        | 199 (290)                                                  | 13.80 (12.09,15.51)                                        | 232 (318)                                                  | 11.01 (9.72, 12.39)                                        | 0.78 (0.64,0.94)                                           |                                                            |
| Unknown                                                    | 220 1                                                      | 71(117) o（ 1)                                              | 15.64 (12.62, 21.62) N.A.                                  | 80 (103) 0)                                                | 11.24 (7.69, 12.91) N.A.                                   | 0.57 (0.41, 0.79)                                          |                                                            |
| Not Reported TumorCellPD-L1Status                          |                                                            |                                                            |                                                            |                                                            |                                                            |                                                            |                                                            |
|                                                            | 724                                                        | 245 (363)                                                  |                                                            |                                                            |                                                            |                                                            |                                                            |
|                                                            |                                                            | 64 (110)                                                   | 16.23 (11.76, 23.72)                                       | 92 (120)                                                   | (6.34,11.24)                                               |                                                            |                                                            |
|                                                            |                                                            |                                                            |                                                            | 1 1）                                                       | 12.25 (N.A., N.A.)                                         |                                                            |                                                            |
| <1%                                                        |                                                            |                                                            | 14.19 (12.55, 16.10)                                       | 269 (361)                                                  | 11.56 (10.64,12.65) 0.75 (0.63,0.90)                       |                                                            |                                                            |
| >= 1%                                                      | 230                                                        |                                                            |                                                            |                                                            | 8.77                                                       | 0.56 (0.40, 0.77)                                          |                                                            |
| Indeterminate/Unevaluable/NotReported1 o（ 0) N.A. 0.25 0.5 | Indeterminate/Unevaluable/NotReported1 o（ 0) N.A. 0.25 0.5 | Indeterminate/Unevaluable/NotReported1 o（ 0) N.A. 0.25 0.5 | Indeterminate/Unevaluable/NotReported1 o（ 0) N.A. 0.25 0.5 | Indeterminate/Unevaluable/NotReported1 o（ 0) N.A. 0.25 0.5 | Indeterminate/Unevaluable/NotReported1 o（ 0) N.A. 0.25 0.5 | Indeterminate/Unevaluable/NotReported1 o（ 0) N.A. 0.25 0.5 | Indeterminate/Unevaluable/NotReported1 o（ 0) N.A. 0.25 0.5 |

Nivo+Chemo

Chemo

HR is not computed for subset (except age, race, region, and sex) category with less than 10 subjects per treatment group.

(A) Gastroesophageal Junction Cancer represents patients with diagnosis GEJ and Siewert-Stein Type II or III or unknown

(B) Esophageal Adenocarcinoma represents patients with diagnosis EAC or Gastroesophageal Junction Cancer with Siewert-Stein Type I

(C) Stratification factors are based on CRF source, not IRT.

Figure 16. Forest Plot of Treatment Effect on PFS per BICR, Primary Definition in Predefined Subsets - All Randomized Subjects with PDL1 CPS ≥ 5

<!-- image -->

|                                             | N   | Nivo + Chemo (NofSubjects) N.ofEvents 95%CI)   | Nivo + Chemo (NofSubjects) N.ofEvents 95%CI)   | Chemo NofEvents (NofSubjects)   | Chemo NofEvents (NofSubjects)   | Unstratified Hazard Ratio(95%Cl) Nivo+Chemovs.Chemo   | Unstratified Hazard Ratio(95%Cl) Nivo+Chemovs.Chemo   |
|---------------------------------------------|-----|------------------------------------------------|------------------------------------------------|---------------------------------|---------------------------------|-------------------------------------------------------|-------------------------------------------------------|
| Overall                                     | 955 | 328(473)                                       | 7.69 (7.03, 9.17)                              | 350 (482)                       | 6.05 (5.55,6.90)                | 0.69 (0.59,0.80)                                      |                                                       |
| Region1                                     |     |                                                |                                                |                                 |                                 |                                                       |                                                       |
| Asia                                        | 228 | 79(117)                                        | 8.54 (6.90,11.56)                              | 81(111)                         | 5.78 (4.50, 7.16)               | 0.67 (0.49,0.92)                                      |                                                       |
| US                                          | 137 | 42 (67)                                        | 9.69 (6.60,13.63)                              | 43(70}                          | 6.08(5.29,7.26)                 | 0.67 (0.43,1.04)                                      |                                                       |
| Restof World                                | 590 | 207 (289)                                      | 7.26 (6.87, 8.57)                              | 226 (301)                       | 5.98 (5.45,6.93)                | 0.70 (0.58, 0.84)                                     |                                                       |
| Region2                                     |     |                                                |                                                |                                 |                                 |                                                       |                                                       |
| Asia[without China]                         | 72  | 28(42)                                         | 8.51 (5.59,13.90)                              | 20(30）                          | 10.94 (6.93,13.86)              | 1.08 (0.61,1.93)                                      |                                                       |
| US                                          | 137 | 42 67)                                         | 9.69 (6.60,13.63)                              | 43(70)                          | 6.08(5.29.7.26)                 | 0.67 (0.43,1.04)                                      |                                                       |
| RoW[including China]                        | 746 | 258 (364)                                      | 7.43 (6.93,8.57)                               | 287 (382)                       | 5.68 (5.06, 6.80)               | 0.67 (0.56, 0.79)                                     |                                                       |
| ECoGPerformanceStatus                       |     |                                                |                                                |                                 |                                 |                                                       |                                                       |
| 0                                           | 397 | 126 (194)                                      | 9.49 (7.62, 11.43)                             | 134 (203)                       | 7.46 (6.67, 8.97)               | 0.76 (0.59, 0.97)                                     |                                                       |
| 1                                           | 557 | 202(279)                                       | 7.00(6.18,8.31)                                | 215(278)                        | 5.55 (4.67,5.91)                | 0.64 (0.52,0.77)                                      |                                                       |
| NotReported                                 | 1   |                                                | N.A.                                           | 11)                             | 7.00 (N.A., N.A.)               |                                                       |                                                       |
| ChemotherapyRegimen                         |     |                                                |                                                |                                 |                                 |                                                       |                                                       |
| XELOX                                       | 454 | 169 (231)                                      | 7.62 (6.74, 9.46)                              | 169 (223)                       | 5.55 (4.67,6.83)                | 0.71 (0.57,0.88)                                      |                                                       |
| FOLFOX                                      | 479 | 157 (237)                                      | 8.31(7.03,9.82)                                | 174 (242)                       | 6.67 (5.68.7.06)                | 0.67 (0.54. 0.83)                                     |                                                       |
| Age Categorization                          |     |                                                |                                                |                                 |                                 |                                                       |                                                       |
| 65                                          | 552 | 177 (266)                                      | 7.52 (6.93, 9.56)                              | 210 (286)                       | 5.68 (5.32,6.67)                | 0.66 (0.54,0.81)                                      |                                                       |
| >65 and<75                                  | 298 | 111 (151)                                      | 8.44(6.97,10.02)                               | 102(147)                        | 6.34(5.36,7.72)                 | 0.69 (0.53,0.90)                                      |                                                       |
| >=75                                        | 105 | 40 (56)                                        | 7.00 (5.19,9.89)                               | 38(49)                          | 7.10 (4.63. 9.76)               | 0.89(0.57.1.39)                                       |                                                       |
| >=65                                        | 403 | 151 (207)                                      | 7.69 (6.97, 9.79)                              | 140 (196)                       | 6.90 (5.55, 7.98)               | 0.74 (0.59.0.93)                                      |                                                       |
| Sex                                         |     |                                                |                                                |                                 |                                 |                                                       |                                                       |
| Male                                        | 680 | 232 (331)                                      | 8.51 (7.26, 9.79)                              | 256 (349)                       | 5.91 (5.49,6.83)                | 0.65 (0.54,0.78)                                      |                                                       |
| Female                                      | 275 | 96 （142)                                       | 6.67 (5.68, 8.31)                              | 94 (133)                        | 6.80 (5.36,8.28)                | 0.81 (0.61, 1.07)                                     |                                                       |
| Race                                        |     |                                                |                                                |                                 |                                 |                                                       |                                                       |
| Asian                                       | 236 | 80(119)                                        | 8.54 (7.03,12.32)                              | 85 (117)                        | 5.75 (4.24, 7.03)               | 0.65 (0.48,0.89)                                      |                                                       |
| White                                       | 655 | 233 (328)                                      | 7.43 (6.97,9.17)                               | 237(327)                        | 6.21( (5.55,6.93)               | 0.70 (0.59,0.84)                                      |                                                       |
| Other                                       | 64  | 15 (26)                                        | 7.00 (4.27. 19.84)                             | 28(38)                          | 5.85 (4.24, 7.98)               | 0.75 (0.40, 1.41)                                     |                                                       |
| Primary Tumor Location at Initial Diagnosis |     |                                                |                                                |                                 |                                 |                                                       |                                                       |
| GEJCancer(A)                                | 170 | 61(84)                                         | 7.10 (6.28,10.02)                              | 61(86)                          | 6.97 (5.55, 8.25)               | 0.84 (0.58,1.19)                                      |                                                       |
| GastricCancer                               | 667 | 225(333)                                       | 8.34(7.10,9.76)                                | 249(334)                        | 5.82 (5.49,6.87)                | 0.64 (0.53,0.76)                                      |                                                       |
| Esophageal Adenocarcinoma(B)                | 118 | 42(56)                                         | 5.88 (4.47.9.56)                               | 40(62)                          | 5.45 (4.21,6.93)                | 0.82 (0.53.1.28)                                      |                                                       |

<div style=\"page-break-after: always\"></div>

|                                                      |     | Nivo +Chemo NofEvents (NofSubjects)( (95%C)   | Nivo +Chemo NofEvents (NofSubjects)( (95%C)   | Chemo NofEvents (NofSubjects)   | Chemo NofEvents (NofSubjects)   | Unstratified HazardRatio(95%Cl) Nivo+Chemovs.Chemo   | Unstratified HazardRatio(95%Cl) Nivo+Chemovs.Chemo   |
|------------------------------------------------------|-----|-----------------------------------------------|-----------------------------------------------|---------------------------------|---------------------------------|------------------------------------------------------|------------------------------------------------------|
| DiseaseStage at Initial Diagnosis                    | N   |                                               |                                               |                                 |                                 |                                                      |                                                      |
| StageI-II                                            | 46  | 12（19）                                        | 9.69 (5.55.24.64)                             | 20 (27)                         | 7.13 (5.32. 9.72)               | 0.54 (0.26.1.12)                                     |                                                      |
| StageIll                                             | 131 | 48 (99                                        | 6.97 (5.68,9.92)                              | 45(65)                          | 6.93 (5.06, 8.41)               | 0.83(0.55.1.25)                                      |                                                      |
| StageIV                                              | 776 | 267 (387)                                     | 7.69(7.03,9.40)                               | 285 (389)                       | 5.75 (5.45, 6.54)               | 0.67 (0.57,0.80)                                     |                                                      |
| Not Reported                                         | 2   | 1 1)                                          | 2.89 (N.A., N.A.)                             |                                 | N.A.                            |                                                      |                                                      |
| Disease Status                                       |     |                                               |                                               |                                 |                                 |                                                      |                                                      |
| Locally Recurrent/Advanced                           | 40  | 11 (.19)                                      | 10.02 (5.45, N.A.)                            | 18(.21)                         | 6.93 (3.02,9.72)                | 0.41 (0.19,0.87)                                     |                                                      |
| Metastatic                                           | 915 | 317(454)                                      | 7.56(6.97,9.00)                               | 332(461)                        | 5.95 (5.55,6.83)                | 0.71(0.61,0.83)                                      |                                                      |
| PriorSurgeryRelated toCurrentCancer                  |     |                                               |                                               |                                 |                                 |                                                      |                                                      |
| Yes                                                  | 202 | 65 (97)                                       | 9.63 (6.77, 11.30)                            | 71(105)                         | 6.67 (4.53,7.03)                | 0.64 (0.45,0.89)                                     |                                                      |
| No                                                   | 753 | 263 (376)                                     | 7.52 (6.97, 8.54)                             | 279 (377)                       | 5.98 (5.55, 6.90)               | 0.70 (0.59, 0.83)                                    |                                                      |
| PriorRadiotherapy                                    |     |                                               |                                               |                                 |                                 |                                                      |                                                      |
| Yes                                                  | 86  | 37(.44)                                       | 6.28 (4.11,6.93)                              | 27(.42)                         | 8.25 (6.93, 11.37)              | 1.61( (0.98,2.66)                                    |                                                      |
| No                                                   | 869 | 291 (429)                                     | 8.34(7.26,9.72)                               | 323 (440)                       | 5.78 (5.52, 6.67)               | 0.63 (0.54,0.74)                                     |                                                      |
| Lauren Classification                                |     |                                               |                                               |                                 |                                 |                                                      |                                                      |
| Intestinal Type                                      | 347 | 115 (171)                                     | 8.57 (7.03,10.94)                             | 124(176)                        | 6.80 (5.65,8.25)                | 0.74 (0.57.0.95)                                     |                                                      |
| DiffuseType                                          | 278 | 96(137)                                       | 7.62(6.67,9.69)                               | 103(141)                        | 6.34(5.06,7.59)                 | 0.70 (0.53,0.93)                                     |                                                      |
| Mixed                                                | 67  | 22 (37)                                       | 9.63(5.62,19.48)                              | 2430)                           | 6.93 (5.26,10.41)               | 0.65 (0.36,1.16)                                     |                                                      |
| Unknown                                              | 263 | 95(128)                                       | 6.97 (5.82,8.34)                              | 99(135)                         | 4.76 (4.17, 6.14)               | 0.61(0.46,0.82)                                      |                                                      |
| WHOHistologicClassificationPresence ofSignetRingCell |     |                                               |                                               |                                 |                                 |                                                      |                                                      |
| Yes                                                  | 141 | 50(.72)                                       | 7.49 (5.75.10.94)                             | 51(69)                          | 6.14 (4.86,7.03)                | 0.64 (0.43,0.95)                                     |                                                      |
| No                                                   | 814 | 278 (401)                                     | 8.31(7.03,9.46)                               | 299 (413)                       | 6.05 (5.55, 6.93)               | 0.70(0.59,0.82)                                      |                                                      |
| TNM Classification Metastasis                        |     |                                               |                                               |                                 |                                 |                                                      |                                                      |
| MO                                                   | 37  | 11 (.18)                                      | 10.02 (4.70, N.A.)                            | 15 (.19)                        | 6.98 (2.86,9.76)                | 0.45 (0.20,0.98)                                     |                                                      |
| M1                                                   | 869 | 303(428)                                      | 7.33(6.93,8.51)                               | 318(441)                        | 6.05 (5.55.6.87)                | 0.74 (0.63,0.86)                                     |                                                      |
| Unknown/Mx                                           | 12  | 8                                             | 8.57 (4.21,19.84)                             | 24                              | 7.11 (4.67, 9.56)               |                                                      |                                                      |
| Not Reported                                         | 37  | 8(19)                                         | 13.11 (7.52, 22.31)                           | 15(18)                          | 5.03 (1.74, 7.20)               | 0.19 (0.07, 0.48)                                    |                                                      |
| AtLeastOneTargetLesionperBICR                        |     |                                               |                                               |                                 |                                 |                                                      |                                                      |
| Yes                                                  | 770 | 266 (379)                                     | 7.10 (6.83,8.44)                              | 296 (391)                       | 5.59 (5.03,6.28)                | 0.66 (0.56.0.78)                                     |                                                      |
| No                                                   | 156 | 53 （80）                                       | 9.69(7.69,11.37)                              | 51(76)                          | 7.33(5.78,10.94)                | 0.82 (0.56,1.20)                                     |                                                      |
| Not Reported                                         | 29  | 9 14)                                         | 13.16 (4.70, 25.66)                           | 3(15)                           | 24.87 (6.28, 24.87)             | 1.74 (0.46,6.63)                                     |                                                      |

|                                                                                                               | N                                                                                                             | Nivo+Chemo N.of Events mPFS (Nof Subjects)(95%Cl)                                                             | Nivo+Chemo N.of Events mPFS (Nof Subjects)(95%Cl)                                                             | Chemo NofEvents (NofSubjects)(95%Cl)                                                                          | Chemo NofEvents (NofSubjects)(95%Cl)                                                                          | Unstratified HazardRatio(95%Cl) Nivo+Chemovs.Chemo                                                            |                                                                                                               |
|---------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|
| NumberofOrganswithBaselineLesionOutsidePrimaryLocation(Gastric,Gastroesophageal Junction andEsophagus)perBICR | NumberofOrganswithBaselineLesionOutsidePrimaryLocation(Gastric,Gastroesophageal Junction andEsophagus)perBICR | NumberofOrganswithBaselineLesionOutsidePrimaryLocation(Gastric,Gastroesophageal Junction andEsophagus)perBICR | NumberofOrganswithBaselineLesionOutsidePrimaryLocation(Gastric,Gastroesophageal Junction andEsophagus)perBICR | NumberofOrganswithBaselineLesionOutsidePrimaryLocation(Gastric,Gastroesophageal Junction andEsophagus)perBICR | NumberofOrganswithBaselineLesionOutsidePrimaryLocation(Gastric,Gastroesophageal Junction andEsophagus)perBICR | NumberofOrganswithBaselineLesionOutsidePrimaryLocation(Gastric,Gastroesophageal Junction andEsophagus)perBICR | NumberofOrganswithBaselineLesionOutsidePrimaryLocation(Gastric,Gastroesophageal Junction andEsophagus)perBICR |
| <=1                                                                                                           | 196                                                                                                           | 70 (66)                                                                                                       | 9.17 (7.10.11.20)                                                                                             | 55 (97)                                                                                                       | 8.57 (6.93.11.10)                                                                                             | 0.94 (0.66.1.35)                                                                                              |                                                                                                               |
| >=2                                                                                                           | 759                                                                                                           | 258(374)                                                                                                      | 7.33 (6.93, 8.54)                                                                                             | 295 (385)                                                                                                     | 5.55 (4.93, 6.14)                                                                                             | 0.64(0.54,0.76)                                                                                               |                                                                                                               |
| Time from Initial DiseaseDiagnosis toRandomization                                                            | Time from Initial DiseaseDiagnosis toRandomization                                                            | Time from Initial DiseaseDiagnosis toRandomization                                                            | Time from Initial DiseaseDiagnosis toRandomization                                                            | Time from Initial DiseaseDiagnosis toRandomization                                                            | Time from Initial DiseaseDiagnosis toRandomization                                                            | Time from Initial DiseaseDiagnosis toRandomization                                                            | Time from Initial DiseaseDiagnosis toRandomization                                                            |
| <6Months                                                                                                      | 805                                                                                                           | 273 (399)                                                                                                     | 8.31 (7.03,9.49)                                                                                              | 299 (406)                                                                                                     | 5.78 (5.49,6.54)                                                                                              | 0.67 (0.57, 0.79)                                                                                             |                                                                                                               |
| 6Months-<1Year                                                                                                | 30                                                                                                            | 6 (6                                                                                                          | 6.97 (1.77.13.93)                                                                                             | 18(21)                                                                                                        | 5.65 (4.24,16.76)                                                                                             |                                                                                                               |                                                                                                               |
| >=1Year                                                                                                       | 120                                                                                                           | 49(65)                                                                                                        | 7.10(5.98,9.72)                                                                                               | 33(55)                                                                                                        | 7.26(6.93,8.38)                                                                                               | 0.86 (0.55, 1.34)                                                                                             |                                                                                                               |
| Peritoneal Metastases                                                                                         |                                                                                                               |                                                                                                               |                                                                                                               |                                                                                                               |                                                                                                               |                                                                                                               |                                                                                                               |
| Yes                                                                                                           | 197                                                                                                           | 74(101)                                                                                                       | 6.08 (5.39.8.34)                                                                                              | 77 (96)                                                                                                       | 5.32 (4.17.6.83)                                                                                              | 0.67(0.48,0.92)                                                                                               |                                                                                                               |
| No                                                                                                            | 729                                                                                                           | 245(358)                                                                                                      | 8.31 (7.10.9.59)                                                                                              | 270(371)                                                                                                      | 6.24 (5.59,6.93)                                                                                              | 0.68 (0.57.0.81)                                                                                              |                                                                                                               |
| NotReported                                                                                                   | 29                                                                                                            | 9(14)                                                                                                         | 13.16 (4.70, 25.66)                                                                                           | 3(15)                                                                                                         | 24.87 (6.28, 24.87)                                                                                           | 1.74 (0.46,6.63)                                                                                              |                                                                                                               |
| Liver Metastases                                                                                              |                                                                                                               |                                                                                                               |                                                                                                               |                                                                                                               |                                                                                                               |                                                                                                               |                                                                                                               |
| Yes                                                                                                           | 408                                                                                                           | 131 (191)                                                                                                     | 6.97 (6.28,8.31)                                                                                              | 172 (217)                                                                                                     | 5.26 (4.21,5.75)                                                                                              | 0.61 (0.48,0.76)                                                                                              |                                                                                                               |
| No                                                                                                            | 518                                                                                                           | 188 (268)                                                                                                     | 8.41(7.43.9.79)                                                                                               | 175(250)                                                                                                      | 6.93 (5.82.7.59)                                                                                              | 0.76 (0.62.0.93)                                                                                              |                                                                                                               |
| Not Reported                                                                                                  | 29                                                                                                            | 6 （14)                                                                                                        | 13.16 (4.70, 25.66)                                                                                           | 3(15)                                                                                                         | 24.87(6.28,24.87)                                                                                             | 1.74 4(0.46,6.63)                                                                                             |                                                                                                               |
| HER-2 Status at Study Entry                                                                                   |                                                                                                               |                                                                                                               |                                                                                                               |                                                                                                               |                                                                                                               |                                                                                                               |                                                                                                               |
| Positive                                                                                                      | 7                                                                                                             | 3)                                                                                                            | N.A. (2.83, N.A.)                                                                                             | 1（ 4)                                                                                                         | 6.93 (N.A.,N.A.)                                                                                              |                                                                                                               |                                                                                                               |
| Negative                                                                                                      | 543                                                                                                           | 184 (272)                                                                                                     | 8.28(6.80,9.56)                                                                                               | 186(271)                                                                                                      | 6.93(5.68,7.33)                                                                                               | 0.78 (0.64,0.96)                                                                                              |                                                                                                               |
| Unknown                                                                                                       | 5                                                                                                             | 2 2)                                                                                                          | 1.69 (0.49.2.89)                                                                                              | 3)                                                                                                            | 9.71 (2.66.16.76)                                                                                             |                                                                                                               |                                                                                                               |
| Not Reported                                                                                                  | 400                                                                                                           | 141(196)                                                                                                      | 7.69 (6.97, 9.79)                                                                                             | 161(204)                                                                                                      | 5.55 (4.50, 6.24)                                                                                             | 0.57 (0.45, 0.72)                                                                                             |                                                                                                               |
| Baseline Albumin                                                                                              |                                                                                                               |                                                                                                               |                                                                                                               |                                                                                                               |                                                                                                               |                                                                                                               |                                                                                                               |
| <LLN                                                                                                          | 222                                                                                                           | 82(106)                                                                                                       | 5.88 (4.47.7.69)                                                                                              | 88(116)                                                                                                       | 5.06 (3.78.6.34)                                                                                              | 0.74 (0.54.1.00)                                                                                              |                                                                                                               |
| >=LLN                                                                                                         | 869                                                                                                           | 234(351)                                                                                                      | 8.44 (7.23,9.79)                                                                                              | 249(347)                                                                                                      | 6.67 (5.75.6.97)                                                                                              | 0.68 (0.57,0.81)                                                                                              |                                                                                                               |
| Not Reported                                                                                                  | 35                                                                                                            | 12 (16)                                                                                                       | 7.62 (5.55, 13.83)                                                                                            | 13 (19)                                                                                                       | 6.28 (3.38, 11.37)                                                                                            | 0.66 (0.30, 1.47)                                                                                             |                                                                                                               |
| Microsatellite Instability                                                                                    |                                                                                                               |                                                                                                               |                                                                                                               |                                                                                                               |                                                                                                               |                                                                                                               |                                                                                                               |
| MSI-H                                                                                                         | 34                                                                                                            | 9(.18)                                                                                                        | 12.48 (2.89, N.A.)                                                                                            | 12(.16)                                                                                                       | 4.27 (1.97, 7.13)                                                                                             | 0.32 2（0.12,0.85)                                                                                             |                                                                                                               |
| MSS                                                                                                           | 846                                                                                                           | 294 (423)                                                                                                     | 8.31(7.06,9.46)                                                                                               | 303(423)                                                                                                      | 6.21 (5.59,6.93)                                                                                              | 0.70 (0.59, 0.82)                                                                                             |                                                                                                               |
| Invalid                                                                                                       | 14                                                                                                            | 5                                                                                                             | 4.24 (0.30,9.99)                                                                                              | 6（8)                                                                                                          | 5.55 (1.41, 13.83)                                                                                            |                                                                                                               |                                                                                                               |
| NotReported                                                                                                   | 61                                                                                                            | 20 (26)                                                                                                       | 6.54 (4.24,8.28)                                                                                              | 29(35)                                                                                                        | 5.78(3.55,8.97)                                                                                               | 0.87 (0.49,1.54)                                                                                              |                                                                                                               |
| H.Pylori                                                                                                      |                                                                                                               |                                                                                                               |                                                                                                               |                                                                                                               |                                                                                                               |                                                                                                               |                                                                                                               |
| Yes                                                                                                           | 126                                                                                                           | 46 (65)                                                                                                       | 7.00 (5.59,13.83)                                                                                             | 45(61)                                                                                                        | 5.91 (4.24, 8.54)                                                                                             | 0.75 (0.50,1.14)                                                                                              |                                                                                                               |
| No                                                                                                            | 608                                                                                                           | 194(290)                                                                                                      | 8.31 (6.97, 9.40)                                                                                             | 230 (318)                                                                                                     | 6.34 (5.55, 6.93)                                                                                             | 0.71(0.58,0.86)                                                                                               |                                                                                                               |
| Unknown                                                                                                       | 220                                                                                                           | 88(117)                                                                                                       | 7.69 (6.51,10.84)                                                                                             | 75(103)                                                                                                       | 5.55 (4.34,6.93)                                                                                              | 0.59(0.43,0.82)                                                                                               |                                                                                                               |
| Not Reported                                                                                                  | 1                                                                                                             | 0                                                                                                             | N.A.                                                                                                          |                                                                                                               | N.A.                                                                                                          |                                                                                                               |                                                                                                               |
| Tumor Cell PD-L1Status                                                                                        |                                                                                                               |                                                                                                               |                                                                                                               |                                                                                                               |                                                                                                               |                                                                                                               |                                                                                                               |
| < 1%                                                                                                          | 724                                                                                                           | 258 (363)                                                                                                     | 7.52 (6.97, 8.57)                                                                                             | 261 (361)                                                                                                     | 6.67 (5.78, 6.97)                                                                                             | 0.76 (0.64,0.91)                                                                                              |                                                                                                               |
| >= 1%                                                                                                         | 230                                                                                                           | 70 (110)                                                                                                      | 9.89 (6.97,13.83)                                                                                             | 88 （120)                                                                                                      | 4.76 (4.04,5.68)                                                                                              | 0.51 (0.37,0.71)                                                                                              |                                                                                                               |
| Indeterminate/Unevaluable/NotReported                                                                         |                                                                                                               | 0 (o                                                                                                          | N.A.                                                                                                          | 1（ 1                                                                                                          | 7.13 (N.A., N.A.)                                                                                             |                                                                                                               |                                                                                                               |

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 17. Forest Plot of Treatment Effect on Overall Survival in Predefined Subsets - All Randomized Subjects

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

HR is not computed for subsct (except age, race, region, and sex) category with less than 10 subjects per treatment group. (A) Gastroesophageal Junction Cancer reprcsents patients with diagnosis GEJ and Siewert-Stein Type II or IlI or unknown (B) Esophageal Adenocarcinoma represcnts patients with diagnosis EAC or Gastrocsophageal Junction Cancer with Siewert-Stein Type I

(C) Stratification factors are based on CRF sourcc, not IRT.

## Patient-Reported Outcomes (PRO) - All randomised subjects (Exploratory endpoints)

Questionnaire completion rates were acceptable, with ≥ 90% of subjects completing assessments at baseline and ≥ 80% at most time points during the treatment period.

## Time to Disease-Related Symptom Deterioration - All Randomized Subjects

Symptom deterioration was defined as a clinically meaningful decline in GaCS score (worsening from baseline ≥ 8.2 points) during the treatment period. Subjects without deterioration while on treatment were censored at the last GaCS assessment.

A total of 194/789 subjects in the nivo+chemo arm and 193/792 subjects in the chemo arm experienced a disease-related symptom deterioration event. Median time to symptom deterioration (TTSD) in all randomized subjects was not reached (95% CI: 22.64, N.A.) in the nivo+chemo arm and was 21.03 months (95% CI: 12.45, N.A.) in the chemo arm. Subjects in the nivo+chemo arm had a decreased risk (HR: 0.77, 95% CI: 0.63, 0.95) of deterioration compared to subjects in the chemo arm.

## EQ5D -3L Descriptive System and Utility Index

Mean baseline EQ-5D-3L UI scores in all randomized subjects were similar in the nivo+chemo (0.7339, SD: 0.2611) and chemo (0.7404, SD: 0.2398) arms. Subjects in the nivo+chemo arm had improvement in mean UI scores at all on-treatment assessments after baseline through Week 103 (last time point with N ≥ 10). The mean change from baseline met or exceeded the minimum important difference (MID) (≥ 0.08 points) at Weeks 91, 97, and 103. Subjects in the chemo arm had improvement in mean UI scores at most on-treatment assessments, with the mean change from baseline exceeding the MID at Week 97.

There was a decrease from baseline (worsening) that approached or exceeded the MID for both arms at most follow-up visits.

<div style=\"page-break-after: always\"></div>

Figure 18. Mean Changes in EQ-5D-3L Utility Index Score from Baseline - All Randomized Subjects - with Baseline and at Least One Post-Baseline Assessment

<!-- image -->

EQ Visual Analogue Scale

Mean baseline EQ-5D-3L VAS scores in all randomized subjects were similar in the nivo+chemo (71.8, SD: 17.9) and chemo (71.8, SD: 18.2) arms. Overall, the mean EQ-5D-3L VAS scores in all randomized subjects increased (improved) over time in both arms. The mean change from baseline in the nivo+chemo arm met or exceeded the MID (≥ 7 points) at all the time points where there were ≥ 10 subjects eligible to respond, starting at Week 85. The mean change from baseline did not meet or exceed the MID for the chemo arm.

## Updated analysis (DBL 16-Feb-2021; minimum follow-up: 19.4 months)

Updated  overall  survival  (OS),  progression-free  survival  (PFS),  objective  response  rate  (ORR)  and duration of response (DoR) per blinded independent central review (BICR) data with nivolumab+chemotherapy  (nivo+chemo)  over  chemotherapy  (chemo)  for  CA209649  were  provided during the procedure from an updated database lock (DBL) of 16-Feb-2021. The clinical cut-off (last patient last visit [LPLV]) was 04-Jan-2021. These update analyses are descriptive in nature.

Table 25.  Summary of Overall Survival in CA209649 - Updated Analysis vs Primary CSR Analysis

|                                             | Primary CSR Analysis 10-Jul-2020 Database Lock (Minimum Follow-up: 12.1 mo.)   | Primary CSR Analysis 10-Jul-2020 Database Lock (Minimum Follow-up: 12.1 mo.)   | Updated Analysis 16-Feb-2021 Database Lock (Minimum Follow-up: 19.4 mo.)   | Updated Analysis 16-Feb-2021 Database Lock (Minimum Follow-up: 19.4 mo.)   |
|---------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|
| Overall Survival                            | Nivo+Chemo                                                                     | Chemo                                                                          | Nivo+Chemo                                                                 | Chemo                                                                      |
| All Randomized Subjects with PD- L1 CPS ≥ 5 | All Randomized Subjects with PD- L1 CPS ≥ 5                                    | All Randomized Subjects with PD- L1 CPS ≥ 5                                    | All Randomized Subjects with PD- L1 CPS ≥ 5                                | All Randomized Subjects with PD- L1 CPS ≥ 5                                |
| Events, n/N (%)                             | 309/473 (65.3)                                                                 | 362/482 (75.1)                                                                 | 344/473 (72.7)                                                             | 397/482 (82.4)                                                             |
| Median OS (95% CI) a , mo.                  | 14.39 (13.11, 16.23)                                                           | 11.10 (10.02, 12.09)                                                           | 14.42 (13.14, 16.26)                                                       | 11.10 (10.02, 12.09)                                                       |
| Stratified HR (95% CI) b                    | 0.71 (0.61, 0.83)                                                              | 0.71 (0.61, 0.83)                                                              | 0.69 (0.60, 0.81)                                                          | 0.69 (0.60, 0.81)                                                          |

<div style=\"page-break-after: always\"></div>

| All Randomized Subjects with PD- L1 CPS ≥ 1   | All Randomized Subjects with PD- L1 CPS ≥ 1   | All Randomized Subjects with PD- L1 CPS ≥ 1   |                      |                      |
|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|----------------------|----------------------|
| Events, n/N (%)                               | 434/641 (67.7)                                | 492/655 (75.1)                                | 478/641 (74.6)       | 540/656* (82.3)      |
| Median OS (95% CI) a , mo.                    | 13.96 (12.55, 14.98)                          | 11.33 (10.64, 12.25)                          | 14.00 (12.55, 15.11) | 11.33 (10.58, 12.12) |
| Stratified HR (95% CI) b                      | 0.77 (0.68, 0.88)                             | 0.77 (0.68, 0.88)                             | 0.75 (0.66, 0.85)    | 0.75 (0.66, 0.85)    |
| All Randomized Subjects                       |                                               |                                               |                      |                      |
| Events, n/N (%)                               | 544/789 (68.9)                                | 591/792 (74.6)                                | 603/789 (76.4)       | 647/792 (81.7)       |
| Median OS (95% CI) a , mo.                    | 13.83 (12.55, 14.55)                          | 11.56 (10.87, 12.48)                          | 13.93 (12.55, 14.65) | 11.56 (10.87, 12.48) |
| Stratified HR (95% CI) b                      | 0.80 (0.71, 0.90)                             | 0.80 (0.71, 0.90)                             | 0.79 (0.70, 0.88)    | 0.79 (0.70, 0.88)    |

Abbreviations: chemo - chemotherapy, CI - confidence interval, CPS - combined positive score, CSR - clinical study report, DBL - database lock, HR - hazard ratio, Nivo - nivolumab, OS - overall survival, PD-L1 - programmed deathligand 1

*   One subject has CPS status changed for the updated DBL comparing with the previous DBL.

Source: Table S.5.22.A.1, Table S.5.222.A.1, Table S.5.222.A.2, Table S.5.22.EU.1, Table S.5.23.EU.1, and Table S.5.22.EU.3 of Appendix 2

Table 26. Summary of Other Key Efficacy Results - Updated Analysis from CA209649 (16Feb-2021 Database Lock)

| Minimum Follow-up: 19.4 mo.                                | All Randomized Subjects with PD- L1 CPS ≥ 5                | All Randomized Subjects with PD- L1 CPS ≥ 5                | All Randomized Subjects   | All Randomized Subjects   |
|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|---------------------------|---------------------------|
| Efficacy Parameter                                         | Nivo+Chemo                                                 | Chemo                                                      | Nivo+Chemo                | Chemo                     |
| PFS per BICR (1ºDefinition)                                |                                                            |                                                            |                           |                           |
| Events, n/N (%)                                            | 342/473 (72.3)                                             | 366/482 (75.9)                                             | 581/789 (73.6)            | 579/792 (73.1)            |
| Median PFS (95% CI) a , months                             | 8.31 (7.03, 9.26)                                          | 6.05 (5.55, 6.90)                                          | 7.75 (7.13, 8.57)         | 6.93 (6.67, 7.13)         |
| HR (95% CI) b                                              | 0.68 (0.59, 0.79)                                          | 0.68 (0.59, 0.79)                                          | 0.78 (0.69, 0.88)         | 0.78 (0.69, 0.88)         |
| ORR per BICR (CR + PR) in All Randomized Subjects          | ORR per BICR (CR + PR) in All Randomized Subjects          | ORR per BICR (CR + PR) in All Randomized Subjects          |                           |                           |
| N responders/N (%)                                         | 238/473 (50.3)                                             | 183/482 (38.0)                                             | 371/789 (47.0)            | 293/792 (37.0)            |
| 95% CI c                                                   | (45.7, 54.9)                                               | (33.6, 42.5)                                               | (43.5, 50.6)              | (33.6, 40.5)              |
| Difference of ORR (95% CI) d                               | 13.3 (7.2, 19.3)                                           | 13.3 (7.2, 19.3)                                           | 12.3 (7.7, 17.0)          | 12.3 (7.7, 17.0)          |
| ORR per BICR (CR + PR) in Subjects with Measurable Disease | ORR per BICR (CR + PR) in Subjects with Measurable Disease | ORR per BICR (CR + PR) in Subjects with Measurable Disease |                           |                           |
| N responders/N (%)                                         | 227/378 (60.1)                                             | 176/390 (45.1)                                             | 352/604 (58.3)            | 279/607 (46.0)            |
| 95% CI c                                                   | (54.9, 65.0)                                               | (40.1, 50.2)                                               | (54.2, 62.2)              | (41.9, 50.0)              |
| Difference of ORR (95% CI) d                               | 16.4 (9.7, 23.1)                                           | 16.4 (9.7, 23.1)                                           | 13.1 (7.6, 18.5)          | 13.1 (7.6, 18.5)          |
| DoR per BICR in Subjects with Measurable Disease           | DoR per BICR in Subjects with Measurable Disease           | DoR per BICR in Subjects with Measurable Disease           |                           |                           |
| N events/N responders (%)                                  | 153/227 (67.4)                                             | 133/176 (75.6)                                             | 247/352 (70.2)            | 216/279 (77.4)            |
| Median (95% CI) a , months                                 | 9.69 (8.25, 12.22)                                         | 6.97 (5.62, 7.85)                                          | 8.54 (7.69, 10.22)        | 6.93 (5.82, 7.16)         |

<div style=\"page-break-after: always\"></div>

- d The difference in response rate (Nivo+Chemo vs Chemo) is not the simple difference between the rates but is adjusted for the stratification factors based on the DerSimonian and Laird methodology

Abbreviations: BICR - blinded independent central review, chemo - chemotherapy, CI - confidence interval, CPS combined positive score, CR - complete response, DoR - duration of response, HR - hazard ratio, Nivo - nivolumab, ORR - objective response rate, PD-L1 - programmed death-ligand 1, PFS - progression-free survival, PR - partial response, RECIST - Response Evaluation Criteria in Solid Tumors

Source:  Table  S.5.22.EU.2,  Table  S.5.22.EU.4,  Table  S.5.9.EU.1,  Table  S.5.9.EU.2,  Table  S.5.9.EU.3,  Table S.5.9.EU.4, Figure S.5.11.EU.1 and Figure S.5.11.EU.2 of Appendix 2

Further to the above updated analysis were submitted by PD-L1 CPS categorie.

Table 27. Efficacy of Nivolumab + Chemotherapy vs Chemotherapy by Baseline PD-L1 CPS Status - Updated Analysis from CA209649 (16-Feb-2021 Database Lock)

| All Randomized Subjects             | CPS <1             | CPS <1             | CPS ≥1            | CPS ≥1            | CPS<5             | CPS<5             | CPS≥5              | CPS≥5             | CPS<10            | CPS<10            | CPS≥10            | CPS≥10                  |
|-------------------------------------|--------------------|--------------------|-------------------|-------------------|-------------------|-------------------|--------------------|-------------------|-------------------|-------------------|-------------------|-------------------------|
| Minimum Follow-up: 19.4 mo.         | Nivo+ Chemo N=140  | Chemo N=123        | Nivo+ Chemo N=641 | Chemo N=656       | Nivo+ Chemo N=308 | Chemo N=297       | Nivo+ Chemo N= 473 | Chemo N =482      | +OAIN Chemo N=406 | Chemo N=386       | Nivo+             | Chemo Chemo N=375 N=393 |
| OS                                  |                    |                    |                   |                   |                   |                   |                    |                   |                   |                   |                   |                         |
| HR (95% CI)a                        | 0.96 (0.73, 1.25)  | 0.96 (0.73, 1.25)  | 0.74 (0.66, 0.84) | 0.74 (0.66, 0.84) | 0.94 (0.79, 1.13) | 0.94 (0.79, 1.13) | 0.69 (0.59, 0.79)  | 0.69 (0.59, 0.79) | 0.91 (0.78, 1.07) | 0.91 (0.78, 1.07) | 0.66 (0.56, 0.77) | 0.66 (0.56, 0.77)       |
| Events,                             | 117                | 99                 | 478               | 540               | 251               | 242               | 344                | 397               | 330               | 319               | 265               | 320                     |
| (%)u                                | (83.6)             | (80.5)             | (74.6)            | (82.3)            | (81.5)            | (81.5)            | (72.7)             | (82.4)            | (81.3)            | (82.6)            | (70.7)            | (81.4)                  |
| Median OS, mo                       | 13.08              | 12.48              | 14.00             | 11.33             | 12.42             | 12.09             | 14.42              | 11.10             | 12.55             | 12.48             | 15.11             | 10.87                   |
|                                     | (9.82,             | (9.99,             | (12.55,           | (10.58,           | (10.61,           | (10.97,           | (13.14,            | (10.02,           | (11.07,           | (11.14,           | (13.77,           | (9.82,                  |
| (95% CI)b                           | 16.46)             | 13.83)             | 15.11)            | 12.12)            | 14.26)            | 13.24)            | 16.26)             | 12.09)            | 14.19)            | 13.17)            | 16.79)            | 11.89)                  |
| PFS per BICR (primary definition)   |                    |                    |                   |                   |                   |                   |                    |                   |                   |                   |                   |                         |
| HR (95% CI)a                        | 0.91 (0.68, 1.22)  | 0.91 (0.68, 1.22)  | 0.75 (0.66, 0.85) | 0.75 (0.66, 0.85) | 0.95 (0.78, 1.14) | 0.95 (0.78, 1.14) | 0.68 (0.59, 0.79)  | 0.68 (0.59, 0.79) | 0.92 (0.78, 1.08) | 0.92 (0.78, 1.08) | 0.65 (0.55, 0.77) | 0.65 (0.55, 0.77)       |
| Events,                             | 100                | 78                 | 475               | 493               | 233               | 205               | 342                | 366               | 310               | 271               | 265               | 300                     |
| n (%)                               | (71.4)             | (63.4)             | (74.1)            | (75.2)            | (75.6)            | (69.0)            | (72.3)             | (75.9)            | (76.4)            | (70.2)            | (67.2)            | (73.5)                  |
| Median PFS, mo.                     | 8.67               | 8.11               | 7.52              | 6.90              | 7.46              | 8.15              | 8.31               | 6.05              | 7.49              | 7.72              | 8.34              | 5.78                    |
|                                     | (6.93,             | (6.87,             | (7.03,            | (6.08,            | (6.97,            | (7.06,            | (7.03,             | (5.55,            | (7.03,            | (6.97,            | (7.00,            | (5.45,                  |
| (95% CI)b                           | 9.69)              | 9.82)              | 8.51)             | 7.03)             | 8.64)             | 8.67)             | 9.26)              | 6.90)             | 8.44)             | 8.31)             | 9.76)             | 6.87)                   |
| ORR per BICR (CR+PR)c               |                    |                    |                   |                   |                   |                   |                    |                   |                   |                   |                   |                         |
| Subjects with measurable disease, N | 94                 | 84                 | 504               | 514               | 220               | 208               | 378                | 390               | 299               | 280               | 299               | 318                     |
| ORR,%                               | 51.1               | 40.5               | 59.7              | 46.3              | 55.5              | 46.2              | 60.1               | 45.1              | 57.9              | 46.8              | 58.9              | 44.3                    |
| (95% CI)                            | (41, 62)           | (30, 52)           | (55, 64)          | (42,51)           | (49, 62)          | (39, 53)          | (55, 65)           | (40, 50)          | (52, 64)          | (41, 53)          | (53, 65)          | (39, 50)                |
| CR, n/N (%)                         | 6/                 | 4/84               | 54/504            | 31/514            | 15/220            | 9/208             | 46/378             | 26/390            | 28/299            | 15/280            | 33/299            | 20/318                  |
|                                     | (7.4)              | (4.8)              | (10.7)            | (6.0)             | (6.8)             | (4.3)             | (12.2)             | (6.7)             | (9.4)             | (5.4)             | (11.0)            | (6.3)                   |
| PR, n/N (%)                         | 41/94              | 30/84              | 247/504 (49.0)    | 207/514 (40.3)    | 107/220 (48.6)    | 87/208 (41.8)     | 181/378 (47.9)     | 150/390 (38.5)    | 145/299 (48.5)    | 116/280 (41.4)    | 143/299 (47.8)    | 121/318 (38.1)          |
|                                     | (43.6) (35.7) 10.6 | (43.6) (35.7) 10.6 | 13.4              | 13.4              | 9.3               | 9.3               | 14.9               | 14.9              | 11.1              | 11.1              | 14.5              | 14.5                    |
| Difference in ORR, %d (95% CI)      | (-4.0, 24.5)       | (-4.0, 24.5)       | (7.3, 19.4)       | (7.3, 19.4)       | (-0.2, 18.5)      | (-0.2, 18.5)      | (7.9, 21.8)        | (7.9, 21.8)       | (2.9, 19.0)       | (2.9, 19.0)       | (6.6, 22.2)       | (6.6, 22.2)             |

| AllRandomized Subjects                  | CPS<1                                   | CPS<1                                   | CPS≥1                                   | CPS≥1                                   | CPS<5                                   | CPS<5                                   | CPS≥5                                   | CPS≥5                                   | CPS<10                                  | CPS<10                                  | CPS≥10                                  | CPS≥10                                  |
|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|
| Minimum Follow-up: 19.4 mo.             | Nivo+ Chemo N=140                       | Chemo N=123                             | +OXIN Chemo N=641                       | Chemo N=656                             | Nivo+ Chemo N=308                       | Chemo N=297                             | +OYN Chemo N = 473                      | Chemo N=482                             | +OXYN Chemo N= 406                      | Chemo N=386                             | Nivo+ Chemo N=375                       | Chemo N=393                             |
| DoRper BICRin all measurable responders | DoRper BICRin all measurable responders | DoRper BICRin all measurable responders | DoRper BICRin all measurable responders | DoRper BICRin all measurable responders | DoRper BICRin all measurable responders | DoRper BICRin all measurable responders | DoRper BICRin all measurable responders | DoRper BICRin all measurable responders | DoRper BICRin all measurable responders | DoRper BICRin all measurable responders | DoRper BICRin all measurable responders | DoRper BICRin all measurable responders |
| Median DoRb, mo. (95% CI)               | 6.97                                    | 6.97                                    | 8.64                                    | 6.93                                    | 7.69                                    | 6.90                                    | 9.69                                    | 6.97                                    | 7.69                                    | 6.83                                    | 9.92                                    | 7.03                                    |
| Median DoRb, mo. (95% CI)               | (5.16,                                  | (5.45,                                  | (7.89,                                  | (5.78,                                  | (6.24,                                  | (5.65,                                  | (8.25,                                  | (5.62,                                  | (6.57,                                  | (5.55,                                  | (8.44,                                  | (5.65,                                  |
| Median DoRb, mo. (95% CI)               | 12.12)                                  | 9.49)                                   | 10.94)                                  | 7.56)                                   | 9.92)                                   | 8.05)                                   | 12.22)                                  | 7.85)                                   | 9.69)                                   | 7.10)                                   | 12.71)                                  | 8.44)                                   |

- c In subjects with measurable disease. Confidence interval based on the Clopper and Pearson method.

d   Unweighted difference in objective response rate (Nivo+Chemo - Chemo). Two-sided 95% confidence interval for unweighted difference was calculated using Newcombe method.

Abbreviations: BICR - blinded independent central review, chemo - chemotherapy, CI - confidence interval, CPS combined positive score, CR - complete response, DoR - duration of response, HR - hazard ratio, nivo - nivolumab, ORR - objective response rate, OS - overall survival, PD-L1 - programmed death-ligand 1, PFS - progression-free survival, PR - partial response

Source: Figure S.9.3.EU.1, Figure S.9.3.EU.2, Table S.9.4.EU.1, Figure 5.12.EU.1 and Figure S.9.5.EU.1 of Appendix 2

## Summary of main study(ies)

The following tables summarise the efficacy results from the main studies supporting the present

<div style=\"page-break-after: always\"></div>

application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 268. Summary of Efficacy for trial CA209649 (CheckMate 649)

| Title: Study CA209649 Phase 3, randomised, multicenter, open-label study in subjects with previously untreated advanced or metastatic gastric, gastroesophageal junction cancer or oesophageal adenocarcinoma   | Title: Study CA209649 Phase 3, randomised, multicenter, open-label study in subjects with previously untreated advanced or metastatic gastric, gastroesophageal junction cancer or oesophageal adenocarcinoma   | Title: Study CA209649 Phase 3, randomised, multicenter, open-label study in subjects with previously untreated advanced or metastatic gastric, gastroesophageal junction cancer or oesophageal adenocarcinoma   | Title: Study CA209649 Phase 3, randomised, multicenter, open-label study in subjects with previously untreated advanced or metastatic gastric, gastroesophageal junction cancer or oesophageal adenocarcinoma                                                                                                                                                                                                                                                                                                                                                                                              |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                | Study CA209649 (EUDRACT Number 2016-001018-76)                                                                                                                                                                  | Study CA209649 (EUDRACT Number 2016-001018-76)                                                                                                                                                                  | Study CA209649 (EUDRACT Number 2016-001018-76)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Design                                                                                                                                                                                                          | Phase 3, randomized, multicenter, open-label study of nivolumab plus ipilimumab or nivolumab in combination with oxaliplatin plus fluoropyrimidine vs oxaliplatin plus fluoropyrimidine                         | Phase 3, randomized, multicenter, open-label study of nivolumab plus ipilimumab or nivolumab in combination with oxaliplatin plus fluoropyrimidine vs oxaliplatin plus fluoropyrimidine                         | Phase 3, randomized, multicenter, open-label study of nivolumab plus ipilimumab or nivolumab in combination with oxaliplatin plus fluoropyrimidine vs oxaliplatin plus fluoropyrimidine                                                                                                                                                                                                                                                                                                                                                                                                                    |
|                                                                                                                                                                                                                 | Duration of enrolment period:                                                                                                                                                                                   | Duration of enrolment period:                                                                                                                                                                                   | From 17-Apr-2017 to 27-May-2019 subjects were concurrently randomised to the nivo+chemo and chemo arms                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Hypothesis                                                                                                                                                                                                      | Superiority                                                                                                                                                                                                     | Superiority                                                                                                                                                                                                     | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Treatments groups                                                                                                                                                                                               | Nivolumab + chemotherapy (XELOX or FOLFOX)                                                                                                                                                                      | Nivolumab + chemotherapy (XELOX or FOLFOX)                                                                                                                                                                      | Nivolumab + XELOX: Nivolumab 360 mg IV on Day 1, Q3W Oxaliplatin 130 mg/m 2 IV on Day 1, Q3W Capecitabine 1000 mg/m 2 orally BID on Days 1 to 14 of each treatment cycle, Q3W Nivolumab + FOLFOX : Nivolumab 240 mg IV on Day 1, Q2W Oxaliplatin 85 mg/m 2 IV on Day 1, Q2W Leucovorin 400 mg/m 2 IV on Day 1, Q2W Fluorouracil 400 mg/m 2 IV on Day 1, Q2W Fluorouracil 1200 mg/ m 2 IV continuous infusion over 24 hours daily on Days 1 and 2, Q2W Treatment was given until disease progression, unacceptable toxicity, maximum 24 months treatment (for nivo) or subject withdrawal of consent. N=789 |
|                                                                                                                                                                                                                 | Chemotherapy (XELOX or FOLFOX)                                                                                                                                                                                  | Chemotherapy (XELOX or FOLFOX)                                                                                                                                                                                  | Oxaliplatin 130 mg/m 2 IV on Day 1, Q3W Capecitabine 1000 mg/m 2 orally BID on Days 1 to 14 of each treatment cycle, Q3W FOLFOX : Oxaliplatin 85 mg/m 2 IV on Day 1, Q2W Leucovorin 400 mg/m 2 IV on Day 1, Q2W Fluorouracil 400 mg/m 2 IV on Day 1, Q2W Fluorouracil 1200 mg/ m 2 IV continuous infusion over 24 hours daily on Days 1 and 2, Q2W Treatment was given until disease progression, unacceptable toxicity or subject withdrawal of consent. N=792                                                                                                                                            |
| Endpoints and definitions                                                                                                                                                                                       | Primary endpoint                                                                                                                                                                                                | Progression free survival ( PFS ) in subjects PD-L1 CPS≥5                                                                                                                                                       | Time from randomisation to the date of the first progressive disease or death due to anay cause as assessed by BIRC per RECIST 1.1. The primary population was all randomised subjects with PD- L1 CPS≥5                                                                                                                                                                                                                                                                                                                                                                                                   |
|                                                                                                                                                                                                                 | Primary endpoint                                                                                                                                                                                                | Overall survival ( OS ) in subjects PD-L1 CPS≥5                                                                                                                                                                 | Time from randomisation to the date of death from any cause. The primary population was all randomised subjects with PD- L1 CPS≥5                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|                                                 | Secondary endpoint                                                                                                                           | OS in subjects                                                                                                                               | OS in subjects                                                                                                                               | See definition above                                                                                                                                                                                   | See definition above                                                                                                                                                                                   |
|-------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                 | Secondary endpoint                                                                                                                           | PD-L1 CPS≥ 1 OS in all randomised subjects                                                                                                   | PD-L1 CPS≥ 1 OS in all randomised subjects                                                                                                   | See definition above                                                                                                                                                                                   | See definition above                                                                                                                                                                                   |
|                                                 | Secondary endpoint                                                                                                                           | PFS in all randomised                                                                                                                        | PFS in all randomised                                                                                                                        | See definition above                                                                                                                                                                                   | See definition above                                                                                                                                                                                   |
|                                                 | Secondary endpoint                                                                                                                           | Objective response rate ( ORR ) in all randomised                                                                                            | Objective response rate ( ORR ) in all randomised                                                                                            | Number of randomised subjects with a best overal response of complete response or partial response based on BIRC assessment (using RECIST v1.1 criteria), divided by the number of randomised subjects | Number of randomised subjects with a best overal response of complete response or partial response based on BIRC assessment (using RECIST v1.1 criteria), divided by the number of randomised subjects |
| Database lock 10-Jul-2020                       | Database lock 10-Jul-2020                                                                                                                    | Database lock 10-Jul-2020                                                                                                                    | Database lock 10-Jul-2020                                                                                                                    | Database lock 10-Jul-2020                                                                                                                                                                              | Database lock 10-Jul-2020                                                                                                                                                                              |
| Results and Analysis                            | Results and Analysis                                                                                                                         | Results and Analysis                                                                                                                         | Results and Analysis                                                                                                                         | Results and Analysis                                                                                                                                                                                   | Results and Analysis                                                                                                                                                                                   |
| Analysis description                            | Primary Analysis                                                                                                                             | Primary Analysis                                                                                                                             | Primary Analysis                                                                                                                             | Primary Analysis                                                                                                                                                                                       | Primary Analysis                                                                                                                                                                                       |
| Analysis population and time point description  | Intent to treat (ITT) for OS and PFS The primary population was all randomised subjects with PD- L1 CPS≥5 Clinical cut-off date: 27 May 2020 | Intent to treat (ITT) for OS and PFS The primary population was all randomised subjects with PD- L1 CPS≥5 Clinical cut-off date: 27 May 2020 | Intent to treat (ITT) for OS and PFS The primary population was all randomised subjects with PD- L1 CPS≥5 Clinical cut-off date: 27 May 2020 | Intent to treat (ITT) for OS and PFS The primary population was all randomised subjects with PD- L1 CPS≥5 Clinical cut-off date: 27 May 2020                                                           | Intent to treat (ITT) for OS and PFS The primary population was all randomised subjects with PD- L1 CPS≥5 Clinical cut-off date: 27 May 2020                                                           |
| Descriptive statistics and estimate variability | Minimum follow-up: 12.1 Treatment group                                                                                                      | Minimum follow-up: 12.1 Treatment group                                                                                                      | months Nivolumab +                                                                                                                           | months Nivolumab +                                                                                                                                                                                     | Chemotherapy                                                                                                                                                                                           |
|                                                 | Number of subject                                                                                                                            | Number of subject                                                                                                                            | 473                                                                                                                                          | 473                                                                                                                                                                                                    | 482                                                                                                                                                                                                    |
|                                                 | Median OS in PD-L1 CPS ≥ 5                                                                                                                   | Median OS in PD-L1 CPS ≥ 5                                                                                                                   | 14.39                                                                                                                                        | 14.39                                                                                                                                                                                                  | 11.10                                                                                                                                                                                                  |
|                                                 | 95% confidence                                                                                                                               | 95% confidence                                                                                                                               | 13.11, 16.23                                                                                                                                 | 13.11, 16.23                                                                                                                                                                                           | 10.02, 12.09                                                                                                                                                                                           |
|                                                 | interval (CI) Median PFS in PD-L1 CPS≥5                                                                                                      | interval (CI) Median PFS in PD-L1 CPS≥5                                                                                                      | 7.69                                                                                                                                         | 7.69                                                                                                                                                                                                   | 6.05                                                                                                                                                                                                   |
|                                                 | (months) 95% CI                                                                                                                              | (months) 95% CI                                                                                                                              | 7.03, 9.1                                                                                                                                    | 7.03, 9.1                                                                                                                                                                                              | 5.55, 6.90                                                                                                                                                                                             |
|                                                 | Number of subject                                                                                                                            | Number of subject                                                                                                                            | 789                                                                                                                                          | 789                                                                                                                                                                                                    | 792                                                                                                                                                                                                    |
|                                                 | Median OS                                                                                                                                    | Median OS                                                                                                                                    | 13.83                                                                                                                                        | 13.83                                                                                                                                                                                                  | 11.56                                                                                                                                                                                                  |
|                                                 | (months) 95% CI                                                                                                                              | (months) 95% CI                                                                                                                              | 12.55, 14.55                                                                                                                                 | 12.55, 14.55                                                                                                                                                                                           | 10.87, 12.48                                                                                                                                                                                           |
|                                                 | Median PFS (months)                                                                                                                          | Median PFS (months)                                                                                                                          | 7.66                                                                                                                                         | 7.66                                                                                                                                                                                                   | 6.93                                                                                                                                                                                                   |
|                                                 | 95% CI                                                                                                                                       |                                                                                                                                              | 7.10, 8.54                                                                                                                                   | 7.10, 8.54                                                                                                                                                                                             | 6.60, 7.13                                                                                                                                                                                             |
|                                                 |                                                                                                                                              |                                                                                                                                              |                                                                                                                                              |                                                                                                                                                                                                        | 45.3                                                                                                                                                                                                   |
|                                                 | ORR (%) 95% CI                                                                                                                               | ORR (%) 95% CI                                                                                                                               | 54.7, 64.8                                                                                                                                   | 54.7, 64.8                                                                                                                                                                                             | 40.3, 50.4                                                                                                                                                                                             |
| Effect estimate per comparison                  | Primary endpoint                                                                                                                             | Primary endpoint                                                                                                                             | Comparison groups                                                                                                                            | Comparison groups                                                                                                                                                                                      | Nivo+chemo vs chemo                                                                                                                                                                                    |
|                                                 | OS in subjects with PD- L1 CPS≥5                                                                                                             | OS in subjects with PD- L1 CPS≥5                                                                                                             | Hazard ratio (HR)                                                                                                                            | Hazard ratio (HR)                                                                                                                                                                                      | 0.71                                                                                                                                                                                                   |
|                                                 |                                                                                                                                              |                                                                                                                                              | 98.4% CI                                                                                                                                     | 98.4% CI                                                                                                                                                                                               | 0.59, 0.86                                                                                                                                                                                             |
|                                                 |                                                                                                                                              |                                                                                                                                              | P-value                                                                                                                                      | P-value                                                                                                                                                                                                | <0.0001                                                                                                                                                                                                |
|                                                 | Primary endpoint PFS in subjects with PD-                                                                                                    | Primary endpoint PFS in subjects with PD-                                                                                                    |                                                                                                                                              |                                                                                                                                                                                                        | 0.68                                                                                                                                                                                                   |
|                                                 | L1 CPS≥5                                                                                                                                     | L1 CPS≥5                                                                                                                                     | Hazard ratio (HR)                                                                                                                            | Hazard ratio (HR)                                                                                                                                                                                      | 0.56, 0.81                                                                                                                                                                                             |
|                                                 |                                                                                                                                              |                                                                                                                                              | 98% CI                                                                                                                                       | 98% CI                                                                                                                                                                                                 | <0.0001                                                                                                                                                                                                |
|                                                 |                                                                                                                                              |                                                                                                                                              | P-value                                                                                                                                      | P-value                                                                                                                                                                                                |                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| Secondary endpoint OS in the all-randomised population   | Comparison groups   | Nivo+chemo vs chemo   |
|----------------------------------------------------------|---------------------|-----------------------|
| Secondary endpoint OS in the all-randomised population   | Hazard ratio (HR)   | 0.80                  |
| Secondary endpoint OS in the all-randomised population   | 99.3% CI            | 0.68, 0.94            |
| Secondary endpoint OS in the all-randomised population   | P-value             | 0.0002                |
| Secondary endpoint PFS in the all-randomised population  | Comparison groups   | Nivo+chemo vs chemo   |
| Secondary endpoint PFS in the all-randomised population  | Hazard ratio (HR)   | 0.77                  |
| Secondary endpoint PFS in the all-randomised population  | 95% CI              | 0.68, 0.87            |
| Secondary endpoint PFS in the all-randomised population  | P-value             | Not tested            |
| Secondary endpoint ORR in the all randomised population  | Comparison groups   | Nivo+chemo vs chemo   |
| Secondary endpoint ORR in the all randomised population  | Difference          | 12.8                  |
| Secondary endpoint ORR in the all randomised population  | 95% CI              | 7.3, 18.2             |
| Secondary endpoint ORR in the all randomised population  | P-value             | Not tested            |

Notes Enrollment in CA209649 started in Oct-2016 for the nivo+ipi and chemo arms. The nivo+chemo arm was added in Mar-2017 based on Revised Protocol 02 (Amendment 08). Enrollment to the nivo+ipi arm was closed on 05Jun2018. Data from the nivo+ipi arm have not been provided so far.

## Analysis performed across trials (pooled analyses and meta-analysis)

Not applicable

## Clinical studies in special populations

Not applicable

## Supportive study(ies)

Not applicable

## 2.4.3. Discussion on clinical efficacy

Through the current variation application, the MAH is seeking approval for a new indication for OPDIVO, for the first-line treatment of adult patients with advanced or metastatic gastric (GC), gastro oesophageal junction  (GEJ)  or  oesophageal  adenocarcinoma  (OAC)  in  combination  with  fluoropyrimidine  and platinum-based combination chemotherapy.

The  evidence  in  support  of  the  claimed  indication  is  based  on  results  from  the  study  CA209649 (CheckMate 649).

## Design and conduct of clinical studies

The  study  CA209649  is  a  Phase  3,  randomised,  multicentre,  open-label  study  of  nivolumab  plus ipilimumab or nivolumab in combination with chemotherapy (oxaliplatin plus fluoropyrimidine) versus chemotherapy  (oxaliplatin  plus  fluoropyrimidine)  in  subjects  with  previously  untreated  advanced  or metastatic GC, GEJ cancer or OAC. The nivolumab plus ipilimumab arm was closed to enrolment per DMC recommendation due to an increased early death rate and toxicity, although subjects randomized to this arm  continued to receive treatment with study drugs per protocol. Data from the nivolumab+ipilimumab arm have not been provided with the current application.

The study was open-label, but considering one of the primary endpoints was overall survival (OS) and progression free survival (PFS) was assessed by a BIRC, this is considered acceptable.

<div style=\"page-break-after: always\"></div>

## Patient population

Overall,  the  inclusion  and  exclusion  criteria  for  study  CA209649  appear  acceptable.  Patients  with advanced  or  metastatic  GC,  GEJ  or  distal  oesophageal  carcinoma  with  histologically  confirmed predominant adenocarcinoma who were treatment naïve for advanced or metastatic disease, with an ECOG  performance  status  or  0  or  1  were  included  in  the  study.  Prior  adjuvant/neoadjuvant chemotherapy, radiotherapy and/or chemoradiotherapy for GC or GEJ were allowed. This was also the case for OAC patients who were only eligible for enrollment in study CA209649 after the revised Protocol 04 (dated 05-Jan-2018). Patients with known HER2-positive status as well as those with untreated CNS metastases were excluded.

Patients were included in the study regardless PD-L1 expression. However, tumour tissue was required for PD-L1 expression determination by a central lab. Patients with non-evaluable results were not allowed to enter the study.

## Treatments

Treatment  recommendations  for  advanced  or  metastatic  GC,  GEJ  and  OAC,  are  almost  the  same, therefore,  the  inclusion  of  these  different  types  of  tumours  in  the  study  is  considered  acceptable. Regimens including platinum compounds (oxaliplatin or cisplatin) plus fluoropyrimidine (capecitabine, fluorouracil) are considered the standard of care in the first-line setting in patients HER2-negative (ESMO 2016; NCCN 2020). Moreover, oxaliplatin may be preferred over cisplatin due to lower toxicity (NCCN 2020). Therefore, the comparator (i.e., XELOX or FOLFOX) is considered acceptable.

In study CA209649 patients were randomised in a 1:1:1 ratio to receive nivolumab + ipilimumab for 4 cycles  followed  by  nivolumab  monotherapy;  nivolumab  plus  chemotherapy  (XELOX  or  FOLFOX)  or chemotherapy  (XELOX  or  FOLXOX).  According  to  the  protocol,  the  investigator  can  choose  either capecitabine or fluorouracil, based on local standards. Nivolumab was administered at a dose of 360 mg Q3W when administered in combination with XELOX (oxaliplatin + capecitabine) and at a dose of 240 mg  Q2W  when  administered  in  combination  with  FOLFOX  (oxaliplatin  +  leucovorin  +  fluorouracil). Treatment with nivolumab was continued until progressive disease, unacceptable toxicity, withdrawal consent or up to a maximum of 24 months.

The  randomisation  was  changed  twice  during  the  trial.  The  trial  initially  had  two  arms,  i.e.  a nivolumab+ipilimumab arm and a chemotherapy arm. Later, on 07 Dec 2016, the nivolumab+chemotherapy arm was added. As outlined above enrolment in the nivolumab+ipilimumab arm was stopped on 5 Jun 2018 following a recommendation from the DMC due to the observed increased early death rate and the increased toxicity rate in that arm.

Stratification factors included the chemotherapy regimen (XELOX vs. FOLFOX), PDL1 expression (≥1% vs. &lt;1% or indeterminate), region (Asia vs. North America vs. rest of the world) and ECOG (0 vs. 1). Stratification factors are considered acceptable.

## Sample size

Sample size was changed during the study several times (e.g., Protocol 02, 05, 08) from originally 1,349 to 2,005 in total based on different choice of primary analysis population (e.g. all comers, TC PD-L1 ≥1%, PD-L1 CPS≥5) and different timing of a nalysis (event or time driven).

The sample size at the final Protocol 09 was based on simulations assuming a piecewise exponential curve for PFS and OS in CPS≥5 in the chemotherapy arm, accounting for a delay in treatment effect. Assumptions of PFS were: a chemotherapy median of 5.5 months; HR=1 for 3 months (yielding 99% power) or 6 months (yielding 60% power) followed by HR=0.56 afterwards. For OS the power was 85% based on a chemotherapy arm median of 11 months; HR=1 for 6 months followed by HR=0.65.

<div style=\"page-break-after: always\"></div>

## Efficacy endpoints

The dual primary endpoints of the study were OS and PFS as assessed by BIRC per RECIST 1.1 criteria in patients with PDL1 CPS≥5. Secondary endpoints included OS in patients with PD -L1 CPS≥1, CPS≥10 and  all  randomised  subjects;  PFS  as  assessed  by  BIRC  in  patients  with  PDL1  CPS≥1,  10  and  all randomised  subjects  and  ORR  (by  BIRC)  in  subjects  with  PDL1  CPS≥1,  5,  10  and  all  randomised subjects.  Duration  of  response,  time  to  symptom  deterioration  (TTSD),  PFS  and  ORR  according  to investigator assessment and PFS2 were exploratory endpoints in study CA209649.

The choice of the primary and secondary endpoints is considered appropriate. However, several major changes in the endpoints as well as in the primary efficacy population were performed during the study (see protocol amendments below).

## Statistical methods

The primary endpoints changed during the trial (see details below). Throughout the protocol changes, the different primary OS and possibly PFS type endpoints were analysed using a two-sided stratified logrank test and a stratified Cox model with treatment as only covariate. Randomisation stratification factors included  region,  ECOG  and  PDL1  ≥1  in  all  protocols.  Since  the  addition  of  the  nivolumab  + chemotherapy arm (Protocol 02), the chemotherapy chosen before randomization (XELOX or FOLFOX) was  added  as  stratification  factor.  Concurrent  randomized  patients  were  used  for  nivolumab  + chemotherapy  arm  vs.  the  chemotherapy  arm  comparison  (i.e.  since  the  start  of  the  1:1:1 randomisation).

The OS in all comers in the nivolumab + chemotherapy arm vs. the chemotherapy arm (introduced since Protocol 02), was in most protocols not a primary endpoint, but in all protocols its analysis was stratified by region, ECOG, type of chemotherapy and PD-L1 status.

Multiple  testing  strategy  changed  during  the  study  (see  below)  but  were  variants  of  the  graphical approach (Bonferroni splits, hierarchical testing and alpha allocation). Therefore, each of the various strategies per se controlled the type I error.

The primary PFS definition censored for subsequent therapy. A secondary definition of PFS included the first  PFS  event regardless including when it occurred after start of new therapy from SAP version 2 onwards (Protocol 09).

Time to event endpoints (e.g. OS and PFS) were analysed using Kaplan-Meyer methodology and Cox proportional hazard models. Sensitivity analyses were planned regarding the impact of: non-proportional hazards (a max combo test to account for early or late separation of curves or analysing in two separate periods); disbalance in (possible) prognostic factors (multivariate Cox regression models); imbalance between the CPS strata (multivariate Cox regression); stratification (e.g. unstratified analyses).

Binary endpoints (e.g., ORR): the stratified difference was estimated using DerSimonian-Laird method; the stratified odds ratio using the Mantel-Haenszel method.

## Efficacy data and additional analyses

A total of 2,687 patients were enrolled in the study, of whom 1,581 were randomised to receive either nivo+chemo (n=789) or chemo (n =792). According to the MAH, the frequency of subjects enrolled but not randomized, i.e. 1,106 not randomized out of the 2,687 enrolled subjects in the CA209649 Primary CSR (41.2%), is an overestimate that does not reflect the actual screen failure rate as subjects were randomized to 3 treatment arms. The screen failure rate for the entire study was 36.3% (1,155/3,186 enrolled subjects). Among the 1,155 subjects who were not randomized the most frequent reason was 'subject no longer meets study criteria.' This group consists of 900 subjects and the most common failed study criteria among them were: i) having known human epidermal growth

<div style=\"page-break-after: always\"></div>

factor receptor 2 (HER2) positive status [130 (14.4%)], ii) not providing tumour tissue for biomarker analyses [130 (14.4%)] and iii) having (ECOG) Performance Sta tus (PS) score ≥2 [108 (12.0%)] .

There were 32 patients who were randomised but not treated, most of them in the control arm (25 [3.2%] vs. 7 [0.9%]) and in most cases due to withdrawal of consent.

At  the  time  of  the  data  cut-off,  around  8%  of  patients  remained  on  treatment  (84  [10.7%]  in  the nivo+chemo arm and 39 [5.1%] in the chemo arm). The main reason for treatment discontinuation was disease progression in both treatment arms (66% nivo+chemo vs. 69% chemo). In the nivo+chemo arm  there  were  20  (2.6%)  patients  who  discontinued  treatment  due  to  completion  of  the  2-year treatment period.

## Conduct of the study

One of the main concerns of the study relates to the multiple and critical amendments of the protocol which call into question the integrity of the trial moreover considering that study CA209649 is open label and therefore more prone to bias. The original protocol was dated 4 May 2016 and thereafter 29 protocol amendments (including 9 global and 20 country specific) have been performed. The main critical changes are described below.

The original study design aimed to compare nivolumab + ipilimumab with chemotherapy, but early in the study (Protocol 02; dated 7 Dec 2016) a new nivolumab-plus-chemotherapy arm was added. This change  was  performed  when  only  3  patients  had  been  enrolled.  At  the  same  time,  the  type  of chemotherapy  (i.e.  XELOX  vs.  FOLFOX)  was  introduced  as  stratification  factor  (determined  before patients  were  randomized).  This  strengthens  the  comparison.  Before  the  randomization  changed  to 1:1:1, a total of 83 patients had already been randomized. However, the nivolumab + chemotherapy vs. chemotherapy comparison is only based on patients that were randomized since the introduction of this arm, which is methodologically sound. The primary endpoint (at that time) was OS in all PD-L1+ subjects.

With Amendment 17 (Protocol 04; dated 5 Jan 2018), the primary efficacy population was changed to all  comers  and  PFS  and  ORR  were  added  as  primary  endpoints  in  the  nivo+chemo  arm.  Moreover, patients with distal oesophageal adenocarcinoma (OAC) were also allowed to enter the study.

As previously mentioned, the sample size has been modified several times.

Further, per Protocol 07 (Amendment 23; dated 14 Sep 2018) the primary population was changed to subjects with PDL1 CPS≥5 when 1,449 patients had been randomised. CPS was defined as the number of PD-L1 positive cells (tumour cells, lymphocytes and macrophages) divided by the total number of viable tumour cells, multiplied by 100 (i.e. CPS is a composite score that incorporates both tumour and tumour-associated immune cell PD-L1 expression). As scoring could be done retrospectively and blindly, this is considered acceptable.

According to the Applicant, the change in the primary efficacy population was based on external data (i.e.  studies  KEYNOTE  059,  KEYNOTE  061  and  CA209032). While the rationale for using PD-L1 CPS instead of TC PD-L1 as a better predictor or response could be understood (Kelly. Am Soc Clin Oncol Educ Book. 2017), further justification was required regarding the chosen cutoff (i.e. CPS≥5) . The MAH provided  some  additional  details  regarding  that  their  choice,  as  outlined  above,  was  only  based  on external data, i.e. results from study CA209032 and other CPS data available at that time from the literature (KEYNOTE-059 and KEYNOTE 061). The selected cut-off CPS ≥ 5 can be considered reasonable even  if  others,  e.g.  CPS ≥ 10  could  also  have  been  considered.  Additional  aspects  such  as  expected prevalence could also have played a role in the final decision, favouring a lower cut-off.

The prevalence of subjects with PDL1 CPS≥5 was initially not accurately known (estimated at 35%) and the possibility that an increase in sample size could be needed was prospectively contemplated. After a blinded review of the first 203 subjects' CPS score, an even lower than expected prevalence was reported (i.e. 27%) that lead to an increase in sample size by addition of 356 subjects (revised Protocol 08). In

<div style=\"page-break-after: always\"></div>

March 2019, PD-L1 CPS results from one pathologist at one of the two central laboratories undergoing the scoring were identified by the MAH as having a lower proportion of CPS positive cases at the ≥1 threshold compared with other pathologists. The pathologist incorrectly interpreted/implemented one of the steps within the predefined CPS scoring algorithm/methodology and as a result, 914 of the 1,399 accessions were disqualified and re-scored. During the rescoring the pathologists were blinded to the previous CPS score and treatment information and no issues have been identified that can be considered to have an impact on the integrity/reliability of the (submitted) revised data.

Following resolution of the scoring issue of the samples detailed above the prevalence was reported as of 60%, almost double of the initially expected value. To justify that this discrepancy did not impact the reported results the MAH provided the results of pre-planned sensitivity analyses of OS and PFS for subjects with CPS ≥ 5 conducted to reflect the design per Revised Protocol 07 (based on sample size and events per the assumed 35% prevalence). The results were consistent to those of the primary analyses of both OS and PFS.

Indeed, the primary endpoints and/or sample size and/or the multiple testing strategy were changed multiple times. In all protocols OS in all comers was part of the multiple testing strategy. However, this strategy was changed between each of the following protocols: 02, 03, 04, 05, 07, 08 (SAP v1), and 09 (final protocol, SAP v2 and v3). Changes entailed: timing of analysis (event or time driven), order of testing of the endpoints before OS in all comers would be tested, statistical significance levels, presence of  interim  analyses  and  sample  size  (number  of  events/total  number  of  patients).  In  this  context  a detailed  justification/explanation  of  all  the  amendments  performed  in  the  protocol  to  further  justify whether these changes were driven by external or internal data was submitted even if no new information was provided. A description of how access to data was controlled during the study was also provided and no major issues were identified that would have had an impact on the results and B/R assessment for the applied indication.

The original definition of PFS censored for subsequent therapy, thus aimed at estimating the effect as if no  subsequent  therapy  would  have  been  used  (hypothetical  strategy).  However,  censoring  may  be informative and thus the estimate could be biased. In the last protocol, a secondary definition of PFS included the first PFS event regardless including when it occurred after start of new therapy (treatment policy  strategy).  This  is  the  analysis  recommended  in  appendix  1  of  the  EMA  anticancer  guideline (CHMP/27994/2008 Rev. 1). BICR assessments were requested if investigator PD was determined and in case subsequent or local palliative therapy was started, if was requested to continue BIRC scans if clinically feasible. This limits informative censoring in the BICR assessment.

In  addition  to  the  above,  previous  EMA  inspections  revealed  that  BioClinica  procedures  allowed investigator sites to send and store images without proper de-identification. The process of transfer and storage of images used in study CA209649 has the potential to comply with the General Data Protection Regulation (GDPR) and ICH-GCP Guideline (E6(R2) and there are no indications that the privacy of trial participants in study CA209649 was violated. The fact that BioClinica allows submitting images with personal identifiers and investigators does not represent a robust process that ensures rights of the trial participants and this is still considered a weakness in the overall process and has the potential to violate the privacy of trial participants. The issue will not be further pursued within this type II variation, as it does not have a negative impact on the B/R. However, it remains the responsibility of the MAH that CROs involved in the clinical trials running within the EU will adhere to the GDPRand ICH-GCP Guideline.

With regards to protocol deviations, relevant protocol deviations were reported in 21 (1.3%) patients and it was comparable between treatment arms. In the nivo+chemo arm, use of prohibited anti-cancer therapy was the main reason (8 [1.0%] nivo+chemo vs. 4 [0.5%] chemo). Overall, no concern is raised over possible impact of protocol deviations on efficacy results.

## Baseline data

<div style=\"page-break-after: always\"></div>

Overall, baseline characteristics of patients included in the study were balanced between treatment arms and the patient population appears representative of the intended target population. Patients included in the study had a median age of 61 years (range: 18, 90), with 9.7% being 75 years or older. The majority of patients were male (70%), White (69%) and had an ECOG performance status of 0 (44%) or 1 (56%). Patients with ECOG ≥2 we re not allowed to enter the study. Nearly half of patients (48%) were  current/former  smokers.  In  the  majority  of  patients,  the  initial  diagnosis  was  gastric  cancer (70.2%), followed by GEJ cancer (16.4%) and EA (13.3%). The vast majority of patients had a metastatic disease. Liver and peritoneal metastases were present in 39% and 24%, respectively. It is important to note that per inclusion/exclusion criteria, patients with known HER2 positive status were not allowed to enter the study. However, there were 7 (0.4%) patients whose tumour was HER2 positive and in addition there were 643 (40.7 %) patients for whom HER2 status was undetermined, i.e. not reported (test was not  performed;  634  patients)  or  unknown  (test  was  performed  but  the  result  was  unavailable;  9 patients). With regards to prior treatment, 13.7% of patients had received prior adjuvant (7.5%) or neoadjuvant (6.9%) treatment. There was one patient in the nivo+chemo arm who received prior treatment in the metastatic setting, however this issue is not considered of clinical relevance.

## Efficacy outcomes

All analyses were on patients concurrently randomized to the nivo+chemo or chemo arm (i.e. since start of 1:1:1 randomisation to nivo+ipi, nivo+chemo, chemo arms). Since Protocol 02, the OS analysis in all comers was stratified according to region, ECOG, type of chemotherapy and PD-L1 status.

The study met its primary endpoints. Nivo+chemo demonstrated a statistically significant and clinically meaningful improvement in OS (HR 0.71; 98.4% CI: 0.59, 0.86) and PFS (HR 0.68; 98% CI: 0.56, 0.81) over chemotherapy alone in patients with CPS≥5. Median OS was of 14.39 (95% CI: 13.11, 16.23) months in the nivo+chemo group and 11.10 (95% CI: 10.02, 12.09) months in the chemo group. Median PFS was of 7.69 (95% CI: 7.03, 9.17) and 6.05 (95% CI: 5.55, 6.90) months, in the nivo+chemo and chemo groups, respectively. At the time of the data cut-off the median follow-up in patients with PD-L1 CPS≥5 was 13.57 months in the nivo+chemo arm and 10.66 months in the chemo arm.

While patients with PDL1 CPS≥5 represent the primary efficacy population, a broad indication was initially requested for nivo+chemo (i.e. regardless of PD-L1 CPS expression). OS in the all randomised patients (n=1581) was assessed as a secondary endpoint. However, since a hierarchical testing strategy was used, type I error control is warranted and therefore these results can be considered interpretable. OS in the overall population, with an event rate of 65% in the nivo+chemo arm and 75% in the chemo arm, showed a statistically significant benefit of nivo+chemo over chemo (HR 0.80; 99.3% CI: 0.68, 0.94). Median OS was of 13.83 (95% CI: 12.55, 14.55) months and 11.56 (95% CI: 10.87, 12.48) months in the experimental and control arm, respectively.

Results in terms of PFS in the overall population were consistent with the OS analysis and favoured also the nivo+chemo arm, although the benefit appears lower than in the PDL1 CPS≥5 population (HR 0.77; 95% CI: 0.68, 0.87). Median PFS was 7.66 (95%CI: 7.10, 8.54) months in the nivo+chemo arm versus 6.93 (95% CI: 6.60, 7.13) months in the chemo arm. The ORR was higher in the nivo+chemo arm compared with the chemo arm (58% vs. 46.1%, respectively), in patients with measurable disease at baseline. Median duration of response was also higher in the nivo+chemo arm (8.51 months vs. 6.93 months). The median follow-up in the all-randomised patients was 13.1 months in the nivo+chemo arm and 11.1 months in the chemo arm.

Even though statistical significance was reached with nivo+chemo over chemo in terms of OS (and also PFS) in the all-randomised patient population, the effect appears to be driven by patients with PD-L1 CPS≥5. In patients with PD -L1 CPS &lt;5 no clear benefit was observed with nivo+chemo over chemo (HR 0.94; 95% CI: 0.78, 1.13), with a median OS of 12.42 and 12.25 in the nivo+chemo and control arm, respectively. Although K-M curves tended to separate after 12 months, interpretation of the curve at

<div style=\"page-break-after: always\"></div>

that timepoint was difficult due to high numbers of censoring. Also, a similar pattern was observed in patients with PD-L1 CPS &lt;10 (HR 0.94; 95% CI: 0.80, 1.10]) and in subjects with PDL1 CPS ≥5 and &lt;10 (HR 0.92; 95% CI: 0.66, 1.28). Of note, PFS results were consistent with OS data in these subgroups of patients. While it was acknowledged that these results come from an exploratory analysis, considering that a broad indication was applied (i.e. regardless of PD-L1 CPS status), the MAH was requested to further justify the benefit of nivo+chemo in the intended target population. Updated efficacy data with a DBL of 16 Feb 2021, providing 7.3 months of additional follow-up (minimum follow-up 19.4 months) were submitted including updated efficacy data by PD-L1 CPS status using different cut-offs (i.e. 1, 5 and 10). Taking into account the new submitted data still no apparent benefit is observed in patients with PD-L1 CPS&lt;5 in terms of OS (HR 0.94; 95% CI: 0.79, 1.13), with a median of 12.42 and 12.09 months, respectively, the same percentage of OS events, and KM curves overlapping. Bearing in mind the increased toxicity of the combination compared with chemo alone, a positive benefit-risk balance cannot be concluded for patients with PD-L1 CPS&lt;5. Therefore, the indication was restricted to patients with PDL1 CPS≥5, which in fact was the pri mary efficacy population in the study.

The results observed for OS in the all-randomised patient population were consistent for most of the subgroups analysed. However, the benefit of nivo+chemo over chemo appears less clear in patients with GEJ cancer (HR 0.9; 95% CI: 0.67, 1.21), OAC (HR 0.82; 95% CI: 0.60, 1.13), patients who had received prior radiotherapy (HR 0.92; 95% CI: 0.64, 1.33), patients with a diffuse type (HR 0.91; 95% CI: 0.74, 1.10),  presence  of  Signet  Ring  Cell  (HR  0.96;  95%  CI:  0.73,  1.25)  and  in  patients  with  peritoneal metastases (HR 1.03; 95% CI: 0.82, 1.29). GC/GEJC/OAC is known to be a heterogeneous disease and the  details  and  discussion  provided  by  the  MAH  allow  to  conclude  that  there  is  no  well-established biological rationale / reason why the results in any of the above subgroups should be challenged, also considering that the trial was not powered to determine the effect in those subgroups. As discussed by the MAH the small(er) sample sizes and imbalances in various baseline disease characteristics and other factors, not a single one, are likely to have contributed to the lower treatment effect observed in those particular subgroups.

In contrast, the benefit of nivo+chemo seems higher in patients with microsatellite instability (MSI) high (HR 0.37; 95% CI: 0.16, 0.87) although data are limited due to the small number of patients (n=44). Determination of MSI status was performed retrospectively by central laboratories. Of the 1581 patients randomised, 44 (2.8%) were MSI-H while 1377 (87.1%) were microsatellite stable (MSS).

Finally, the MAH was requested to restrict the indication to HER2-negative patients given the inclusion/exclusion criteria and differences in prognosis and treatment of this patient population, unless a broad indication (i.e. HER2 agnostic) could be sufficiently justified. In this context the Applicant provided a discussion of the results from the subgroup analysis in patients with negative vs. undetermined HER2 status, with an observed HR for OS of 0.85 (95% CI: 0.73, 0.99) and 0.71 (95% CI: 0.59, 0.85), respectively. Since the actual rate of HER2 negative subjects among the HER2 not reported/unknown subjects in the study is not known, the MAH conducted some simulations aimed at demonstrating that the reported treatment benefit with nivo+chemo vs. chemo alone in the HER2 negative subgroup could in fact be an underestimation. Results from that analysis appear to support that as an increasing proportion of subjects who are not reported/unknown are included as HER2negative, the HR decreases, indicating greater treatment effect from nivo+chemo vs. chemo, but caution is needed when interpreting these data. Further, the MAH discussed other factors that may have played a role in the reported efficacy differences between the two subgroups i.e. regional differences, status of the disease at baseline and subsequent therapy received. Based on those results/discussion the MAH proposed to revise the indication as follows (revisions underlined): ' OPDIVO in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with HER2 negative (or undetermined) advanced or metastatic gastric, gastro oesophageal junction or oesophageal adenocarcinoma (see sections 4.4

<div style=\"page-break-after: always\"></div>

and 5.1). '. The revised proposal was not considered acceptable. The MAH argues that (descriptive) data showed clinical benefit in nivo+chemo over chemo in HER2 undetermined patients (40.3% of the study population), and that the safety profile was manageable and acceptable in these patients. While it can be acknowledged that patients with undetermined status appear to benefit from treatment (see above), the need to specify them in the indication is not considered appropriate. 'Undetermined' HER2 status does not constitute a recognized subgroup of patients within the target population and therefore the indication was amended to include treatment of HER2-negative patients only.

## Additional expert consultation

Not applicable

## Assessment of paediatric data on clinical efficacy

Not applicable

## 2.4.1. Conclusions on the clinical efficacy

In study CA209649 treatment with nivolumab in combination with chemotherapy (XELOX or FOLFOX) showed a statistically significant OS and PFS benefit compared with chemotherapy (XELOX or FOLFOX) alone in patients with HER2-negative advanced or metastatic GC, GEJ or OAC whose tumours express PD-L1 with a CPS ≥ 5.

## 2.5. Clinical safety

## Introduction

Safety data from 782 subjects treated with first-line nivo+chemo (nivolumab 240 mg + FOLFOX Q2W or nivolumab 360 mg + XELOX Q3W) and from 767 control subjects (treated with FOLFOX or XELOX) from study CA209649 were used to characterize the safety profile of this combination regimen in subjects with advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma.

## Patient exposure

The  last  subject  randomization  occurred  on  27-May-2019  and  the  clinical  cutoff  occurred  on 27-May-2020. The DBL occurred on 10-Jul-2020. Minimum follow-up (date of the last subject randomized to LPLV) was 12.1 months. A total of 1581 subjects were concurrently randomized in the nivo+chemo and chemo arms: 789 to the nivo+chemo arm and 792 to the chemo arm. 1549 subjects were treated: 782 with nivo+chemo and 767 with chemo. Of the 1549 treated subjects, 123 (7.9%) subjects were continuing in the treatment at the time of database lock: 84 (10.7%) nivo+chemo-treated subjects and 39 (5.1%) chemo-treated subjects. The overall rates of discontinuation were 89.3% and 94.9% in the nivo+chemo and chemo arms, respectively. The primary reason for not continuing in the treatment period  was  disease  progression  in  both  treatment  arms  (1043  subjects,  67.3%):  515  (65.9%) nivo+chemo-treated subjects and 528 (68.8%) chemo-treated subjects. Overall, 61 (3.9%) subjects withdrew consent and did not complete the treatment period: 20 (2.6%) in the nivo+chemo arm and 41 (5.3%) in the chemo.

Overall, the median (min - max) duration of therapy was 6.75 (0.0 - 33.5) months in the nivo+chemo arm and 4.86 (0.0 - 34.9) months in the chemo arm (Figure 20). Among all treated subjects, 54.3% and 38.7% had a duration of therapy &gt; 6 months in the nivo+chemo and chemo arms, respectively.

<div style=\"page-break-after: always\"></div>

In the nivo+chemo arm, the median (min - max) duration of therapy was 6.49 (0.1 - 33.5) months with nivo+XELOX and 7.01 (0.0 - 30.0) months with nivo+FOLFOX.

In the chemo arm, the median (min - max) duration of therapy was 4.86 (0.0 - 34.9) months with XELOX and 4.80 (0.1 - 33.2) months with FOLFOX.

The median (min - max) number of doses received by all treated subjects and the proportion of subjects who received ≥ 90% of the planned dose intensity are shown in Table 29. Of note, prior to revised Protocol 07 (Amendment 23), all components were delayed together if a dose delay was required.

Figure 20. Kaplan-Meier Plot of Time to Treatment Discontinuation - All Treated Subjects

<!-- image -->

Number of Subjects at Risk

Nivo + Chemo

## Chemo

76760644729721713799

70

45

33

23

18

10

107

4

Nivo + Chemo (events : 698/782), median and 95% Cl : 6.75 (6.11, 7.36)

Chemo (events : 728/767), median and 95% Cl : 4.86 (4.47, 5.29)

---

Symbols represent censored observations

Source: Figure S.4.1.3

2

0

1

0

0

<div style=\"page-break-after: always\"></div>

Table 29. Cumulative Dose and Relative Dose Intensity Summary - All Treated Subjects

------------------------------------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------------------------------------

|                                                                     | Nivo + Chemo N = 782 ------------------------------------------------------------- Nivolumab+XELOX N1 = 360   | Nivo + Chemo N = 782 ------------------------------------------------------------- Nivolumab+XELOX N1 = 360   | Nivo + Chemo N = 782 ------------------------------------------------------------- Nivolumab+XELOX N1 = 360                                                        | Chemo N = 767 ------------------------------------------ XELOX N1 =         | Chemo N = 767 ------------------------------------------ XELOX N1 =   |
|---------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------|
|                                                                     | ------------------------------------------------------------- Nivolumab (mg) N = 360                          | Oxaliplatin (mg/m^2) N = 360                                                                                  | Capecitabine (mg/m^2) N = 360 ------------------------------------------------------------------------------------------------------------------------------------ | 361 ------------------------------------------ Oxaliplatin (mg/m^2) N = 361 | Capecitabine (mg/m^2) N = 361                                         |
| NUMBER OF DOSES RECEIVED MEAN (SD)                                  |                                                                                                               |                                                                                                               |                                                                                                                                                                    |                                                                             |                                                                       |
| MEDIAN MIN - MAX                                                    | 11.36 (9.23) 8.00 1.0 - 35.0                                                                                  | 6.48 (4.13) 6.00 1.0 - 34.0                                                                                   | 10.88 (9.38) 7.00 1.0 - 47.0                                                                                                                                       | 6.70 (5.27) 6.00 1.0 - 47.0                                                 | 9.27 (8.20) 7.00 1.0 - 48.0                                           |
| DURATION OF THERAPY (MONTHS) MEAN (SD) MEDIAN MIN - MAX             | 7.90 (6.78) 5.45 0.0 - 24.0                                                                                   | 4.32 (3.15) 3.99 0.0 - 23.2                                                                                   | 8.01 (6.94) 5.63 0.1 - 33.5                                                                                                                                        | 4.39 (4.08) 3.68 0.0 - 34.4                                                 | 6.64 (6.06) 4.70 0.0 - 34.9                                           |
| CUMULATIVE DOSE                                                     |                                                                                                               |                                                                                                               |                                                                                                                                                                    |                                                                             |                                                                       |
| MEAN (SD) MEDIAN MIN - MAX                                          | 4090.71 (3324.92) 2880.00 240.0 - 12600.0                                                                     | 759.27 (447.29) 726.60 78.1 - 3676.0                                                                          | 252602.25 (211230.13) 176388.81 1822.9 - 1059942.2                                                                                                                 | 787.22 (574.16) 689.73 111.8 - 4356.6                                       | 241991.61 (378778.66) 166729.48 961.5 - 5060929.3                     |
| INTENSITY                                                           | INTENSITY                                                                                                     | INTENSITY                                                                                                     | INTENSITY                                                                                                                                                          | INTENSITY                                                                   | INTENSITY                                                             |
| RELATIVE DOSE >= 110% 90% TO < 110% 70% TO < 90% 50% TO < 70% < 50% | 0 252 ( 70.0) 102 ( 28.3) 6 ( 1.7) 0                                                                          | 2 ( 0.6) 157 ( 43.6) 132 ( 36.7) 64 ( 17.8) 5 ( 1.4)                                                          | 13 ( 3.6) 109 ( 30.3) 109 ( 30.3) 88 ( 24.4) 41 ( 11.4)                                                                                                            | 3 ( 0.8) 174 ( 48.2) 137 ( 38.0) 43 ( 11.9) 4 ( 1.1)                        | 11 ( 3.0) 121 ( 33.5) 118 ( 32.7) 77 ( 21.3) 34 ( 9.4)                |

<div style=\"page-break-after: always\"></div>

------------------------------------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------------------------------------

|                                                                                                                                      | Nivo + Chemo N = 782 -------------------------------------------------------------------------------------------------------- Nivolumab+FOLFOX N1 = 422   | Nivo + Chemo N = 782 -------------------------------------------------------------------------------------------------------- Nivolumab+FOLFOX N1 = 422   | Nivo + Chemo N = 782 -------------------------------------------------------------------------------------------------------- Nivolumab+FOLFOX N1 = 422   | Nivo + Chemo N = 782 -------------------------------------------------------------------------------------------------------- Nivolumab+FOLFOX N1 = 422   | Nivo + Chemo N = 782 -------------------------------------------------------------------------------------------------------- Nivolumab+FOLFOX N1 = 422   |
|--------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|
| ------------------------------------------------------------------------------------------------------------------------------------ | Nivolumab (mg) N = 422                                                                                                                                    | Oxaliplatin (mg/m^2) N = 422                                                                                                                              | Leucovorin (mg/m^2) N = 422                                                                                                                               | 5-Fluorouracil (mg/m^2) N = 420                                                                                                                           | -------------------------------------------------------------------------------------------------------- 5-Fluorouracil Continuous (mg/m^2) N = 422       |
| NUMBER OF DOSES RECEIVED MEAN (SD) MEDIAN MIN - MAX                                                                                  | 17.17 (12.73) 13.50 1.0 - 53.0                                                                                                                            | 9.37 (4.81) 10.00 1.0 - 36.0                                                                                                                              | 14.67 (11.41) 12.00 1.0 - 59.0                                                                                                                            | 13.92 (11.06) 11.00 1.0 - 59.0                                                                                                                            | 15.25 (11.36) 12.00 1.0 - 59.0                                                                                                                            |
| DURATION OF THERAPY (MONTHS) MEAN (SD) MEDIAN MIN - MAX                                                                              | 8.47 (6.50) 6.74 0.0 - 24.0                                                                                                                               | 4.58 (2.84) 4.60 0.0 - 20.7                                                                                                                               | 7.16 (5.74) 5.52 0.0 - 29.9                                                                                                                               | 6.84 (5.64) 5.29 0.0 - 29.9                                                                                                                               | 7.56 (5.76) 5.85 0.0 - 30.0                                                                                                                               |
| CUMULATIVE DOSE MEAN (SD) MEDIAN MIN - MAX                                                                                           | 4152.01 (3104.86) 3240.00 240.0 - 12720.0                                                                                                                 | 764.90 (509.50) 749.20 83.2 - 6841.7                                                                                                                      | 5041.41 (4101.22) 3992.99 117.6 - 22096.0                                                                                                                 | 5395.60 (4758.13) 4004.53 393.4 - 44880.8                                                                                                                 | 36021.25 (28989.81) 27615.35 1195.9 - 233700.9                                                                                                            |
| RELATIVE DOSE INTENSITY >= 110% 90% TO < 110% 70% TO < 90% 50% TO < 70% < 50% NOT REPORTED                                           | 0 238 ( 56.4) 168 ( 39.8) 12 ( 2.8) 4 ( 0.9) 0                                                                                                            | 15 ( 3.6) 145 ( 34.4) 171 ( 40.5) 78 ( 18.5) 13 ( 3.1) 0                                                                                                  | 0 155 ( 36.7) 155 ( 36.7) 81 ( 19.2) 31 ( 7.3) 0                                                                                                          | 27 ( 6.4) 155 ( 36.9) 138 ( 32.9) 81 ( 19.3) 19 ( 4.5) 0                                                                                                  | 45 ( 10.7) 136 ( 32.2) 167 ( 39.6) 60 ( 14.2) 14 ( 3.3) 0                                                                                                 |

<div style=\"page-break-after: always\"></div>

------------------------------------------------------------------------------------------------------------------------------------

----------------- --- --- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

| Chemo N = 767 -------------------------------------------------------------------------------------------------------- FOLFOX N1 = 406   |
|------------------------------------------------------------------------------------------------------------------------------------------|

The Number of doses of Capecitabine is the number of cycles where at least one dose of Capecitabine was administered.

Source: Table S.4.2.3

<div style=\"page-break-after: always\"></div>

Chemotherapy dose modifications were permitted per local standard starting with cycle 2. Dose reduction was  not  allowed  for  nivolumab.  In  all  treated  subjects,  dose  delays  were  the  most  common  dose modification in both the nivo+chemo and chemo arms, while dose interruption and dose reductions were less common.

Dose delays of study drug (proportion of subjects with at least 1 dose delay) were reported as follows:

- Nivo+chemo arm:
- -Nivo+XELOX: 66.7% for nivolumab, 59.4% for oxaliplatin, and 66.4% for capecitabine.
- -Nivo+FOLFOX: 78.2% for nivolumab, 74.6% for oxaliplatin, 77.0% for leucovorin, 75.8% for 5FU bolus, and 78.9% for 5-FU continuous.
- Chemo arm:
- -XELOX: 48.2% for oxaliplatin and 54.8% for capecitabine.
- -FOLFOX: 70.2% for oxaliplatin, 71.4% for leucovorin, 70.6% for 5-FU bolus, and 73.4% for 5FU continuous.

Dose reductions of chemotherapy (proportion of subjects with at least 1 dose reduction) were reported as follows:

- Nivo+chemo arm:
- -Nivo+XELOX: 46.4% for oxaliplatin
- -Nivo+FOLFOX: 41.0% for oxaliplatin, 26.8% for leucovorin, 30.9% for 5-FU bolus, and 42.9% for 5-FU continuous.
- Chemo arm:
- -XELOX: 40.2% for oxaliplatin
- -FOLFOX: 44.6% for oxaliplatin, 34.5% for leucovorin, 36.3% for 5-FU bolus, and 37.2% for 5FU continuous.

Infusion interruptions in all treated subjects occurred most frequently during oxaliplatin administration in both the nivo+chemo and chemo arms. The proportion of subjects with at least 1 infusion interrupted were reported as follows in all treated subjects:

- Nivo+chemo arm:
- -Nivo+XELOX: 3.1% for nivolumab, 6.7% for oxaliplatin
- -Nivo+FOLFOX: 4.0% for nivolumab, 15.6% for oxaliplatin, 8.8% for leucovorin, 1.0% for 5-FU, and 9.5% for 5-FU continuous.
- Chemo arm:
- -XELOX: 5.8% for oxaliplatin
- -FOLFOX: 7.6% for oxaliplatin, 4.2% for leucovorin, 2.0% for 5-FU bolus, and 5.9% for 5-FU continuous.

Infusion  rate  reductions in  all  treated  subjects  occurred  most  frequently  during  oxaliplatin administration in both the nivo+chemo and chemo arms. The proportion of subjects with at least 1 infusion rate reduction were reported as follows in all treated subjects:

- Nivo+chemo arm:

<div style=\"page-break-after: always\"></div>

- -Nivo+XELOX: 2.2% for nivolumab, 6.9% for oxaliplatin
- -Nivo+FOLFOX: 3.6% for nivolumab, 16.6% for oxaliplatin, 10.0% for leucovorin, 10.9% for 5FU bolus, and 10.2% for 5-FU continuous.
- Chemo arm:
- -XELOX: 5.3% for oxaliplatin
- -FOLFOX: 7.6% for oxaliplatin, 4.9% for leucovorin, 3.7% for 5-FU bolus, and 4.7% for 5-FU continuous.

The most commonly reported cause of dose delay for nivolumab and chemotherapy was AE. Please refer to the section discontinuations for a more detailed discussion of AEs leading to discontinuation, dose reductions, and dose delays.

## Adverse events

Safety results are provided for all patients that were randomised and treated in the nivo+chemo and chemo arms in study CA209649 (N=1549). A summary of the safety profile is shown in the table below.

Table 30. Summary of Safety - All Treated Subjects

|                          | No. of Subjects (%)    | No. of Subjects (%)   |
|--------------------------|------------------------|-----------------------|
| Safety Parameters        | Nivo + Chemo (N = 782) | Chemo (N = 767)       |
| Deaths                   | 538 ( 68.8)            | 572 ( 74.6)           |
| Primary Reason for Death |                        |                       |
| Disease                  | 465 ( 59.5)            | 506 ( 66.0)           |
| Study Drug Toxicity      | 12 ( 1.5)              | 4 ( 0.5)              |
| Unknown                  | 12 ( 1.5)              | 18 ( 2.3)             |
| Other                    | 49 ( 6.3)              | 44 ( 5.7)             |

|                                          | Adverse Event Grades   | Adverse Event Grades   | Adverse Event Grades   | Adverse Event Grades   |
|------------------------------------------|------------------------|------------------------|------------------------|------------------------|
|                                          | Any Grade              | Grade 3-4              | Any Grade              | Grade 3-4              |
| All-causality SAEs                       | 423 ( 54.1)            | 281 ( 35.9)            | 335 ( 43.7)            | 229 ( 29.9)            |
| Drug-related SAEs                        | 172 ( 22.0)            | 131 ( 16.8)            | 93 ( 12.1)             | 77 ( 10.0)             |
| All-causality AEs leading to DC          | 371 ( 47.4)            | 194 ( 24.8)            | 251 ( 32.7)            | 113 ( 14.7)            |
| Drug-Related AEs leading to DC           | 284 ( 36.3)            | 132 ( 16.9)            | 181 ( 23.6)            | 67 ( 8.7)              |
| All-causality AEs                        | 776 ( 99.2)            | 540 ( 69.1)            | 752 ( 98.0)            | 456 ( 59.5)            |
| Drug-related AEs                         | 738 ( 94.4)            | 462 ( 59.1)            | 679 ( 88.5)            | 341 ( 44.5)            |
| ≥ 15% of Subjects in Any Treatment Group |                        |                        |                        |                        |
| Nausea                                   | 323 ( 41.3)            | 20 ( 2.6)              | 292 ( 38.1)            | 19 ( 2.5)              |
| Diarrhea                                 | 253 ( 32.4)            | 35 ( 4.5)              | 206 ( 26.9)            | 24 ( 3.1)              |
| Neuropathy Peripheral                    | 221 ( 28.3)            | 31 ( 4.0)              | 190 ( 24.8)            | 22 ( 2.9)              |
| Anaemia                                  | 203 ( 26.0)            | 47 ( 6.0)              | 171 ( 22.3)            | 21 ( 2.7)              |
| Fatigue                                  | 202 ( 25.8)            | 30 ( 3.8)              | 173 ( 22.6)            | 17 ( 2.2)              |
| Vomiting                                 | 195 ( 24.9)            | 17 ( 2.2)              | 166 ( 21.6)            | 24 ( 3.1)              |
| Neutropenia                              | 191 ( 24.4)            | 118 (15.1)             | 181 ( 23.6)            | 93 ( 12.1)             |
| Neutrophil Count Decreased               | 158 ( 20.2)            | 83 (10.6)              | 118 ( 15.4)            | 67 ( 8.7)              |
| Thrombocytopenia                         | 157 ( 20.1)            | 19 ( 2.4)              | 145 ( 18.9)            | 13 ( 1.7)              |
| Decreased Appetite                       | 157 ( 20.1)            | 14 ( 1.8)              | 139 ( 18.1)            | 13 ( 1.7)              |
| Platelet Count Decreased                 | 156 ( 19.9)            | 20 ( 2.6)              | 115 ( 15.0)            | 19 ( 2.5)              |
| Peripheral Sensory Neuropathy            | 137 ( 17.5)            | 16 ( 2.0)              | 119 ( 15.5)            | 14 ( 1.8)              |

<div style=\"page-break-after: always\"></div>

|                                      | No. of Subjects (%)    | No. of Subjects (%)    | No. of Subjects (%)   | No. of Subjects (%)   |
|--------------------------------------|------------------------|------------------------|-----------------------|-----------------------|
| Safety Parameters                    | Nivo + Chemo (N = 782) | Nivo + Chemo (N = 782) | Chemo (N = 767)       | Chemo (N = 767)       |
| Aspartate Aminotransferase Increased | 122 (15.6)             | 12 ( 1.5)              | 69 ( 9.0)             | 5 ( 0.7)              |
| All-causality Select AEs             |                        |                        |                       |                       |
| Endocrine                            | 117 ( 15.0)            | 7 ( 0.9)               | 14 ( 1.8)             | 1 ( 0.1)              |
| Gastrointestinal                     | 315 ( 40.3)            | 48 ( 6.1)              | 260 ( 33.9)           | 29 ( 3.8)             |
| Hepatic                              | 267 ( 34.1)            | 45 ( 5.8)              | 186 ( 24.3)           | 29 ( 3.8)             |
| Pulmonary                            | 41 ( 5.2)              | 14 ( 1.8)              | 6 ( 0.8)              | 1 ( 0.1)              |
| Renal                                | 58 ( 7.4)              | 11 ( 1.4)              | 24 ( 3.1)             | 7 ( 0.9)              |
| Skin                                 | 262 ( 33.5)            | 27 ( 3.5)              | 137 ( 17.9)           | 7 ( 0.9)              |
| Hypersensitivity/Infusion Reactions  | 118 ( 15.1)            | 19 ( 2.4)              | 45 ( 5.9)             | 11 ( 1.4)             |
| Drug-Related Select AEs              |                        |                        |                       |                       |
| Endocrine                            | 107 ( 13.7)            | 5 ( 0.6)               | 3 ( 0.4)              | 0                     |
| Gastrointestinal                     | 262 ( 33.5)            | 43 ( 5.5)              | 207 ( 27.0)           | 25 ( 3.3)             |
| Hepatic                              | 203 ( 26.0)            | 29 ( 3.7)              | 134 ( 17.5)           | 16 ( 2.1)             |
| Pulmonary                            | 40 ( 5.1)              | 14 ( 1.8)              | 4 ( 0.5)              | 1 ( 0.1)              |
| Renal                                | 26 ( 3.3)              | 6 ( 0.8)               | 8 ( 1.0)              | 1 ( 0.1)              |
| Skin                                 | 214 ( 27.4)            | 26 ( 3.3)              | 105 (13.7)            | 6 ( 0.8)              |

<div style=\"page-break-after: always\"></div>

|                                                            | No. of Subjects (%)                                        | No. of Subjects (%)                                        | No. of Subjects (%)                                        | No. of Subjects (%)                                        |
|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|
| Safety Parameters                                          | Nivo + Chemo (N = 782)                                     | Nivo + Chemo (N = 782)                                     | Chemo (N = 767)                                            | Chemo (N = 767)                                            |
|                                                            | Adverse                                                    | Event Grades                                               | Event Grades                                               |                                                            |
|                                                            | Any Grade                                                  | Grade 3-4                                                  | Any Grade                                                  | Grade 3-4                                                  |
| Hypersensitivity/Infusion Reactions                        | 111 ( 14.2)                                                | 17 ( 2.2)                                                  | 42 ( 5.5)                                                  | 11 ( 1.4)                                                  |
| All-causality IMAEs within 100 days of last dose           | All-causality IMAEs within 100 days of last dose           | All-causality IMAEs within 100 days of last dose           | All-causality IMAEs within 100 days of last dose           | All-causality IMAEs within 100 days of last dose           |
| Treated with Immune Modulating Medication                  | Treated with Immune Modulating Medication                  | Treated with Immune Modulating Medication                  | Treated with Immune Modulating Medication                  | Treated with Immune Modulating Medication                  |
| Diarrhea/Colitis                                           | 26 ( 3.3)                                                  | 17 ( 2.2)                                                  | 0                                                          | 0                                                          |
| Hepatitis                                                  | 19 ( 2.4)                                                  | 13 ( 1.7)                                                  | 0                                                          | 0                                                          |
| Pneumonitis                                                | 33 ( 4.2)                                                  | 15 ( 1.9)                                                  | 0                                                          | 0                                                          |
| Nephritis/Renal Dysfunction                                | 4 ( 0.5)                                                   | 2 ( 0.3)                                                   | 0                                                          | 0                                                          |
| Rash                                                       | 51 ( 6.5)                                                  | 11 ( 1.4)                                                  | 4 ( 0.5)                                                   | 0                                                          |
| Hypersensitivity/Infusion Reactions                        | 6 ( 0.8)                                                   | 1 ( 0.1)                                                   | 0                                                          | 0                                                          |
| All-causality Endocrine IMAEs within 100 days of last dose | All-causality Endocrine IMAEs within 100 days of last dose | All-causality Endocrine IMAEs within 100 days of last dose | All-causality Endocrine IMAEs within 100 days of last dose | All-causality Endocrine IMAEs within 100 days of last dose |
| With or Without Immune Modulating Medication               | With or Without Immune Modulating Medication               | With or Without Immune Modulating Medication               | With or Without Immune Modulating Medication               | With or Without Immune Modulating Medication               |
| Adrenal Insufficiency                                      | 5 ( 0.6)                                                   | 1 ( 0.1)                                                   | 2 ( 0.3)                                                   | 2 ( 0.3)                                                   |
| Hypophysitis                                               | 6 ( 0.8)                                                   | 3 ( 0.4)                                                   | 0                                                          | 0                                                          |
| Hypothyroidism/Thyroiditis                                 | 74 ( 9.5)                                                  | 0                                                          | 6 ( 0.8)                                                   | 0                                                          |
| Diabetes Mellitus                                          | 2 ( 0.3)                                                   | 1 ( 0.1)                                                   | 0                                                          | 0                                                          |
| Hyperthyroidism                                            | 23 ( 2.9)                                                  | 0                                                          | 2 ( 0.3)                                                   | 0                                                          |
| All-causality OESIs within 100 days of last dose           | All-causality OESIs within 100 days of last dose           | All-causality OESIs within 100 days of last dose           | All-causality OESIs within 100 days of last dose           | All-causality OESIs within 100 days of last dose           |
| With or Without Immune Modulating Medication               | With or Without Immune Modulating Medication               | With or Without Immune Modulating Medication               | With or Without Immune Modulating Medication               | With or Without Immune Modulating Medication               |
| Pancreatitis                                               | 3 ( 0.4)                                                   | 2 ( 0.3)                                                   | 2 ( 0.3)                                                   | 1 ( 0.1)                                                   |
| Encephalitis                                               | 1 ( 0.1)                                                   | 1 ( 0.1)                                                   | 0                                                          | 0                                                          |
| Myositis/Rhabdomyolysis                                    | 0                                                          | 0                                                          | 2 ( 0.3)                                                   | 2 ( 0.3)                                                   |
| Myasthenic Syndrome                                        | 0                                                          | 0                                                          | 0                                                          | 0                                                          |
| Demyelination                                              | 0                                                          | 0                                                          | 0                                                          | 0                                                          |
| Guillain-Barre Syndrome                                    | 1 ( 0.1)                                                   | 1 ( 0.1)                                                   | 0                                                          | 0                                                          |
| Uveitis                                                    | 1 ( 0.1)                                                   | 1 ( 0.1)                                                   | 0                                                          | 0                                                          |
| Myocarditis                                                | 2 ( 0.3)                                                   | 1 ( 0.1)                                                   | 0                                                          | 0                                                          |
| Graft Versus Host Disease                                  | 0                                                          | 0                                                          | 0                                                          | 0                                                          |

MedDRA version 23.0 CTCAE version 4.0. All events are within 30 days of the last  dose  of  study  drug,  unless otherwise indicated (e.g. any time for deaths, 100 days for IMAEs and OESIs).

Abbreviations: AEs - adverse events, CTC - Common Toxicity Criteria, DC - discontinuation, IMAEs - immunemediated  adverse  events,  IMM  -  immune  modulating  medication,  MedDRA  -  Medical  Dictionary  for  Regulatory Activities, OESI - other events of special interest, SAEs - serious adverse events

Source: Table S.6.15.3 (deaths), Table S.6.3.1.2.5 (all-causality SAEs), Table S.6.3.1.2.6 (drug-related SAEs), Table S.6.4.2.5 (all-causality AEs leading to DC), Table S.6.4.2.6 (drug-related AEs leading to DC), Table S.6.1.31.3 (allcausality AEs); Table S.6.1.32.3 (drug-related AEs); Table S.6.5.2.9 (all-causality select AEs), Table S.6.5.2.11 (allcausality endocrine select AEs), Table S.6.5.2.10 (drug-related select AEs), Table S.6.5.2.12 (drug-related endocrine select  AEs),  Table  S.6.202.16  (non-endocrine  IMAEs),  Table  S.6.202.13  (endocrine  IMAEs),  Table  S.6.5.3.3.5 (OESIs).

## Adverse events (regardless of causality)

Any-grade AEs (regardless of causality) were reported in 776 (99.2%) subjects in the nivo+chemo arm, and 752 (98.0%) subjects in the chemo arm (Table 30 and Table 31).

The most frequently reported AEs (regardless of causality) were:

- Nivo+chemo: nausea (47.6%), diarrhoea (39.4%), and anaemia (38.2%).

<div style=\"page-break-after: always\"></div>

- Chemo: nausea (43.5%), diarrhoea (33.6%), and anaemia (33.1%).

Grade 3-4 AEs (regardless of causality) were reported in 540 (69.1%) subjects in the nivo+chemo arm, and 456 (59.5%) subjects in the chemo arm.

The most frequently reported Grade 3-4 AEs (regardless of causality) were:

- Nivo+chemo: neutropaenia (16.9%), decreased neutrophil count (11.5%), and anaemia (11.0%).
- Chemo: neutropaenia (13.0%), decreased neutrophil count (9.1%), and anaemia (7.3%).

## Drug-related adverse events

Any grade drug-related AEs were reported in 738 (94.4%) subjects in the nivo+chemo arm, and 679 (88.5%) subjects in the chemo arms (Table 30 and Table 32 ).

The most frequently reported drug-related AEs were:

- Nivo+chemo: nausea (41.3%), diarrhoea (32.4%), and neuropathy peripheral (28.3%).
- Chemo: nausea (38.1%), diarrhoea (26.9%), and neuropathy peripheral (24.8%).

Grade 3-4 drug-related AEs were reported in 462 (59.1%) subjects in the nivo+chemo arm, and 341 (44.5%) subjects in the chemo arm.

The most frequently reported Grade 3-4 drug-related AEs were:

- Nivo+chemo: neutropaenia (15.1%), decreased neutrophil count (10.6%), and anaemia (6.0%).
- Chemo: neutropaenia (12.1%), decreased neutrophil count (8.7%), and diarrhoea and vomiting (each 3.1%).

<div style=\"page-break-after: always\"></div>

Table 81 . Adverse Events by Worst CTC Grade in ≥ 5% of All Treated Subjects

| ------------------------------------------------------------------------------------------------------------------------------------                              |       |               |                                                      |             |       |       |        |             |         |           |                                                    |                                                    |      |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|---------------|------------------------------------------------------|-------------|-------|-------|--------|-------------|---------|-----------|----------------------------------------------------|----------------------------------------------------|------|
| System Organ Class (%) Preferred Term (%)                                                                                                                         | Any   | Grade         | N -------------------------------------------- Grade | = 782 3-4   | Grade | 5     |        | Any Grade   | N Grade | = 767 3-4 | -------------------------------------------- Grade | -------------------------------------------- Grade | 5    |
| ------------------------------------------------------------------------------------------------------------------------------------ TOTAL SUBJECTS WITH AN EVENT | 776 ( | 99.2)         | 540                                                  | ( 69.1)     | 81 (  | 10.4) | 752    | ( 98.0)     | 456     | ( 59.5)   | 63                                                 | (                                                  | 8.2) |
| Gastrointestinal disorders                                                                                                                                        | 639   | ( 81.7)       | 179                                                  | ( 22.9)     | 3 (   | 0.4)  | 564    | ( 73.5)     | 155     | ( 20.2)   | 0                                                  |                                                    |      |
| Nausea                                                                                                                                                            | 372   | 47.6)         | 25                                                   | ( 3.2)      | 0     |       | 334    | 43.5)       | 28      | ( 3.7)    | 0                                                  |                                                    |      |
| Diarrhoea                                                                                                                                                         | 308   | ( ( 39.4)     | 40                                                   | ( 5.1)      | 0     |       | 258    | ( ( 33.6)   | 28      | ( 3.7)    | 0                                                  |                                                    |      |
| Vomiting                                                                                                                                                          | 245   | ( 31.3)       | 33                                                   | ( 4.2)      | 0     |       | 221    | ( 28.8)     | 32      | ( 4.2)    | 0                                                  |                                                    |      |
| Constipation                                                                                                                                                      | 193   | ( 24.7)       | 5                                                    | ( 0.6)      | 0     |       | 160    | ( 20.9)     | 3       | ( 0.4)    | 0                                                  |                                                    |      |
| Abdominal pain                                                                                                                                                    | 151   | ( 19.3)       | 17                                                   | ( 2.2)      | 0     |       | 120    | ( 15.6)     | 16      | ( 2.1)    | 0                                                  |                                                    |      |
| Abdominal pain upper                                                                                                                                              | 72    | ( 9.2)        | 5                                                    | ( 0.6)      | 0     |       | 69     | ( 9.0)      | 4       | ( 0.5)    | 0                                                  |                                                    |      |
| Dysphagia                                                                                                                                                         | 66    | ( 8.4)        | 15                                                   | ( 1.9)      | 0     |       | 57     | ( 7.4)      | 18      | ( 2.3)    | 0                                                  |                                                    |      |
| Stomatitis                                                                                                                                                        | 64    | 8.2)          | 7                                                    | ( 0.9)      | 0     |       | 51     | ( 6.6)      | 1       | ( 0.1)    | 0                                                  |                                                    |      |
| Abdominal distension                                                                                                                                              | 50    | ( ( 6.4)      | 1                                                    | ( 0.1)      | 0     |       | 34     | ( 4.4)      | 1       | ( 0.1)    | 0                                                  |                                                    |      |
| Nervous system disorders                                                                                                                                          | 517   | ( 66.1)       | 94                                                   | ( 12.0)     | 1 (   | 0.1)  | 472    | ( 61.5)     | 65      | ( 8.5)    | 0                                                  |                                                    |      |
| Neuropathy peripheral                                                                                                                                             | 232   | ( 29.7)       | 34                                                   | ( 4.3)      | 0     |       | 201    | ( 26.2)     | 23      | ( 3.0)    | 0                                                  |                                                    |      |
| Peripheral sensory neuropathy                                                                                                                                     | 143   | ( 18.3)       | 16                                                   | ( 2.0)      | 0     |       | 121    | ( 15.8)     | 14      | ( 1.8)    | 0                                                  |                                                    |      |
| Headache                                                                                                                                                          | 86    | ( 11.0)       | 6                                                    | ( 0.8)      | 0     |       | 47     | ( 6.1)      | 2       | ( 0.3)    | 0                                                  |                                                    |      |
| Paraesthesia                                                                                                                                                      | 70    | 9.0)          | 2                                                    | ( 0.3)      | 0     |       | 68     | ( 8.9)      | 2       | ( 0.3)    | 0                                                  |                                                    |      |
| Dizziness                                                                                                                                                         | 52    | ( ( 6.6)      | 1                                                    | ( 0.1)      | 0     |       | 54     | ( 7.0)      | 2       | 0.3)      | 0                                                  |                                                    |      |
| Dysgeusia                                                                                                                                                         | 46    | ( 5.9)        | 0                                                    |             | 0     |       | 41     | ( 5.3)      | 0       | (         | 0                                                  |                                                    |      |
| Hypoaesthesia                                                                                                                                                     | 44 (  | 5.6)          | 2                                                    | ( 0.3)      | 0     |       | 33     | ( 4.3)      | 0       |           | 0                                                  |                                                    |      |
| General disorders and administration site                                                                                                                         | 513   | ( 65.6)       | 83                                                   | ( 10.6)     | 2 (   | 0.3)  | 426    | ( 55.5)     | 59      | ( 7.7)    | 2                                                  | (                                                  | 0.3) |
| conditions                                                                                                                                                        | 257   | ( 32.9)       | 41                                                   | ( 5.2)      | 0     |       | 219    | ( 28.6)     | 25      | ( 3.3)    | 0                                                  |                                                    |      |
| Fatigue Pyrexia                                                                                                                                                   | 147   | 18.8)         | 8                                                    | ( 1.0)      | 0     |       | 83     | 10.8)       | 3       | ( 0.4)    | 0                                                  |                                                    |      |
| Asthenia                                                                                                                                                          | 115   | ( ( 14.7)     | 17                                                   | ( 2.2)      | 0     |       | 111    | ( ( 14.5)   | 15      | ( 2.0)    | 0                                                  |                                                    |      |
| Oedema peripheral                                                                                                                                                 | 86    | ( 11.0)       | 3                                                    | ( 0.4)      | 0     |       | 53     | ( 6.9)      | 1       | ( 0.1)    | 0                                                  |                                                    |      |
| Mucosal inflammation                                                                                                                                              | 74 (  | 9.5)          | 7                                                    | 0.9)        | 0     |       | 47     | ( 6.1)      | 5       | ( 0.7)    | 0                                                  |                                                    |      |
| Malaise                                                                                                                                                           | 52 (  | 6.6)          | 2                                                    | ( ( 0.3)    | 0     |       | 50     | ( 6.5)      | 2       | ( 0.3)    | 0                                                  |                                                    |      |
| Investigations                                                                                                                                                    | 484   | ( 61.9)       | 213                                                  | ( 27.2)     | 0     |       | 399    | ( 52.0)     | 150     | ( 19.6)   | 0                                                  |                                                    |      |
| Neutrophil count decreased                                                                                                                                        | 170   | ( 21.7)       | 90                                                   | ( 11.5)     | 0     |       | 124    | ( 16.2)     | 70      | ( 9.1)    | 0                                                  |                                                    |      |
| Platelet count decreased                                                                                                                                          | 168   | ( 21.5)       | 22                                                   | ( 2.8)      | 0     |       | 122 96 | ( 15.9)     | 20      | ( 2.6)    | 0                                                  |                                                    |      |
| Aspartate aminotransferase increased                                                                                                                              | 157   | ( 20.1) (     | 19                                                   | ( 2.4)      | 0     |       |        | ( 12.5)     | 9       | ( 1.2)    | 0                                                  |                                                    |      |
| Weight decreased                                                                                                                                                  | 135   | 17.3)         | 10                                                   | ( 1.3)      | 0     |       | 117    | ( 15.3)     | 5       | ( 0.7)    | 0                                                  |                                                    |      |
| White blood cell count decreased                                                                                                                                  | 117   | ( 15.0)       | 25                                                   | ( 3.2)      | 0     |       | 80     | ( 10.4)     | 13      | ( 1.7)    | 0                                                  |                                                    |      |
|                                                                                                                                                                   | 112   | (             |                                                      | (           |       |       | 65     | (           |         | ( 1.2)    | 0                                                  |                                                    |      |
| Alanine aminotransferase increased Lipase increased                                                                                                               | 106   | 14.3) ( 13.6) | 9 55                                                 | 1.2) ( 7.0) | 0 0   |       | 72     | 9.4) ( 8.5) | 9 28    | ( 3.7)    | 0                                                  |                                                    |      |
| Blood alkaline phosphatase increased Amylase increased                                                                                                            | 101   | ( 12.9) (     | 10                                                   | ( 1.3)      | 0     |       | 58     | ( 7.6) (    | 5 3     | ( 0.7) (  | 0                                                  |                                                    |      |
|                                                                                                                                                                   | 90    | 11.5)         | 24                                                   | 3.1)        | 0     |       | 41     | 5.3)        |         | 0.4)      | 0                                                  |                                                    |      |
| Blood bilirubin increased                                                                                                                                         | 76    | ( 9.7)        | 14                                                   | ( ( 1.8)    | 0     |       | 49     | ( 6.4)      | 7       | ( 0.9)    | 0                                                  |                                                    |      |

------------------------------------------------------------------------------------------------------------------------------------

<div style=\"page-break-after: always\"></div>

------------------------------------------------------------------------------------------------------------------------------------

----------------------------------------------------------------------------------------------------------------------

|                                                                                                                                                                                                                           | Nivo+Chemo N            | Nivo+Chemo N                                         | Nivo+Chemo N                                       | Nivo+Chemo N                                      | Nivo+Chemo N   | Nivo+Chemo N   | Nivo+Chemo N           | Chemo N = 767                                      | Chemo N = 767                 | Chemo N = 767                                    | Chemo N = 767                                    | Chemo N = 767   | Chemo N = 767   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|------------------------------------------------------|----------------------------------------------------|---------------------------------------------------|----------------|----------------|------------------------|----------------------------------------------------|-------------------------------|--------------------------------------------------|--------------------------------------------------|-----------------|-----------------|
| System Organ Class (%) Preferred Term (%)                                                                                                                                                                                 | Any                     | Grade                                                | -------------------------------------------- Grade | 3-4                                               | Grade 5        | Grade 5        | Grade 5                | Any Grade                                          | Grade                         | -------------------------------------------- 3-4 | -------------------------------------------- 3-4 | Grade 5         | Grade 5         |
| ------------------------------------------------------------------------------------------------------------------------------------ Blood and lymphatic system disorders Anaemia Neutropenia Thrombocytopenia Leukopenia | 477 299 214 171 67      | ( 61.0) ( 38.2) ( 27.4) ( 21.9) ( 8.6)               | 230 86 132 21 5                                    | ( 29.4) ( 11.0) ( 16.9) ( 2.7) ( 0.6)             | 2 ( 0 0 1 ( 0  | 0.3) 0.1)      | 397 254 192 152 62     | ( 51.8) ( 33.1) ( 25.0) ( 19.8) ( 8.1)             | 167 ( 56 ( 100 ( 16 ( 12 (    | 21.8) 7.3) 13.0) 2.1) 1.6)                       | 0 0 0 0 0                                        |                 |                 |
| Metabolism and nutrition disorders Decreased appetite Hypoalbuminaemia Hypokalaemia Hyperglycaemia Hyponatraemia Hypocalcaemia                                                                                            | 426 224 105 87 77 66 47 | ( 54.5) ( 28.6) ( 13.4) ( 11.1) ( 9.8) ( 8.4) ( 6.0) | 94 28 2 19 12 19 4                                 | ( 12.0) ( 3.6) ( 0.3) ( 2.4) ( 1.5) ( 2.4) ( 0.5) | 0 0 0 0 0 0 0  |                | 363 203 62 65 57 46 26 | ( 47.3) ( 26.5) ( 8.1) ( 8.5) ( 7.4) ( 6.0) ( 3.4) | 68 ( 19 ( 2 ( 20 ( 6 ( 13 ( 0 | 8.9) 2.5) 0.3) 2.6) 0.8) 1.7)                    | 0                                                | 1 ( 0 0 0 0 0   | 0.1)            |
| Skin and subcutaneous tissue disorders Palmar-plantar erythrodysaesthesia syndrome Rash Pruritus                                                                                                                          | 314 103 86 ( 73 (       | ( 40.2) ( 13.2) 11.0) 9.3)                           | 31 12 7 ( 1 (                                      | ( 4.0) ( 1.5) 0.9) 0.1)                           | 0 0 0 0        |                | 201 90 20 15           | ( 26.2) ( 11.7) ( 2.6) ( 2.0)                      | 12 ( 6 ( 0 0                  | 1.6) 0.8)                                        |                                                  | 0 0 0 0         |                 |
| Infections and infestations Pneumonia                                                                                                                                                                                     | 283 45                  | ( 36.2) ( 5.8)                                       | 68 ( 19 (                                          | 8.7) 2.4)                                         | 4 ( 2 (        | 0.5) 0.3)      | 184 32                 | ( 24.0) ( 4.2)                                     | 39 ( 10 (                     | 5.1) 1.3)                                        |                                                  | 0 0             |                 |
| Respiratory, thoracic and mediastinal disorders Cough                                                                                                                                                                     | 263 ( 95 (              | 33.6) 12.1)                                          | 41 ( (                                             | 5.2) 0.1)                                         | 3 ( 0          | 0.4)           | 195                    | ( 25.4) ( 7.7)                                     | 30 ( 0                        |                                                  | 3.9)                                             | 2 ( 0           | 0.3)            |
| Dyspnoea Musculoskeletal and connective tissue disorders Back pain                                                                                                                                                        | 60 224                  | ( 7.7) ( 28.6)                                       | 1 4 16                                             | ( 0.5) ( 2.0)                                     | 0 0            |                | 59 41 147              | ( 5.3) ( 19.2)                                     | 5 ( 19 (                      | 0.7)                                             | 2.5)                                             | 0 0             |                 |
| Arthralgia Neoplasms benign, malignant and unspecified (incl cysts and polyps) Malignant neoplasm progression                                                                                                             | 77 ( 52 ( 138           | 9.8) 6.6) ( 17.6)                                    | 5 1 57                                             | ( 0.6) ( 0.1)                                     | 0 0 60 (       |                | 59 23 107              | ( 7.7) ( 3.0) ( 14.0)                              | 10 2 ( 41 (                   | (                                                | 1.3) 0.3) 5.3)                                   | 0 0 51 (        | 6.6)            |
|                                                                                                                                                                                                                           | 111                     | ( 14.2)                                              | 45                                                 | ( 7.3) ( 5.8)                                     | 60 (           | 7.7) 7.7)      | 92                     | ( 12.0)                                            | 35 (                          |                                                  | 4.6)                                             | 51 (            | 6.6)            |
| Injury, poisoning and procedural complications                                                                                                                                                                            | 127                     | ( 16.2)                                              |                                                    | (                                                 |                |                |                        | 10.6)                                              | 12 (                          |                                                  | 1.6)                                             | 0               |                 |
| Infusion related reaction                                                                                                                                                                                                 |                         |                                                      | 23                                                 | 2.9)                                              | 0              |                | 81                     | (                                                  |                               |                                                  |                                                  |                 |                 |
| Vascular disorders                                                                                                                                                                                                        | 68                      | ( 8.7)                                               | 11 (                                               | 1.4)                                              | 0              |                | 30                     | ( 3.9)                                             | 5                             | (                                                | 0.7)                                             | 0               |                 |
| Hypertension                                                                                                                                                                                                              | 127 41                  | ( 16.2) ( 5.2)                                       | 37 ( 19 (                                          | 4.7) 2.4)                                         | 3 ( 0          | 0.4)           | 90 32                  | ( 11.7) ( 4.2)                                     | 21 ( 11 (                     | 1.4)                                             | 2.7)                                             | 1 ( 0           | 0.1)            |

<div style=\"page-break-after: always\"></div>

| System Organ Class (%) Preferred Term (%)   |                                                                                                                                                                    |                                                    |                                                    |         | ------------------------------------------------------------------------------------------------------------------------------------ Chemo N = 767   | ------------------------------------------------------------------------------------------------------------------------------------ Chemo N = 767   | ------------------------------------------------------------------------------------------------------------------------------------ Chemo N = 767   | ------------------------------------------------------------------------------------------------------------------------------------ Chemo N = 767   |
|---------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|---------|------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|
| System Organ Class (%) Preferred Term (%)   | Any Grade                                                                                                                                                          | -------------------------------------------- Grade | -------------------------------------------- Grade | Grade 5 | Any                                                                                                                                                  | -------------------------------------------- Grade                                                                                                   | -------------------------------------------- Grade                                                                                                   | Grade 5                                                                                                                                              |
| Psychiatric disorders Insomnia              | 3-4 ------------------------------------------------------------------------------------------------------------------------------------ 108 ( 13.8) 7 53 ( 6.8) 2 | 2 0                                                | ( 0.3)                                             | 0 0     | 91 ( 11.9) 59 ( 7.7)                                                                                                                                 |                                                                                                                                                      | Grade 3-4 ( 0.9) ( 0.3)                                                                                                                              | 0 0                                                                                                                                                  |
| Endocrine disorders Hypothyroidism          | 104 ( 13.3) 1 77 ( 9.8) 0                                                                                                                                          | 7 0                                                | ( 0.9)                                             | 0 0     | 12 ( 10 (                                                                                                                                            | 1.6) 1.3)                                                                                                                                            | ( 0.1)                                                                                                                                               | 0 0                                                                                                                                                  |
| Immune system disorders Hypersensitivity    | 85 ( 10.9) 6 52 ( 6.6) 2                                                                                                                                           | 10 5                                               | ( 1.3) ( 0.6)                                      | 0 0     | 33 ( 12 (                                                                                                                                            | 4.3) 1.6)                                                                                                                                            | ( 0.8) ( 0.3)                                                                                                                                        | 0 0                                                                                                                                                  |

------------------------------------------------------------------------------------------------------------------------------------

MedDRA Version: 23.0. CTC Version 4.0. Includes events reported between first dose and 30 days after last dose of study therapy. Source: Table S.6.1.31.3

<div style=\"page-break-after: always\"></div>

Table 32. Drug-Related Adverse Events by Worst CTC Grade in ≥ 5% of All Treated Subjects

| ------------------------------------------------------------------------------------------------------------------------------------                              | Nivo+Chemo N   | Nivo+Chemo N      | Nivo+Chemo N                                       | Nivo+Chemo N                                       | Nivo+Chemo N   | Nivo+Chemo N   | Nivo+Chemo N   |                 |                                                          |       |            |         |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------------------|----------------------------------------------------|----------------------------------------------------|----------------|----------------|----------------|-----------------|----------------------------------------------------------|-------|------------|---------|
| System Organ Class (%) Preferred Term (%)                                                                                                                         | Any            | Grade             | -------------------------------------------- Grade | -------------------------------------------- Grade | Grade          | 5              | Any            | Grade           | N -------------------------------------------- Grade 3-4 | =     | 767        | Grade 5 |
| ------------------------------------------------------------------------------------------------------------------------------------ TOTAL SUBJECTS WITH AN EVENT | 738            | ( 94.4)           | 462                                                | ( 59.1)                                            | 4 (            | 0.5)           | 679            | ( 88.5)         | 341                                                      | (     | 44.5)      | 0       |
| Gastrointestinal disorders                                                                                                                                        | 520            | ( 66.5)           | 88                                                 | ( 11.3)                                            | 1 (            | 0.1)           | 456            | ( 59.5)         | 73                                                       | (     | 9.5)       | 0       |
| Nausea                                                                                                                                                            | 323            | 41.3)             | 20                                                 | 2.6)                                               | 0              |                | 292            | ( 38.1)         | 19                                                       | (     | 2.5)       | 0       |
| Diarrhoea                                                                                                                                                         | 253            | ( ( 32.4)         | 35                                                 | ( ( 4.5)                                           | 0              |                | 206            | ( 26.9)         | 24                                                       | (     | 3.1)       | 0       |
| Vomiting                                                                                                                                                          | 195            | ( 24.9)           | 17 (                                               | 2.2)                                               | 0              |                | 166            | ( 21.6)         | 24                                                       | (     | 3.1)       | 0       |
| Constipation                                                                                                                                                      | 73             | ( 9.3)            | 2 (                                                | 0.3)                                               | 0              |                | 61             | ( 8.0)          | 0                                                        |       |            | 0       |
| Stomatitis                                                                                                                                                        | 57             | ( 7.3)            | 7 (                                                | 0.9)                                               | 0              |                | 47             | 6.1)            | 1                                                        |       | 0.1)       | 0       |
| Abdominal pain                                                                                                                                                    | 39             | ( 5.0)            | 4 (                                                | 0.5)                                               | 0              |                | 38             | ( ( 5.0)        | 3                                                        | ( (   | 0.4)       | 0       |
| Nervous system disorders                                                                                                                                          | 466            | ( 59.6)           | 69 (                                               | 8.8)                                               | 1 (            | 0.1)           | 427            | ( 55.7)         | 45                                                       | (     | 5.9)       | 0       |
| Neuropathy peripheral                                                                                                                                             | 221            | ( 28.3)           | 31 (                                               | 4.0)                                               | 0              |                | 190            | ( 24.8)         | 22                                                       | (     | 2.9)       | 0       |
| Peripheral sensory neuropathy                                                                                                                                     | 137            | ( 17.5)           | 16 (                                               | 2.0)                                               | 0              |                | 119            | ( 15.5)         | 14                                                       |       | 1.8)       | 0       |
| Paraesthesia                                                                                                                                                      | 59             | 7.5)              | 2 (                                                | 0.3)                                               | 0              |                | 61 (           | 8.0)            | 1                                                        | ( (   | 0.1)       | 0       |
| Dysgeusia                                                                                                                                                         | 42             | ( ( 5.4)          | 0                                                  |                                                    | 0              |                | 38 (           | 5.0)            | 0                                                        |       |            | 0       |
| Headache                                                                                                                                                          | 40             | ( 5.1)            | 2 (                                                | 0.3)                                               | 0              |                | 17 (           | 2.2)            | 1                                                        | (     | 0.1)       | 0       |
| Investigations                                                                                                                                                    | 413            | ( 52.8)           | 178                                                | ( 22.8)                                            | 0              |                | 299            | ( 39.0)         | 116                                                      |       | 15.1)      | 0       |
| Neutrophil count decreased                                                                                                                                        | 158            | ( 20.2)           | 83                                                 | ( 10.6)                                            | 0              |                | 118            | ( 15.4)         | 67                                                       | ( (   | 8.7)       | 0       |
| Platelet count decreased                                                                                                                                          | 156            | ( 19.9)           | 20 (                                               | 2.6)                                               | 0              |                | 115            | ( 15.0)         | 19                                                       | (     | 2.5)       | 0       |
| Aspartate aminotransferase increased                                                                                                                              | 122            | ( 15.6)           | 12 (                                               | 1.5)                                               | 0              |                | 69             | ( 9.0)          | 5                                                        | (     | 0.7)       | 0       |
| White blood cell count decreased                                                                                                                                  | 112            | ( 14.3)           | 23 (                                               | 2.9)                                               | 0              |                | 77             | ( 10.0)         | 13                                                       |       | 1.7)       | 0       |
| Alanine aminotransferase increased                                                                                                                                | 89             | ( 11.4)           | 6 (                                                | 0.8)                                               | 0              |                | 50             | ( 6.5)          |                                                          | ( 5 ( | 0.7)       | 0       |
| Lipase increased                                                                                                                                                  | 89             | ( 11.4)           | 45 (                                               | 5.8)                                               | 0              |                | 34             | ( 4.4)          | 16                                                       | (     | 2.1)       | 0       |
| Amylase increased                                                                                                                                                 | 71             | ( 9.1)            | 21                                                 | 2.7)                                               | 0              |                | 22             | ( 2.9)          | 2                                                        | (     | 0.3)       | 0       |
| Blood alkaline phosphatase increased                                                                                                                              | 52             | ( 6.6)            | ( 5 (                                              | 0.6)                                               | 0              |                | 34             | ( 4.4)          | 2                                                        | (     | 0.3)       | 0       |
| Blood bilirubin increased                                                                                                                                         | 48             | ( 6.1)            | 4 (                                                | 0.5)                                               | 0              |                | 32             | ( 4.2)          | 2                                                        | (     | 0.3)       | 0       |
| Weight decreased                                                                                                                                                  | 45             | ( 5.8)            | 2 (                                                | 0.3)                                               | 0              |                | 33 (           | 4.3)            | 1                                                        | (     | 0.1)       | 0       |
| Blood and lymphatic system disorders                                                                                                                              | 390            | ( 49.9)           | 185                                                | ( 23.7)                                            | 1 (            | 0.1)           | 331            | ( 43.2)         | 127                                                      | (     | 16.6)      | 0       |
| Anaemia                                                                                                                                                           | 203            | ( 26.0)           | 47                                                 | ( 6.0)                                             | 0              |                | 171            | ( 22.3)         | 21                                                       | (     | 2.7)       | 0       |
| Leukopenia                                                                                                                                                        | 63             | 8.1)              | 5 (                                                | 0.6)                                               | 0              |                |                | ( 7.2)          | 13                                                       | ( (   | 1.4)       | 0       |
| Neutropenia Thrombocytopenia                                                                                                                                      | 191 157        | ( 24.4) ( 20.1) ( | 118 ( 19 (                                         | 15.1) 2.4)                                         | 0 0            |                | 181 145 55     | ( 23.6) ( 18.9) | 93 11                                                    | (     | 12.1) 1.7) | 0 0     |
|                                                                                                                                                                   | 73             | ( 9.3)            |                                                    |                                                    | 0              |                | 173            | ( 10.6)         |                                                          |       | 1.3)       | 0       |
| General disorders and administration site conditions                                                                                                              | 376            | ( 48.1)           | 49 (                                               | 6.3)                                               | 0              |                | 311            | ( 40.5)         | 35                                                       | (     | 4.6)       | 0       |
|                                                                                                                                                                   |                | (                 | 30 (                                               | 3.8)                                               | 0              |                |                | ( 22.6)         | 17                                                       | (     | 2.2)       |         |
| Fatigue                                                                                                                                                           | 202            | 25.8)             |                                                    |                                                    |                |                |                |                 |                                                          |       |            | 0       |
| Asthenia Pyrexia                                                                                                                                                  | 64 62          | ( 8.2) ( 7.9) (   | 7 ( 4 (                                            | 0.9) 0.5)                                          | 0 0            |                | 81 22 ( 45     | 2.9) 5.9)       | 10 ( 1 (                                                 |       | 0.1) 0.7)  | 0 0     |
| Mucosal                                                                                                                                                           | 42             |                   | 6 (                                                | 0.8)                                               | 0              |                | ( (            |                 | 0                                                        | (     |            | 0       |
| inflammation Malaise                                                                                                                                              |                | 5.4)              | ( 2                                                | 0.3)                                               |                |                | 36             | 4.7)            | 5                                                        |       |            |         |

------------------------------------------------------------------------------------------------------------------------------------

<div style=\"page-break-after: always\"></div>

|                                                                                                                                                                             | Nivo+Chemo N =                                         | Nivo+Chemo N =   | Nivo+Chemo N =   | Nivo+Chemo N =   | ------------------------------------------------------------------------------------------------------------------------------------ Chemo N = 767 --------------------------------------------   | ------------------------------------------------------------------------------------------------------------------------------------ Chemo N = 767 --------------------------------------------   | ------------------------------------------------------------------------------------------------------------------------------------ Chemo N = 767 --------------------------------------------   | ------------------------------------------------------------------------------------------------------------------------------------ Chemo N = 767 --------------------------------------------   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|------------------|------------------|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 782 System Organ Class (%) Preferred Term (%)                                                                                                                               | -------------------------------------------- Any Grade | Grade 3-4        | Grade 3-4        | Grade 5          | Any Grade                                                                                                                                                                                         | Grade 3-4                                                                                                                                                                                         | Grade 3-4                                                                                                                                                                                         | Grade 5                                                                                                                                                                                           |
| ------------------------------------------------------------------------------------------------------------------------------------ Skin and subcutaneous tissue disorders | 251 ( 32.1)                                            | 28               | ( 3.6)           | 0                | 153 ( 19.9)                                                                                                                                                                                       | 9 (                                                                                                                                                                                               | 1.2)                                                                                                                                                                                              | 0                                                                                                                                                                                                 |
| Palmar-plantar erythrodysaesthesia syndrome                                                                                                                                 | 94 ( 12.0)                                             | 11 (             | 1.4)             | 0                | 81 ( 10.6)                                                                                                                                                                                        | 6                                                                                                                                                                                                 | ( 0.8)                                                                                                                                                                                            | 0                                                                                                                                                                                                 |
| Rash                                                                                                                                                                        | 74 ( 9.5)                                              | 7 (              | 0.9)             | 0                | 12 ( 1.6)                                                                                                                                                                                         | 0                                                                                                                                                                                                 |                                                                                                                                                                                                   | 0                                                                                                                                                                                                 |
| Pruritus                                                                                                                                                                    | 54 ( 6.9)                                              | 1 (              | 0.1)             | 0                | 8 ( 1.0)                                                                                                                                                                                          | 0                                                                                                                                                                                                 |                                                                                                                                                                                                   | 0                                                                                                                                                                                                 |
| Metabolism and nutrition disorders                                                                                                                                          | 227 ( 29.0)                                            | 36 (             | 4.6)             | 0                | 193 ( 25.2)                                                                                                                                                                                       | 28                                                                                                                                                                                                | ( 3.7)                                                                                                                                                                                            | 0                                                                                                                                                                                                 |
| Decreased appetite                                                                                                                                                          | 157 ( 20.1)                                            | 14 (             | 1.8)             | 0                | 139 ( 18.1)                                                                                                                                                                                       | 13                                                                                                                                                                                                | ( 1.7)                                                                                                                                                                                            | 0                                                                                                                                                                                                 |
| Endocrine disorders                                                                                                                                                         | 95 ( 12.1)                                             | 5                | ( 0.6)           | 0                | 2 ( 0.3)                                                                                                                                                                                          | 0                                                                                                                                                                                                 |                                                                                                                                                                                                   | 0                                                                                                                                                                                                 |
| Hypothyroidism                                                                                                                                                              | 70 ( 9.0)                                              | 0                |                  | 0                | 2 ( 0.3)                                                                                                                                                                                          | 0                                                                                                                                                                                                 |                                                                                                                                                                                                   | 0                                                                                                                                                                                                 |
| Injury, poisoning and procedural complications                                                                                                                              | 75 ( 9.6)                                              | 12 (             | 1.5)             | 0                | 38 ( 5.0)                                                                                                                                                                                         | 5                                                                                                                                                                                                 | ( 0.7)                                                                                                                                                                                            | 0                                                                                                                                                                                                 |
| Infusion related reaction                                                                                                                                                   | 66 ( 8.4)                                              | 11 (             | 1.4)             | 0                | 30 ( 3.9)                                                                                                                                                                                         | 5                                                                                                                                                                                                 | ( 0.7)                                                                                                                                                                                            | 0                                                                                                                                                                                                 |
| Immune system disorders                                                                                                                                                     | 73 ( 9.3)                                              | 9                | ( 1.2)           | 0                | 27 ( 3.5)                                                                                                                                                                                         | 6                                                                                                                                                                                                 | ( 0.8)                                                                                                                                                                                            | 0                                                                                                                                                                                                 |
| Hypersensitivity                                                                                                                                                            | 48 ( 6.1)                                              | 4                | ( 0.5)           | 0                | 10 ( 1.3)                                                                                                                                                                                         | 2                                                                                                                                                                                                 | ( 0.3)                                                                                                                                                                                            | 0                                                                                                                                                                                                 |

------------------------------------------------------------------------------------------------------------------------------------MedDRA Version: 23.0. CTC Version 4.0. Includes events reported between first dose and 30 days after last dose of study therapy.

Source: Table S.6.1.32.3

<div style=\"page-break-after: always\"></div>

## Potential overlapping AEs

The potential overlapping AEs of nivolumab and chemotherapy, such as gastrointestinal, respiratory, skin and liver toxicities, that were numerically higher in the nivo+chemo arm compared with the chemo arm, as well as nivolumab monotherapy, suggest potentially additive toxicity of the two drugs when used in combination. The most frequently reported potential overlapping AEs (regardless of causality) were the following:

- Nivo+chemo: nausea (47.6%), diarrhoea (39.4%), fatigue (32.9%), vomiting (31.3%), increased aspartate aminotransferase (20.1%), increased alanine aminotransferase (14.3%), palmar-plantar erythrodysaesthesia  syndrome  (13.2%),  increased  blood  alkaline  phosphatase  (12.9%),  rash (11.0%),  increased  blood  bilirubin  (9.7%),  pruritis  (9.3%),  stomatitis  (8.2%),  and  pneumonia (5.8%).
- Chemo:  nausea  (43.5%),  diarrhoea  (33.6%),  vomiting  (28.8%),  fatigue  (28.6%),  increased aspartate  aminotransferase  (12.5%),  palmar-plantar  erythrodysaesthesia  syndrome  (11.7%), increased alanine aminotransferase (9.4%), blood alkaline phosphatase (7.6%), stomatitis (6.6%), increased blood bilirubin (6.4%), pneumonia (4.2%), rash (2.6%), and pruritis (2.0%).

The most frequently reported potential overlapping drug-related AEs were the following:

- Nivo+chemo: nausea (41.3%), diarrhoea (32.4%), fatigue (25.8%), vomiting (24.9%), increased aspartate  aminotransferase  (15.6%),  palmar-plantar  erythrodysaesthesia  syndrome  (12.0%), increased alanine aminotransferase (11.4%), rash (9.5%), stomatitis (7.3%), pruritis (6.9%), blood alkaline phosphatase (6.6%), increased blood bilirubin (6.1%), and pneumonitis (4.5%).
- Chemo: nausea (38.1%), diarrhoea (26.9%), fatigue (22.6%), vomiting (21.6%), palmar-plantar erythrodysaesthesia syndrome (10.6%), increased aspartate aminotransferase (9.0%), increased alanine aminotransferase (6.5%), stomatitis (6.1%), blood alkaline phosphatase (4.4%), increased blood bilirubin (4.2%), rash (1.6%), pruritis (1.0%), and pneumonitis (0.3%).

## Exposure-adjusted adverse events rates

When the AE occurrences were exposure-adjusted, AE incidence rates (per 100 person-year [P-Y]) were 2273.3 with nivo+chemo treatment and 2139.1 with chemo treatment. The most frequently reported exposure adjusted AEs (all causality) for both the nivo+chemo and chemo arms were within the SOC of gastrointestinal disorders (475.5/100 P-Y for nivo+chemo vs. 533.3/100 P-Y for chemo). Nausea was the most frequently reported PT (116.0/100 P-Y for nivo+chemo vs. 128.4/100 P-Y for chemo).

When the drug-related AE occurrences were exposure-adjusted, drug-related AE incidence rates (per 100 P-Y) were 1368.0 with nivo+chemo treatment and 1305.2 for chemo treatment. In the nivo+chemo arm,  the  most  frequently  reported  exposure  adjusted  drug-related  AEs  were  within  the  SOC  of investigations with decreased neutrophil count as the most frequently reported PT (64.5/100 P-Y). In the chemotherapy arm, the most frequently reported exposure adjusted drug-related AEs were within the SOC of gastrointestinal disorders with nausea as the most frequently reported PT (110.6/100 P-Y).

## Select adverse events

In order to characterize AEs of special clinical interest that are potentially associated with the use of nivolumab, the MAH identified select AEs based on the following 4 guiding principles:

- AEs that may differ in type, frequency, or severity from AEs caused by non-immunotherapies
- AEs that may require immunosuppression (e.g., corticosteroids) as part of their management
- AEs whose early recognition and management may mitigate severe toxicity

<div style=\"page-break-after: always\"></div>

- AEs for which multiple event terms may be used to describe a single type of AE, thereby necessitating the pooling of terms for full characterization

Based on these guiding principles and taking into account the types of AEs already observed across studies of nivolumab monotherapy, endocrinopathies, diarrhoea/colitis, hepatitis, pneumonitis, interstitial nephritis, and rash are currently considered to be select AEs. Multiple event terms that may describe each of these were grouped into endocrine, gastrointestinal (GI), hepatic, pulmonary, renal, and skin select AE categories, respectively. Hypersensitivity/infusion reactions were analysed along with the select AE categories, because multiple event terms may be used to describe such events and pooling of terms was, therefore, necessary for full characterisation. Hypersensitivity/infusion reactions do not otherwise meet criteria to be considered select AEs.

The majority of select AEs were Grade 1-2 and most select AEs were considered drug-related by the investigator. The most frequently reported drug-related select AE categories (any grade) were as follows in each treatment arm (Table 30):

- Nivo+chemo: gastrointestinal (33.5%), skin (27.4%) and hepatic (26.0%).
- Chemo: gastrointestinal (27.0%), hepatic (17.5%), and skin (13.7%).

The most frequently reported drug-related select AEs by preferred term (any grade) were as follows in each treatment arm:

- Nivo+chemo: diarrhoea (32.4%), increased AST (15.6%), and palmar-plantar erythrodysaesthesia syndrome (12.0%).
- Chemo: diarrhoea (26.9%), palmar-plantar erythrodysaesthesia syndrome (10.6%), and increased AST (9.0%).

The most frequently reported drug-related serious select AEs by preferred term (any grade) were as follows in each treatment arm:

- Nivo+chemo: diarrhoea (2.2%), pneumonitis (2.2%), and infusion related reaction (0.8%).
- Chemo: diarrhoea (1.3%).

Across the select AE categories, the majority of events in the nivo+chemo arm were manageable using the  established  algorithms,  with  resolution  occurring  when  immune-modulating  medications  (mainly systemic corticosteroids) were administered (Table 33). Most drug-related select AEs with nivo+chemo had resolved (ranging from 43.0% to 98.2% across categories) at the time of database lock. The median time to resolution ranged from 0.14 to 23.43 weeks for select AEs. Some endocrine select AEs were not considered resolved due to the continuing need for hormone replacement therapy.

<div style=\"page-break-after: always\"></div>

Table 33. Onset, Management, and Resolution of Drug-Related Select AEs - Nivolumab + Chemotherapy Treated Subjects (N = 782)

| Category                            | %Treated Subj. with Any Grade/ Grade 3-4 Drug- related Select AE   | Median Time to Onset of Drug- related Select AE (range), wks   |   %Treated Subj. with Drug-related Select AE Leading to DC | %Subj. with Drug- Related Select AE Treated with IMM/ High-dose Corticosteroids a   | Median Time b to Resolution of Drug- related Select AE (range), wks c,d,e   |   %Subj. with Drug-related Select AE that Resolved d , e |
|-------------------------------------|--------------------------------------------------------------------|----------------------------------------------------------------|------------------------------------------------------------|-------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|----------------------------------------------------------|
| Endocrine                           | 13.7 / 0.6                                                         | 15.00 (2.0 - 124.3)                                            |                                                        0.4 | 12.1 / 5.6                                                                          | 72.14 (0.4 - 139.1+)                                                        |                                                     43   |
| Gastrointestinal                    | 33.5 / 5.5                                                         | 4.29 (0.1 - 93.6)                                              |                                                        2.8 | 10.7 / 8.0                                                                          | 1.57 (0.1 - 117.6+)                                                         |                                                     87.4 |
| Hepatic                             | 26.0 / 3.7                                                         | 7.86 (0.1 - 61.3)                                              |                                                        1.2 | 11.3 / 8.9                                                                          | 10.14 (0.4 - 150.6+)                                                        |                                                     78   |
| Pulmonary                           | 5.1 / 1.8                                                          | 23.93 (1.6 - 96.9)                                             |                                                        1.9 | 77.5 / 65.0                                                                         | 10.14 (0.3+ - 121.3+)                                                       |                                                     70   |
| Renal                               | 3.3 / 0.8                                                          | 12.36 (1.7 - 59.4)                                             |                                                        1.2 | 23.1 / 15.4                                                                         | 3.14 (0.1 - 42.4+)                                                          |                                                     73.1 |
| Skin                                | 27.4 / 3.3                                                         | 9.64 (0.1 - 97.4)                                              |                                                        1.4 | 39.3 / 6.5                                                                          | 23.43 (0.1 - 153.6+)                                                        |                                                     57.9 |
| Hypersensitivity/ Infusion Reaction | 14.2 / 2.2                                                         | 10.43 (0.1 - 84.0)                                             |                                                        3.3 | 37.8 / 23.4                                                                         | 0.14 (0.1 - 47.9+)                                                          |                                                     98.2 |

<div style=\"page-break-after: always\"></div>

## Immune-mediated adverse events

IMAE analyses included events, regardless of causality, occurring within 100 days of the last dose (i.e., with  extended  follow-up).  These  analyses  included  IMAE  categories  (diarrhoea/colitis,  hepatitis, pneumonitis, nephritis and renal dysfunction, rash, hypersensitivity/infusion reactions, and endocrine) with PTs describing specific events regardless of causality. These analyses were limited to subjects who received immune-modulating medication for treatment of the event, with the exception of endocrine events,  which  were  included  in  the  analysis  regardless  of  treatment  since  these  events  are  often managed without immunosuppression. In addition, these events were identified by the investigator as IMAEs with no clear alternate etiology and an immune mediated component.

Overall, the majority of IMAEs were Grade 1-2. The most frequently reported IMAEs (any grade) by category were as follows in each treatment arm (Table 30):

- Nivo+chemo: hypothyroidism/thyroiditis (9.5%), rash (6.5%), and pneumonitis (4.2%).
- -Of the treated subjects who experienced non-endocrine IMAEs, a higher frequency of Grade 3-4 IMAEs was observed in the following categories: hepatitis (13/19 subjects), diarrhoea/colitis (17/26  subjects),  nephritis  and  renal  dysfunction  (2/4  subjects)  and  pneumonitis  (15/33 subjects).
- -Of the treated subjects who experienced endocrine IMAEs; a higher frequency of Grade 3-4 IMAEs was observed in hypophysitis (3/6 subjects) and diabetes mellitus (1/2 subjects).
- Chemo: hypothyroidism/thyroiditis (0.8%) and rash (0.5%).

Across IMAE categories, the majority of events were manageable using the established management algorithms, with resolution occurring when immune-modulating medications (mostly systemic corticosteroids)  were  administered  (Table  34).  Except  for  some  endocrine  events,  most  IMAEs  with nivo+chemo treatment had resolved at the time of DBL. Some endocrine IMAEs were not considered resolved due to the continuing need for hormone replacement therapy (Table 34).

Re-challenge  information  was  also  summarized  for  subjects  who  continued  to  receive  nivolumab treatment after the onset of an IMAE (Table 34). A re-challenge was considered as an unsuccessful or positive  re-challenge  if,  after  resolution  of  the  IMAE,  a  new  IMAE  of  the  same  type  occurred  with re-treatment of study drug. A re-challenge was considered as a successful or negative re-challenge if, after resolution of the IMAE, no new IMAEs of the same type occurred with re-treatment.

<div style=\"page-break-after: always\"></div>

Table 34. Onset, Management, and Resolution of All-Causality IMAEs within 100 days of Last Dose - Nivolumab + Chemotherapy Treated Subjects (N = 782)

| IMAE Category               | %Subj. with Any Grade/ Grade 3-4 IMAEs   | Median Time to IMAE Onset (range), wks   | %Subj. with IMAE leading to DC / Dose Delay   | %Subj. with IMAEs Receiving IMM/ High-dose Corticosteroids a   | Median Duration IMM (range), wks   |   %Subj. with Resolution of IMAE d,e | Median b Time to Resolution (range), wks c,d,e   | %Subj. with Recurrence after Reinitiation   |
|-----------------------------|------------------------------------------|------------------------------------------|-----------------------------------------------|----------------------------------------------------------------|------------------------------------|--------------------------------------|--------------------------------------------------|---------------------------------------------|
| Pneumonitis                 | 4.2 / 1.9                                | 25.43 (4.4 - 98.6)                       | 1.8 / 2.0                                     | 100 / 84.8                                                     | 9.29 (0.1 - 94.1)                  |                                 63.6 | 14.86 (0.3+ - 66.6+)                             | 28.6 (2 / 7)                                |
| Diarrhea/Colitis            | 3.3 / 2.2                                | 11.29 (1.6 - 59.1)                       | 2.0 / 1.5                                     | 100 / 69.2                                                     | 6.71 (0.3 - 63.9)                  |                                 84.6 | 4.57 (0.6 - 52.0+)                               | 33.3 (1 / 3)                                |
| Hepatitis                   | 2.4 / 1.7                                | 8.43 (2.1 - 48.0)                        | 0.8 / 1.2                                     | 100 / 78.9                                                     | 6.14 (0.1 - 100.6)                 |                                 89.5 | 8.00 (1.0 - 36.1+)                               | 42.9 (3 / 7)                                |
| Nephritis/Renal Dysfunction | 0.5 / 0.3                                | 14.71 (4.4 - 26.1)                       | 0.4 / 0.4                                     | 100 / 50                                                       | 11.43 (6.1 - 14.4)                 |                                 75   | 12.07 (1.1 - 26.4+)                              | 50.0 (1 / 2)                                |
| Rash                        | 6.5 / 1.4                                | 8.14 (0.1 - 91.3)                        | 0.1 / 1.3                                     | 100 / 23.5                                                     | 7.14 (0.4 - 97.0)                  |                                 78.4 | 7.00 (0.7 - 135.9+)                              | 42.9 (3 / 7)                                |
| Hypersensitivity            | 0.8 / 0.1                                | 3.64 (0.1 - 23.3)                        | 0.1 / 0                                       | 100 / 83.3                                                     | 0.21 (0.1 - 6.0)                   |                                100   | 0.14 (0.1 - 8.0)                                 | N.A.                                        |
| Adrenal Insufficiency       | 0.6 / 0.1                                | 40.86 (15.0 - 57.4)                      | 0 / 0.1                                       | 60 / 0                                                         | 35.86 (15.1 - 41.0)                |                                 20   | N.A. (1.4 - 52.9+)                               | 0 (0 / 0)                                   |
| Hypophysitis                | 0.8 / 0.4                                | 32.86 (16.9 - 49.3)                      | 0 / 0.5                                       | 83.3 / 33.3                                                    | 24.57 (4.7 - 63.1)                 |                                 66.7 | 6.93. (0.4 - 61.9+)                              | 0 (0 / 3)                                   |
| Hypothyroidism/ Thyroiditis | 9.5 / 0                                  | 17.57 (2.0 - 57.9)                       | 0.3 / 0.9                                     | 5.4 / 5.4                                                      | 4.64 (0.4 - 5.1)                   |                                 36.5 | N.A. (1.4 - 139.1+)                              | 0 (0 / 2)                                   |
| Hyperthyroidism             | 2.9 / 0                                  | 11.86 (3.3 - 46.3)                       | 0 / 0.3                                       | 4.3 / 0                                                        | 16.00 (16.0 - 16.0)                |                                 78.3 | 10.00 (1.0 - 68.1+)                              | N.A.                                        |
| Diabetes Mellitus           | 0.3 / 0.1                                | 29.64 (15.9 - 43.4)                      | 0 / 0                                         | 50 / 0                                                         | 0.43 (0.4 - 0.4)                   |                                  0   | N.A. (62.7+ - 88.0+)                             | N.A.                                        |

<div style=\"page-break-after: always\"></div>

- b From Kaplan-Meier estimation.
- c Symbol + indicates a censored value.
- d Subjects who experienced IMAE without worsening from baseline grade were excluded from time to resolution analysis.
- e Events without a stop date or with a stop date equal to the death as well as grade 5 events are considered unresolved.

Abbreviations: DC - discontinuation, IMAE - immune-mediated adverse events, IMM - immune-modulating medication, N.A. - not available/not applicable, subj. - subjects, wks weeks

Source: Table S.6.202.13 (endocrine IMAEs), Table S.6.202.14 (endocrine IMAEs leading to DC), Table S.6.202.15 (endocrine IMAEs leading to dose delay/reduction), Table S.6.202.16 (non-endocrine IMAEs), Table S.6.202.17 (non-endocrine IMAEs leading to DC), Table S.6.202.18 (non-endocrine IMAEs leading to dose delay/reduction), Table S.6.12.91.3 (duration of IMM for IMAE management), Table S.6.217.5 (time to onset of endocrine IMAEs), Table S.6.217.6 (time to onset of non-endocrine IMAEs), Table S.6.219.5 (time to resolution of endocrine IMAEs), Table S.6.219.6 (time to resolution of non-endocrine IMAEs), Table S.6.223.3 (re-challenge with nivolumab). These outputs also include Grade 3-5 and chemotherapy results.

<div style=\"page-break-after: always\"></div>

## Other events of special interest (OESIs)

OESIs are events that do not fulfill all criteria to qualify as IMAEs. These events may differ from those caused  by  non-immunotherapies and may require immunosuppression as part of their management. Analyses  of  OESIs  had  extended  follow-up  (100-day  window);  and  OESIs  included  the  following categories: demyelination, Guillain-Barré syndrome, myasthenic syndrome, pancreatitis, uveitis, encephalitis, myocarditis, graft versus host disease, and myositis/rhabdomyolysis. OESIs (regardless of causality or IMM treatment) with extended follow-up are summarized by category in Table 30 .

OESIs (regardless  of  causality  or  IMM  treatment,  with  extended  follow-up)  were  infrequent  in  both treatment arms (Table 30 and Table 35). Overall, OESIs were reported in 8/782 (1.0%) subjects (10 events) in the nivo+chemo arm and 4/767 (0.5%) subjects (5 events) in the chemo arm. 9/10 OESIs in the nivo+chemo arm and 4/5 OESIs in the chemo arm were resolved at the time of database lock (Table 35).  7/10  and  1/5  OESIs  were  resolved  with  IMM  treatment  in  the  nivo+chemo  and  chemo  arms, respectively.

<div style=\"page-break-after: always\"></div>

Table 35. Treatment, Onset, and Resolution Information for Other Events of Special Interest by Subject -All Treated Subjects

| Event Description                                   | Immune-modulating Medication                             | Onset Date (Study Day)   | Duration of Event (Days)   | Resolution (Yes/No)   |
|-----------------------------------------------------|----------------------------------------------------------|--------------------------|----------------------------|-----------------------|
| Nivo+Chemo                                          |                                                          |                          |                            |                       |
| Guillain-Barre syndrome                             |                                                          |                          |                            |                       |
| Grade 3 drug-related SAE of Guillain-Barre syndrome | meprednisone, gamma globulin, prednisone, hydrocortisone | 13-Sep-2018 (35)         | 35                         | Yes                   |
| Pancreatitis                                        |                                                          |                          |                            |                       |
| Grade 4 drug-related SAE of pancreatitis            | hydrocortisone, dexamethasone                            | 12-Jul-2019 (463)        | 9                          | Yes                   |
| Grade 3 drug-related SAE of acute pancreatitis      | None                                                     | 29-Mar-2018 (78)         | 9                          | Yes                   |
| Grade 2 drug-related AE of autoimmune pancreatitis  | prednisolone                                             | 15-Feb-2018 (53)         | 34                         | Yes                   |
| Grade 1 drug-related AE of autoimmune pancreatitis  | prednisolone                                             | 20-Mar-2018 (86)         | 59                         | Yes                   |
| Uveitis                                             |                                                          |                          |                            |                       |
| Grade 3 drug-related SAE of chorioretinitis         | methylprednisolone                                       | 18-Apr-2018 (59)         | 4                          | Yes                   |
| Encephalitis                                        |                                                          |                          |                            |                       |
| Grade 3 SAE of encephalitis                         | prednisolone, methylprednisolone, dexamethasone          | 15-Jun-2018 (179)        | ongoing                    | No                    |
| Myocarditis                                         |                                                          |                          |                            |                       |
| Grade 1 drug-related AE of myocarditis              | methylprednisolone, prednisolone                         | 13-Dec-2018 (56)         | 110                        | Yes                   |
| Grade 1 AE of myocarditis                           | none                                                     | 02-Apr-2019 (166)        | 22                         | Yes                   |
| Grade 3 drug-related SAE of autoimmune myocarditis  | methylprednisolone, prednisolone                         | 04-Oct-2019 (376)        | 12                         | Yes                   |
| Chemo                                               |                                                          |                          |                            |                       |
| Pancreatitis                                        |                                                          |                          |                            |                       |
| Grade 2 drug-related SAE of acute pancreatitis      | none                                                     | 19-Aug-2018 (4)          | 5                          | Yes                   |
| Grade 3 AE of pancreatitis                          | none                                                     | 01-Aug-2019 (85)         | 11                         | Yes                   |
| Myositis/Rhabdomyolysis                             |                                                          |                          |                            |                       |
| Grade 3 SAE of myositis                             | none                                                     | 14-Mar-2019 (24)         | ongoing                    | No                    |
| Grade 1 AE of myositis                              | none                                                     | May-2019 (N.A.)          | 107                        | Yes                   |
| Grade 3 SAE of myositis                             | prednisolone                                             | 16-Aug-2019 (354)        | 4                          | Yes                   |

Abbreviations: N.A. - not available

Source: Appendix 6.83.1 (by-subject listing, OESIs, immune-modulating medication), Appendix 6.1.1.1 (seriousness, duration of event), Appendix 6.1.1 (duration of event)

<div style=\"page-break-after: always\"></div>

## Serious adverse event and deaths

## Serious adverse events

The  overall  frequencies  of  SAEs  (all-causality  and  drug-related)  were  numerically  higher  with nivo+chemo than with chemo (Table 30, Table 36, Table 37).

Any Grade SAEs (regardless of causality) were reported in 423 (54.1%) subjects in the nivo+chemo arm vs. 335 (43.7%) subjects in the chemo arm. Grade 3-4 SAEs were reported in 281 (35.9%) subjects in the nivo+chemo arm and 229 (29.9%) subjects in the chemo arm.

The most frequently reported SAEs (regardless of causality) were:

- Nivo+chemo: malignant neoplasm progression (13.9%), vomiting (3.2%), and anaemia (3.1%).
- Chemo: malignant neoplasm progression (11.7%), vomiting (3.1%), and dysphagia (2.1%).

Any-grade drug-related SAEs were reported in 172 (22.0%) subjects in the nivo+chemo arm, and 93 (12.1%) subjects in the chemo arm. Grade 3-4 drug-related SAEs were reported in 131 (16.8%) subjects in the nivo+chemo arm, and 77 (10.0%) subjects in the chemo arm.

The most frequently reported drug-related SAEs were:

- Nivo+chemo: diarrhoea (2.2%), pneumonitis (2.2%), and febrile neutropaenia (2.0%).
- Chemo: vomiting (2.3%), diarrhoea (1.3%), and decreased appetite (1.0%).

<div style=\"page-break-after: always\"></div>

Table 36 . Serious Adverse Events Reported in ≥ 2% of All Treated Subjects

|                                                                     | Nivo+Chemo N = 782                                     | Nivo+Chemo N = 782                                     | Nivo+Chemo N = 782   | Nivo+Chemo N = 782   | Nivo+Chemo N = 782   | Nivo+Chemo N = 782   | ------------------------------------------------------------------------------------------------------------------------------------ Chemo N = 767   | ------------------------------------------------------------------------------------------------------------------------------------ Chemo N = 767   | ------------------------------------------------------------------------------------------------------------------------------------ Chemo N = 767                                          | ------------------------------------------------------------------------------------------------------------------------------------ Chemo N = 767                                          | ------------------------------------------------------------------------------------------------------------------------------------ Chemo N = 767   | ------------------------------------------------------------------------------------------------------------------------------------ Chemo N = 767   |
|---------------------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|----------------------|----------------------|----------------------|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|
| System Organ Class (%) Preferred Term (%)                           | -------------------------------------------- Any Grade | -------------------------------------------- Any Grade | Grade                | 3-4                  | Grade                | 5                    | Any Grade                                                                                                                                            | Any Grade                                                                                                                                            | -------------------------------------------- Grade 3-4 ------------------------------------------------------------------------------------------------------------------------------------ | -------------------------------------------- Grade 3-4 ------------------------------------------------------------------------------------------------------------------------------------ | Grade 5                                                                                                                                              | Grade 5                                                                                                                                              |
| TOTAL SUBJECTS WITH AN EVENT                                        | 423                                                    | ( 54.1)                                                | 281                  | ( 35.9)              | 81 (                 | 10.4)                | 335                                                                                                                                                  | ( 43.7)                                                                                                                                              | 229                                                                                                                                                                                         | ( 29.9)                                                                                                                                                                                     | 63 (                                                                                                                                                 | 8.2)                                                                                                                                                 |
| Gastrointestinal disorders                                          | 133 (                                                  | 17.0)                                                  | 103                  | ( 13.2)              | 3 (                  | 0.4)                 | 123                                                                                                                                                  | ( 16.0)                                                                                                                                              | 100                                                                                                                                                                                         | ( 13.0)                                                                                                                                                                                     | 0                                                                                                                                                    |                                                                                                                                                      |
| Vomiting                                                            | 25 (                                                   | 3.2)                                                   | 17 (                 | 2.2)                 | 0                    |                      | 24                                                                                                                                                   | ( 3.1)                                                                                                                                               | 19 (                                                                                                                                                                                        | 2.5)                                                                                                                                                                                        | 0                                                                                                                                                    |                                                                                                                                                      |
| Diarrhoea                                                           | 19                                                     | ( 2.4)                                                 | 14 (                 | 1.8)                 | 0                    |                      | 12 (                                                                                                                                                 | 1.6)                                                                                                                                                 | 9 (                                                                                                                                                                                         | 1.2)                                                                                                                                                                                        | 0                                                                                                                                                    |                                                                                                                                                      |
| Dysphagia                                                           | 10                                                     | ( 1.3)                                                 | 9                    | ( 1.2)               | 0                    |                      | 16 (                                                                                                                                                 | 2.1)                                                                                                                                                 | 15 (                                                                                                                                                                                        | 2.0)                                                                                                                                                                                        | 0                                                                                                                                                    |                                                                                                                                                      |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 123                                                    | ( 15.7)                                                | 55 (                 | 7.0)                 | 60 (                 | 7.7)                 | 100                                                                                                                                                  | ( 13.0)                                                                                                                                              | 39 (                                                                                                                                                                                        | 5.1)                                                                                                                                                                                        | 51 (                                                                                                                                                 | 6.6)                                                                                                                                                 |
| Malignant neoplasm progression                                      | 109                                                    | ( 13.9)                                                | 45 (                 | 5.8)                 | 60 (                 | 7.7)                 | 90 (                                                                                                                                                 | 11.7)                                                                                                                                                | 33 (                                                                                                                                                                                        | 4.3)                                                                                                                                                                                        | 51 (                                                                                                                                                 | 6.6)                                                                                                                                                 |
| Infections and infestations                                         | 72                                                     | ( 9.2)                                                 | 53 (                 | 6.8)                 | 4 (                  | 0.5)                 | 33 (                                                                                                                                                 | 4.3)                                                                                                                                                 | 28 (                                                                                                                                                                                        | 3.7)                                                                                                                                                                                        | 0                                                                                                                                                    |                                                                                                                                                      |
| Pneumonia                                                           | 22                                                     | ( 2.8)                                                 | 16 (                 | 2.0)                 | 2 (                  | 0.3)                 | 10 (                                                                                                                                                 | 1.3)                                                                                                                                                 | 9 (                                                                                                                                                                                         | 1.2)                                                                                                                                                                                        | 0                                                                                                                                                    |                                                                                                                                                      |
| Blood and lymphatic system disorders                                | 52                                                     | ( 6.6)                                                 | 42 (                 | 5.4)                 | 2 (                  | 0.3)                 | 24 (                                                                                                                                                 | 3.1)                                                                                                                                                 | 22 (                                                                                                                                                                                        | 2.9)                                                                                                                                                                                        | 0                                                                                                                                                    |                                                                                                                                                      |
| Anaemia                                                             | 24                                                     | ( 3.1)                                                 | 18 (                 | 2.3)                 | 0                    |                      | 9 (                                                                                                                                                  | 1.2)                                                                                                                                                 | 8 (                                                                                                                                                                                         | 1.0)                                                                                                                                                                                        | 0                                                                                                                                                    |                                                                                                                                                      |
| Febrile neutropenia                                                 | 18                                                     | ( 2.3)                                                 | 16 (                 | 2.0)                 | 1 (                  | 0.1)                 | 7 (                                                                                                                                                  | 0.9)                                                                                                                                                 | 7 (                                                                                                                                                                                         | 0.9)                                                                                                                                                                                        | 0                                                                                                                                                    |                                                                                                                                                      |
| Respiratory, thoracic and mediastinal disorders                     | 45                                                     | ( 5.8)                                                 | 27 (                 | 3.5)                 | 3 (                  | 0.4)                 | 29 (                                                                                                                                                 | 3.8)                                                                                                                                                 | 19 (                                                                                                                                                                                        | 2.5)                                                                                                                                                                                        | 2 (                                                                                                                                                  | 0.3)                                                                                                                                                 |
| Pneumonitis                                                         | 17                                                     | ( 2.2)                                                 | 11                   | ( 1.4)               | 0                    |                      | 1 (                                                                                                                                                  | 0.1)                                                                                                                                                 | 0                                                                                                                                                                                           |                                                                                                                                                                                             | 0                                                                                                                                                    |                                                                                                                                                      |
| General disorders and administration site conditions                | 40 (                                                   | 5.1)                                                   | 19 (                 | 2.4)                 | 2 (                  | 0.3)                 | 30 (                                                                                                                                                 | 3.9)                                                                                                                                                 | 15 (                                                                                                                                                                                        | 2.0)                                                                                                                                                                                        | 2 (                                                                                                                                                  | 0.3)                                                                                                                                                 |
| Pyrexia                                                             | 20                                                     | ( 2.6)                                                 | 5 (                  | 0.6)                 | 0                    |                      | 10 (                                                                                                                                                 | 1.3)                                                                                                                                                 | 3 (                                                                                                                                                                                         | 0.4)                                                                                                                                                                                        | 0                                                                                                                                                    |                                                                                                                                                      |

------------------------------------------------------------------------------------------------------------------------------------

MedDRA Version: 23.0. CTC Version 4.0. Includes events reported between first dose and 30 days after last dose of study therapy.

Source: Table S.6.3.1.2.5

<div style=\"page-break-after: always\"></div>

Table 37. DrugRelated Serious Adverse Events Reported in ≥ 1% of All Treated Subjects

|                                                                                                                                                                   | Nivo+Chemo N   | Nivo+Chemo N   | Nivo+Chemo N                                           | Nivo+Chemo N                                           | Nivo+Chemo N   | ------------------------------------------------------------------------------------------------------------------------------------   | ------------------------------------------------------------------------------------------------------------------------------------   | ------------------------------------------------------------------------------------------------------------------------------------   | ------------------------------------------------------------------------------------------------------------------------------------   | ------------------------------------------------------------------------------------------------------------------------------------   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|----------------|--------------------------------------------------------|--------------------------------------------------------|----------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|
| 782 System Organ Class (%) Preferred Term (%)                                                                                                                     | Any Grade      | Any Grade      | -------------------------------------------- Grade 3-4 | -------------------------------------------- Grade 3-4 | Grade 5        | Any                                                                                                                                    | Any                                                                                                                                    | N -------------------------------------------- Grade Grade 3-4                                                                         | = 767                                                                                                                                  | Grade 5                                                                                                                                |
| ------------------------------------------------------------------------------------------------------------------------------------ TOTAL SUBJECTS WITH AN EVENT | 172 (          | 22.0)          | 131 (                                                  | 16.8)                                                  | 4 ( 0.5)       | 93 (                                                                                                                                   | 12.1)                                                                                                                                  | 77 (                                                                                                                                   | 10.0)                                                                                                                                  | 0                                                                                                                                      |
| Gastrointestinal disorders                                                                                                                                        | 56 (           | 7.2)           | 39 (                                                   | 5.0)                                                   | 1 (            | 0.1) 44                                                                                                                                | ( 5.7)                                                                                                                                 | 36                                                                                                                                     | ( 4.7)                                                                                                                                 | 0                                                                                                                                      |
| Diarrhoea                                                                                                                                                         | 17 (           | 2.2)           | 13 (                                                   | 1.7)                                                   | 0              |                                                                                                                                        | 1.3)                                                                                                                                   |                                                                                                                                        | ( 1.0)                                                                                                                                 | 0                                                                                                                                      |
| Vomiting                                                                                                                                                          | 12 (           | 1.5)           | 7 (                                                    | 0.9)                                                   | 0              | 10 18                                                                                                                                  | ( ( 2.3)                                                                                                                               | 8 14                                                                                                                                   | ( 1.8)                                                                                                                                 | 0                                                                                                                                      |
| Blood and lymphatic system disorders                                                                                                                              | 36 (           | 4.6)           | 32 (                                                   | 4.1)                                                   | 1 (            | 0.1) 16                                                                                                                                | ( 2.1)                                                                                                                                 | 14                                                                                                                                     | ( 1.8)                                                                                                                                 | 0                                                                                                                                      |
| Febrile neutropenia                                                                                                                                               | 16 (           | 2.0)           | 14                                                     | 1.8)                                                   | 1 (            | 0.1) 6                                                                                                                                 | ( 0.8)                                                                                                                                 | 6                                                                                                                                      | ( 0.8)                                                                                                                                 | 0                                                                                                                                      |
| Anaemia                                                                                                                                                           | 11 (           | 1.4)           | 10                                                     | ( ( 1.3)                                               | 0              | 4                                                                                                                                      | ( 0.5)                                                                                                                                 | 3 (                                                                                                                                    | 0.4)                                                                                                                                   | 0                                                                                                                                      |
| Respiratory, thoracic and mediastinal disorders                                                                                                                   | 20 (           | 2.6)           | 13                                                     | ( 1.7)                                                 | 0              | 6                                                                                                                                      | ( 0.8)                                                                                                                                 | 2                                                                                                                                      | ( 0.3)                                                                                                                                 | 0                                                                                                                                      |
| Pneumonitis                                                                                                                                                       | 17 (           | 2.2)           | 11                                                     | ( 1.4)                                                 | 0              | 0                                                                                                                                      |                                                                                                                                        | 0                                                                                                                                      |                                                                                                                                        | 0                                                                                                                                      |
| General disorders and administration site conditions                                                                                                              | 12 (           | 1.5)           | 7                                                      | ( 0.9)                                                 | 0              | 14                                                                                                                                     | ( 1.8)                                                                                                                                 | 8 (                                                                                                                                    | 1.0)                                                                                                                                   | 0                                                                                                                                      |
| Pyrexia                                                                                                                                                           | 8 (            | 1.0)           | 3                                                      | ( 0.4)                                                 | 0              | 3                                                                                                                                      | ( 0.4)                                                                                                                                 | 1 (                                                                                                                                    | 0.1)                                                                                                                                   | 0                                                                                                                                      |
| Metabolism and nutrition disorders                                                                                                                                | 5 (            | 1.4)           | 5                                                      | ( 1.4)                                                 | 0              | 5                                                                                                                                      | ( 1.4)                                                                                                                                 | 5                                                                                                                                      | ( 1.4)                                                                                                                                 | 0                                                                                                                                      |
| Decreased appetite                                                                                                                                                | 3 (            | 0.4)           | 3                                                      | ( 0.4)                                                 | 0              | 8                                                                                                                                      | ( 1.0)                                                                                                                                 | 8                                                                                                                                      | ( 1.0)                                                                                                                                 | 0                                                                                                                                      |

------------------------------------------------------------------------------------------------------------------------------------

MedDRA Version: 23.0. CTC Version 4.0. Includes events reported between first dose and 30 days after last dose of study therapy.

Source: Table S.6.3.1.2.6

<div style=\"page-break-after: always\"></div>

## Deaths

As of the 10-Jul-2020 database lock, the number of treated subjects who died in the nivo+chemo arm was numerically lower vs. the chemo arm (Table 38). Disease progression was the most common cause of death in both arms.

Note that only events that led to death within 24 hours were documented as Grade 5. Events leading to death &gt; 24 hours after onset are reported with the grade at presentation.

Table 38. Death Summary - All Treated Subjects

| ----------------------------------------------------------------------------------------------   |   Nivo+Chemo N = 782 ---------------------------------------------------------------------------------------------- | Nivo+Chemo N = 782 ----------------------------------------------------------------------------------------------   |   Chemo N = 767 | Chemo N = 767   |
|--------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|-----------------|-----------------|
| NUMBER OF SUBJECTS WHO DIED (%) PRIMARY REASON FOR DEATH (%)                                     |                                                                                                                 538 | ( 68.8)                                                                                                             |             572 | ( 74.6)         |
| DISEASE                                                                                          |                                                                                                                 465 | ( 59.5)                                                                                                             |             506 | ( 66.0)         |
| STUDY DRUG TOXICITY                                                                              |                                                                                                                  12 | ( 1.5)                                                                                                              |               4 | ( 0.5)          |
| UNKNOWN                                                                                          |                                                                                                                  12 | ( 1.5)                                                                                                              |              18 | ( 2.3)          |
| OTHER                                                                                            |                                                                                                                  49 | ( 6.3)                                                                                                              |              44 | ( 5.7)          |
| NUMBER OF SUBJECTS WHO DIED WITHIN 30 DAYS OF LAST DOSE (%) PRIMARY REASON FOR DEATH (%)         |                                                                                                                 103 | ( 13.2)                                                                                                             |              89 | ( 11.6)         |
| DISEASE                                                                                          |                                                                                                                  67 | ( 8.6)                                                                                                              |              62 | ( 8.1)          |
| STUDY DRUG TOXICITY                                                                              |                                                                                                                  10 | ( 1.3)                                                                                                              |               4 | ( 0.5)          |
| UNKNOWN                                                                                          |                                                                                                                   3 | ( 0.4)                                                                                                              |               1 | ( 0.1)          |
| OTHER                                                                                            |                                                                                                                  23 | ( 2.9)                                                                                                              |              22 | ( 2.9)          |
| NUMBER OF SUBJECTS WHO DIED WITHIN 100 DAYS OF LAST DOSE (%) PRIMARY REASON FOR DEATH (%)        |                                                                                                                 291 | ( 37.2)                                                                                                             |             266 | ( 34.7)         |
| DISEASE                                                                                          |                                                                                                                 236 | ( 30.2)                                                                                                             |             222 | ( 28.9)         |
| STUDY DRUG TOXICITY                                                                              |                                                                                                                  12 | ( 1.5)                                                                                                              |               4 | ( 0.5)          |
| UNKNOWN                                                                                          |                                                                                                                   4 | ( 0.5)                                                                                                              |               2 | ( 0.3)          |
| OTHER                                                                                            |                                                                                                                  39 | ( 5.0)                                                                                                              |              38 | ( 5.0)          |

----------------------------------------------------------------------------------------------

Source: Table S.6.15.3

## Deaths attributed to study drug toxicity

Death attributed to study drug toxicity was reported in 12 (1.5%) and 4 (0.5%) treated subjects in the nivo+chemo and chemo arms, respectively (Table 38). Per Investigator assessment in the nivo+chemo arm, 3 deaths were due to nivolumab, 2 deaths were due to nivolumab and chemotherapy, and 7 deaths were due to chemotherapy:

- The causes of death due to nivolumab were pulmonitis, intertistial lung disease and pneumonitis.
- The causes of death due to nivolumab and chemotherapy were infection and gastrointestinal toxicity.
- The causes of death due to chemotherapy were neutropaenic fever, intestinal mucositis, stroke, gastrointestinal bleeding, septic shock, pneumonia, and febrile neutropaenia.

Details of deaths due to study drug toxicity are presented below (Table 39).

<div style=\"page-break-after: always\"></div>

Table 39. Study Drug Toxicity Deaths - All Treated Subjects

------------------------------------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------------------------------------

| Randomization Date   | First Dose Date   | Last Dose Date   | Death Date   | Days Since Last Dose   | Cause of Death (AE/SAE)              | Agent with Suspected Causal Relationship                                                                                             |
|----------------------|-------------------|------------------|--------------|------------------------|--------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|
| Nivo+chemo Arm       |                   |                  |              |                        |                                      | ------------------------------------------------------------------------------------------------------------------------------------ |
| 04FEB2019            | 04FEB2019         | 16FEB2019        | 22FEB2019    | 7                      | NEUTRPENIC FEVER                     | OXALIPLATIN, CAPECITABINE                                                                                                            |
| 02OCT2017            | 03OCT2017         | 15OCT2017        | 23OCT2017    | 9                      | INTESTINAL MUCOSITIS                 | CAPECITABINE                                                                                                                         |
| 16OCT2017            | 17OCT2017         | 31OCT2017        | 03NOV2017    | 4                      | STROKE                               | CAPECITABINE                                                                                                                         |
| 07JUN2018            | 07JUN2018         | 13SEP2018        | 13DEC2018    | 92                     | INFECTION                            | NIVOLUMAB, OXALIPLATIN, CAPECITABINE                                                                                                 |
| 08AUG2017            | 08AUG2017         | 11SEP2017        | 25SEP2017    | 15                     | GASTROINTESTINAL BLEEDING            | OXALIPLATIN, CAPECITABINE                                                                                                            |
| 30NOV2018            | 30NOV2018         | 21DEC2018        | 05JAN2019    | 16                     | SEPTIC SHOCK                         | CAPECITABINE                                                                                                                         |
| 14AUG2018            | 15AUG2018         | 07DEC2018        | 22DEC2018    | 16                     | PNEUMONIA                            | OXALIPLATIN, FLUOROURACIL, LEUCOVORIN                                                                                                |
| 04JUL2017            | 06JUL2017         | 21OCT2017        | 20NOV2017    | 31                     | PULMONITIS                           | NIVOLUMAB                                                                                                                            |
| 21AUG2018            | 22AUG2018         | 16NOV2018        | 14DEC2018    | 29                     | INTERTISTIAL LUNG DISEASE            | NIVOLUMAB                                                                                                                            |
| 13FEB2018            | 14FEB2018         | 06JUL2018        | 22SEP2018    | 79                     | PNEUMONITIS                          | NIVOLUMAB                                                                                                                            |
| 30OCT2017            | 30OCT2017         | 30OCT2017        | 09NOV2017    | 11                     | FEBRILE NEUTROPENIA                  | OXALIPLATIN, FLUOROURACIL                                                                                                            |
| 12DEC2018            | 17DEC2018         | 19APR2019        | 07MAY2019    | 19                     | GASTROINTESTINAL TOXICITY            | NIVOLUMAB, OXALIPLATIN, FLUOROURACIL, LEUCOVORIN                                                                                     |
| Chemo Arm            |                   |                  |              |                        |                                      |                                                                                                                                      |
| 06JUL2017            | 06JUL2017         | 13JUL2017        | 02AUG2017    | 21                     | PULMONARY TROMBOEMBOLISM             | OXALIPLATIN                                                                                                                          |
| 03APR2019            | 04APR2019         | 27JUN2019        | 12JUL2019    | 16                     | ASTHENIA and HIPOREXY SEVERE         | OXALIPLATIN, CAPECITABINE                                                                                                            |
| 26APR2018            | 27APR2018         | 28APR2018        | 10MAY2018    | 13                     | STUDY DRUG TOXICITY WITH DIARRHEA    | OXALIPLATIN, CAPECITABINE                                                                                                            |
| 11DEC2018            | 12DEC2018         | 02APR2019        | 24APR2019    | 23                     | ADVERSE EVENT INTERSTICIAL PNEUMONIA | OXALIPLATIN, FLUOROURACIL, LEUCOVORIN                                                                                                |

Deaths may be captured on death, AE, ECOG performance status, status, and follow-up CRF pages. The primary source of death date is the death CRF. If the date is missing, the death date reported on the adverse event case report form is reported. Abbreviations: AE = adverse event; SAE = serious adverse event. Source: Table S.6.15.3, Appendix 6.16.1.

<div style=\"page-break-after: always\"></div>

## Deaths attributed to other reasons

Deaths attributed to other reasons were reported in 49 (6.3%) and 44 (5.7%) of treated subjects in the nivo+chemo and chemo arms, respectively (Table 38). There were 4 events reported as 'related' per investigator: thrombosis mesenteric vessel, disseminated intravascular coagulation, cerebral infarction and pneumonitis. All 4 subjects were in the nivo+chemo arm. Per investigator, the pneumonitis was reported as related to nivolumab and the other 3 events were reported as related to both nivolumab and chemotherapy (Table 40 below)

Table 40. Deaths Attributed to Other Reasons

| ------------------------------------------------------------------------------------------------------------------------------------ Randomization Date   | First Dose Date                                                                                                                                     | Last Dose Date                                                                                                                                      | Death Date                                                                                                                                          | Days Since Last Dose                                                                                                                                | Cause of Death                                                                                                                                      | Specify                                                                                                                                             |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
| ------------------------------------------------------------------------------------------------------------------------------------ Nivo+chemo Arm       | ------------------------------------------------------------------------------------------------------------------------------------ Nivo+chemo Arm | ------------------------------------------------------------------------------------------------------------------------------------ Nivo+chemo Arm | ------------------------------------------------------------------------------------------------------------------------------------ Nivo+chemo Arm | ------------------------------------------------------------------------------------------------------------------------------------ Nivo+chemo Arm | ------------------------------------------------------------------------------------------------------------------------------------ Nivo+chemo Arm | ------------------------------------------------------------------------------------------------------------------------------------ Nivo+chemo Arm |
| 04DEC2018                                                                                                                                                 | 05DEC2018                                                                                                                                           | 26FEB2019                                                                                                                                           | 27FEB2019                                                                                                                                           | 2                                                                                                                                                   | OTHER                                                                                                                                               | THE CAUSE OF DEATH OF THE PATIENT WAS CONSIDERED TO BE MESENTERIC THROMBOSIS                                                                        |
| 04APR2019                                                                                                                                                 | 04APR2019                                                                                                                                           | 17SEP2019                                                                                                                                           | 19OCT2019                                                                                                                                           | 33                                                                                                                                                  | OTHER DISSEMINATED INTRAVASCULAR COAGULATION                                                                                                        | IT HAS RELATED TO STUDY DRUG TOXICITY, IT HAS RELATED TO DISEASES                                                                                   |
| 13APR2018                                                                                                                                                 | 13APR2018                                                                                                                                           | 11SEP2019                                                                                                                                           | 26SEP2019                                                                                                                                           | 16                                                                                                                                                  | OTHER                                                                                                                                               | ACUTE CEREBRAL INFARCTION                                                                                                                           |
| 16APR2019                                                                                                                                                 | 17APR2019                                                                                                                                           | 24OCT2019                                                                                                                                           | 01DEC2019                                                                                                                                           | 39                                                                                                                                                  | OTHER                                                                                                                                               | PNEUMONITIS                                                                                                                                         |

------------------------------------------------------------------------------------------------------------------------------------

Deaths may be captured on death, AE, ECOG performance status, status, and follow-up CRF pages. The primary source of death date is the death CRF. If the date is missing, the death date reported on the adverse event case report form is reported.

Source: Appendix 6.16.1

<div style=\"page-break-after: always\"></div>

## Laboratory findings

A summary of clinical laboratory parameters that worsened relative to baseline is presented in Table 41.

## Haematology

Abnormalities in haematology tests performed during treatment or within 30 days of last dose of study drug were primarily Grade 1-2. Grade 3 or 4 haematologic abnormalities reported in ≥ 5% of subjects were as follows (Table 41):

- Nivo+chemo:  decreased  absolute  neutrophil  count  (29.3%),  decreased  haemoglobin  (13.9%), decreased absolute lymphocytes (12.2%), decreased leukocytes (11.8%), and decreased platelet count (6.8%)
- Chemo: decreased absolute neutrophil count (22.8%), decreased haemoglobin (9.5%), decreased absolute lymphocytes (9.2%), and decreased leukocytes (9.0%)

## Serum chemistry

## Liver tests

During the treatment period, abnormalities in hepatic parameters (all increases) were primarily Grade 12. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) increases were reported more frequently with nivo+chemo (37.0% and 51.7%, respectively) compared with chemo (29.5% and 47.5%, respectively) (Table 41).

Based on laboratory results reported after the first dose and within 30 days of last dose of study therapy, 13/764 (1.7%) subjects in the nivo+chemo arm had concurrent ALT or AST &gt; 3 × upper limit of normal (ULN) with total bilirubin &gt; 2 × ULN within 1 or 30 days, while 6/737 (0.8%) and 7/737 (0.9%) subjects in the chemo arm had concurrent ALT or AST &gt; 3 × ULN with total bilirubin &gt; 2 × ULN within 1 day and within 30 days, respectively (Table 42).

There were 13 subjects in the nivo+chemo arm and 7 subjects in the chemo arm with concurrent ALT or AST &gt;3×ULN with total bilirubin &gt;2×ULN).

In the nivo+chemo arm:

- In 3 subjects, the abnormal hepatic laboratory findings were reported as related to nivolumab alone or to both nivolumab and chemotherapy.
- -All 3 subjects were treated with high dose immune-modulating medication (IMM) and improved after treatment. This improvement supported the etiology as immune-mediated.
- -In  1  of  the  3  subjects,  the  abnormal  hepatic  laboratory  findings  led  to  study  treatment discontinuation.
- In  10  subjects,  the  abnormal  hepatic  laboratory  findings  were  reported  as  not-related  to  study treatment, and other etiologies were implicated.
- -In 6 subjects, abnormal hepatic laboratory findings were due to disease progression with liver or pancreatic metastasis (new lesions or increased existing lesions).
- -In 4 subjects, abnormal hepatic laboratory findings were due to biliary duct stone or biliary duct infections.

In the chemo arm:

- In 2 subjects, abnormal hepatic laboratory findings were reported as related to chemotherapy.

<div style=\"page-break-after: always\"></div>

- -In both subjects, the abnormal hepatic laboratory findings led to study treatment discontinuation.
- In  5  subjects,  abnormal  hepatic  laboratory  findings  were  due  to  disease  progression  with  liver metastasis (new lesions or existing lesion increased).

## Kidney function tests

Most  subjects  with  at  least  1 on-treatment  measurement  had  normal  creatinine  values  during  the treatment reporting period. The abnormalities in creatinine (increased) were primarily reported as Grade 1 or 2. Grade 3-4 increased creatinine level was reported in 8 (1.0%) subjects in the nivo+chemo arm and 4 (0.5%) subjects in the chemo arm (Table 41).

## Thyroid function tests

Thyroid-stimulating hormone (TSH) increases (&gt; ULN) from baseline ( ≤ ULN) were reported in 158/709 (22.3%) subjects in the nivo+chemo arm, and 8/146 (5.5%) subjects in the chemo arm. Decreases (&lt; lower limit of normal [LLN]) from baseline (&gt;= LLN) were reported in 104/709 (14.7%) subjects in the nivo+chemo arm, and 2/146 (1.4%) subjects in the chemo arm (Table 43).

## Electrolytes

Most  subjects  had  normal  electrolyte  levels  during  the  treatment  reporting  period.  Abnormalities  in electrolytes  during  treatment  were  primarily  Grade  1  to  2  in  severity.  The  following  Grade  3  or  4 abnormalities in electrolytes were observed in ≥ 5% of treated subjects with on-treatment laboratory results (Table 41):

- Nivo+chemo: hypokalaemia (6.5%), hyponatraemia (6.3%)
- Chemo: hyponatraemia (5.5%)

<div style=\"page-break-after: always\"></div>

Table 49. Summary of On-Treatment Worst CTC Grade (Grade 1-4 and Grade 3-4) Laboratory Parameters that Worsened Relative to Baseline with 30 Days Follow Up - (SI Conventional Units) - All Treated Subjects

------------------------------------------------------------------------------------------------------------------------------------

|                                                                                                                                                           | Number of Subjects (%)   | Number of Subjects (%)   | Number of Subjects (%)   | Number of Subjects (%)                                   | Number of Subjects (%)                                   | Number of Subjects (%)   | Number of Subjects (%)                                         | Number of Subjects (%)                                         | Number of Subjects (%)   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|--------------------------|--------------------------|----------------------------------------------------------|----------------------------------------------------------|--------------------------|----------------------------------------------------------------|----------------------------------------------------------------|--------------------------|
| Lab Test Description ------------------------------------------------------------------------------------------------------------------------------------ | N(A)                     | Grade                    | 1-4                      | Chemo ---------------------------------------- Grade 3-4 | Chemo ---------------------------------------- Grade 3-4 | N(A)                     | Chemo ---------------------------------------- Grade 1-4 Grade | Chemo ---------------------------------------- Grade 1-4 Grade | 3-4                      |
| HEMOGLOBIN (B)                                                                                                                                            | 765                      | 450                      | ( 58.8)                  | 106 (                                                    | 13.9)                                                    | 735                      | 439 ( 59.7)                                                    | 70 (                                                           | 9.5)                     |
| PLATELET COUNT                                                                                                                                            | 762                      | 515                      | ( 67.6)                  | 52 (                                                     | 6.8)                                                     | 732                      | 458 ( 62.6)                                                    | 32 (                                                           | 4.4)                     |
| LEUKOCYTES                                                                                                                                                | 764                      | 524                      | ( 68.6)                  | 90 (                                                     | 11.8)                                                    | 733                      | 433 ( 59.1)                                                    | 66 (                                                           | 9.0)                     |
| LYMPHOCYTES (ABSOLUTE)                                                                                                                                    | 763                      | 446                      | ( 58.5)                  | 93 (                                                     | 12.2)                                                    | 732                      | 361 ( 49.3)                                                    | 67 (                                                           | 9.2)                     |
| ABSOLUTE NEUTROPHIL COUNT                                                                                                                                 | 764                      | 556                      | ( 72.8)                  | 224 (                                                    | 29.3)                                                    | 732                      | 456 ( 62.3)                                                    | 167 (                                                          | 22.8)                    |
| ASPARTATE AMINOTRANSFERASE                                                                                                                                | 764                      | 395                      | ( 51.7)                  | 35 (                                                     | 4.6)                                                     | 731                      | 347 ( 47.5)                                                    | 14 (                                                           | 1.9)                     |
| ALANINE AMINOTRANSFERASE                                                                                                                                  | 764                      | 283                      | ( 37.0)                  | 26 (                                                     | 3.4)                                                     | 731                      | 216 ( 29.5)                                                    | 14 (                                                           | 1.9)                     |
| BILIRUBIN, TOTAL                                                                                                                                          | 761                      | 182                      | ( 23.9)                  | 23 (                                                     | 3.0)                                                     | 732                      | 163 ( 22.3)                                                    | 15 (                                                           | 2.0)                     |
| CREATININE                                                                                                                                                | 765                      | 115                      | ( 15.0)                  | 8 (                                                      | 1.0)                                                     | 735                      | 67 ( 9.1)                                                      | 4 (                                                            | 0.5)                     |
| HYPERNATREMIA                                                                                                                                             | 767                      | 84                       | ( 11.0)                  | 4 (                                                      | 0.5)                                                     | 733                      | 52 ( 7.1)                                                      | 0                                                              |                          |
| HYPONATREMIA                                                                                                                                              | 767                      | 258                      | ( 33.6)                  | 48 (                                                     | 6.3)                                                     | 733                      | 177 ( 24.1)                                                    | 40 (                                                           | 5.5)                     |
| HYPERKALEMIA                                                                                                                                              | 766                      | 110                      | ( 14.4)                  | 11 (                                                     | 1.4)                                                     | 733                      | 77 ( 10.5)                                                     | 5 (                                                            | 0.7)                     |
| HYPOKALEMIA                                                                                                                                               | 766                      | 203                      | ( 26.5)                  | 50 (                                                     | 6.5)                                                     | 733                      | 177 ( 24.1)                                                    | 35 (                                                           | 4.8)                     |
| HYPERCALCEMIA                                                                                                                                             | 748                      | 46                       | ( 6.1)                   | 2 (                                                      | 0.3)                                                     | 725                      | 41 ( 5.7)                                                      | 1 (                                                            | 0.1)                     |
| HYPOCALCEMIA                                                                                                                                              | 748                      | 326                      | ( 43.6)                  | 12 (                                                     | 1.6)                                                     | 725                      | 271 ( 37.4)                                                    | 7 (                                                            | 1.0)                     |
| HYPERGLYCEMIA                                                                                                                                             | 408                      | 166                      | ( 40.7)                  | 17 (                                                     | 4.2)                                                     | 407                      | 155 ( 38.1)                                                    | 11 (                                                           | 2.7)                     |
| HYPOGLYCEMIA                                                                                                                                              | 407                      | 48                       | ( 11.8)                  | 3 (                                                      | 0.7)                                                     | 405                      | 37 ( 9.1)                                                      | 1 (                                                            | 0.2)                     |

Toxicity Scale: CTC version 4.0

Includes laboratory results reported between first dose and last dose of therapy + 30 days

(A) N: Subjects with a CTC Graded Laboratory Result for the given parameter from both Baseline and On-treatment. Percentages are based on N as denominator.

(B) Per Anemia criteria in CTC version 4.0 there is no grade 4 for hemoglobin. Source: Appendix GA.USPI.6.6

------------------------------------------------------------------------------------------------------------------------------------

<div style=\"page-break-after: always\"></div>

Table 102. On-Treatment Laboratory Abnormalities in Specific Liver Tests (SI Units) - All Treated Subjects

-----------------------------------------------------------------------------------------------

BILIRUBIN &gt; 2XULN WITHIN ONE DAY

BILIRUBIN &gt; 2XULN WITHIN 30 DAYS

| Abnormality                                                                                               | Nivo    | +                                                                                                           | Chemo N = 767       | Total N = 1549        |
|-----------------------------------------------------------------------------------------------------------|---------|-------------------------------------------------------------------------------------------------------------|---------------------|-----------------------|
| (%)                                                                                                       | N       | Chemo = 782 ----------------------------------------------------------------------------------------------- |                     |                       |
|                                                                                                           | N       | = 766                                                                                                       | N = 737             | N = 1503              |
| ALT OR AST > 3XULN                                                                                        | 107 ( ( | 14.0) 5.5)                                                                                                  | 55 ( 7.5) 18 ( 2.4) | 162 ( 10.8) 60 ( 4.0) |
| ALT OR AST > 5XULN ALT OR AST > 10XULN                                                                    | 42 13 ( | 1.7)                                                                                                        | 2 ( 0.3)            | 15 ( 1.0)             |
| ALT OR AST > 20XULN                                                                                       | 3 (     | 0.4)                                                                                                        | 1 ( 0.1)            | 4 ( 0.3)              |
|                                                                                                           | N       | = 764                                                                                                       | N = 737             | N = 1501              |
| TOTAL BILIRUBIN > 2XULN                                                                                   | 39      | ( 5.1)                                                                                                      | 41 ( 5.6)           | 80 ( 5.3)             |
| CONCURRENT ALT OR AST ELEVATION > 3XULN WITH TOTAL BILIRUBIN > 2XULN WITHIN ONE DAY CONCURRENT ALT OR AST | 13      | ( 1.7)                                                                                                      | 6 ( 0.8)            | 19 ( 1.3)             |
| ELEVATION > 3XULN WITH TOTAL BILIRUBIN > 2XULN WITHIN 30 DAYS                                             | 13      | ( 1.7)                                                                                                      | 7 ( 0.9)            | 20 ( 1.3)             |

-----------------------------------------------------------------------------------------------Includes laboratory results reported after the first dose and within 30 days of last dose of study therapy. Denominator corresponds to subjects with at least one on-treatment measurement of the corresponding laboratory parameter

Source: Table S.7.6.4 [SI units]

<div style=\"page-break-after: always\"></div>

Table 43. On-Treatment Laboratory Abnormalities in Specific Thyroid Tests (SI Units) - All Treated Subjects With At Least One On-Treatment TSH Measurement

-----------------------------------------------------------------------------------------------

TSH &gt; ULN

TSH &gt; ULN

TSH &lt; LLN

TSH &lt; LLN

WITH FT3/FT4 TEST MISSING (A)(B) 17 (  2.4)                1 (  0.7)               18 (  2.1)

| Abnormality (%)                                                       |   Nivo + N = | Chemo 709   |       | Chemo N = 146   |   N = ----------------------------------------------------------------------------------------------- | Total 855   |
|-----------------------------------------------------------------------|--------------|-------------|-------|-----------------|-------------------------------------------------------------------------------------------------------|-------------|
| TSH > ULN                                                             |          222 | ( 31.3)     | 25    | ( 17.1)         |                                                                                                   247 | ( 28.9)     |
| TSH > ULN WITH TSH <= ULN AT BASELINE                                 |          158 | ( 22.3)     |       | 8 ( 5.5)        |                                                                                                   166 | ( 19.4)     |
| TSH > ULN WITH AT LEAST ONE FT3/FT4 TEST VALUE < LLN (A)              |          111 | ( 15.7)     | 12    | ( 8.2)          |                                                                                                   123 | ( 14.4)     |
| WITH ALL OTHER FT3/FT4 TEST VALUES >= LLN (A) WITH FT3/FT4            |           84 | ( 11.8)     | 8     | ( 5.5)          |                                                                                                    92 | ( 10.8)     |
| TEST MISSING (A)(B)                                                   |           27 | ( 3.8)      | 5     | ( 3.4)          |                                                                                                    32 | ( 3.7)      |
| TSH < LLN                                                             |          119 | ( 16.8)     | 6     | ( 4.1)          |                                                                                                   125 | ( 14.6)     |
| TSH < LLN WITH TSH >= LLN AT BASELINE TSH < LLN                       |          104 | (           | 14.7) | 2 ( 1.4)        |                                                                                                   106 | ( 12.4)     |
| WITH AT LEAST ONE FT3/FT4 TEST VALUE > ULN (A) WITH ALL OTHER FT3/FT4 |           45 | (           | 6.3)  | 3 ( 2.1)        |                                                                                                    48 | ( 5.6)      |
| TEST VALUES <= ULN (A)                                                |           57 | (           | 8.0)  | 2 ( 1.4)        |                                                                                                    59 | 6.9)        |
| WITH FT3/FT4 TEST MISSING (A)(B)                                      |           17 | (           | 2.4)  | 1 ( 0.7)        |                                                                                                    18 | ( ( 2.1)    |

-----------------------------------------------------------------------------------------------Includes laboratory results reported after the first dose and within 30 days of last dose of study therapy.

(B) Includes subjects with TSH abnormality and with no FT3/FT4 test values in the 2-week window or with non-abnormal value(s) from only one of the two tests and no value from the other test.

(A) Within a 2-week window after the abnormal TSH test date.

Source: Table S.7.6.3 [SI units]

<div style=\"page-break-after: always\"></div>

## Pregnancy tests

All pregnancy tests were negative during the study.

## Vital signs and physical findings

Vital  signs  and  oxygen  saturation  by  pulse  oximetry  were  monitored  and  recorded  at  the  site  per institutional standard of care during screening and treatment visits. These assessments were intended to  be  used  as  safety  monitoring  by  the  treating  physician.     Any  clinically  meaningful  safety  events related to these vital signs were captured and reported as adverse events (AEs) or serious adverse events (SAEs) (Table 30). There was a higher frequency of vital sign related AEs and SAEs in nivo+chemo vs. chemo treated subjects, consistent with the entire safety profile; however, overall these events were infrequent. The majority of events in both treatment arms were Grade 1-2, and Grade 3-4 events were rare. There was 1 drug-related Grade 5 febrile neutropenia event reported in the nivo+chemo arm, as well as 2 Grade 5 arrhythmia events (1 in each treatment arm) that were unrelated to study treatment.

<div style=\"page-break-after: always\"></div>

Table 44. Summary of Adverse Events Related to Vital Signs - All Treated Subjects from CA209649 (10-Jul-2020 Database Lock)

|                     | No. of Subjects (%)   | No. of Subjects (%)   | No. of Subjects (%)   | No. of Subjects (%)   |
|---------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| Safety Parameters   | Nivo+Chemo (N =782)   | Nivo+Chemo (N =782)   | Chemo (N =767)        | Chemo (N =767)        |
|                     | Adverse Event Grades  | Adverse Event Grades  | Adverse Event Grades  | Adverse Event Grades  |
|                     | Any Grade             | Grade 3-4             | Any Grade             | Grade 3-4             |
| All-causality SAEs  |                       |                       |                       |                       |
| Pyrexia             | 20 (2.6)              | 5 (0.6)               | 10 (1.3)              | 3 (0.4)               |
| Febrile neutropenia | 18 (2.3)              | 16 (2.0)              | 7 (0.9)               | 7 (0.9)               |
| Hypotension         | 1 (0.1)               | 1 (0.1)               | 0                     | 0                     |
| Arrhythmia          | 1 (0.1)               | 0                     | 1 (0.1)               | 0                     |
| Tachycardia         | 1 (0.1)               | 0                     | 1 (0.1)               | 0                     |
| Drug-related SAEs   |                       |                       |                       |                       |
| Febrile neutropenia | 16 (2.0)              | 14 (1.8)              | 6 (0.8)               | 6 (0.8)               |
| Pyrexia             | 8 (1.0)               | 3 (0.4)               | 3 (0.4)               | 1 (0.1)               |
| All-causality AEs   |                       |                       |                       |                       |
| Pyrexia             | 147 (18.8)            | 8 (1.0)               | 83 (10.8)             | 3 (0.4)               |
| Hypertension        | 41 (5.2)              | 19 (2.4)              | 32 (4.2)              | 11 (1.4)              |
| Hypotension         | 24 (3.1)              | 4 (0.5)               | 15 (2.0)              | 1 (0.1)               |
| Febrile neutropenia | 22 (2.8)              | 19 (2.4)              | 11 (1.4)              | 11 (1.4)              |
| Chills              | 16 (2.0)              | 0                     | 12 (1.6)              | 0                     |
| Tachycardia         | 12 (1.5)              | 0                     | 6 (0.8)               | 0                     |
| Bradycardia         | 1 (0.1)               | 0                     | 3 (0.4)               | 0                     |
| Arrhythmia          | 1 (0.1)               | 0                     | 1 (0.1)               | 0                     |
| Drug-related AEs    |                       |                       |                       |                       |
| Pyrexia             | 64 (8.2)              | 4 (0.5)               | 22 (2.9)              | 1 (0.1)               |
| Febrile neutropenia | 20 (2.6)              | 17 (2.2)              | 9 (1.2)               | 9 (1.2)               |
| Hypertension        | 9 (1.2)               | 5 (0.6)               | 5 (0.7)               | 2 (0.3)               |
| Chills              | 5 (0.6)               | 0                     | 4 (0.5)               | 0                     |
| Hypotension         | 4 (0.5)               | 0                     | 2 (0.3)               | 0                     |
| Tachycardia         | 3 (0.4)               | 0                     | 1 (0.1)               | 0                     |
| Bradycardia         | 1 (0.1)               | 0                     | 0                     | 0                     |

MedDRA Version: 23.0; CTC Version 4.0. Includes events reported between first dose and 30 days after last dose of study therapy.

Source: Refer to Table S.6.1.1.1 (All-causality AEs), Table S.6.1.32.3 (Drug-related AEs),

Table S.6.3.1.2.5 (All-causality SAEs), and Table S.6.3.1.2.6 (Drug-related SAEs) of the CA209649 Primary CSR

## Safety in special populations

## Intrinsic and extrinsic factors

The  frequencies  of  drug-related  AEs  in  the  nivo+chemo  arm  for  subgroups  of  age,  gender,  race, geographic region are shown in Table 45. The following differences were observed:

<div style=\"page-break-after: always\"></div>

- Among all nivo+chemo treated subjects, the frequencies of drug-related Grade 3-4 AEs in the US (includes US and Canada) (72.1%) appeared to be higher than those in other regions (Asia [54.2%] and ROW [57.4%) and also higher compared with the all-treated population (59.1%).
- -Of note, drug-related Grade 3-4 AEs in the nivo+chemo arm were higher with nivo+FOLFOX (67.8%) compared with nivo+XELOX (48.9%) and drug-related Grade 3-4 AEs in the chemo arm were higher with FOLFOX (49.5%) compared with XELOX (38.8%). Most treated subjects from the US and Canada received FOLFOX: 92.2% (119/129) of subjects in the nivo+chemo arm and 91.1% (113/124) of subjects in the chemo arm.
- In both treatment arms, the frequencies of Grade 3-4 drug-related AEs appeared to be higher in female subjects compared with male subjects (67.5% vs. 55.2% in the nivo+chemo arm, 54.9% vs. 40.1% in the chemo arm).
- The frequencies of Grade 3-4 drug-related AEs in the nivo+chemo arm were numerically higher (with at least a 10% difference) compared with the chemo arm for the most of the subgroups of age, gender, race and geographic region; this is consistent with all treated subjects, where drug-related Grade 3-4 AEs were 14.6% higher with nivo+chemo vs. chemo.

<div style=\"page-break-after: always\"></div>

Table 45. Drug-Related Adverse Events by Worst CTC Grade and by Age, Gender, Race, Region, and Chemotherapy Backbone - All Treated Subjects (CA209649)

|                         | Drug-related Adverse Events (n/N [%])   | Drug-related Adverse Events (n/N [%])   | Drug-related Adverse Events (n/N [%])   | Drug-related Adverse Events (n/N [%])   | Drug-related Adverse Events (n/N [%])   | Drug-related Adverse Events (n/N [%])   |
|-------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|
|                         | Nivo+Chemo                              | Nivo+Chemo                              | Nivo+Chemo                              | Chemo                                   | Chemo                                   | Chemo                                   |
|                         | Any Grade                               | Grade 3-4                               | Grade 5 a                               | Any Grade                               | Grade 3-4                               | Grade 5 a                               |
| Total                   | 738/782 (94.4)                          | 462/782 (59.1)                          | 4/782 (0.5)                             | 679/767 (88.5)                          | 341/767 (44.5)                          | 0                                       |
| By Age (years)          |                                         |                                         |                                         |                                         |                                         |                                         |
| < 65                    | 445/470 (94.7)                          | 270/470 (57.4)                          | 1/470 (0.2)                             | 419/475 (88.2)                          | 208/475 (43.8)                          | 0                                       |
| ≥ 65                    | 293/312 (93.9)                          | 192/312 (61.5)                          | 3/312 (1.0)                             | 260/292 (89.0)                          | 133/292 (45.5)                          | 0                                       |
| ≥ 65 and < 75           | 219/235 (93.2)                          | 145/235 (61.7)                          | 2/235 (0.9)                             | 202/221 (91.4)                          | 98/221 (44.3)                           | 0                                       |
| ≥ 75                    | 74/77 (96.1)                            | 47/77 (61.0)                            | 1/77 (1.3)                              | 58/71 (81.7)                            | 35/71 (49.3)                            | 0                                       |
| ≥ 75 and < 85           | 72/75 (96.0)                            | 46/75 (61.3)                            | 1/75 (1.3)                              | 53/65 (81.5)                            | 33/65 (50.8)                            | 0                                       |
| ≥ 85                    | 2/2 (100.0)                             | 1/2 (50.0)                              | 0                                       | 5/6 (83.3)                              | 2/6 (33.3)                              | 0                                       |
| By Sex                  |                                         |                                         |                                         |                                         |                                         |                                         |
| Male                    | 499/533 (93.6)                          | 294/533 (55.2)                          | 3/533 (0.6)                             | 476/543 (87.7)                          | 218/543 (40.1)                          | 0                                       |
| Female                  | 239/249 (96.0)                          | 168/249 (67.5)                          | 1/249 (0.4)                             | 203/224 (90.6)                          | 123/224 (54.9)                          | 0                                       |
| By Race                 |                                         |                                         |                                         |                                         |                                         |                                         |
| White                   | 517/551 (93.8)                          | 332/551 (60.3)                          | 4/551 (0.7)                             | 449/523 (85.9)                          | 228/523 (43.6)                          | 0                                       |
| Asian (including China) | 182/185 (98.4)                          | 104/185 (56.2)                          | 0                                       | 174/183 (95.1)                          | 87/183 (47.5)                           | 0                                       |
| By Region               |                                         |                                         |                                         |                                         |                                         |                                         |
| North America           | 125/129 (96.9)                          | 93/129 (72.1)                           | 0                                       | 118/124 (95.2)                          | 63/124 (50.8)                           | 0                                       |
| Rest of the World       | 439/476 (92.2)                          | 273/476 (57.4)                          | 4/476 (0.8)                             | 396/469 (84.4)                          | 198/469 (42.2)                          | 0                                       |
| Asia (including         | 174/177 (98.3)                          | 96/177 (54.2)                           | 0                                       | 165/174 (94.8)                          | 80/174 (46.0)                           | 0                                       |
| By Chemo                |                                         |                                         |                                         |                                         |                                         |                                         |
| XELOX                   | 342/360 (95.0)                          | 176/360 (48.9)                          | 2/360 (0.6)                             | 314/361 (87.0)                          | 140/361 (38.8)                          | 0                                       |
| FOLFOX                  | 396/422 (93.8)                          | 286/422 (67.8)                          | 2/422 (0.5)                             | 365/406 ( 89.9)                         | 201/406 (49.5)                          | 0                                       |

MedDRA Version: 23.0; CTC Version 4.0; Includes events reported between first dose and 30 days after last dose of study therapy.

Database lock: 10-Jul-2020; Minimum follow-up was 12.1 months

Source: refer to Table S.6.1.32.3 (all treated), Table S.6.1.5.7 (age), Table S.6.1.5.5 (sex), Table S.6.1.5.6 (race),

Table S.6.1.5.8 (region), and Table S.6.1.7.2 (chemo) in the CA209649 Primary CSR)

The special population 'age groups' is discussed in more detail. The frequencies of all causality total AEs, AEs leading to discontinuation, and AEs by MedDRA High-level Group Term (HLGT)/SMQs/SOC by age group are presented for nivo+chemo and chemo treated subjects in Table 46.

The frequencies of all causality AEs for subgroups of age &lt; 65, 65 to 74, and 75 to 84 years were generally similar to the frequencies reported for the overall study population by treatment, with a few exceptions:

## · Nivo+chemo:

- -Numerically lower frequencies ( ≥ 10% difference) were reported in the 75 to 84 years of age subgroup vs. the overall population for total SAEs (41.3% vs. 54.1), SAEs with

<div style=\"page-break-after: always\"></div>

hospitalization/prolongation  (34.7%  vs.  46.9%),  and  anticholinergic  syndrome  (22.7%  vs. 35.8%).

- Chemo:
- -Numerically higher frequencies ( ≥ 10% difference) were reported in the 75 to 84 years of age subgroup vs. the overall population for SAEs with fatal (death) outcome (27.7% vs. 13.8%), and sum of postural hypotension, falls, blackouts, syncope, dizziness, ataxia, fractures (21.5% vs. 10.4%).

Interpretation is limited by the small number of subjects in the &gt; 85 years of age subgroup.

## Safety in subgroups by chemotherapy backbone

Safety data for all treated subjects by chemotherapy backbone (XELOX and FOLFOX) are presented in Table 47. The frequencies of any grade AEs (all causality) and drug-related AEs were generally similar between the nivo+chemo arm compared with the chemo arm regardless of the backbone chemotherapy (FOLFOX or XELOX); however numerically higher frequencies of Grade 3-4 AEs (all causality) and Grade 3-4 drug-related AEs were observed in the nivo+chemo arm compared with the chemo arm, regardless of the backbone chemotherapy (FOLFOX or XELOX). Also numerically higher frequencies of Grade 3-4 all causality  AEs  and  Grade  3-4  drug-related  AEs  were  observed  in  subjects  who  received  FOLFOX  as backbone chemotherapy compared with XELOX; this was observed in both the nivo+chemo and chemo arms. The frequencies of all causality and drug-related select AEs and IMAEs were generally similar between nivo+FOLFOX and nivo+XELOX.

## Safety in subjects with PDL1 CPS ≥ 5 and CPS ≥ 1

Safety data for all treated subjects with PDL1 CPS ≥ 5 in the nivo+chemo and the chemo arms were consistent with the safety data for all treated subjects.

With nivo+chemo treatment, the overall frequency of death was numerically higher for subjects with PD-L1 CPS &lt; 5 (73.9%) compared with subjects with PDL1 CPS ≥ 5 (65.2%). This difference was attributed mainly to disease progression, where the frequency was 65.0% in subjects with PD-L1 CPS &lt; 5 vs. 55.6% in subjects with PDL1 CPS ≥ 5. The frequency of death due to study drug toxicity for treated subjects in the nivo+chemo arm was comparable for subjects with PD-L1 CPS &lt; 5 (1.0%) and subjects with PDL1 CPS ≥ 5 (1.7%). The frequencies of AEs (all ca usality and drug-related), SAEs (all causality and drug-related), AEs leading to discontinuation (all causality and drug-related), select AEs, and OESI were comparable in subjects with PDL1 CPS ≥ 5 and PD -L1 CPS &lt; 5. The numerically higher frequencies of all causality and drug related SAEs and AEs leading to discontinuation that were observed with nivo+chemo vs. chemo in all treated subjects, were also observed in the PDL1 CPS ≥ 5 and &lt; 5 subgroups (with similar differences for nivo+chemo vs. chemo in the 2 subgroups).

Also for the subgroup with PDL1 CPS ≥ 1, safety data were consistent with the safety data for all treated subjects.

<div style=\"page-break-after: always\"></div>

Table 46. Summary of Safety Results by Age Group - All Treated Subjects

------------------------------------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------------------------------------

| MedDRA Terms (%)                                                                                            | ------------------------------------------------------------------------------------------------------------------------------------ Age Group (Years)   | ------------------------------------------------------------------------------------------------------------------------------------ Age Group (Years)   | ------------------------------------------------------------------------------------------------------------------------------------ Age Group (Years)   | ------------------------------------------------------------------------------------------------------------------------------------ Age Group (Years)   | ------------------------------------------------------------------------------------------------------------------------------------ Age Group (Years)   | ------------------------------------------------------------------------------------------------------------------------------------ Age Group (Years)   |
|-------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|
| MedDRA Terms (%)                                                                                            | < 65 N = 470                                                                                                                                             | 65-74 N =                                                                                                                                                | ---------------------------------------------------------- 235                                                                                           | 75-84 N = 75 ------------------------------------------------------------------------------------------------------------------------------------        | >= 85 N = 2                                                                                                                                              | Total = 782                                                                                                                                              |
| TOTAL SUBJECTS WITH AN EVENT                                                                                | 468 ( 99.6)                                                                                                                                              | 232 (                                                                                                                                                    | 98.7)                                                                                                                                                    | 74 ( 98.7)                                                                                                                                               | 2 (100.0)                                                                                                                                                | 776 ( 99.2)                                                                                                                                              |
| SERIOUS AE - TOTAL FATAL (DEATH) HOSPITALIZATION/PROLONGATION LIFE-THREATENING CANCER DISABILITY/INCAPACITY | 260 ( 55.3) 73 ( 15.5) 229 ( 48.7) 15 ( 3.2) 3 ( 0.6) 3 ( 0.6)                                                                                           | 131 ( 44 ( 111 ( 7 ( 1 ( 0                                                                                                                               | 55.7) 18.7) 47.2) 3.0) 0.4)                                                                                                                              | 31 ( 41.3) 11 ( 14.7) 26 ( 34.7) 2 ( 2.7) 0 0                                                                                                            | 1 ( 50.0) 0 1 ( 50.0) 0 0 0                                                                                                                              | 423 ( 54.1) 128 ( 16.4) 367 ( 46.9) 24 ( 3.1) 4 ( 0.5) 3 ( 0.4)                                                                                          |
| AE LEADING TO DISCONTINUATION                                                                               | 210 ( 44.7)                                                                                                                                              | 121                                                                                                                                                      | ( 51.5)                                                                                                                                                  | 39 ( 52.0)                                                                                                                                               | 1 ( 50.0)                                                                                                                                                | 371 ( 47.4)                                                                                                                                              |
| PSYCHIATRIC DISORDERS                                                                                       | 65 ( 13.8)                                                                                                                                               | 32                                                                                                                                                       | ( 13.6)                                                                                                                                                  | 11 ( 14.7)                                                                                                                                               | 0                                                                                                                                                        | 108 ( 13.8)                                                                                                                                              |
| NERVOUS SYSTEM DISORDERS                                                                                    | 313 ( 66.6)                                                                                                                                              | 151 (                                                                                                                                                    | 64.3)                                                                                                                                                    | 53 ( 70.7)                                                                                                                                               | 0                                                                                                                                                        | 517 ( 66.1)                                                                                                                                              |
| ACCIDENT AND INJURIES                                                                                       | 29 ( 6.2)                                                                                                                                                | 15 (                                                                                                                                                     | 6.4)                                                                                                                                                     | 8 ( 10.7)                                                                                                                                                | 1 ( 50.0)                                                                                                                                                | 53 ( 6.8)                                                                                                                                                |
| CARDIAC DISORDERS                                                                                           | 30 ( 6.4)                                                                                                                                                | 20                                                                                                                                                       | ( 8.5)                                                                                                                                                   | 6 ( 8.0)                                                                                                                                                 | 0                                                                                                                                                        | 56 ( 7.2)                                                                                                                                                |
| VASCULAR DISORDERS                                                                                          | 69 ( 14.7)                                                                                                                                               | 40 (                                                                                                                                                     | 17.0)                                                                                                                                                    | 17 ( 22.7)                                                                                                                                               | 1 ( 50.0)                                                                                                                                                | 127 ( 16.2)                                                                                                                                              |
| CEREBROVASCULAR DISORDERS                                                                                   | 7 ( 1.5)                                                                                                                                                 | 8 (                                                                                                                                                      | 3.4)                                                                                                                                                     | 3 ( 4.0)                                                                                                                                                 | 0                                                                                                                                                        | 18 ( 2.3)                                                                                                                                                |
| INFECTIONS AND INFESTATIONS                                                                                 | 161 ( 34.3)                                                                                                                                              | 99 (                                                                                                                                                     | 42.1)                                                                                                                                                    | 23 ( 30.7)                                                                                                                                               | 0                                                                                                                                                        | 283 ( 36.2)                                                                                                                                              |
| ANTICHOLINERGIC SYNDROME                                                                                    | 168 ( 35.7)                                                                                                                                              | 95 (                                                                                                                                                     | 40.4)                                                                                                                                                    | 17 ( 22.7)                                                                                                                                               | 0                                                                                                                                                        | 280 ( 35.8)                                                                                                                                              |
| QUALITY OF LIFE DECREASED                                                                                   | 0                                                                                                                                                        | 0                                                                                                                                                        |                                                                                                                                                          | 0                                                                                                                                                        | 0                                                                                                                                                        | 0                                                                                                                                                        |
| SUM OF POSTURAL HYPOTENSION, FALLS, BLACKOUTS, SYNCOPE, DIZZINESS, ATAXIA, FRACTURES                        | 45 ( 9.6)                                                                                                                                                | 31                                                                                                                                                       | ( 13.2)                                                                                                                                                  | 6 ( 8.0)                                                                                                                                                 | 1 ( 50.0)                                                                                                                                                | 83 ( 10.6)                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

------------------------------------------------------------------------------------------------------------------------------------

|                                                                                                             | ------------------------------------------------------------------------------------------------------------------------------------ Age Group (Years)   | ------------------------------------------------------------------------------------------------------------------------------------ Age Group (Years)   | ------------------------------------------------------------------------------------------------------------------------------------ Age Group (Years)   | ------------------------------------------------------------------------------------------------------------------------------------ Age Group (Years)   | ------------------------------------------------------------------------------------------------------------------------------------ Age Group (Years)   | ------------------------------------------------------------------------------------------------------------------------------------ Age Group (Years)   | ------------------------------------------------------------------------------------------------------------------------------------ Age Group (Years)   | ------------------------------------------------------------------------------------------------------------------------------------ Age Group (Years)   |
|-------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|
| MedDRA Terms (%)                                                                                            | < N =                                                                                                                                                    | ---------------------------------------------------------- 65 475                                                                                        | N =                                                                                                                                                      | 65-74 221                                                                                                                                                | 75-84 N = 65                                                                                                                                             | >= 85 N = 6                                                                                                                                              | N = ------------------------------------------------------------------------------------------------------------------------------------                 | Total 767                                                                                                                                                |
| TOTAL SUBJECTS WITH AN EVENT                                                                                | 466                                                                                                                                                      | ( 98.1)                                                                                                                                                  | 219                                                                                                                                                      | ( 99.1)                                                                                                                                                  | 61 ( 93.8)                                                                                                                                               | 6 (100.0)                                                                                                                                                | 752                                                                                                                                                      | ( 98.0)                                                                                                                                                  |
| SERIOUS AE - TOTAL FATAL (DEATH) HOSPITALIZATION/PROLONGATION LIFE-THREATENING CANCER DISABILITY/INCAPACITY | 202 55 175 11 3 0                                                                                                                                        | ( 42.5) ( 11.6) ( 36.8) ( 2.3) ( 0.6)                                                                                                                    | 96 ( 32 ( 78 ( 5 ( 1 ( 0                                                                                                                                 | 43.4) 14.5) 35.3) 2.3) 0.5)                                                                                                                              | 33 ( 50.8) 18 ( 27.7) 25 ( 38.5) 0 0 0                                                                                                                   | 4 ( 66.7) 1 ( 16.7) 3 ( 50.0) 0 0 0                                                                                                                      | 335 106 281 16 4 0                                                                                                                                       | ( 43.7) ( 13.8) ( 36.6) ( 2.1) ( 0.5)                                                                                                                    |
| AE LEADING TO DISCONTINUATION                                                                               | 142                                                                                                                                                      | ( 29.9)                                                                                                                                                  | 77 (                                                                                                                                                     | 34.8)                                                                                                                                                    | 29 ( 44.6)                                                                                                                                               | 3 ( 50.0)                                                                                                                                                | 251                                                                                                                                                      | ( 32.7)                                                                                                                                                  |
| PSYCHIATRIC DISORDERS                                                                                       | 64                                                                                                                                                       | ( 13.5)                                                                                                                                                  | 20 (                                                                                                                                                     | 9.0)                                                                                                                                                     | 6 ( 9.2)                                                                                                                                                 | 1 ( 16.7)                                                                                                                                                | 91                                                                                                                                                       | ( 11.9)                                                                                                                                                  |
| NERVOUS SYSTEM DISORDERS                                                                                    | 295                                                                                                                                                      | ( 62.1)                                                                                                                                                  | 132 (                                                                                                                                                    | 59.7)                                                                                                                                                    | 40 ( 61.5)                                                                                                                                               | 5 ( 83.3)                                                                                                                                                | 472                                                                                                                                                      | ( 61.5)                                                                                                                                                  |
| ACCIDENT AND INJURIES                                                                                       | 22 (                                                                                                                                                     | 4.6)                                                                                                                                                     | 20 (                                                                                                                                                     | 9.0)                                                                                                                                                     | 8 ( 12.3)                                                                                                                                                | 0                                                                                                                                                        | 50                                                                                                                                                       | ( 6.5)                                                                                                                                                   |
| CARDIAC DISORDERS                                                                                           | 26 (                                                                                                                                                     | 5.5)                                                                                                                                                     | 14 (                                                                                                                                                     | 6.3)                                                                                                                                                     | 2 ( 3.1)                                                                                                                                                 | 0                                                                                                                                                        | 42                                                                                                                                                       | ( 5.5)                                                                                                                                                   |
| VASCULAR DISORDERS                                                                                          | 48                                                                                                                                                       | ( 10.1)                                                                                                                                                  | 37 (                                                                                                                                                     | 16.7)                                                                                                                                                    | 4 ( 6.2)                                                                                                                                                 | 1 ( 16.7)                                                                                                                                                | 90                                                                                                                                                       | ( 11.7)                                                                                                                                                  |
| CEREBROVASCULAR DISORDERS                                                                                   | 5 (                                                                                                                                                      | 1.1)                                                                                                                                                     | 5 (                                                                                                                                                      | 2.3)                                                                                                                                                     | 2 ( 3.1)                                                                                                                                                 | 0                                                                                                                                                        | 12                                                                                                                                                       | ( 1.6)                                                                                                                                                   |
| INFECTIONS AND INFESTATIONS                                                                                 | 110                                                                                                                                                      | ( 23.2)                                                                                                                                                  | 54 (                                                                                                                                                     | 24.4)                                                                                                                                                    | 19 ( 29.2)                                                                                                                                               | 1 ( 16.7)                                                                                                                                                | 184                                                                                                                                                      | ( 24.0)                                                                                                                                                  |
| ANTICHOLINERGIC SYNDROME                                                                                    | 129                                                                                                                                                      | ( 27.2)                                                                                                                                                  | 55 (                                                                                                                                                     | 24.9)                                                                                                                                                    | 17 ( 26.2)                                                                                                                                               | 1 ( 16.7)                                                                                                                                                | 202                                                                                                                                                      | ( 26.3)                                                                                                                                                  |
| QUALITY OF LIFE DECREASED                                                                                   | 0                                                                                                                                                        |                                                                                                                                                          | 0                                                                                                                                                        |                                                                                                                                                          | 0                                                                                                                                                        | 0                                                                                                                                                        | 0                                                                                                                                                        |                                                                                                                                                          |
| SUM OF POSTURAL HYPOTENSION, FALLS, BLACKOUTS, SYNCOPE, DIZZINESS, ATAXIA, FRACTURES                        | 43 (                                                                                                                                                     | 9.1)                                                                                                                                                     | 23 (                                                                                                                                                     | 10.4)                                                                                                                                                    | 14 ( 21.5)                                                                                                                                               | 0                                                                                                                                                        | 80                                                                                                                                                       | ( 10.4)                                                                                                                                                  |

## Treatment group: Chemotherapy N = 767

------------------------------------------------------------------------------------------------------------------------------------

Includes events reported between first dose and 30 days after last dose of study therapy Source: Appendix GC.424-EUSCS

MedDRA Version: 23.0; CTC Version 4.0

<div style=\"page-break-after: always\"></div>

Table 47. Summary of Safety in Subgroups by Chemotherapy Backbone - All Treated Subjects

|                                     | No. of Subjects (%)   | No. of Subjects (%)   | No. of Subjects (%)   | No. of Subjects (%)   | No. of Subjects (%)          | No. of Subjects (%)          | No. of Subjects (%)   | No. of Subjects (%)   |
|-------------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|------------------------------|------------------------------|-----------------------|-----------------------|
|                                     | Nivo + XELOX          | Nivo + XELOX          | XELOX                 | XELOX                 | FOLFOX Nivo + FOLFOX (N=422) | FOLFOX Nivo + FOLFOX (N=422) | FOLFOX (N=406)        | FOLFOX (N=406)        |
|                                     |                       |                       | Adverse Event         | Adverse Event         | Adverse Event                | Adverse Event                |                       |                       |
|                                     | Any Grade             | Grade 3-4             | Any Grade             | Grade 3-4             | Any Grade                    | Grade 3-4                    | Any Grade             | Grade 3-4             |
| All-causality AEs                   | 357 (99.2)            | 209 (58.1)            | 353 (97.8)            | 192 (53.2)            | 419 (99.3)                   | 331 (78.4)                   | 399 (98.3)            | 264 (65.0)            |
| Drug-Related AEs                    | 342 (95.0)            | 176 (48.9)            | 314 (87.0)            | 140 (38.8)            | 396 (93.8)                   | 286 (67.8)                   | 365 (89.9)            | 201 (49.5)            |
| All-causality Select AEs            |                       |                       |                       |                       |                              |                              |                       |                       |
| Endocrine                           | 59 (16.4)             | 5 (1.4)               | 5 (1.4)               | 1 (0.3)               | 58 (13.7)                    | 2 (0.5)                      | 9 (2.2)               | 0                     |
| Gastrointestinal                    | 139 (38.6)            | 19 (5.3)              | 118 (32.7)            | 19 (5.3)              | 176 (41.7)                   | 29 (6.9)                     | 142 (35.0)            | 10 (2.5)              |
| Hepatic                             | 142 (39.4)            | 23 (6.4)              | 109 (30.2)            | 13 (3.6)              | 125 (29.6)                   | 22 (5.2)                     | 77 (19.0)             | 16 (3.9)              |
| Pulmonary                           | 14 (3.9)              | 3 (0.8)               | 4 (1.1)               | 0                     | 27 (6.4)                     | 11 (2.6)                     | 2 (0.5)               | 1 (0.2)               |
| Renal                               | 28 (7.8)              | 1 (0.3)               | 10 (2.8)              | 4 (1.1)               | 30 (7.1)                     | 10 (2.4)                     | 14 (3.4)              | 3 (0.7)               |
| Skin                                | 137 (38.1)            | 15 (4.2)              | 82 (22.7)             | 3 (0.8)               | 125 (29.6)                   | 12 (2.8)                     | 55 (13.5)             | 4 (1.0)               |
| Hypersensitivity/ Infusion Reaction | 40 (11.1)             | 6 (1.7)               | 20 (5.5)              | 5 (1.4)               | 78 (18.5)                    | 13 (3.1)                     | 25 (6.2)              | 6 (1.5)               |
| Drug-Related Select AEs             |                       |                       |                       |                       |                              |                              |                       |                       |
| Endocrine                           | 55 (15.3)             | 3 (0.8)               | 0                     | 0                     | 52 (12.3)                    | 2 (0.5)                      | 3 (0.7)               | 0                     |
| Gastrointestinal                    | 115 (31.9)            | 17 (4.7)              | 98 (27.1)             | 17 (4.7)              | 147 (34.8)                   | 26 (6.2)                     | 109 (26.8)            | 8 (2.0)               |
| Hepatic                             | 113 (31.4)            | 17 (4.7)              | 80 (22.2)             | 7 (1.9)               | 90 (21.3)                    | 12 (2.8)                     | 54 (13.3)             | 9 (2.2)               |
| Pulmonary                           | 14 (3.9)              | 3 (0.8)               | 3 (0.8)               | 0                     | 26 (6.2)                     | 11 (2.6)                     | 1 (0.2)               | 1 (0.2)               |
| Renal                               | 10 (2.8)              | 0                     | 3 (0.8)               | 0                     | 16 (3.8)                     | 6 (1.4)                      | 5 (1.2)               | 1 (0.2)               |
| Skin                                | 116 (32.2)            | 14 (3.9)              | 74 (20.5)             | 3 (0.8)               | 98 (23.2)                    | 12 (2.8)                     | 31 (7.6)              | 3 (0.7)               |
| Hypersensitivity/ Infusion Reaction | 37 (10.3)             | 4 (1.1)               | 19 (5.3)              | 5 (1.4)               | 74 (17.5)                    | 13 (3.1)                     | 23 (5.7)              | 6 (1.5)               |

<div style=\"page-break-after: always\"></div>

|                                                                                                         | No. of Subjects (%)                                                                                     | No. of Subjects (%)                                                                                     | No. of Subjects (%)                                                                                     | No. of Subjects (%)                                                                                     | No. of Subjects (%)                                                                                     | No. of Subjects (%)                                                                                     | No. of Subjects (%)                                                                                     | No. of Subjects (%)                                                                                     |
|---------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
|                                                                                                         | XELOX                                                                                                   | XELOX                                                                                                   | XELOX                                                                                                   | XELOX                                                                                                   | FOLFOX                                                                                                  | FOLFOX                                                                                                  | FOLFOX                                                                                                  | FOLFOX                                                                                                  |
| Safety Parameters                                                                                       | Nivo + XELOX (N=360)                                                                                    | Nivo + XELOX (N=360)                                                                                    | XELOX (N=361)                                                                                           | XELOX (N=361)                                                                                           | Nivo + FOLFOX (N=422)                                                                                   | Nivo + FOLFOX (N=422)                                                                                   | FOLFOX (N=406)                                                                                          | FOLFOX (N=406)                                                                                          |
|                                                                                                         | Adverse Event Grades                                                                                    | Adverse Event Grades                                                                                    | Adverse Event Grades                                                                                    | Adverse Event Grades                                                                                    | Adverse Event Grades                                                                                    | Adverse Event Grades                                                                                    | Adverse Event Grades                                                                                    | Adverse Event Grades                                                                                    |
|                                                                                                         | Any Grade                                                                                               | Grade 3-4                                                                                               | Any Grade                                                                                               | Grade 3-4                                                                                               | Any Grade                                                                                               | Grade 3-4                                                                                               | Any Grade                                                                                               | Grade 3-4                                                                                               |
| All-causality IMAEs within 100 days of last dose treated with Immune Modulating Medication              | All-causality IMAEs within 100 days of last dose treated with Immune Modulating Medication              | All-causality IMAEs within 100 days of last dose treated with Immune Modulating Medication              | All-causality IMAEs within 100 days of last dose treated with Immune Modulating Medication              | All-causality IMAEs within 100 days of last dose treated with Immune Modulating Medication              | All-causality IMAEs within 100 days of last dose treated with Immune Modulating Medication              | All-causality IMAEs within 100 days of last dose treated with Immune Modulating Medication              | All-causality IMAEs within 100 days of last dose treated with Immune Modulating Medication              | All-causality IMAEs within 100 days of last dose treated with Immune Modulating Medication              |
| Diarrhea/Colitis                                                                                        | 13 (3.6)                                                                                                | 7 (1.9)                                                                                                 | 0                                                                                                       | 0                                                                                                       | 13 (3.1)                                                                                                | 10 (2.4)                                                                                                | 0                                                                                                       | 0                                                                                                       |
| Hepatitis                                                                                               | 12 (3.3)                                                                                                | 8 (2.2)                                                                                                 | 0                                                                                                       | 0                                                                                                       | 7 (1.7)                                                                                                 | 5 (1.2)                                                                                                 | 0                                                                                                       | 0                                                                                                       |
| Pneumonitis                                                                                             | 11 (3.1)                                                                                                | 4 (1.1)                                                                                                 | 0                                                                                                       | 0                                                                                                       | 22 (5.2)                                                                                                | 11 (2.6)                                                                                                | 0                                                                                                       | 0                                                                                                       |
| Nephritis/Renal Dysfunction                                                                             | 1 (0.3)                                                                                                 | 0                                                                                                       | 0                                                                                                       | 0                                                                                                       | 3 (0.7)                                                                                                 | 2 (0.5)                                                                                                 | 0                                                                                                       | 0                                                                                                       |
| Rash                                                                                                    | 25 (6.9)                                                                                                | 5 (1.4)                                                                                                 | 1 (0.3)                                                                                                 | 0                                                                                                       | 26 (6.2)                                                                                                | 6 (1.4)                                                                                                 | 3 (0.7)                                                                                                 | 0                                                                                                       |
| Hypersensitivity/ Infusion Reaction                                                                     | NR                                                                                                      | NR                                                                                                      | NR                                                                                                      | NR                                                                                                      | 6 (1.4)                                                                                                 | 1 (0.2)                                                                                                 | 0                                                                                                       | 0                                                                                                       |
| All-causality Endocrine IMAEs within 100 days of last dose with or without Immune Modulating Medication | All-causality Endocrine IMAEs within 100 days of last dose with or without Immune Modulating Medication | All-causality Endocrine IMAEs within 100 days of last dose with or without Immune Modulating Medication | All-causality Endocrine IMAEs within 100 days of last dose with or without Immune Modulating Medication | All-causality Endocrine IMAEs within 100 days of last dose with or without Immune Modulating Medication | All-causality Endocrine IMAEs within 100 days of last dose with or without Immune Modulating Medication | All-causality Endocrine IMAEs within 100 days of last dose with or without Immune Modulating Medication | All-causality Endocrine IMAEs within 100 days of last dose with or without Immune Modulating Medication | All-causality Endocrine IMAEs within 100 days of last dose with or without Immune Modulating Medication |
| Adrenal Insufficiency                                                                                   | 2 (0.6)                                                                                                 | 0                                                                                                       | 1 (0.3)                                                                                                 | 1 (0.3)                                                                                                 | 3 (0.7)                                                                                                 | 1 (0.2)                                                                                                 | 1 (0.2)                                                                                                 | 1 (0.2)                                                                                                 |
| Hypophysitis                                                                                            | 5 (1.4)                                                                                                 | 2 (0.6)                                                                                                 | 0                                                                                                       | 0                                                                                                       | 1 (0.2)                                                                                                 | 1 (0.2)                                                                                                 | 0                                                                                                       | 0                                                                                                       |
| Hypothyroidism/ thyroiditis                                                                             | 29 (8.1)                                                                                                | 0                                                                                                       | 1 (0.3)                                                                                                 | 0                                                                                                       | 45 (10.7)                                                                                               | 0                                                                                                       | 5 (1.2)                                                                                                 | 0                                                                                                       |
| Diabetes Mellitus                                                                                       | 2 (0.6)                                                                                                 | 1 (0.3)                                                                                                 | 0                                                                                                       | 0                                                                                                       | NR                                                                                                      | NR                                                                                                      | NR                                                                                                      | NR                                                                                                      |
| Hyperthyroidism                                                                                         | 14 (3.9)                                                                                                | 0                                                                                                       | 2 (0.6)                                                                                                 | 0                                                                                                       | 9 (2.1)                                                                                                 | 0                                                                                                       | 0                                                                                                       | 0                                                                                                       |

MedDRA v23.0; CTC v4.0. All events are within 30 days of the last dose of study drug, unless otherwise indicated (e.g. any time for deaths, 100 days for IMAEs). Abbreviations: AEs - adverse events, CTC - Common Toxicity Criteria, DC - discontinuation, IMAEs - immune-mediated adverse events, IMM - immune modulating medication, MedDRA - Medical Dictionary for Regulatory Activities, NR - none reported; OESI - other events of special interest, SAEs - serious adverse events Source: Refer to Table S.6.1.7.1 (all causality AEs), Table S.6.1.7.2 (drug-related AEs), of the CA209649 Primary CSR 1 and Table S.6.5.2.1.A.1 (all causality Select AEs), Table S.6.5.2.1.A.2 (Select endocrine AEs), Table S.6.5.2.1.A.3 (drug-related Select AEs), Table S.6.5.2.1.A.4 (drug-related endocrine AEs), Table S.6.202.1.A.2 (IMAEs), Table S.6.202.1.A.1 (endocrine IMAEs) in Appendix 1

<div style=\"page-break-after: always\"></div>

## Safety related to drug-drug interactions and other interactions

No data provided.

## Discontinuation due to adverse events

AEs leading to discontinuation were defined as events when 1 or more study drugs of a multidrug regimen were discontinued, even if the subject remained on treatment or in follow-up. The overall frequencies of all-causality and drug-related AEs leading to discontinuation were numerically higher in the nivo+chemo arm compared with the chemo arm (Table 30).

Any-grade AEs leading to discontinuation (regardless of causality) were reported in 371 (47.4%) subjects in the nivo+chemo arm, and 251 (32.7%) subjects in the chemo arm (Table 30). Grade 3-4 AEs leading to discontinuation were reported in 194 (24.8%) subjects in the nivo+chemo arm, and 113 (14.7%) subjects in the chemo arm.

The most common AEs leading to discontinuation (regardless of causality) were:

- Nivo+chemo:  neuropathy  peripheral  (7.8%),  malignant  neoplasm  progression  (4.7%),  and peripheral sensory neuropathy (4.5%).
- Chemo:  neuropathy  peripheral  (5.3%),  peripheral  sensory  neuropathy  (4.7%)  and  malignant neoplasm progression (3.7%).

Any-grade drug-related AEs leading to discontinuation were reported in 284 (36.3%) subjects in the  nivo+chemo  arm,  and  181  (23.6%)  subjects  in  the  chemo  arm.  Grade 3-4  AEs  leading  to discontinuation were reported in 132 (16.9%) subjects in the nivo+chemo arm, and 67 (8.7%) subjects in the chemo arm.

The most common drug-related AEs leading to discontinuation were:

- Nivo+chemo: neuropathy peripheral (7.5%) and peripheral sensory neuropathy (4.5%).
- Chemo: neuropathy peripheral (5.2%) and peripheral sensory neuropathy (4.7%).

The most common reason for AEs leading to dose delays or reductions in both the nivo+chemo and chemo arms was haematologic toxicity. Dose reductions were not permitted with nivolumab treatment, but they were permitted with chemotherapy as per local standard. The most frequently reported AEs of any grade leading to dose delay or reduction were as follows:

- Nivo+chemo arm: neutropaenia (20.1%), decreased neutrophil count (13.7%), decreased platelet count (10.7%), thrombocytopaenia (10.1%), and diarrhoea (7.8%).
- Chemo arm: neutropaenia (16.6%), decreased neutrophil count (10.2%), decreased platelet count (8.3%), thrombocytopaenia (7.0%), and diarrhoea (6.8%).

The most frequently reported drug-related AEs of any grade leading to dose delay or reduction were as follows:

- Nivo+chemo arm: neutropaenia (18.2%), decreased neutrophil count (13.2%), decreased platelet count (10.5%), thrombocytopaenia (9.5%), and diarrhoea (7.3%).
- Chemo arm: neutropaenia (15.9%), decreased neutrophil count (9.9%), decreased platelet count decreased (8.0%), thrombocytopaenia (6.8%), and diarrhoea (6.4%).

<div style=\"page-break-after: always\"></div>

## Immunological events

Of  the  681  nivolumab  ADA  evaluable  subjects  in  the  nivo+chemo  arm,  33  (4.8%)  subjects  were nivolumab ADA positive at baseline and 60 (8.8%) subjects were nivolumab ADA positive after the start of treatment (Table 4.1.2-1). The number of nivolumab ADA positive subjects was similar in subjects who received nivo+XELOX vs. nivo+FOLFOX (33 [10.3%] vs. 27 [7.5%]).

- One (0.1%) subject was considered persistent positive and 2 (0.3%) subjects were neutralizing ADA positive.
- The highest titer value observed in nivolumab ADA positive subjects was 256. All other titers were low, ranging from 0 to 32.

## Effect of immunogenicity on efficacy

Of the 60 subjects that were nivolumab ADA positive after nivo+chemo treatment, 5 subjects (8.3%) had a CR, 29 (48.3%) had a PR, and 19 (31.7%) had SD. The ORR among the ADA positive subjects (56.7%) was similar to the ORR (58.0%) in all randomized subjects in the nivo+chemo arm. An ADA positive result at the first testing timepoint did not appear to correlate with early disease progression or death. For the 2 subjects with neutralizing ADA positive, both had PR with a PFS of more than 1 year. Overall, the incidence of ADA or neutralizing ADA did not appear to have negative effects on the efficacy of nivo+chemo in this population.

A swimmers plot of ADA and NAb occurrence in relation to PFS, BOR per BICR and OS in all randomized subjects is presented in Figure 21.

Figure 91. Anti-Drug Antibody and NAb Occurence in Relation to PFS, BOR per BICR and OS All Treated Subjects with ADA Positive

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

Bar indicates progression free survival. Source: Figure S.7.2

## Effect of immunogenicity on safety

The  effect  of  immunogenicity  on  safety  was  assessed  in  the  nivo+chemo  arm.  The  frequency  of hypersensitivity/infusion reactions in the ADA-evaluable subjects was 18.3% (11/60) in nivolumab ADA positive subjects and 15.8% (98/621) in nivolumab ADA negative subjects (Table 48).

Table  48.  Select  Adverse  Events  of  Hypersensitivity/Infusion  Reaction  by  ADA  status (Positive, Negative) - All Treated Subjects with ADA Positive or ADA Negative

| -----------------------------------------------------------------------------------------------   | Nivo +                                                                            | Nivo +                                                                                                                      | Nivo +   |
|---------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|----------|
| Preferred Term (%)                                                                                | --------------------------------------------------- Nivolumab ADA Positive N = 60 | Nivolumab ADA Negative = 621 ---------------------------------------------------------------------------------------------- |          |
| TOTAL SUBJECTS WITH AN EVENT                                                                      | 11 ( 18.3)                                                                        | 98 ( 15.8)                                                                                                                  |          |
| Anaphylactic reaction                                                                             | 2 ( 3.3)                                                                          | ( 0.5)                                                                                                                      |          |
| Bronchospasm                                                                                      | 0                                                                                 | 3 1 ( 0.2)                                                                                                                  |          |
| Hypersensitivity                                                                                  | 3 ( 5.0)                                                                          | 45 ( 7.2)                                                                                                                   |          |
| Infusion related hypersensitivity reaction                                                        | 0                                                                                 | 3 ( 0.5)                                                                                                                    |          |
| Infusion related reaction                                                                         | 6 ( 10.0)                                                                         | 57 ( 9.2)                                                                                                                   |          |

MedDRA Version: 23.0

-----------------------------------------------------------------------------------------------

CTC Version 4.0 Includes events between first dose and within the last dose of therapy + 100 days.

Source: Table S.7.11

## Post marketing experience

Nivolumab was first approved on 04-Jul-2014 in Japan for unresectable melanoma and has since been approved in multiple countries, including the US and in the EU, and for other indications as monotherapy (e.g., metastatic NSCLC, advanced renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, and esophageal squamous cell carcinoma). In US, nivolumab monotherapy was also approved for hepatocellular carcinoma, microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer, and small cell lung cancer.

The MAH states that based on pharmacovigilance activities conducted by BMS Worldwide Patient Safety, review of post marketing safety data is consistent with, and confirms the clinical trial safety data for

<div style=\"page-break-after: always\"></div>

nivolumab.  The  safety  profile  of  nivolumab  in  the  post  marketing  setting  remains  favourable.  Post marketing  data  for  nivolumab  are  subject  to  continued  active  pharmacovigilance  monitoring  and reporting as per applicable safety reporting requirements. Continuous safety monitoring ensures that updated safety information is available in a timely manner and that any future changes to the benefitrisk  profile  of  nivolumab  are  appropriately  managed  and  reported.  For  the  most  current  company assessment of post marketing data and risk management actions for nivolumab, the MAH refers to nivolumab  Periodic  Benefit-Risk  Evaluation  Report  (PBRER)  Number  10  (submitted  in  a  separate procedure).

## Safety to support the SmPC

In Section 4.8 of the proposed OPDIVO SmPC for the current application, a new column for the CA209649 data is added to the adverse reaction table (Table 8), which contains approved data for Study CA2099LA (Adverse reactions with nivolumab in combination with other therapeutic agents). The newly added column is for the 782 subjects with advanced or metastatic GC/GEJC/EAC from Study CA209649 treated with first-line nivo+chemo (nivolumab 240 mg + FOLFOX Q2W or nivolumab 360 mg + XELOX Q3W). This regimen has a different composition than other approved regimens; therefore, these data are not pooled.

Also in Section 4.8 of the proposed OPDIVO SmPC for the current application, a new column in Table 11 has been added (Immune-related adverse reactions leading to permanent discontinuation or requiring high-dose corticosteroids by dosing regimen, nivolumab in combination with other therapeutic agents). The newly added column presents data for nivo+chemo (nivolumab 240 mg + FOLFOX Q2W or nivolumab 360  mg  +  XELOX  Q3W)  for  the  first-line  treatment  of  advanced  or  metastatic  gastric  or  gastrooesophageal junction or oesophageal adenocarcinoma (CA209649).

## Remapping of preferred terms

Some Medical Dictionary for Regulatory Activities (MedDRA) preferred terms (PTs) were remapped for the purposes of generating summary tables to support Section 4.8 of the nivolumab SmPC (nivolumab 240 mg + FOLFOX Q2W or nivolumab 360 mg + XELOX Q3W in first-line advanced or metastatic gastric or gastro-oesophageal junction or oesophageal adenocarcinoma). Remapping allows for pooling of PTs representing the same or similar clinical conditions.

## Identification of clinically relevant adverse reactions

Selection of specific adverse reactions to be presented in Section 4.4 and Section 4.8 of the nivolumab SmPC was based on clinical relevance as determined by the BMS medical reviewer. PTs that met 1 or more of the following criteria were excluded from the SmPC:

- Overly general/non-specific
- No suspected causal relationship to nivolumab per BMS medical review
- Single case events with limited data
- Medical concept captured under a different term

## Presentation of clinically relevant adverse reactions

The list of clinically relevant adverse reactions with nivolumab in combination with chemotherapy in gastric, GEJ, or oesophageal adenocarcinoma is presented in Table 49 alongside the approved data from CA2099LA (and also in Section 4.8 of the OPDIVO SmPC). In this table, the frequencies are presented by system organ class and by frequency grouping as follows: very common ( ≥ 1/10); common ≥ 1/100 to &lt; 1/10); uncommon ( ≥ 1/1,000 to &lt; 1/100); rare ( ≥ 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000). Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.

<div style=\"page-break-after: always\"></div>

Table  49.  Adverse  Reactions  with  Nivolumab  in  Combination  with  Chemotherapy  or Ipilimumab and Chemotherapy

|                                                 | Nivolumab in combination with chemotherapy                              | Nivolumab in combination with ipilimumab and chemotherapy                                         |
|-------------------------------------------------|-------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| Infections and infestations                     | Infections and infestations                                             |                                                                                                   |
| Very common                                     | upper respiratory tract infection                                       |                                                                                                   |
| Common                                          | pneumonia                                                               | conjunctivitis, pneumonia, respiratory tract infection                                            |
| Blood and lymphatic system disorders            | Blood and lymphatic system disorders                                    |                                                                                                   |
| Common                                          | febrile neutropaenia, eosinophilia                                      | febrile neutropaenia                                                                              |
| Uncommon                                        |                                                                         | eosinophilia                                                                                      |
| Immune system disorders                         | Immune system disorders                                                 |                                                                                                   |
| Common                                          | hypersensitivity, infusion related reaction                             | infusion-related reaction, hypersensitivity                                                       |
| Endocrine disorders                             | Endocrine disorders                                                     |                                                                                                   |
| Very common                                     |                                                                         | hypothyroidism                                                                                    |
| Common                                          | hypothyroidism, hyperthyroidism                                         | hyperthyroidism, adrenal insufficiency, hypophysitis, thyroiditis                                 |
| Uncommon                                        | hypopituitarism, adrenal insufficiency, hypophysitis, diabetes mellitus | hypopituitarism, hypoparathyroidism                                                               |
| Metabolism and nutrition disorders              | Metabolism and nutrition disorders                                      |                                                                                                   |
| Very common                                     | decreased appetite                                                      | decreased appetite                                                                                |
| Common                                          |                                                                         | dehydration, hypoalbunaemia, hypophosphataemia                                                    |
| Nervous system disorders                        | Nervous system disorders                                                |                                                                                                   |
| Very common                                     | peripheral neuropathy, headache                                         |                                                                                                   |
| Common                                          | paraesthesia , dizziness                                                | peripheral neuropathy, dizziness                                                                  |
| Uncommon                                        | Guillain-Barré syndrome                                                 | polyneuropathy, autoimmune neuropathy (including facial and abducens nerve paresis), encephalitis |
| Eye disorders                                   | Eye disorders                                                           |                                                                                                   |
| Common                                          | dry eye, blurred vision                                                 | dry eye                                                                                           |
| Uncommon                                        | uveitis                                                                 | blurred vision, episcleritis                                                                      |
| Cardiac disorders                               | Cardiac disorders                                                       |                                                                                                   |
| Common                                          | tachycardia                                                             |                                                                                                   |
| Uncommon                                        | myocarditis                                                             | tachycardia, atrial fibrillation, bradycardia                                                     |
| Vascular disorders                              | Vascular disorders                                                      |                                                                                                   |
| Common                                          | thrombosis, hypertension                                                |                                                                                                   |
| Uncommon                                        |                                                                         | hypertension                                                                                      |
| Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders                         |                                                                                                   |
| Very common                                     | cough                                                                   |                                                                                                   |
| Common                                          | pneumonitis, dyspnoea                                                   | pneumonitis, dyspnoea, cough                                                                      |
| Uncommon                                        |                                                                         | pleural effusion                                                                                  |
| Gastrointestinal disorders                      | Gastrointestinal disorders                                              |                                                                                                   |
| Very common                                     | diarrhoea, stomatitis, vomiting, nausea, abdominal pain, constipation   | nausea, diarrhoea, vomiting                                                                       |
| Common                                          | colitis, dry mouth                                                      | constipation, stomatitis, abdominal pain, colitis, dry mouth, pancreatitis                        |
| Uncommon                                        | pancreatitis                                                            |                                                                                                   |
| Hepatobiliary disorders                         | Hepatobiliary disorders                                                 |                                                                                                   |
| Common                                          |                                                                         | hepatitis                                                                                         |
| Uncommon                                        | hepatitis                                                               |                                                                                                   |
| Skin and subcutaneous tissue disorders          | Skin and subcutaneous tissue disorders                                  | Skin and subcutaneous tissue disorders                                                            |

<div style=\"page-break-after: always\"></div>

| Very common                                          | palmar-plantar erythrodysaesthaesia syndrome, rash a                                                                                                                                                                                                                                                                                                                        | rash a , pruritus                                                                                                                                                                                                                                                            |
|------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Common                                               | pruritus, skin hyperpigmentation, alopecia, dry skin, erythema                                                                                                                                                                                                                                                                                                              | alopecia, dry skin, erythema, urticaria                                                                                                                                                                                                                                      |
| Uncommon                                             |                                                                                                                                                                                                                                                                                                                                                                             | psoriasis, Stevens-Johnson syndrome, vitiligo                                                                                                                                                                                                                                |
| Not known                                            |                                                                                                                                                                                                                                                                                                                                                                             | lichen sclerosus, other lichen disorders                                                                                                                                                                                                                                     |
| Musculoskeletal and connective tissue disorders      | Musculoskeletal and connective tissue disorders                                                                                                                                                                                                                                                                                                                             | Musculoskeletal and connective tissue disorders                                                                                                                                                                                                                              |
| Very common                                          | musculoskeletal pain b                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                              |
| Common                                               | arthralgia, muscular weakness                                                                                                                                                                                                                                                                                                                                               | musculoskeletal pain b , arthralgia, arthritis                                                                                                                                                                                                                               |
| Uncommon                                             |                                                                                                                                                                                                                                                                                                                                                                             | muscular weakness, muscle spasms, polymyalgia rheumatica                                                                                                                                                                                                                     |
| Renal and urinary disorders                          | Renal and urinary disorders                                                                                                                                                                                                                                                                                                                                                 | Renal and urinary disorders                                                                                                                                                                                                                                                  |
| Common                                               | renal failure,                                                                                                                                                                                                                                                                                                                                                              | renal failure (including acute kidney injury)                                                                                                                                                                                                                                |
| Uncommon                                             | nephritis, cystitis noninfective e                                                                                                                                                                                                                                                                                                                                          | nephritis, cystitis noninfective e                                                                                                                                                                                                                                           |
| General disorders and administration site conditions | General disorders and administration site conditions                                                                                                                                                                                                                                                                                                                        | General disorders and administration site conditions                                                                                                                                                                                                                         |
| Very common                                          | fatigue, pyrexia, oedema (including peripheral oedema)                                                                                                                                                                                                                                                                                                                      | fatigue                                                                                                                                                                                                                                                                      |
| Common                                               |                                                                                                                                                                                                                                                                                                                                                                             | pyrexia, oedema (including peripheral oedema)                                                                                                                                                                                                                                |
| Uncommon                                             |                                                                                                                                                                                                                                                                                                                                                                             | chills, chest pain                                                                                                                                                                                                                                                           |
| Investigations                                       | Investigations                                                                                                                                                                                                                                                                                                                                                              | Investigations                                                                                                                                                                                                                                                               |
| Very common                                          | anaemia c,d , thrombocytopaenia c , leucopoenia c , lymphopaenia c , neutropaenia c , increased transaminases c , increased total bilirubin c , increased creatinine c , hypernatraemia c , hyponatraemia c , hyperkalaemia c , hypokalaemia c , hypocalcaemia c , hypoglycaemia c , hyperglycaemia c , increased lipase, increased alkaline phosphatase, increased amylase | anaemia c,d , thrombocytopaenia c , leucopoenia c , lymphopaenia c , neutropaenia c , increased alkaline phophatase c , increased transaminases c , increased creatinine c , increased amylase c , increased lipase c , hypokalaemia c , hypomagnesaemia c , hyponatraemia c |
| Common                                               | hypercalcaemia c                                                                                                                                                                                                                                                                                                                                                            | increased total bilirubin c , increased thyroid stimulating hormone                                                                                                                                                                                                          |
| Uncommon                                             |                                                                                                                                                                                                                                                                                                                                                                             | increased gamma-glutamyltransferase                                                                                                                                                                                                                                          |

- a Rash is a composite term which includes maculopapular rash, rash erythematous, rash pruritic, rash macular, rash morbilliform, rash papular, rash generalised, dermatitis, dermatitis acneiform, dermatitis allergic, dermatitis atopic, dermatitis bullous, drug eruption, exfoliative rash, nodular rash, and rash vesicular.
- b Musculoskeletal pain is a composite term which includes back pain, bone pain, musculoskeletal chest pain, myalgia, neck pain, pain in extremity, spinal pain, and musculoskeletal discomfort.
- c Frequencies of laboratory terms reflect the proportion of patients who experienced a worsening from baseline in laboratory measurements.
- d Anaemia is a composite term which includes iron deficiency anaemia and haemoglobin decreased.
- e Reported in clinical studies and in the post-marketing setting.

To calculate the frequencies of laboratory adverse reactions, the MAH used the laboratory abnormality change  from  baseline  tables,  except  for  hyperglycemia  in  advanced  or  metastatic  GC/GEJC/EAC; hyperglycemia was based on the reported adverse reaction. This presentation is a conservative approach intended to capture the frequency of all laboratory abnormalities regardless of causality. In doing so, the denominator used to compute frequency is the number of patients for whom laboratory abnormalities data were reported, as opposed to all treated patients. Hence, there is variability in the denominator for each individual laboratory abnormality and their respective reported frequencies.

<div style=\"page-break-after: always\"></div>

## Posology and method of administration (section 4.2), and special warnings and precautions for use (section 4.4) - Update of information related to adverse reactions of special interest

Text on the proposed dosage and administration of OPDIVO in combination with XELOX or FOLFOX is provided in Section 4.2 of the OPDIVO SmPC.

Guidelines for permanent discontinuation or withholding of OPDIVO in combination with chemotherapy are provided in Section 4.2 of the OPDIVO SmPC.

Guidelines for the management of immune-related adverse reactions are provided in Section 4.4 of the OPDIVO SmPC. In this application, no amendments or changes in the management of immune-related adverse reactions is proposed based on the data from CA209649.

The following disease-specific precaution is added to Section 4.4 of the proposed OPDIVO SmPC: Patients who had baseline ECOG performance score ≥ 2, untreated CNS metastases , active, known, or suspected autoimmune disease, or medical conditions requiring systemic immunosuppression were excluded from the clinical trial in gastric, GEJ or oesophageal adenocarcinoma (see sections 4.5 and 5.1 of the OPDIVO SmPC). In the absence of data, nivolumab in combination with chemotherapy should be used with caution in these populations after careful consideration of the potential benefit/risk on an individual basis. Study CA209649 excluded patients with known HER2-positive status. Patients with undetermined status were allowed in the study and represented 40.3% of patients (see section 5.1 of the OPDIVO SmPC).

The MAH proposed to pool the following studies: nivolumab monotherapy, nivolumab in combination with chemotherapy, nivolumab in combination with ipilimumab (with or without chemotherapy), and maintain the nivolumab combination with cabozantinib separate due to the distinct safety profile.

The general approach will be that pooled data will be assessed side by side, to identify any potential differential safety profile of clinical relevance. Then, each pool will be displayed side by side with data from  studies  of  the  same  tumour  type  within  that  pool.  Based  on  these  assessments  text  will  be developed for the SmPC to describe any major potential differences of clinical relevance between and within pools warranting different management for an indication or specific treatment combination, or awareness.

The plan for pooling and assessment of the pooled data are acceptable, as in line with the SmPC Guidance and the approach as described in Appendix 3 to the Guideline on the clinical evaluation of anticancer medicinal products, i.e. the Summary of Product Characteristics for an Anticancer medicinal product mock-up of 4.8. This will be pursued in a future worksharing procedure for nivolumab and ipilimumab.

## 2.5.1. Discussion on clinical safety

The database to characterise the safety profile of nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with advanced or  metastatic  gastric,  gastro-oesophageal  junction  or  oesophageal  adenocarcinoma  is  based  on  782 patients treated with nivo+chemo in the investigational arm (360 in combination with XELOX, 422 in combination with FOLFOX) and 767 patients treated with chemo in the control arm (361 XELOX, 406 FOLFOX) in study CA209649. In the nivo+chemo arm patients were treated with nivolumab 360 mg plus XELOX Q3W or nivolumab 240 mg plus FOLFOX Q2W. The chemo arm included XELOX Q3W and FOLFOX Q2W. Subjects were treated until disease progression, unacceptable toxicity, or a maximum of 2 years (for nivolumab treatment). The last patient was randomised in May 2019 and DBL occurred in July 2020.

Patient  exposureMinimum  follow-up  of  the  1549  patients  treated  in  study  CA209649  was  12.1 months. Median (min-max) duration of therapy was 6.75 (0.0-33.5) months in the nivo+chemo arm and 4.86 (0.0-34.9) months in the chemo arm. It is noted that in the nivo+chemo group median duration of therapy  of  the  nivolumab  component  was  longer  than  for  the  chemotherapy  component.  Especially

<div style=\"page-break-after: always\"></div>

exposure of oxaliplatin was shorter, which was also observed in the chemo control arm. Median duration of  chemotherapy  was  longer  in  the  nivo+chemo  arm  compared  to  the  chemo  arm,  suggesting  that tolerability to chemotherapy did not decrease by the addition of nivolumab. In the nivo+chemo arm 89.3% discontinued and 94.9% in the chemo arm. The primary reason for discontinuation of treatment was disease progression in both treatment arms: 65.9% in the nivo+chemo group and 68.8% in the chemo group. In the nivo+XELOX arm the proportion of patients receiving ≥ 90% of the planned dose intensity  was  70.0%  for  nivolumab,  44.2%  for  oxaliplatin,  and  33.9%  for  capecitabine.  In  the nivo+FOLFOX arm this was 56.4% for nivolumab, 38.0% for oxaliplatin, 36.7% for leucovorin, 43.3% for 5-FU bolus, and 42.9% for 5-FU continuous. In the chemo arm 49.0% for oxaliplatin and 36.5% for capecitabine received ≥ 90% of the planned dose intensity in the XELOX arm and for the FOLFOX arm this  was  45.0%  for  oxaliplatin,  44.8%  for  leucovorin,  49.3%  for  5-FU  bolus,  and  51.0%  for  5-FU continuous. Prior to revised protocol 07, all components of the combination treatment were delayed together if a dose delay was required which can explain the relatively low dose intensity of all components including nivolumab. The majority of patients received ≥ 70% of the planned dose intensities of each component and exposure to chemotherapy was generally comparable in the nivo+chemo vs. chemo arm. This implies that adding nivolumab to a XELOX or FOLFOX regimen does not lead to a decreased dose intensity of the chemotherapy component.

Adverse eventsAlmost all patients reported an AE during study treatment (99.2% in the nivo+chemo group vs. 98.0% in the chemo group). The most reported AEs were nausea (47.6%), diarrhoea (39.4%), and anaemia (38.2%) for the nivo+chemo arm. In the chemo arm nausea (43.5%), diarrhoea (33.6%), and anaemia (33.1%) were most commonly reported. When looking specifically to drug-related AEs, most often nausea (41.3%), diarrhoea (32.4%), and neuropathy peripheral (28.3%) were seen in the nivo+chemo arm. For the chemo arm, most frequently drug-related AEs reported were also nausea (38.1%), diarrhoea  (26.9%),  and  neuropathy  peripheral  (24.8%).  Grade  3-4  AEs  were  observed  in 69.1% vs. 59.5% in the nivo+chemo vs. chemo arm, respectively. Neutropaenia (16.9%), decreased neutrophil count (11.5%), and anaemia (11.0%) were the most commonly seen Grade 3-4 AEs in the nivo+chemo arm; neutropaenia (13.0%), decreased neutrophil count (9.1%), and anaemia (7.3%) in the chemo arm. As shown by the frequencies of the most common AEs, the type of AEs are overlapping (gastrointestinal toxicity, bone marrow depression, and peripheral neuropathy) but the incidences are numerically higher in the nivo+chemo vs. the chemo arm suggesting additive toxicity when combining nivolumab with chemotherapy. The observed AEs are also more severe in grade, with a 10% difference in reported Grade 3-4 AEs between the treatment groups.

Serious  adverse  eventsThe  overall  frequencies  of  SAEs  (all-causality  and  drug-related)  were numerically higher with nivo+chemo than with chemo. Any Grade SAEs (regardless of causality) were reported in 54.1% in the nivo+chemo arm vs. 43.7% in the chemo arm. The most frequently reported SAEs in the nivo+chemo group were malignant neoplasm progression (13.9%), vomiting (3.2%), and anaemia (3.1%). For the chemo arm these were malignant neoplasm progression (11.7%), vomiting (3.1%), and dysphagia (2.1%). Any-grade drug-related SAEs were reported in 22.0% in the nivo+chemo arm and in 12.1% in the chemo arm. The most frequently reported drug-related SAEs were diarrhoea (2.2%), pneumonitis (2.2%), and febrile neutropaenia (2.0%) in the nivo+chemo arm. These numbers again show that the toxicity observed in the nivo+chemo group is more severe than in the chemo group.

DeathsThe  number  of  treated  patients  who  died  in  the  nivo+chemo  arm  was  numerically  lower compared to the chemo arm. Disease progression was the most common cause of death in both arms. Death attributed to study drug toxicity was reported in 12 (1.5%) and 4 (0.5%) treated patients in the nivo+chemo  and  chemo  arms,  respectively.  Per  investigator  assessment,  3  deaths  were  due  to nivolumab, 2 deaths were due to nivolumab and chemotherapy, and 7 deaths were due to chemotherapy in the nivo+chemo arm. The causes of death due to nivolumab were pulmonitis, interstitial lung disease and  pneumonitis.  The  causes  of  death  due  to  nivolumab  and  chemotherapy  were  infection  and

<div style=\"page-break-after: always\"></div>

gastrointestinal toxicity. The causes of death due to chemotherapy were neutropaenic fever, intestinal mucositis, stroke, gastrointestinal bleeding, septic shock, pneumonia, and febrile neutropaenia. Deaths attributed to other reasons were reported in 6.3% and 5.7% of treated patients in the nivo+chemo and chemo arms, respectively. There were 4 events reported as 'related' per investigator (all in nivo+chemo arm):  thrombosis  mesenteric  vessel,  disseminated  intravascular  coagulation,  cerebral  infarction  and pneumonitis. Per investigator, the pneumonitis was reported as related to nivolumab and the other 3 events were reported as related to both nivolumab and chemotherapy.  The MAH explained that in the 4  cases  of  death  'attributed  to  other  reasons'  that  were  reported  as  'related'  per  investigator,  the investigators captured the deaths as 'other' because the cause of death was attributed to multiple factors or in case study drug toxicity could not be fully ruled out.

DiscontinuationsThe overall frequencies of all-causality and drug-related AEs leading to discontinuation were numerically higher in the nivo+chemo (47.4% and 36.3%) arm compared with the chemo  arm  (32.7%  and  23.6%).  The  most  common  AEs  leading  to  discontinuation  (regardless  of causality) were neuropathy peripheral (7.8%), malignant neoplasm progression (4.7%), and peripheral sensory  neuropathy  (4.5%)  in  the  nivo+chemo  arm.  For  the  chemo  arm  these  were  neuropathy peripheral (5.3%), peripheral sensory neuropathy (4.7%) and malignant neoplasm progression (3.7%). The most frequently observed drug-related AEs leading to discontinuation in the nivo+chemo arm were neuropathy peripheral (7.5%) and peripheral sensory neuropathy (4.5%). The most common reason for AEs leading to dose delays or reductions in both the nivo+chemo and chemo arms was haematologic toxicity. Although the reasons for discontinuation are not unexpected, the number of discontinuations are high in both arms with a 15% higher incidence in the nivo+chemo arm compared to the chemo arm. The high  number  of  discontinuations  due  to  AEs  in  the  control  arm  reflect  that  toxicity  of  first-line chemotherapy  treatment  with  XELOX  or  FOLFOX  in  this  patient  population  is  considerable  and  the addition of nivolumab worsens the toxicity profile.

Adverse events of special interestBased on previous experience with (nivolumab) immunotherapy, the  MAH  defined  AEs  of  special  interest  and  reported  on  select  adverse  events,  immune-mediated adverse events (IMAEs) and other events of special interest (OESIs). Endocrine, gastrointestinal, hepatic, pulmonary, renal, skin and hypersensitivity/infusion reactions were analysed as select AE categories. The  most  frequently  reported  drug-related  select  AE  categories  were  gastrointestinal  (33.5%),  skin (27.4%) and hepatic (26.0%) in the nivo+chemo arm and gastrointestinal (27.0%), hepatic (17.5%), and skin (13.7%) in the chemo arm. On PT level, diarrhoea (32.4%), increased AST (15.6%), and palmar-plantar erythrodysaesthesia syndrome  (12.0%)  were most commonly  reported in the nivo+chemo arm. In the chemo arm, these were diarrhoea (26.9%), palmar-plantar erythrodysaesthesia syndrome (10.6%), and increased AST (9.0%). Most select AEs were Grade 1-2 and had resolved at the time  of  database  lock  with  a  median  time  to  resolution  ranging  from  0.14  to  72.14  weeks.  Some endocrine select AEs were not considered resolved due to the continuing need for hormone replacement therapy.

IMAEs  included  diarrhoea/colitis, hepatitis, pneumonitis,  nephritis and  renal dysfunction, rash, hypersensitivity/infusion  reactions,  and  endocrine  events  occurring  within  100  days  of  the  last  dose irrespective of causality but identified by the investigator with no clear etiology and an immune-mediated component. With the exception of endocrine events, IMAEs were limited to events needing immunemodulating medication. The majority of IMAEs were Grade 1-2 and the most frequently reported IMAEs in  the  investigational  arm  were  hypothyroidism/thyroiditis  (9.5%),  rash  (6.5%),  and  pneumonitis (4.2%). In the chemo arm hypothyroidism/thyroiditis and rash were most frequently observed with an incidence  of  &lt;1%.  The  majority  of  events  were  manageable  using  the  established  management algorithms, with resolution occurring when immune-modulating medications (mostly systemic corticosteroids) were administered. Except for some endocrine events, most IMAEs with nivo+chemo treatment had resolved at the time of DBL.

<div style=\"page-break-after: always\"></div>

OESIs are events that do not fulfill all criteria to qualify as IMAEs. These events may differ from those caused  by  non-immunotherapies and may require immunosuppression as part of their  management. Overall, OESIs were reported in 8/782 (1.0%) patients (10 events) in the nivo+chemo arm and 4/767 (0.5%) patients (5 events) in the chemo arm. The events observed in the nivo+chemo arm were Grade 3 Guillain-Barre syndrome, Grade 2 chorioretinitis, Grade 3 encephalitis, 4 events of pancreatitis (Grade 1-4), and 3 events of myocarditis (Grade 1 and 3). 9/10 OESIs in the nivo+chemo arm and 4/5 OESIs in the chemo arm were resolved at the time of database lock. 7/10 and 1/5 OESIs were resolved with immune-modulating medication in the nivo+chemo and chemo arms, respectively.

The provided data on adverse events of special interest show that the toxicity profile of nivo+chemo is not only overlapping (see section on AEs above), but also differs from the chemo arm with the occurrence of immune-related adverse events. There are no suggestions that the addition of XELOX or FOLOX to nivolumab induces unexpected immune-related adverse events based on experience with previously approved indications.

Laboratory findingsOn-treatment laboratory abnormalities were more frequently observed in the nivo+chemo arm vs. the chemo arm, for haematology (main difference was found in decreased absolute neutrophil count), liver tests, kidney functions tests, and thyroid tests. Most laboratory abnormalities were Grade 1-2. Based on laboratory results reported after the first dose and within 30 days of last dose of study therapy, 13/764 (1.7%) patients in the nivo+chemo arm had concurrent ALT or AST &gt;3 × ULN with total bilirubin &gt;2 × ULN within 1 or 30 days, while 6/737 (0.8%) and 7/737 (0.9%) patients in the chemo arm had concurrent ALT or AST &gt;3 × ULN with total bilirubin  &gt;2 × ULN within 1 day and within 30 days, respectively. In 3 of the 13 cases in the nivo+chemo arm, the abnormal hepatic laboratory findings were reported as related to nivolumab alone or to both nivolumab and chemotherapy. All 3 patients were treated with high dose immune-modulating medication and improved after treatment, supporting that the aetiologie was immune-mediated. In 1 case the patients had to discontinue study treatment due to the abnormal hepatic laboratory findings led to study treatment discontinuation.

Safety  in  subgroupsDifferences  between  frequencies  of  drug-related  AEs  were  observed  for subgroups. In the group of patients treated with nivo+chemo the frequency of Grade 3-4 AEs was higher in the US/Canada population (72.1%) vs. other regions (~55% and overall 59%). Of note, most patients in the US/Canada regions received FOLFOX and the number of Grade 3-4 AEs was higher in the FOLFOX versus XELOX group (67.8% in the nivo+FOLFOX group and 49.5% in the nivo+XELOX group), possibly explaining the differences found based on geographic region. In both treatment arms, female patients experienced more Grade 3-4 drug-related AEs compared to males.

The frequencies of all causality AEs for subgroups of age &lt;65, 65 to 74, and 75 to 84 years were generally similar to the frequencies reported for the overall study population by treatment. It is noted that for the age  group  75-84  years  treated  with  nivo+chemo,  the  number  of  SAEs,  vascular  disorders  and anticholinergic syndrome were lower. Conclusions are however difficult to draw with the small number of patients in this group (n=75). Only 2 patients older than 85 years were treated with nivo+chemo.

Safety data for all treated patients with PDL1 CPS ≥5 or ≥1 in the nivo+chemo and the chemo arms were consistent with the safety data for all treated patients.

ImmunogenicityOf the 681 nivolumab ADA evaluable patients in the nivo+chemo arm, 33 (4.8%) patients were nivolumab ADA positive at baseline and 60 (8.8%) patients were nivolumab ADA positive after the start of treatment. One (0.1%) patient was considered persistent positive and 2 (0.3%) patients were neutralizing ADA positive. The ORR among the ADA positive subjects (56.7%) was similar to the ORR (58.0%) in all randomised patients in the nivo+chemo arm. For the 2 patients with neutralising ADA positive, both had PR with a PFS of more than 1 year. The frequency of hypersensitivity/infusion reactions in the ADA-evaluable patients was 18.3% (11/60) in nivolumab ADA positive patients and 15.8%  (98/621)  in  nivolumab  ADA  negative  patients.  The  incidence  of  ADA's  is  similar  to  what  is

<div style=\"page-break-after: always\"></div>

previously reported for nivolumab in other tumour types. The presence of ADA's did not appear to have an effect on the occurrence of hypersensitivity/infusion reactions.

This is  the  first  application  combining  nivolumab  mono-immunotherapy with chemotherapy and it is therefore difficult to put the toxicity profile into perspective with what is known for nivolumab. When comparing  reported  frequencies  with  the  approved  indication  of  nivolumab  in  combination  with ipilimumab and 2 cycles of platinum-based chemotherapy for first-line metastatic NSCLC, all causality AEs and drug-related deaths appear to occur in similar frequencies. Grade 3-4 AEs (mainly drug-related), Grade 3-4 SAEs and discontinuations are reported more often in the study investigating gastric cancer (study  CA209649)  compared  with  the  NSCLC  study  (study  CA2099LA;  see  also  EPAR  procedure EMEA/H/C/xxxx/WS/1783). It is however also noted that for the treatment of NSCLC, patients were treated with only 2 cycles of chemotherapy and also the toxicity of the chemo arm in the study with gastric patients is higher than in the chemo arm of study with NSCLC patients. Furthermore, the patients groups studied (NSCLC or gastric cancer) are different populations. Definitive conclusions about how the safety profile found in CA209649 compares to other nivolumab studies are therefore difficult to make.

Data for the nivo+ipi arm were not provided in this procedure. Enrollment was stopped in this arm due to observed increased early death rate in nivolumab plus ipilimumab arm as well as the increased toxicity rate. The final analysis of the nivo+ipi arm is planned for July 2021 and data submission for Q4 2021. The nivo+ipi arm of study CA209649 is added to the Letter of Recommendation. Of note, at the most recent safety review of the study in March 2021, the DMC recommended that the study should continue as planned.

## 2.5.2. Conclusions on clinical safety

Treatment of nivo+chemo is characterised by substantial toxicity with a high number of discontinuations. Nivo+chemo treatment is less tolerated than treatment with chemo only as shown by the higher number of  (drug-related)  AEs,  Grade  3-4  AEs,  SAEs,  drug-related  deaths  due  to  AEs,  and  AEs  leading  to discontinuations. It is noted that the toxicity profile of the chemo control arm in this first-line population is  already  considerable.  Next  to  nivolumab and chemotherapy overlapping toxicities such as gastrointestinal AEs, bone marrow depression, and peripheral neuropathy, also nivolumab-specific toxicity with immune-related AEs are observed with the addition of nivolumab to the chemotherapy regimen. Although the type of AEs are reflective of the known safety profile of nivolumab immunotherapy and chemotherapy and no new safety issues were identified, the severity of the toxicity is considerable and should be valued against the observed benefit in patients with advanced or metastatic gastric, gastro-oesophageal or oesophageal adenocarcinoma.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH submitted an updated RMP version with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan

The PRAC considered that the risk management plan version 21.2 is acceptable.

<div style=\"page-break-after: always\"></div>

The CHMP endorsed the Risk Management Plan version 21.2 with the following content:

## Safety concerns

Table  :

Summary of Safety Concerns

| Important identified risks   | Immune-related pneumonitis Immune-related colitis Immune-related hepatitis Immune-related nephritis and renal dysfunction Immune-related endocrinopathies Immune-related skin ARs Other immune-related ARs Severe infusion reactions   |
|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important potential risks    | Embryofetal toxicity Immunogenicity Complications of allogeneic HSCT following nivolumab therapy in cHL Risk of GVHD with Nivolumab after allogeneic HSCT                                                                              |
| Missing information          | Patients with severe hepatic and/or renal impairment Patients with autoimmune disease Patients already receiving systemic immunosuppressants before starting nivolumab                                                                 |

## Pharmacovigilance plan

Table:

## Ongoing and Planned Additional Pharmacovigilance Activities

| Study / Status                                                                                                                                                                                                                  | Summary of objectives                                                                                                                                                                                                           | Safety concerns addressed                                                                                                                                                                                                                                                                                                                             | Milestone(s)                                                                                                                                                                                                                    | Due Date(s)                                                                                                                                                                                                                     |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization None                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization None                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization None                                                                                                                                                                                                                       | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization None                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization None                                                                                                 |
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances None | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances None | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances None                                                                                                                       | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances None | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances None |
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                   | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                   | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                                                                                                                                         | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                   | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                   |
| CA209234: Pattern of use and safety/effectivenes s of nivolumab in routine oncology practice Ongoing                                                                                                                            | To assess use pattern, effectiveness, and safety of nivolumab, and management of important identified risks of nivolumab in patients with lung cancer or melanoma in routine oncology practice                                  | Postmarketing use safety profile, management and outcome of immune-related pneumonitis, colitis, hepatitis, nephritis and renal dysfunction, endocrinopathies, rash, other immune-related adverse reactions (uveitis, pancreatitis, demyelination, Guillain-Barre syndrome, myasthenic syndrome, encephalitis, myositis, myocarditis, rhabdomyolysis, | 1. Interim report 2. Final CSR submission                                                                                                                                                                                       | Interim results provided annually 4Q2024                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

## Table: Ongoing and Planned Additional Pharmacovigilance Activities

| Study / Status                                                                                                    | Summary of objectives                                                     | Safety concerns addressed                                                                           | Milestone(s)                                                       | Due Date(s)                                          |
|-------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|--------------------------------------------------------------------|------------------------------------------------------|
| CA209835: A registry study in patients with Hodgkin lymphoma who underwent post- nivolumab allogeneic HSCTOngoing | To assess transplant- related complications following prior nivolumab use | infusion reactions Postmarketing safety assessment of the outcome of post-nivolumab allogeneic HSCT | 1. Annual update 2. Interim CSR submission 3. Final CSR submission | With PSUR starting at DLP 03-Jul-2017 06-2019 4Q2022 |

## Risk minimisation measures

Table  : Summary of Risk Minimization Measures

| Safety Concern                                                                                                                                                                                             | Risk Minimization Measures                                                                                                   | Pharmacovigilance Activities                                                                                                                                                                    |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Immune-related pneumonitis Immune-related colitis Immune-related hepatitis Immune-related nephritis and renal dysfunction Immune-related endocrinopathies Immune-related skin ARs Other immune-related ARs | Routine risk minimization measures: SmPC Sections 4.2, 4.4 and 4.8 Additional risk minimization measures: Patient Alert Card | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: Postmarketing pharmacoepidemiology study (CA209234) |
| Severe Infusion Reactions                                                                                                                                                                                  | Routine risk minimization measures: SmPC Sections 4.4 and 4.8 Additional risk minimization measures: None                    | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: Postmarketing pharmacoepidemiology study (CA209234) |
| Embryofetal toxicity                                                                                                                                                                                       | Routine risk minimization measures: SmPC Sections 4.6 and 5.3 Additional risk minimization measures: None                    | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None                                                |
| Immunogenicity                                                                                                                                                                                             | Routine risk minimization measures: SmPC Section 4.8 Additional risk minimization measures: None                             | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None                                                |

<div style=\"page-break-after: always\"></div>

Table  :

## Summary of Risk Minimization Measures

| Safety Concern                                                                   | Risk Minimization Measures                                                                                | Pharmacovigilance Activities                                                                                                                                          |
|----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Complications of allogeneic HSCT following nivolumab therapy in cHL              | Routine risk minimization measures: SmPC Sections 4.4 and 4.8 Additional risk minimization measures: None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: Registry study (CA209835) |
| Risk of GVHD with nivolumab after allogeneic HSCT                                | Routine risk minimization measures: SmPC Section 4.4 and 4.8 Additional risk minimization measures: None  | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None                      |
| Patients with severe hepatic and/or renal impairment                             | Routine risk minimization measures: SmPC Sections 4.2 and 5.2 Additional risk minimization                | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance                                       |
| Patients with autoimmune disease                                                 | Routine risk minimization measures: SmPC Section 4.4 Additional risk minimization                         | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance                                       |
| Patients already receiving systemic immunosuppressants before starting nivolumab | Routine risk minimization measures: SmPC Sections 4.4 and 4.5                                             | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None                                                                    |

## 2.7. Changes to the Product Information

As a result of this variation, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 6.6 of the SmPC are being updated. The Package Leaflet (PL) is updated accordingly.

Please refer to Attachment 1.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

The MAH is seeking an extension of indication for OPDIVO in combination with fluoropyrimidine- and platinum-based  combination  chemotherapy  for  the  first-line  treatment  of  adult  patients  with  HER2negative advanced or metastatic gastric, gastrooesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS)≥5.

## 3.1.1. Disease or condition

Gastric  cancer  (GC)  is  the  5 th   leading  cancer  and  the  3 rd   leading  cause  of  cancer-related  deaths worldwide. Oesophageal cancer is the 7 th  leading cancer and the 6 th  leading cause of cancer-related deaths  worldwide.  GC/gastric  oesophageal  junction  carcinoma  (GEJC)/oesophageal  adenocarcinoma (OAC) remain a leading cause of cancer-related mortality worldwide, with an estimated 1 million deaths worldwide in 2018.

Adenocarcinoma is the most common (&gt; 90%) histological subtype for GCs worldwide and OAC has increased in North America and Europe (EU).

## 3.1.2. Available therapies and unmet medical need

Treatment  recommendations  for  advanced  or  metastatic  GC,  GEJ  and  OAC,  are  almost  the  same. Platinum compounds (oxaliplatin and cisplatin) and fluoropyrimidines (5-fluorouracil, capecitabine, and tegafur/gimeracil/oteracil potassium) are considered first-line standard-of-care treatments for metastatic GC/GEJC/OAC across geographic regions (ESMO 2016; NCCN 2020).

In patients with HER2 positive tumour, the addition of trastuzumab to platinum and fluoropyrimidinebased chemotherapy is recommended.

## 3.1.3. Main clinical studies

The  evidence  in  support  of  the  claimed  indication  is  based  on  results  from  the study  CA209649 (CheckMate  649).  The  study  CA209649  is  a  Phase  3,  randomised,  multicentre,  open-label  study  of nivolumab plus ipilimumab or nivolumab in combination with chemotherapy  (oxaliplatin plus fluoropyrimidine) versus chemotherapy (oxaliplatin plus fluoropyrimidine) in subjects with previously untreated advanced or metastatic gastric, gastro oesophageal junction (GEJ) cancer or oesophageal adenocarcinoma (OAC).

The primary endpoints were overall survival (OS) and progression free survival (PFS), as assessed by BIRC per RECIST 1.1 criteria, in patients with PDL1 CPS≥5. OS in patients with PD -L1 CPS≥1 and all randomised patients were included as secondary endpoints. Other secondary endpoint were PFS and ORR. A hierarchical testing strategy was used for the primary endpoints and OS in PD-L1 CP S≥1 and all -randomised patients.

All the analyses presented below are on patients concurrently randomized to the nivo+chemo or chemo arm. A total of 1,581 were randomised to receive either nivo+chemo (n=789) or chemo (n =792).

## 3.2. Favourable effects

Primary endpoints (PD-L1 CPS≥5 )

<div style=\"page-break-after: always\"></div>

OS results  (even  rate  65.3%  nivo+chemo  vs.  75.1%  chemo)  showed  a  statistically  significant improvement in favour of the nivo+chemo arm over chemo arm (HR 0.71; 98.4% CI: 0.59, 0.86). Median OS was of 14.39 (95% CI: 13.11, 16.23) months in the nivo+chemo group and 11.10 (95% CI: 10.02, 12.09) months in the chemo group.

PFS results were also statistically significant in favour of the nivo+chemo arm (HR 0.68; 98% CI: 0.56, 0.81). Median PFS was 7.69 (95% CI: 7.03, 9.17) months and 6.05 (95% CI: 5.55, 6.90) months, in the nivo+chemo and chemo groups, respectively.

## Secondary endpoints

In  patients  with  PDL1  CPS≥1  a  statistically  significant  improvement  in  OS  was  observed  with nivo+chemo over chemo (HR 0.77; 99.3 CI: 0.64, 0.92). Median PFS was 13.96 (95% CI: 12.55, 14.98) months in the nivo+chemo arm vs. 11.33 (95% CI: 10.64, 12.25) months in the chemo arm.

OS in the all-randomised patients (event rate of 69% in the nivo+chemo arm and 75% in the chemo arm), show a statistically significant benefit of nivo+chemo over control ( HR of 0.80 [99.3% CI: 0.68, 0.94] ). Median OS was of 13.83 (95% CI: 12.55, 14.55) months and 11.56 (95% CI: 10.87, 12.48) months in the experimental and control arm, respectively.

Results in terms of PFS in  the all-randomised patients were consistent with the OS analysis and favoured also the nivo+chemo arm (HR 0.77; 95% CI: 0.68, 0.87). Median PFS was 7.66 (95%CI: 7.10, 8.54) months in the nivo+chemo arm versus 6.93 (95% CI: 6.60, 7.13) months in the chemo arm.

The ORR was  higher  in  the  nivo+chemo  arm  compared  with  the  chemo  arm  (58%  vs.  46.1%, respectively), in the all-randomised patients with measurable disease at baseline.

## Updated efficacy data

During  the  procedure  updated  efficacy  data,  including  OS  as  well  as  PFS,  ORR  and  DoR  per  BICR, providing  7.3  months  of  additional  follow-up  (DBL  of  16-Feb-2021)  were  submitted.  Results  are consistent with those previously reported.

## 3.3. Uncertainties and limitations about favourable effects

While statistically  significant  benefit  of  nivo+chemo  over  chemo in terms of  OS (and also PFS)  was observed in the all-randomised patient population the effect appears to be driven by patients with PDL1 CPS≥5 , which comprises the primary efficacy population in this study. In patients with PD-L1 CPS &lt;5 no clinically meaningful benefit was observed. Therefore, the indication has been restricted to patients with PDL1 CPS≥5.

Patients with known HER2-positive status were not allowed to enter the study. However, there were 643 (40.7%) patients for whom HER2 status was undetermined. Although it is expected that most of these patients were HER2-negative (based on the expected prevalence of HER2 positivity in the intended target population) this has not been confirmed. In the absence of such confirmation, no conclusion can be drawn  on  whether  HER2-positive  patients  could  also  benefit  from  the  addition  of  nivolumab  to chemotherapy treatment. This has been reflected in the wording of the indication. In fact, to demonstrate the  effect  of  nivolumab+chemotherapy  in  HER2-positive  patients  a  different  study  design,  with  a comparator including trastuzumab, would normally have been required.

## 3.4. Unfavourable effects

The database used for the safety profile of nivo+chemo in patients with advanced or metastatic gastric, gastro-oesophageal or oesophageal adenocarcinoma consists of 782 patients treated with nivo+chemo and is compared with 767 patients treated with chemo control with a minimum follow-up of 12.1 months.

<div style=\"page-break-after: always\"></div>

Median duration of therapy was 6.75 months in the nivo+chemo arm and 4.86 months in the chemo arm.

Nivo+chemo treatment is less well tolerated than treatment with chemo only as shown by the higher number of (drug-related) AEs (all causality 99.2% vs. 98.0%, drug-related 94.4% vs. 88.5%), Grade 34 AEs (69.1% vs. 59.5%), SAEs (54.1% vs. 43.7%), drug-related deaths due to AEs (1.5% vs. 0.5%), and AEs leading to discontinuations (47.4% vs. 32.7%).

Next to nivolumab and chemotherapy overlapping toxicities such as gastro-intestinal AEs, bone marrow depression, and peripheral neuropathy, also nivolumab-specific toxicity with immune-related AEs are observed. The most commonly reported AEs in the nivo+chemo group were nausea (47.6%), diarrhoea (39.4%),  and  anaemia  (38.2%).  When  looking  specifically  to  drug-related  AEs,  most  often  nausea (41.3%), diarrhoea (32.4%), and neuropathy peripheral (28.3%) were seen in the nivo+chemo arm. As expected, select AEs, immune-mediated adverse events (IMAEs), and other events of special interest (OESIs) occurred more frequently with nivo+chemo relative to chemotherapy.

The most common AEs leading to discontinuation in the nivo+chemo arm (regardless of causality) were neuropathy  peripheral  (7.8%),  malignant  neoplasm  progression  (4.7%),  and  peripheral  sensory neuropathy (4.5%).

The causes of death due to nivolumab were pulmonitis, interstitial lung disease and pneumonitis. The causes of death due to nivolumab and chemotherapy were infection and gastrointestinal toxicity.

## 3.5. Uncertainties and limitations about unfavourable effects

The safety profile is based on an open-label design study which might introduce bias in the reporting of AEs. The type of AEs reported is however not unexpected with what is known about nivolumab and XELOX/FOLFOX treatments.

## 3.6. Effects Table

Effects Table for nivolumab in combination with oxaliplatin plus fluoropyrimidine for the treatment of adult patients with previously untreated advanced or metastatic gastric, gastroesophageal junction cancer or esophageal adenocarcinoma (GC/GEJC/EAC) (data cutoff: July 2020) - Study CA209649 (CheckMate 649)

| Effect                                                | Short description                                                   | Unit                                                  | Treatment                                             | Control                                               | Uncertainties / Strength of evidence                  | References                                            |
|-------------------------------------------------------|---------------------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
| Favourable Effects                                    | Favourable Effects                                                  | Favourable Effects                                    | Favourable Effects                                    | Favourable Effects                                    | Favourable Effects                                    | Favourable Effects                                    |
| Primary endpoints (PD- L1 CPS≥5; n=955)               | Primary endpoints (PD- L1 CPS≥5; n=955)                             | Primary endpoints (PD- L1 CPS≥5; n=955)               | Primary endpoints (PD- L1 CPS≥5; n=955)               | Primary endpoints (PD- L1 CPS≥5; n=955)               | Primary endpoints (PD- L1 CPS≥5; n=955)               | Primary endpoints (PD- L1 CPS≥5; n=955)               |
| OS                                                    | Overall survival Time from randomisation until death from any cause | Median, months (95%CI)                                | 14.39 (13.11, 16.23)                                  | 11.10 (10.02, 12.09)                                  | HR 0.71 (98.4% CI: 0.59, 0.86) p<0.0001               | CSR                                                   |
| PFS                                                   | Progression free survival                                           | Median, months (95%CI)                                | 7.69 (7.03, 9.17)                                     | 6.05 (5.55, 6.90)                                     | HR 0.68 (98% CI: 0.56, 0.81) P<0.0001                 | CSR                                                   |
| Secondary endpoints (All randomised patients; n=1581) | Secondary endpoints (All randomised patients; n=1581)               | Secondary endpoints (All randomised patients; n=1581) | Secondary endpoints (All randomised patients; n=1581) | Secondary endpoints (All randomised patients; n=1581) | Secondary endpoints (All randomised patients; n=1581) | Secondary endpoints (All randomised patients; n=1581) |
| OS                                                    | Overall survival                                                    | Median, months                                        | 13.83 (12.55,                                         | 11.56 (10.87,                                         | HR 0.80                                               | CSR                                                   |

<div style=\"page-break-after: always\"></div>

| Effect               | Short description                                                                                         | Unit                   | Treatment                        | Control                        | Uncertainties /                                    | References           |
|----------------------|-----------------------------------------------------------------------------------------------------------|------------------------|----------------------------------|--------------------------------|----------------------------------------------------|----------------------|
|                      |                                                                                                           |                        |                                  |                                | Strength of evidence                               |                      |
| PFS                  | Progression free survival                                                                                 | Median, months (95%CI) | 7.66 (7.10, 8.54)                | 6.93 (6.60, 7.13)              | HR 0.77 (95% CI: 0.68, 0.87)                       | CSR                  |
| ORR                  | Overall response rate per BIRC (complete response + partial response) in subjects with measurable disease | % (95% CI)             | 58.0                             | 46.1                           | Difference 12.8 (95% CI: 7.3, 18.2)                | CSR                  |
| Unfavourable Effects | Unfavourable Effects                                                                                      | Unfavourable Effects   | Unfavourable Effects             | Unfavourable Effects           | Unfavourable Effects                               | Unfavourable Effects |
| Grade 3- 4 AEs       | All causality (drug-related)                                                                              | %                      | 69.1 (59.1)                      | 59.5 (44.5)                    | Open label study, compared to control chemotherapy | CSR                  |
| SAEs                 | All causality (drug-related)                                                                              | %                      | 54.1 (22.0)                      | 43.7 (12.1)                    |                                                    | CSR                  |
| AEs leading to DC    | All causality (drug-related)                                                                              | %                      | 47.4 (36.3)                      | 32.7 (23.6)                    |                                                    | CSR                  |
| Deaths               | Deaths due to study drug toxicity                                                                         | %                      | 1.5                              | 0.5                            |                                                    | CSR                  |
| Select AEs           | All causality select AE Endocrine Gastrointestinal Hepatic Pulmonary Renal Skin                           | %                      | 15.0 40.3 34.1 5.2 7.4 33.5 15.1 | 1.8 33.9 24.3 0.8 3.1 17.9 5.9 |                                                    | CSR                  |

Abbreviations: OS=overall survival, PFS=progression free survival, ORR=overall response rate, AE= adverse event, CI= confidence interval, CSR= clinical study report, DC= discontinuation, HR= hazard ratio, IR= infusion reaction, SAE= serious adverse event

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

In study CA209649 treatment with nivolumab in combination with chemotherapy (XELOX or FOLFOX) showed a statistically significant OS benefit compared with chemotherapy (XELOX or FOLFOX) alone in the all-randomised patient population. However, results appear to be driven by patients with PD-L1 CPS≥5 with lack of efficacy benefit observed in patients with PD-L1 CPS &lt;5. Therefore, the indication has been restricted to patients with PDL1 CPS≥5, which in fact was the primary efficacy population in this study.

<div style=\"page-break-after: always\"></div>

From a safety point of view, treatment of nivo+chemo is characterised by substantial toxicity with a high number of discontinuations. Nivo+chemo treatment is less tolerated than treatment with chemo only as shown by the higher number of (drug-related) AEs, Grade 3-4 AEs, SAEs, drug-related deaths due to AEs, and AEs leading to discontinuations. It is noted that the toxicity profile of the chemo control arm in this  first-line  population  is  already  considerable.  Next  to  nivolumab  and  chemotherapy  overlapping toxicities  such  as  gastro-intestinal  AEs,  bone  marrow  depression,  and  peripheral  neuropathy,  also nivolumab-specific toxicity with immune-related AEs are observed with the addition of nivolumab to the chemotherapy regimen. Although the type of AEs are reflective of the known safety profile of nivolumab immunotherapy and chemotherapy and no new safety issues were identified, the severity of the toxicity is considerable and should be valued against the observed benefit in patients with advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma.

Finally, the wording of the indication has been revised to include treatment of HER2-negative patients only.

## 3.7.2. Balance of benefits and risks

In  study  CA209649  nivolumab  in  combination  with  chemotherapy  demonstrated  superiority  over chemotherapy alone in OS, PFS and ORR in the overall population (i.e. regardless of PD-L1 CPS status). However, considering the lack of efficacy benefit observed with nivolumab+chemotherapy in patients with  PD-L1  CPS&lt;5  and  that  the  proposed  combination  is  more  toxic  and  less  well  tolerated  than chemotherapy alone, the benefit/risk ratio in patients with PD-L1 CPS&lt;5 is currently considered negative. Therefore, the indication has been restricted to patients with PDL1 CPS≥5 .

## 3.7.3. Additional considerations on the benefit-risk balance

N/A

## 3.8. Conclusions

The benefit/risk ratio of OPDIVO in combination with fluoropyrimidine- and platinum-based chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic GC, GEJ or OAC is considered positive for patients whose tumours express PD-L1 with a CPS ≥ 5.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to use OPDIVO (nivolumab) in combination with fluoropyrimidine- and platinum-based combination chemotherapy, in first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-oesophageal junction (GEJ) or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) ≥ 5 (Study CA209649); as a

<div style=\"page-break-after: always\"></div>

consequence, sections 4.1, 4.2, 4,4, 4.8, 5.1 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 21.2 of the RMP has also been submitted.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annex(es) I and IIIB and to the Risk Management Plan are recommended.

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion 'Opdivo-H-C-3985-II-0096'

1 Rizvi NA, Hellmann MD, Brahmer JR, et al. Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small cell lung cancer. Journal of Clinical Oncology 2016; 34:2969-2979.

2 Fuchs CS, Ohtsu A, Tabernero J, et al. Preliminary safety data from KEYNOTE059:  pembrolizumab  plus  5-fluorouracil  (5-FU)  and  cisplatin  for  first-line  treatment  of advanced gastric cancer. Journal of Clinical Oncology 2016; 34:4037-4037.

3 Kang Y-K, Kato K, Chung HC, et al. Interim safety and clinical activity of nivolumab (Nivo)  in  combination  with  S-1/capecitabine  plus  oxaliplatin  in  patients  (pts)  with previously  untreated  unresectable  advanced  or  recurrent  gastric/  gastroesophageal junction  (G/GEJ)  cancer:  part  1  study  of  ATTRACTION-04  (ONO-4538-37).  Annals  of Oncology 2017; 28:Abstract 671P.

4 Smyth E and Petty R. Pembrolizumab versus paclitaxel  in  gastro-oesophageal adenocarcinoma. Lancet 2018; 392:97-98.

5 Kulangara K, Guerrero L, Posch A, et al. Investigation of PD-L1 expression and response to pembrolizumab (pembro) in gastric cancer (GC) and cervical cancer (CC) using combined  positive  score  (CPS)  and  tumour  proportion  score  (TPS).  Journal  of  Clinical Oncology 2018; 36:4065.